<SEC-DOCUMENT>0001493152-21-004012.txt : 20210216
<SEC-HEADER>0001493152-21-004012.hdr.sgml : 20210216
<ACCEPTANCE-DATETIME>20210216165249
ACCESSION NUMBER:		0001493152-21-004012
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20210216
DATE AS OF CHANGE:		20210216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanara MedTech Inc.
		CENTRAL INDEX KEY:			0000714256
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				592220004
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-251652
		FILM NUMBER:		21640134

	BUSINESS ADDRESS:	
		STREET 1:		1200 SUMMIT AVE
		STREET 2:		SUITE 414
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76102
		BUSINESS PHONE:		817-529-2300

	MAIL ADDRESS:	
		STREET 1:		1200 SUMMIT AVE
		STREET 2:		SUITE 414
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WOUND MANAGEMENT TECHNOLOGIES, INC.
		DATE OF NAME CHANGE:	20080611

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MB SOFTWARE CORP
		DATE OF NAME CHANGE:	19960805

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INAV TRAVEL CORPORATION
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>form424b5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
pursuant to Rule 424(b)(5)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-251652</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(To
Prospectus Dated January 4, 2021)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt">1,100,000
Shares of Common Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_001.jpg" ALT="https:||sanaramedtech.com|wp-content|uploads|2019|08|logo-footer.png" STYLE="height: 59px; width: 177px"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt">Sanara
MedTech Inc.</FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are offering 1,100,000
shares of common stock of Sanara MedTech Inc. Our common stock is currently listed on The Nasdaq Capital Market under the symbol
&ldquo;SMTI.&rdquo; On February 11, 2021, the last reported sale price of our common stock on The Nasdaq Capital Market was $41.00
per share.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our common stock involves a high degree of risk. See the section of this prospectus supplement entitled &ldquo;Risk Factors&rdquo;
beginning on page S-14 of this prospectus supplement and page 4 of the accompanying prospectus and the risk factors in the documents
incorporated by reference in this prospectus supplement and the accompanying prospectus to read about factors you should consider
before buying our common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the accuracy or adequacy of this prospectus supplement. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify"><FONT STYLE="font-size: 10pt">Public offering price</FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">25.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">27,500,000.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Underwriting discounts and commissions<SUP>(1) </SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.75</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,925,000.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify">Proceeds, before expenses, to us</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">23.25</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">25,575,000.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    the section entitled &ldquo;Underwriting&rdquo; beginning on page S-84 of this prospectus supplement for a description of
    the compensation payable to the underwriters.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
May 10, 2019, we effected a reverse stock split of the issued and outstanding shares of our common stock at a ratio of one share
for every 100 shares. All share and per share information in this prospectus supplement have been adjusted to reflect the reverse
stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underwriters have the option to purchase up to an additional
165,000 shares of common stock at the public offering
price, less underwriting discounts and commissions, within 30 days of the date of this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters expect to deliver the securities to purchasers in the offering on or about February 17,
2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Cantor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus supplement is &nbsp;February 12,
2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE
OF CONTENTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus
Supplement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT
    THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-ii</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS
    SUPPLEMENT SUMMARY</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUMMARY
    HISTORICAL CONSOLIDATED FINANCIAL INFORMATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-12</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK
    FACTORS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-14</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY
    STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-40</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE
    OF PROCEEDS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-42</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MARKET
    INFORMATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-43</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND
    POLICY</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-43</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-44</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT&rsquo;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-45</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BUSINESS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-54</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-76</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL
    U.S. FEDERAL INCOME AND ESTATE TAX CONSIDERATIONS FOR NON-U.S. HOLDERS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-81</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNDERWRITING</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-84</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL
    MATTERS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-93</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-93</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE
    YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-93</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION
    OF DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-93</FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: top"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px; text-transform: uppercase"><A HREF="#about">
                                About This Prospectus</A></FONT></DIV>
</TD>
<TD STYLE="text-align: right; vertical-align: top; width: 0.5in"><DIV STYLE="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">ii<BR>
                                         </FONT></DIV>
</TD>
</TR><TR STYLE="background-color: White">
<TD STYLE="vertical-align: top"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="text-transform: uppercase"><A HREF="#cautionary"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Cautionary
                                Statement Regarding Forward-Looking Statements</FONT></A></FONT></DIV>
</TD>
<TD STYLE="text-align: right; vertical-align: top"><DIV STYLE="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">iii<BR>
                                         </FONT></DIV>
</TD>
</TR><TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: top"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="text-transform: uppercase"><A HREF="#propsectsum"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Prospectus
                                Summary</FONT></A></FONT></DIV>
</TD>
<TD STYLE="text-align: right; vertical-align: top"><DIV STYLE="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">1<BR></FONT></DIV>
</TD>
</TR><TR STYLE="background-color: White">
<TD STYLE="vertical-align: top"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="text-transform: uppercase"><A HREF="#riskfactor"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Risk
                                Factors</FONT></A></FONT></DIV>
</TD>
<TD STYLE="text-align: right; vertical-align: top"><DIV STYLE="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">4<BR></FONT></DIV>
</TD>
</TR><TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: top"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="text-transform: uppercase"><A HREF="#useofproceed"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Use
                                of Proceeds</FONT></A></FONT></DIV>
</TD>
<TD STYLE="text-align: right; vertical-align: top"><DIV STYLE="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">5<BR></FONT></DIV>
</TD>
</TR><TR STYLE="background-color: White">
<TD STYLE="vertical-align: top"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="text-transform: uppercase"><A HREF="#descriptionofcapstock"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Description
                                of Capital Stock</FONT></A></FONT></DIV>
</TD>
<TD STYLE="text-align: right; vertical-align: top"><DIV STYLE="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">6<BR></FONT></DIV>
</TD>
</TR><TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: top"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="text-transform: uppercase"><A HREF="#decofwarrants"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Description
                                of Warrants</FONT></A></FONT></DIV>
</TD>
<TD STYLE="text-align: right; vertical-align: top"><DIV STYLE="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">10<BR>
                                         </FONT></DIV>
</TD>
</TR><TR STYLE="background-color: White">
<TD STYLE="vertical-align: top"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="text-transform: uppercase"><A HREF="#descofunits"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Description
                                of Units</FONT></A></FONT></DIV>
</TD>
<TD STYLE="text-align: right; vertical-align: top"><DIV STYLE="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">12<BR>
                                         </FONT></DIV>
</TD>
</TR><TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: top"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="text-transform: uppercase"><A HREF="#planofdistro"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Plan
                                of Distribution</FONT></A></FONT></DIV>
</TD>
<TD STYLE="text-align: right; vertical-align: top"><DIV STYLE="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">13<BR>
                                         </FONT></DIV>
</TD>
</TR><TR STYLE="background-color: White">
<TD STYLE="vertical-align: top"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="text-transform: uppercase"><A HREF="#legalmatter"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Legal
                                Matters</FONT></A></FONT></DIV>
</TD>
<TD STYLE="text-align: right; vertical-align: top"><DIV STYLE="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">16<BR>
                                         </FONT></DIV>
</TD>
</TR><TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: top"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="text-transform: uppercase"><A HREF="#experts"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Experts</FONT></A></FONT></DIV>
</TD>
<TD STYLE="text-align: right; vertical-align: top"><DIV STYLE="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">16<BR>
                                         </FONT></DIV>
</TD>
</TR><TR STYLE="background-color: White">
<TD STYLE="vertical-align: top"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="text-transform: uppercase"><A HREF="#whereyoucanfind"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Where
                                You Can Find More Information</FONT></A></FONT></DIV>
</TD>
<TD STYLE="text-align: right; vertical-align: top"><DIV STYLE="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">16<BR>
                                         </FONT></DIV>
</TD>
</TR><TR STYLE="background-color: rgb(204,238,255)">
<TD STYLE="vertical-align: top"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="text-transform: uppercase"><A HREF="#incorpbyref"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Incorporation
                                of Documents by Reference</FONT></A></FONT></DIV>
</TD>
<TD STYLE="text-align: right; vertical-align: top"><DIV STYLE="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">16<BR>
                                         </FONT></DIV>
</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>ABOUT
THIS PROSPECTUS SUPPLEMENT</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the U.S. Securities
and Exchange Commission (the &ldquo;SEC&rdquo;) utilizing a &ldquo;shelf&rdquo; registration process. This document is in two
parts. The first part is this prospectus supplement, which describes the specific terms of this offering and also adds to and
updates information contained in the accompanying prospectus and the documents incorporated by reference herein. The second part,
the accompanying prospectus, provides more general information. Generally, when we refer to this prospectus, we are referring
to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus
supplement and the information contained in the accompanying prospectus or any document incorporated by reference therein filed
prior to the date of this prospectus supplement, you should rely on the information in this prospectus supplement; provided that
if any statement in one of these documents is inconsistent with a statement in another document having a later date&mdash;for
example, a document incorporated by reference in the accompanying prospectus&mdash;the statement in the document having the later
date modifies or supersedes the earlier statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any
document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including,
in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,
warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made.
Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state
of our affairs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in this prospectus supplement, the accompanying prospectus, any free writing prospectus
or document incorporated by reference herein or therein. Neither we nor the underwriters have authorized anyone to provide you
with different or additional information. The information contained in this prospectus supplement, the accompanying prospectus,
any free writing prospectus or document incorporated by reference herein or therein is accurate only as of the respective dates
thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our
common stock. Our business, financial condition, results of operations and prospects may have changed since those dates. It is
important for you to read and consider all information contained in this prospectus supplement and the accompanying prospectus,
including the documents incorporated by reference herein and therein, in making your investment decision. You should also read
and consider the information in the documents to which we have referred you in the sections entitled &ldquo;Where You Can Find
More Information&rdquo; and &ldquo;Incorporation of Documents by Reference&rdquo; in this prospectus supplement and in the accompanying
prospectus, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering to sell, and seeking offers to buy, our common stock only in jurisdictions where offers and sales are permitted.
The distribution of this prospectus supplement and the accompanying prospectus and the offering of our common stock in certain
jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement
and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of our common
stock and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus
supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation
of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any
jurisdiction in which it is unlawful for such person to make such an offer or solicitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated or the context otherwise requires, financial data included, or incorporated by reference, in this prospectus
supplement and the accompanying prospectus reflects the business and operations of Sanara MedTech Inc. and its consolidated subsidiaries
and all references herein to &ldquo;Sanara MedTech Inc.,&rdquo; &ldquo;Sanara MedTech,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo;
&ldquo;our&rdquo; or &ldquo;us&rdquo; refer to Sanara MedTech Inc. and its consolidated subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Industry
and Market Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, information contained in, or incorporated by reference into, this prospectus supplement and the accompanying
prospectus concerning our industry, our market share and the markets that we serve is based on information from independent industry
and research organizations, other third-party sources (including industry publications, surveys and forecasts) and management
estimates. Management estimates are derived from publicly available information released by independent industry analysts and
third-party sources, as well as data from our internal research, and are based on assumptions made by us upon reviewing such data
and our knowledge of such industry and markets that we believe to be reasonable. Although we believe the data from these third-party
sources is reliable, we have not independently verified any such information. In addition, projections, assumptions and estimates
of the future performance of the industry in which we operate and our future performance are necessarily subject to uncertainty
and risk due to a variety of factors, including those described in &ldquo;Risk Factors&rdquo; and &ldquo;Cautionary Statement
Regarding Forward-Looking Statements.&rdquo; These and other factors could cause results to differ materially from those expressed
in the estimates made by third parties and by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trademarks,
Trade Names and Service Marks</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara,
Sanara MedTech, our logo and other trademarks or service marks appearing in this prospectus supplement, the accompanying prospectus
and the documents incorporated by reference herein and therein are the property of Sanara MedTech Inc. Trade names, trademarks
and service marks of other companies appearing in this prospectus supplement, the accompanying prospectus and the documents incorporated
by reference herein and therein are the property of their respective owners. Solely for convenience, the trademarks, service marks
and trade names included in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference
herein and therein are without the &reg;, &trade; or other applicable symbols, but such references are not intended to indicate,
in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors
to these trademarks, service marks and trade names.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_002"></A>PROSPECTUS
SUPPLEMENT SUMMARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>This
summary highlights certain significant aspects of our business and this offering and is a summary of information contained elsewhere
in this prospectus supplement, in the accompanying prospectus and the documents incorporated by reference herein and therein.
This summary does not contain all of the information that you should consider before deciding to invest in our securities. You
should read the entire prospectus supplement, the accompanying prospectus, any free writing prospectus prepared by us or on our
behalf and the information incorporated by reference herein and therein carefully, including the sections titled &ldquo;Risk Factors,&rdquo;
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; and &ldquo;Business,&rdquo;
and our financial statements and related notes thereto, before making an investment decision. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes
and reduce healthcare expenditures in the chronic and surgical wound and skin care markets. Our portfolio of products and services
will allow us to deliver comprehensive wound and skin care solutions for patients in all care settings, including acute (hospitals
and long-term acute care hospitals (&ldquo;LTACHs&rdquo;)) and post-acute (wound care clinics, physician offices, skilled nursing
facilities (&ldquo;SNFs&rdquo;), home health, hospice, and retail). Each of our products, services, and technologies contribute
to our overall goal of achieving better clinical outcomes at a lower overall cost for patients regardless of where they receive
care. We strive to be one of the most innovative and comprehensive providers of effective wound and skin care products and technologies
and are continually seeking to expand our offerings for patients requiring wound and skin care treatments across the entire continuum
of care in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently market seven products across chronic and surgical wound care applications and have multiple products in our pipeline.
We license our products from research and development partners Applied Nutritionals, LLC (&ldquo;AN&rdquo;) (through a sublicense
with CGI Cellerate RX, LLC (&ldquo;CGI Cellerate RX&rdquo;), an affiliate of The Catalyst Group, Inc. (&ldquo;Catalyst&rdquo;))
and Rochal Industries, LLC (&ldquo;Rochal&rdquo;) and have the right to exclusively distribute certain products under development
by Cook Biotech Inc. (&ldquo;Cook Biotech&rdquo;). In 2021, we intend to begin marketing three biologic products for surgical
and wound care applications pursuant to our marketing and distribution agreement with Cook Biotech. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2020, we formed a subsidiary, United Wound and Skin Solutions LLC (&ldquo;UWSS&rdquo;), to hold certain investments and operations
in wound and skin care virtual consult services. We anticipate that our various service offerings will allow clinicians/physicians
utilizing our technologies to collect and analyze large amounts of data on patient conditions and outcomes that will improve treatment
protocols and ultimately lead to more evidence-based formulary to improve patient outcomes. We intend to launch our initial virtual
consult service offerings in 2021. Through a combination of our UWSS services and our Sanara products, we believe we will be able
to offer patient care solutions at every step in the continuum of wound and skin care from diagnosis through healing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Market
Scale</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
study by a physician at the Department of Surgery for the Indiana University Health Comprehensive Wound Center found that approximately
8.2 million patients suffer from surgical and chronic wounds each year in the United States. Furthermore, according to an article
published by the <I>American College of Surgeons and Surgical Infection Society</I>, in the United States, the annual treatment
cost projections for all wounds is approximately $28 billion with the estimated annual cost of surgical site infections ranging
from $3.5 billion to $10 billion. The U.S. teledermatology market alone is estimated to grow from $5 billion in 2019 to $45 billion
by 2027 according to a research report by Fortune Business Insights. In addition to our surgical wound and chronic wound divisions,
the Company is planning to launch virtual consult services through UWSS for both virtual wound and virtual skin (dermatology)
consultations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Summary
of our Product &amp; Service Offerings and Development Programs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are committed to developing and commercializing innovative products that address the challenges physicians face in diagnosing
and treating wound and skin care ailments. The following table sets forth our product and service portfolio:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT><IMG SRC="new_002.jpg" ALT="" STYLE="height: 354px; width: 630px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
surgical wound care products, CellerateRX Surgical Activated Collagen (Powder and Gel) (collectively, &ldquo;CellerateRX Surgical&rdquo;),
are used in a wide range of surgical specialties to help promote patient healing and reduce the risk of complications. The product
is used in specialties including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology,
Mohs surgery, neurosurgery, oncology, orthopedic (hip and knee, sports, spine, joint, foot and ankle, ortho trauma and ortho oncology), plastic/reconstructive, podiatric, urology, and vascular. Currently, substantially all of our revenue is derived
from the sale of surgical wound care products. We anticipate that chronic wound care products and UWSS technology-based services
will become meaningful drivers of revenue in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
chronic wound care products, HYCOL Hydrolyzed Collagen (Powder and Gel) (collectively, &ldquo;HYCOL&rdquo;), BIAKO&#772;S Skin
and Wound Cleanser (&ldquo;BIAKO&#772;S AWC&rdquo;) and BIAKO&#772;S Skin and Wound Gel, are used across the post-acute continuum
of care, including home health, hospice, physician offices, podiatrists, retail, SNFs, and wound care centers. Our chronic wound
care products can be used on stage I-IV pressure ulcers, diabetic foot ulcers (&ldquo;DFUs&rdquo;), venous stasis, arterial, post-surgical
wounds, first- and second-degree burns and donor sites. BIAKO&#772;S AWC is also available in an irrigation bottle (BIAKO&#772;S
Antimicrobial Skin and Wound Irrigation Solution) that can be used in conjunction with negative pressure wound therapy installation
and dwell (&ldquo;NPWTi-d&rdquo;) and other wound irrigation needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have a robust pipeline of products under development for both the chronic and surgical wound care and virtual consult
markets. We believe our pipeline efforts will deepen our comprehensive portfolio of offerings as well as allow us to address additional
clinical applications. Wound care products in our pipeline include an over-the-counter hand and skin cleanser, an antimicrobial
skin protectant, a debrider product that leverages the body&rsquo;s own enzymes and moisture, a new wound bed preparation device
for use with BIAKO&#772;S AWC, next generation CellerateRX and HYCOL, a novel dressing that delivers oxygen to the wound bed,
and a sterile BIAKO&#772;S product for use in surgical settings. Additionally, Sanara expects to commercialize three products
with Cook Biotech in the second half of 2021. The first two, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular
Matrix, are currently 510(k) cleared for use in the surgical wound care segment, and VIM Amnion Matrix is categorized by the U.S.
Food and Drug Administration (&ldquo;FDA&rdquo;) as an HCT/P, subject to regulation under Section 361 of the Public Health Service
Act (&ldquo;PHSA&rdquo;) (for which no premarket approval or clearance is required).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
UWSS technology-based services we expect to launch in 2021 include: an electronic medical record (&ldquo;EMR&rdquo;) software
platform for both wound and skin conditions (WounDerm, LLC f/k/a Woundyne Medical, LLC (&ldquo;WounDerm&rdquo;)),
skin and wound virtual consult services (DirectDerm Inc. &ldquo;DirectDerm&rdquo; and MGroup Integrated Physician Services, P.A.
&ldquo;MGroup&rdquo;), and diagnostic products and services for chronic wounds (Precision Healing Inc. &ldquo;Precision Healing&rdquo;).
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
detailed below, following the anticipated launch of UWSS&rsquo;s service offerings, we expect to be able to provide wound treatment
solutions for patients across the entire acute and post-acute continuum of care:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="new_003.jpg" ALT="" STYLE="height: 363px; width: 645px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Strategy
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Drive
                                         additional market penetration as well as geographic expansion for our products.</I> We
                                         intend to leverage our comprehensive product and technology-based services portfolio
                                         and relationships with key constituents to deepen our presence in the surgical and chronic
                                         wound and skin care markets. We believe the breadth and flexibility of the products we
                                         offer allow us to address a wide variety of wound types and sizes and offer significant
                                         new opportunities for sales growth. In addition, we believe that as we continue to offer
                                         new products and technology-based services, our salesforce&rsquo;s ability to reach additional
                                         customers in new and existing geographic regions while penetrating further in existing
                                         customer accounts will be enhanced.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expand
                                         into new markets for our products and services.</I> In 2020 we made significant investments
                                         in virtual consult technologies and services. The COVID-19 pandemic has dramatically
                                         increased demand for these services with expanded reimbursements and patients being more
                                         comfortable seeing their care provider virtually. We believe that the virtual consult
                                         technologies and services that we will offer, when combined with our innovative and highly
                                         efficacious products, will offer a differentiated comprehensive wound and skin care solution
                                         for patients and care givers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Launch
                                         new innovative products.</I> We are actively working with third-party research and development
                                         partners to develop additional proprietary products for the chronic and surgical wound
                                         and skin care markets. We expect these products and services to deepen our portfolio
                                         of technologies to treat chronic wounds as well as improve surgical site outcomes. We
                                         are focused on offering additional products and services that are more efficacious than
                                         competing products and services and provide a stronger value proposition (lower total
                                         cost to heal and less time to heal leading to reduced costs to the healthcare system).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Capture
                                         patients throughout the entire continuum of care.</I> We intend to continue expanding
                                         our platform to aid in treating wound and skin care patients as they progress through
                                         the healing process in all care settings. As discussed above, in June 2020, we formed
                                         a subsidiary, UWSS, to hold certain investments in technologies and operations in wound
                                         and skin care virtual consult services. We believe our service offerings will allow us
                                         to collect and analyze large amounts of data on patient conditions and outcomes that
                                         will improve treatment protocols and ultimately lead to more evidence-based healing formularies
                                         to improve outcomes in the future. We anticipate that this data will also enable us to
                                         participate in the creation of new standards of care that promote patient compliance
                                         and enable direct dialogue between patients, clinicians and payors, resulting in greater
                                         satisfaction for patients, their caregivers, clinicians and payors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Seek
                                         and establish partnerships and product, technology, and/or services acquisitions.</I>
                                         We plan to continue to seek and establish partnerships in the United States and internationally
                                         to provide innovative products, services, and technologies. We believe that partnerships
                                         will be a key driver of our growth in the future. We also intend to selectively pursue
                                         acquisitions of businesses and technologies that complement our existing strategy and
                                         footprint.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Achieve
                                         meaningful operating margin improvement.</I> We expect to increase our margins through
                                         a dual-pronged approach. First, as we scale the sales of our products, the leverage on
                                         salaries and infrastructure costs (legal, finance, commercial operations support and
                                         rent) as a percentage of revenue should decrease, increasing our operating margin. Second,
                                         we expect to achieve higher gross and operating margins as our UWSS services are commercialized
                                         and reach sufficient scale.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Competitive
Strengths </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Comprehensive
                                         solution for improved wound care outcomes.</I> We are dedicated to offering a comprehensive
                                         portfolio of products and services to improve wound care treatment outcomes. We are currently
                                         developing the capability to provide telehealth services for the diagnosis and treatment
                                         of wound and skin care patients. Our product offerings are able to disinfect wounds and
                                         accelerate the body&rsquo;s healing process for acute and chronic wounds and allow clinicians
                                         to provide a consistent plan of care for a patient from diagnosis through treatment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Wound
                                         care products for all care settings.</I> Our wound care product portfolio allows clinicians
                                         to personalize solutions to meet the needs of individual wound care patients in all care
                                         settings including acute (hospitals and LTACHs) and post-acute (wound care clinics, physician
                                         offices, SNFs, home health, hospice, and retail). Our experienced wound care sales force
                                         is highly trained to assist clinicians to effectively deploy the full complement of our
                                         product portfolio to effectively treat wounds.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Innovative
                                         pipeline and proven clinical performance.</I> We have a robust pipeline of chronic and
                                         surgical wound and skin care products that we expect to market in the near term. We believe
                                         the efficacy of our offerings, will be proven via statistically significant collected
                                         and analyzed clinical and health economic outcomes data, resulting in expanded adoption
                                         of our products at a lower overall cost to payors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Attractive
                                         markets for acute and chronic wound care.</I> We believe the acute and chronic wound
                                         care markets will continue to see accelerated growth given favorable global tailwinds
                                         that include an aging population, increasing costs of health care, recognition of difficult-to-treat
                                         infection threats such as biofilms, and the increasing prevalence of diabetes and obesity.
                                         We believe there will be growing adoption of our products due to their clinical efficacy
                                         and cost effectiveness for all key constituents compared to traditional wound care products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Proven
                                         executive leadership team with a long-term track record of value creation.</I> We are
                                         led by a dedicated and seasoned management team with significant industry experience
                                         who have successfully executed our strategic implementation to date by launching new
                                         products and technologies through investment in new areas of growth. We believe our management
                                         has the vision and experience to implement our future growth strategy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Market
Opportunities for our Products and Technology-Based Services </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, Centers for Medicare &amp; Medicaid Services&rsquo; (&ldquo;CMS&rdquo;) reimbursement methodology for home health
agencies and SNFs (Patient Driven Group Model (&ldquo;PDGM&rdquo;) and Patient Driven Payment Model (&ldquo;PDPM&rdquo;), respectively)
created unique opportunities to provide efficacious wound healing inside of those sites of care in unprecedented fashion. With
those payment models now focused on a patient&rsquo;s characteristics (including number of wounds and skin conditions) rather
than the volume of services provided, greater remuneration is provided to home health agencies and SNFs for the treatment of wound
care patients. As a result, the incentive to transfer patients with both acute and chronic wounds to more burdensome and costly
care settings, such as inpatient or outpatient wound-care centers, has been discouraged or eliminated. This shift in vertical
economics provides us with a unique opportunity, in adjunctive fashion with home health agencies and SNFs, to deliver highly technical
and comprehensive wound care where this most vulnerable patient population resides thus achieving CMS&rsquo;s desired results:
better patient outcomes at a lower total cost of care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chronic
and Other Hard-to-Heal Wounds </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to a study published by the <I>Value in Health</I> journal, roughly 15% of the Medicare beneficiary population has chronic nonhealing
wounds. Chronic wounds do not advance through the phases of healing in a normal progression and do not show significant progress
toward healing in 30 days. Factors contributing to the chronicity of the wound may include pressure / friction, trauma; insufficient
blood flow and oxygenation in locations such as the lower extremities; increased bacterial load; excessive proteases; degraded
growth factors; matrix metalloproteinases (&ldquo;MMPs&rdquo;); senescent / aberrant cells; or inappropriate treatment.
Examples of chronic wounds include DFUs, venous leg ulcers (&ldquo;VLUs&rdquo;), arterial ulcers, pressure ulcers and hard-to-heal
surgical/traumatic wounds. In each of the various wound types, the presence of biofilms is a frequent cause for chronification
of wounds and the removal of biofilms is a crucial step to commence healing. Biofilms need to be eradicated to prevent further
deterioration of the wound that may result in additional negative patient outcomes. If not effectively treated, these wounds can
lead to potentially severe complications, including further infection, osteomyelitis, fasciitis, amputation and increased mortality.
Chronic wounds are primarily seen in the elderly population. For example, a 2019 study published in <I>Advances in Wound Care
</I>reported that in the United States, 3% of the population over the age of 65 had open wounds. According to the same study,
in 2020, the U.S. government estimated that the elderly population totaled 55 million people, suggesting that chronic wounds will
continue to be an increasingly persistent problem in this population. Four common chronic and other hard-to-heal wounds are: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Diabetic
                                         Foot Ulcers.</I> Diabetes can lead to a reduction in blood flow, which can cause patients
                                         to lose sensation in their feet and may prevent them from noticing injuries, sometimes
                                         leading to the development of DFUs, which are open sores or ulcers on the feet that may
                                         take several weeks to heal, if ever. According to the 2020 National Diabetes Statistics
                                         Report by the Center for Disease Control and Prevention, in the United States alone,
                                         over 34 million people, or approximately 10% of the population, suffer from diabetes,
                                         a chronic, life-threatening disease. Of those that suffer from diabetes, approximately
                                         1.7 million people (or 5% of diabetics in the United States) will develop DFUs on a yearly
                                         basis, according to the CEO of Corstrata, a digital healthcare and wound management firm
                                         specializing in the treatment of foot ulcers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Venous
                                         Leg Ulcers.</I> VLUs develop as a result of vascular insufficiency, or the inability
                                         for the vasculature of the leg to return blood back toward the heart properly and, according
                                         to a 2013 report published by the <I>International Journal of Tissue Repair and Regeneration</I>,
                                         VLUs affect approximately 600,000 people per year in the United States alone. These ulcers
                                         usually form on the sides of the lower leg, above the ankle and below the calf, and are
                                         slow to heal and often recur if preventative steps are not taken. The risk of venous
                                         ulcers can be increased as a result of a blood clot forming in the deep veins of the
                                         legs, obesity, smoking, lack of physical activity or work that requires many hours of
                                         standing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pressure
                                         Ulcers.</I> Pressure ulcers, also known as decubitus ulcers or bed sores, are injuries
                                         to skin and underlying tissue resulting from prolonged pressure, or pressure in combination
                                         with shear or friction. Constant pressure on an area of skin reduces blood supply to
                                         the area and over time can cause the skin to break down and form an open ulcer. These
                                         often occur in patients who are hospitalized or confined to a chair or bed and most often
                                         form on the skin over bony areas, where there is little cushion between the bone and
                                         the skin, such as heels, ankles, hips and the tailbone. Annually, 2.5 million pressure
                                         ulcers are treated in the United States in acute care facilities alone, according to
                                         a 2006 study published in the <I>Journal of the American Medical Association</I>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Surgical/traumatic
                                         wounds.</I> Surgical wounds form as a result of various types of surgical procedures
                                         such as investigative or corrective, minor or major, open (traditional) or minimal access
                                         surgery, elective or emergency, and incisions (simple cuts) or excision (removal of tissue),
                                         among others. Traumatic wounds form as a result of cuts, lacerations or puncture wounds,
                                         which have caused damage to the skin and underlying tissue. Severe traumatic wounds may
                                         require surgical intervention to close the wound and stabilize the patient. Surgical/traumatic
                                         hard-to-heal wounds develop for various reasons, such as local surgical complications,
                                         suboptimal closure techniques, presence of foreign materials, exposed bones or tendons
                                         and infection. In the United States, millions of people receive post-surgical wound care
                                         annually, and the typical operative patient has comorbidities that create challenges
                                         with post-operative wound healing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reverse
Stock Split</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
May 10, 2019, we effected a reverse stock split of the issued and outstanding shares of our common stock at a ratio of one share
for every 100 shares. All share and per share information in this prospectus supplement have been adjusted to reflect the reverse
stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Impact
of the COVID-19 Pandemic</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
in March 2020, many states issued orders suspending elective surgeries in order to free-up hospital resources to treat COVID-19
patients. This resulted in a reduction in demand for our surgical products beginning in the second half of March 2020.
Additionally, most states limited access to SNFs to only resident caregivers, which impeded our ability to provide education and
product training to the clinicians who use our products in these facilities. These restrictions resulted in an overall decline
in sales for the second quarter of 2020. During the third quarter of 2020, we saw a strong rebound in product sales as restrictions
on elective surgeries eased in our primary markets in Texas, Florida, and the southeastern United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
for the three months ended September 30, 2020 was $4.3 million, a $1.3 million increase from the three months ended June 30, 2020
and represented a record high sales quarter for our Company. With certain states recently experiencing a spike in COVID-19 cases,
the Company may again experience swings in monthly sales if more stringent restrictions are imposed on elective surgeries. For
example, Texas Governor Greg Abbott has issued a standing executive order requiring that hospitals in any Trauma Service Area
(as defined in the executive order) that has had seven consecutive days in which the number of COVID-19 hospitalized patients
as a percentage of total hospital capacity exceeds 15 percent postpone all surgeries and procedures that are not medically necessary
to diagnose or correct a serious medical condition of, or to preserve the life of, a patient, until such time as the Trauma Service
Area reaches seven consecutive days in which the number of COVID-19 hospitalized patients as a percentage of total hospital capacity
is 15 percent or less.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the COVID-19 pandemic, we significantly reduced costs in areas such as payroll, consulting, business travel, and other
discretionary spending. The duration of the pandemic is uncertain; however, management believes that elective surgical procedures
will continue to be performed with the exception of certain geographic COVID-19 hotspots. We will continue to closely monitor
the COVID-19 pandemic in order to ensure the safety of our people and our ability to serve our customers and patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Entry
into Loan Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 15, 2021, we entered into a loan agreement (the &ldquo;Loan Agreement&rdquo;) with Cadence Bank, N.A. (&ldquo;Cadence&rdquo;)
that provides for a $2.5 million revolving line of credit. The revolving line of credit matures on January 13, 2023 and is secured
by substantially all of our assets. Proceeds from the line of credit are to be used to provide us with additional working capital
in support of current assets and for other general corporate purposes and may not be used for acquisitions. The line of credit
contains customary representations and warranties and requires us to maintain compliance with certain financial covenants, including
minimum liquidity and tangible net worth requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preliminary
Summary Results for Fourth Quarter and Fiscal Year 2020</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2021, we announced certain unaudited preliminary results for the fourth quarter and full fiscal year ended December
31, 2020 described below. Our estimated unaudited financial condition and results of operations as of and for the fourth quarter
and full fiscal year ended December 31, 2020 presented below are preliminary and are subject to change based upon the completion
of our quarter-end and year-end closing procedures and further financial review. Our independent registered public accounting
firm has not audited, reviewed, compiled or performed any procedures with respect to this preliminary financial information. Our
actual results may differ from these estimates as a result of the completion of our quarter-end and year-end closing procedures,
review adjustments and other developments that may arise between now and the time our financial results for the fourth quarter
and year are finalized. Our financial statements for the fourth quarter and year ended December 31, 2020 will not be available
until after this offering is completed, and consequently will not be available to you prior to investing in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fourth quarter and full fiscal year ended December 31, 2020, our unaudited preliminary results are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
                                         revenue of approximately of $4.8 million for the three months ended December 31, 2020,
                                         compared to revenue of $3.4 million for the three months ended December 31, 2019, representing
                                         a 43% increase.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
                                         revenue of approximately $15.6 million for the year ended December 31, 2020, compared
                                         to revenue of approximately $11.8 million for the year ended December 31, 2019, a 32%
                                         increase from the prior year. The higher revenues in 2020 were primarily due to the continued
                                         execution of our strategy to expand our sales force and independent distribution network
                                         in both new and existing U.S. markets.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
                                         and cash equivalents were approximately $0.5 million as of December 31, 2020.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
of Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investment in our securities involves a high degree of risk. The occurrence of one or more of the events or circumstances described
in the section titled &ldquo;Risk Factors,&rdquo; alone or in combination with other events or circumstances, may materially adversely
affect our business, financial condition and operating results. In that event, the trading price of our securities could decline,
and you could lose all or part of your investment. Below is a summary of our risk factors. See &ldquo;Risk Factors&rdquo; for
additional details.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         COVID-19 pandemic in the United States has and may continue to negatively impact our
                                         business, financial condition and results of operations.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         have had a history of losses, which may continue as we expand our selling efforts.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         revenue growth for a particular period is difficult to predict, and a shortfall in forecast
                                         revenues may harm our operating results.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         current comprehensive wound and skin care strategy involves growth through acquisitions
                                         and investments, which requires us to incur substantial costs and potential liabilities
                                         for which we may never realize the anticipated benefits.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                         we cannot meet our future capital requirements, our business will suffer.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
                                         to retain and recruit key personnel would harm our ability to meet key objectives.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
                                         to manage our growth strategy could harm our business.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         operate in highly competitive markets and face competition from large, well-established
                                         medical device manufacturers and telehealth providers as well as new market entrants,
                                         and if we are unable to compete within our markets or our products and services do not
                                         gain market acceptance, our operating results and financial condition could suffer.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security
                                         breaches and other disruptions could compromise our information and expose us to liability,
                                         which would cause our business and reputation to suffer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                         we fail to maintain an effective system of internal controls over financial reporting,
                                         we may not be able to accurately report our financial results or prevent fraud and our
                                         business may be harmed and our stock price may be adversely impacted.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Loan Agreement governing our revolving line of credit includes restrictive terms, and
                                         our failure to comply with any of these terms could result in a default, which would
                                         have an adverse effect on our business.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         rely on our research and development partners to design, manufacture and supply the products
                                         we have licensed for marketing.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         future success will largely depend on our ability to maintain and further grow clinical
                                         acceptance and adoption of our products, and we may be unable to adequately educate healthcare
                                         practitioners on the use and benefits of our products.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
                                         could invent products superior to ours and cause our products and technologies to become
                                         obsolete.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruption
                                         of, or changes in, our distribution model or customer base could harm our sales and margins.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                         we are unable to manage product inventory in an effective manner, our profitability could
                                         be impaired.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
                                         of any third-party assessments to demonstrate desired outcomes in proposed endpoints
                                         may result in adverse regulatory actions, reduce physician usage or adoption of our products,
                                         or reduce the price, coverage and/or reimbursement for our products, which could have
                                         a negative impact on our business performance.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         may have exposure to product liability claims.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interruptions
                                         in the supply of our products or inventory loss may adversely affect our business, results
                                         of operations and financial condition.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         planned expansion into wound and skin care virtual consult and other services will require
                                         entrance into several markets in which we have little or no experience and is dependent
                                         on our relationships with affiliated professional entities to provide physician services.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
                                         and frequent state legislative and regulatory changes specific to telemedicine may present
                                         us with additional requirements and state compliance costs, with potential operational
                                         impacts in certain jurisdictions.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                         we are unable to adequately protect our intellectual property rights, we may not be able
                                         to compete effectively.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CellerateRX
                                         Surgical no longer has patent protection. Accordingly, CellerateRX Surgical may be subject
                                         to competition from the sale of substantially equivalent products that could adversely
                                         affect our business and operations.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         are heavily dependent on technologies and products we have licensed from third parties,
                                         and we may need to license technologies and products in the future, and if we fail to
                                         obtain licenses we need, or fail to comply with our payment obligations in the agreements
                                         under which we in-license intellectual property and other rights from third parties,
                                         we could lose our ability to develop and commercialize our products.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         may be found to infringe on intellectual property rights of others.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         business is affected by numerous regulations relating to the labeling, marketing and
                                         sale of our products.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delays
                                         in or changes to the FDA clearance and approval processes or ongoing regulatory requirements
                                         could make it more difficult for us to obtain FDA clearance or approval of new products
                                         or comply with ongoing requirements.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                         in reimbursement policies and regulations by governmental or other third-party payors
                                         may have an adverse impact on the use of our products.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         rely on our research and development partners to comply with applicable laws and regulations
                                         relating to product classification and FDA marketing authorization.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         and our employees and contractors are subject, directly or indirectly, to federal, state
                                         and foreign healthcare fraud and abuse laws, including false claims laws. If we are unable
                                         to comply, or have not fully complied, with such laws, we could face substantial penalties.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         or our research and development partners&rsquo; use and disclosure of personally identifiable
                                         information is subject to federal and state privacy and security regulations, and our
                                         failure to comply with those regulations or to adequately secure the information we hold
                                         could result in significant liability or reputational harm and, in turn, a material adverse
                                         effect on our client base, business, financial condition and results of operations.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                         we fail to comply with extensive healthcare laws and government regulations, we could
                                         suffer penalties or be required to make significant changes to our operations.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         officers, employees, independent contractors, principal investigators and commercial
                                         partners may engage in activities that are improper under other laws and regulations,
                                         which would create liability for us.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         could be adversely affected if healthcare reform measures substantially change the market
                                         for medical care or healthcare coverage in the United States.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defects,
                                         failures or quality issues associated with our products could lead to product recalls
                                         or safety alerts, adverse regulatory actions, litigation and negative publicity that
                                         could materially adversely affect our reputation, business, results of operations and
                                         financial condition.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
                                         may experience immediate and substantial dilution.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
                                         will have broad discretion as to the use of the net proceeds from this offering, and
                                         we may not use these proceeds effectively.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                         is possible that we will require additional capital to meet our financial obligations
                                         and support business growth, and this capital might not be available on acceptable terms
                                         or at all; new investors face possible future dilution.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         trading price of the shares of our common stock is highly volatile, and purchasers of
                                         our common stock could incur substantial losses.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         common stock does not have a vigorous trading market, and you may not be able to sell
                                         your securities at or near ask prices, or at all.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         potential sale of large amounts of common stock may have a negative effect upon the market
                                         value of our shares.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                         few of our existing shareholders own a large percentage of our voting stock and have
                                         control over matters requiring shareholder approval and may delay or prevent a change
                                         in control or otherwise lead to actual or potential conflicts of interest.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         Certificate of Formation includes provisions limiting the personal liability of our directors
                                         for breaches of fiduciary duties under Texas law.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Texas
                                         law and our Certificate of Formation and bylaws contain anti-takeover provisions that
                                         could delay or discourage takeover attempts that shareholders may consider favorable.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         failure to meet the continued listing requirements of The Nasdaq Capital Market could
                                         result in a delisting of our common stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in Texas on December 14, 2001. On March 15, 2019, we entered into a Share Exchange Agreement with CGI Cellerate
RX, an affiliate of Catalyst, pursuant to which we acquired Catalyst&rsquo;s 50% equity interest in Cellerate, LLC (&ldquo;Cellerate&rdquo;)
in exchange for 1,136,815 shares of our newly created Series F Convertible Preferred Stock (the &ldquo;Cellerate Acquisition&rdquo;).
Prior to the consummation of the Cellerate Acquisition, we and Catalyst each owned a 50% equity interest in Cellerate. The Cellerate
Acquisition was accounted for as a reverse merger, and Cellerate was deemed to be the accounting acquirer. In May 2019, we changed
our name to Sanara MedTech Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 1200 Summit Ave, Suite 414, Fort Worth, Texas 76102, telephone number (817) 529-2300.
Our website address is <I>www.sanaramedtech.com</I>. Information accessed through our website is not incorporated into this prospectus
supplement and is not a part of this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    stock offered by us</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,100,000
    shares</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    stock to be outstanding immediately after this offering</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,379,610
                                                         shares. If the underwriters&rsquo; option to purchase additional shares of common stock is exercised in full, the total
                                                         number of shares of common stock outstanding immediately after this offering will
                                                         be 7,544,610.</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option
    to purchase additional shares of common stock</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have granted the underwriters a 30-day option to purchase up to an additional 165,000 shares
    of common stock at the public offering price, less underwriting discounts and commissions. Unless we indicate otherwise or
    the context otherwise requires, all information in this prospectus supplement assumes no exercise of the underwriters&rsquo;
    option to purchase additional shares of common stock.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
    of proceeds</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently intend to use the net proceeds we receive from this offering to expand our salesforce and for further development
    of our products, services and technologies pipeline, clinical studies, a $600,000 investment in Precision Healing that is
    required to be made in February 2021 and general corporate purposes, including working capital. In addition, pursuant to our
    product license agreement with Rochal, dated July 7, 2019, we are required to pay Rochal $750,000, which, at our option, may
    be paid in cash or shares of our common stock, or a combination of cash and shares of our common stock (the &ldquo;Capital
    Raise Payment&rdquo;), if we sell shares of our common stock for gross proceeds in the amount of at least $10 million on or
    prior to December 31, 2022. Accordingly, we may use a portion of the proceeds from this offering to pay Rochal the Capital
    Raise Payment pursuant to the product license agreement. See the section entitled &ldquo;Use of Proceeds&rdquo; beginning on
    page S-42 of this prospectus supplement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividend
    policy</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any
    future earnings for use in the operation of our business and do not anticipate paying any cash dividends in the foreseeable
    future. See &ldquo;Dividend Policy&rdquo; beginning on page S-43 of this prospectus supplement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
    factors</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
    in our common stock involves a high degree of risk. See the section entitled &ldquo;Risk Factors&rdquo; beginning on page
    S-14 of this prospectus supplement and page 4 of the accompanying prospectus and the other information included elsewhere,
    or incorporated by reference, in this prospectus supplement and the accompanying prospectus for a discussion of factors you
    should carefully consider before deciding to invest in our common stock.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
    Nasdaq Capital Market Symbol</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;SMTI&rdquo;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock to be outstanding immediately after this offering is based on 6,279,610 outstanding shares of
common stock as of September 30, 2020 and excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,500
                                         shares of common stock issuable upon the exercise of outstanding stock options at a weighted
                                         average exercise price of $6.00 per share as of September 30, 2020;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">1,769,122
                                         shares of common stock reserved for future issuance under the Sanara MedTech Inc.
                                         Restated 2014 Omnibus Long-Term Incentive Plan (the &ldquo;2014 Plan&rdquo;) as of September
                                         30, 2020; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,536
                                         shares of common stock issued in January 2021 pursuant to an equity exchange agreement
                                         whereby we acquired all of the issued and outstanding equity interests of WounDerm;
                                         and</FONT></TD></TR>                                                                                                                                                                                                   <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&#9679;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">30,000 shares of common stock that we may issue to Rochal upon the
completion of this offering for purposes of the Capital Raise Payment.</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, except as otherwise indicated, all information in this prospectus supplement assumes no exercise by the underwriters
of their option to purchase 165,000 additional shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_003"></A>SUMMARY
HISTORICAL CONSOLIDATED FINANCIAL INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our summary consolidated historical financial data for the periods presented below. The summary consolidated
financial data as of December 31, 2019 and 2018 and for each of the years in the two-year period ended December 31, 2019 have
been derived from our audited consolidated financial statements and related notes incorporated by reference in this prospectus
supplement and the accompanying prospectus. The summary unaudited condensed consolidated financial data as of September 30, 2020
and 2019 and for the nine-month periods ended September 30, 2020 and 2019 have been derived from our unaudited condensed consolidated
financial statements and related notes incorporated by reference in this prospectus supplement and the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
historical results are not necessarily indicative of the results of operations for future periods. You should read the following
summary historical consolidated financial data in conjunction with the section entitled &ldquo;Management&rsquo;s Discussion and
Analysis of Financial Condition and Results of Operations&rdquo; and our consolidated financial statements and related notes incorporated
by reference in this prospectus supplement and the accompanying prospectus, as well as our latest Annual Report on Form 10-K and
Quarterly Report on Form 10-Q, incorporated by reference herein. See &ldquo;Where You Can Find More Information.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">Successor
    (1)</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">Predecessor
    (1)</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">Nine
    Months Ended<BR>
(Unaudited)</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">January
    1, 2019<BR>
    &ndash; December 31,<BR>
    2019</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">August
    28, 2018<BR>
    &ndash; December 31,<BR>
    2018</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">January
    1, 2018 <BR>
    &ndash; August 27,<BR>
    2018</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font: 7pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0 2.15pt 0 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>September
                                         30,</B></FONT></P> <P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0 2.15pt 0 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>2020</B></FONT></P></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font: 7pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0 2.15pt 0 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>September
                                         30,</B></FONT></P> <P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0 2.15pt 0 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>2019</B></FONT></P></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"><FONT STYLE="font-size: 8pt">Statements
    of Operations Data:</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-size: 8pt">Revenues</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">11,766,763</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">3,006,320</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">5,773,552</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">10,797,838</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">8,413,667</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Costs of goods sold</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">1,209,300</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">371,421</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">480,703</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">1,126,798</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">909,333</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Gross profit</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">10,557,463</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">2,634,899</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">5,292,849</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">9,671,040</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">7,504,334</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Operating expenses:</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Selling, general and administrative
    expenses</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">13,067,569</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">2,519,469</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">5,126,650</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">13,613,989</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">8,649,186</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Depreciation and amortization</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">119,951</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">511</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">56,425</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">209,606</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">72,644</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Bad debt expense</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">110,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">12,558</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">30,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">60,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Total operating expenses</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">13,297,520</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">2,519,980</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">5,195,633</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">13,853,595</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">8,781,830</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Operating income (loss)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(2,740,057</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">114,919</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">97,216</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(4,182,555</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(1,277,496</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Other income / (expense)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(95,721</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">23,367</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(60,038</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">3,863</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(80,780</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Net income (loss)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(2,835,778</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">138,286</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">37,178</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(4,178,692</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(1,358,276</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Less: Net loss attributable
    to noncontrolling interests</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(21,690</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(68,745</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(7,311</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Net income (loss) attributable
    to Sanara MedTech Inc.</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(2,814,088</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">138,286</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">37,178</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(4,109,947</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(1,350,965</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Series C Preferred Stock
    dividends</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(28,061</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Series C Preferred Stock
    inducement dividends</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(103,197</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Net income (loss) attributable
    to Sanara MedTech common shareholders</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(2,814,088</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">138,286</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(94,080</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(4,109,947</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(1,350,965</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Balance Sheet Data
    (at end of period):</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Cash and cash equivalents</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">6,611,928</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">176,421</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">2,120,243</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">160,711</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Total assets</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">11,117,162</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">1,709,458</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">9,651,658</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">4,313,022</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Total shareholders&rsquo;
    equity (deficit)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">6,392,400</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">586,797</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">5,563,344</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(1,930,103</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">Successor
    (1)</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">Predecessor
    (1)</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">Nine
    Months Ended<BR> (Unaudited)</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">January
    1, 2019<BR> &ndash; December 31,<BR> 2019</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">August
    28, 2018<BR> &ndash; December 31,<BR> 2018</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 8pt">January
    1, 2018 <BR> &ndash; August 27,<BR> 2018</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font: 7pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0 2.15pt 0 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>September
                                         30,</B></FONT></P> <P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>2020</B></FONT></P></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font: 7pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0 2.15pt 0 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>September
                                         30,</B></FONT></P> <P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>2019</B></FONT></P></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Cash Flow Data:</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 35%; text-align: left"><FONT STYLE="font-size: 8pt">Net cash flows
    provided by (used in) operating activities</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">(2,167,401</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">195,709</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">321,370</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">(3,443,449</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">(1,333,878</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Net cash flows provided
    by (used in) investing activities</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(1,197,097</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(19,288</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(8,482</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(1,657,456</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">(681,832</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">Net cash flows from financing
    activities</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">9,800,005</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">609,220</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 8pt">2,000,000</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Effective August 28, 2018, the Company consummated definitive agreements that continued operations to market the Company&rsquo;s
principal product, CellerateRX, through a 50% ownership interest in a newly formed entity, Cellerate, which began operations on
September 1, 2018. The remaining 50% ownership interest was held by an affiliate of Catalyst, which acquired the exclusive license
to CellerateRX products. Cellerate conducted operations with an exclusive sublicense from the Catalyst affiliate to distribute
CellerateRX products in the United States, Canada and Mexico (which sublicense was subsequently amended to include worldwide distribution
rights). In connection with the formation of Cellerate, the Company issued a convertible promissory note to an affiliate of Catalyst
in the original principal amount of $1.5 million, which was convertible into shares of the Company&rsquo;s common stock at a conversion
price of $9.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2019, the Company acquired Catalyst&rsquo;s 50% interest in Cellerate in exchange for the issuance of 1,136,815 shares
of the Company&rsquo;s newly created Series F Convertible Preferred Stock. Each share of Series F Convertible Preferred Stock
was convertible at the option of the holder, at any time, into two shares of common stock. Additionally, each holder of Series
F Convertible Preferred Stock was entitled to vote on all matters submitted for a vote of the Company&rsquo;s shareholders with
votes equal to the number of shares of common stock into which such holder&rsquo;s shares of Series F Convertible Preferred Stock
could then be converted. Following the closing of the Cellerate Acquisition, Mr. Ronald T. Nixon, Founder and Managing Partner
of Catalyst, was elected to the Company&rsquo;s board of directors, effective March 15, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Cellerate Acquisition was accounted for as a reverse merger and recapitalization because, immediately following the completion
of the transaction, Catalyst could obtain effective control of the Company upon conversion of its convertible preferred stock
and convertible promissory note, both of which could occur at Catalyst&rsquo;s option. Additionally, Cellerate&rsquo;s officers
and senior executive positions continued on as management of the combined entity after consummation of the Cellerate Acquisition.
For accounting purposes, Cellerate was deemed to be the acquirer in the transaction and, consequently, the Cellerate Acquisition
was treated as a recapitalization of Sanara MedTech. As part of the reverse merger and recapitalization, the net liabilities existing
in the Company as of the date of the Cellerate Acquisition totaling approximately $1,666,537, which included $508,973 of cash,
were converted to equity as part of the Cellerate Acquisition. No step-up in basis or intangible assets or goodwill was recorded
in this transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the reverse merger, Cellerate&rsquo;s assets, liabilities and results of operations are the historical financial statements
of the registrant, and Cellerate&rsquo;s assets, liabilities and results of operations have been combined with Sanara MedTech
effective as of the date of the closing of the Cellerate Acquisition. This summary consolidated financial data identifies Cellerate
as &ldquo;Successor&rdquo; for the twelve-month period ended December 31, 2019, and on the balance sheet date of December 31,
2018. Upon its formation on August 28, 2018, Cellerate succeeded to the business and operations of Sanara MedTech. As a result,
Sanara MedTech is identified as &ldquo;Predecessor&rdquo; for the periods preceding August 28, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_004"></A>RISK
FACTORS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other
information in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and
therein, before deciding whether to invest in our common stock. You should also consider the risks, uncertainties and assumptions
discussed under the heading &ldquo;Risk Factors&rdquo; included in our most recent annual report on Form 10-K and the subsequent
quarterly reports on Form 10-Q and other reports that we file with the SEC and that are incorporated herein by reference, and
which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. If any
of the following risks actually occur, our business, results of operations and financial condition could be materially adversely
affected. In this case, the trading price of our common stock would likely decline, and you might lose part or all your investment
in our common stock. The risks and uncertainties described below are not the only ones facing us. Additional risks and uncertainties
not presently known to us, or that we currently see as immaterial, may also harm our business. Please also read carefully the
section below entitled &ldquo;Cautionary Statement Regarding Forward-Looking Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to How We Operate Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
COVID-19 pandemic in the United States has and may continue to negatively impact our business, financial condition and results
of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic is ongoing in the United States and most of the world. On January 30, 2020 the World Health Organization declared
a global emergency, and since that time governments have instituted measures to attempt to contain spread of the virus, including
temporary limitations on non-essential business activities and elective surgical procedures in hospitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
majority of our revenue is currently generated from the sale of products in connection with surgical procedures, and a significant
portion of those sales are to hospitals. Beginning in March 2020, many states issued orders suspending elective surgeries in order
to free-up hospital resources to treat COVID-19 patients. This resulted in a reduction in demand for our surgical products beginning in the second half of March 2020. Additionally, most states limited access to SNFs to only resident caregivers, which
impeded our ability to provide education and product training to the clinicians who use our products in these facilities. These
restrictions resulted in an overall decline in sales for the second quarter of 2020. During the third quarter of 2020, we saw
a strong rebound in product sales as restrictions on elective surgeries eased in our primary markets in Texas, Florida, and the
southeastern United States. However, with certain states recently experiencing a spike in COVID-19 cases and consequently reinstating
recently relaxed restrictions, we may again experience swings in monthly sales if surgeries are postponed and subsequently rescheduled.
For example, Texas Governor Greg Abbott has issued a standing executive order requiring that hospitals in any Trauma Service Area
(as defined in the executive order) that has had seven consecutive days in which the number of COVID-19 hospitalized patients
as a percentage of total hospital capacity exceeds 15 percent postpone all surgeries and procedures that are not medically necessary
to diagnose or correct a serious medical condition of, or to preserve the life of, a patient, until such time as the Trauma Service
Area reaches seven consecutive days in which the number of COVID-19 hospitalized patients as a percentage of total hospital capacity
is 15 percent or less.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extent to which these events impact our business will depend on future developments regarding the rate of infection of the virus
and the further or lessening of current or new restrictions put in place to contain the pandemic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have had a history of losses, which may continue as we expand our selling efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred net losses in most years since we began our current operations in 2004. We plan to continue making significant investments
in our sales force and clinical programs, which substantially increase our operating expenses. Consequently, we will need to continue
our revenue growth to become profitable in future periods. We cannot offer any assurance that we will be able to generate future
sales growth. If we fail to achieve profitability, our stock price may decline, and you may lose part or all of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
revenue growth for a particular period is difficult to predict, and a shortfall in forecast revenues may harm our operating results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are a relatively small company, our revenue growth and, consequently, results of operations are difficult to predict. We plan
our operating expense levels based primarily on forecasted revenue levels. A shortfall in revenue could lead to operating results
being below expectations as we may not be able to quickly reduce our fixed expenses in response to short-term revenue shortfalls.
We have experienced fluctuations in revenue and operating results from quarter to quarter and anticipate that these fluctuations
will continue until we achieve a critical mass with our product and service sales. These fluctuations can result from a variety
of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic
                                         conditions worldwide, as well as economic conditions specific to the healthcare industry,
                                         which could affect the ability of surgical and post-acute facilities to purchase our
                                         products and could result in a reduction in elective operative procedures;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">governmental
                                         regulations, including those adopted in response to the COVID-19 pandemic;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         uncertainty surrounding our ability to attract new customers and retain existing customers;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in reimbursement rates for our products by government and private insurers;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         length and variability of our sales cycle, especially gaining approvals for the use of
                                         our products in additional hospitals and surgery centers, which makes it difficult to
                                         forecast the quarter in which our sales will occur;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issues
                                         including delays in the sourcing of our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         timing of regulatory approvals;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         timing of operating expense relating to the expansion of our business and operations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in the pricing of our products and those of our competitors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         development of new wound care products or product enhancements by our competitors; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
                                         events, circumstances, outcomes and amounts differing from assumptions and estimates
                                         used in preparing our operating plan and how well we execute our strategy and operating
                                         plans.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a consequence, operating results for a particular future period are difficult to predict and prior results are not necessarily
indicative of future results. Any of the foregoing factors, or any other factors discussed elsewhere herein, could have a material
adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
current comprehensive wound and skin care strategy involves growth through acquisitions and investments, which requires us to
incur substantial costs and potential liabilities for which we may never realize the anticipated benefits.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to internally generated growth, our current strategy to expand into wound and skin care virtual consult and other services
involves growth through acquisitions and investments. Between January 1, 2020 and December 31, 2020, we have made minority shareholder
investments in two businesses at a total cost of approximately $1.1 million, and as of January 31, 2021, we were committed to
invest an additional $0.6 million in such businesses. In addition, in January 2021 we acquired WounDerm for aggregate consideration
of 29,536 shares of our common stock. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to continue implementing our growth strategy, and our strategy ultimately may be unsuccessful. We engage in evaluations
of potential acquisitions and investments and are in various stages of discussion regarding possible acquisitions, certain of
which, if consummated, could be significant to us. Any new acquisition or investment could result in material transaction expenses,
increased interest and amortization expense, increased depreciation expense and increased operating expense, any of which could
have a material adverse effect on our operating results. In addition, if we are unable to integrate businesses and operations
that we acquire in the future, our profitability could suffer. These acquisitions and investments also involve other risks, including
diversion of management resources otherwise available for the running of our business and the development of our business as well
as risks associated with entering markets in which our marketing teams and sales force has limited experience or where experienced
distribution alliances are not available. We may not be able to identify suitable acquisition or investment candidates in the
future, obtain acceptable financing or consummate any future acquisitions or investments. In addition, certain potential acquisitions
may be subject to antitrust and competition laws, which could impact our ability to pursue strategic acquisitions and could result
in mandated divestitures. If we are unsuccessful in our current strategy to expand into wound and skin care virtual consult and
other services, we may be unable to meet our financial targets and our financial performance could be materially and adversely
affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we cannot meet our future capital requirements, our business will suffer.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a history of operating losses and negative cash flow from operating activities, and future results of operations involve
significant risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially
from expectations include, but are not limited to, demand for our products and services, new product and service offerings from
competitors, regulatory approval of our new products, technological change, and dependence on key personnel. Although we have
taken steps to improve our overall liquidity, if our cash flow is insufficient, we may be forced to seek additional debt or equity
financing in order to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fund
                                         operating losses;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
                                         marketing to address the market for surgical, wound and skin care products and services;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">take
                                         advantage of opportunities, including more rapid expansion or acquisitions of complementary
                                         products or businesses;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire,
                                         train and retain employees;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
                                         and/or distribute new products; and/or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">respond
                                         to economic and competitive pressures.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our capital needs are met through the issuance of equity or convertible debt securities, the percentage ownership of our current
shareholders may be reduced which may have a negative impact on the market price of our common stock. Our future success may be
determined in large part by our ability to obtain additional financing, and the incurrence of indebtedness would result in increased
debt service obligations which could result in operating and financing covenants that would restrict our operations. There can
be no assurance that such financing would be available or, if available, that such financing could be obtained upon terms acceptable
to us. If adequate funds are not available, or are not available on acceptable terms, our operating results and financial condition
may suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to retain and recruit key personnel would harm our ability to meet key objectives.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends, in large part, on our ability to attract and retain skilled executive, managerial, sales and marketing personnel.
We compete for such personnel with other companies, some of which have greater financial resources than we do to recruit and retain
personnel. There can be no assurance that we will be able to find and attract additional qualified employees or retain any such
executive officers and other key personnel. The inability to hire qualified personnel or the loss of services of our executive
officers or key personnel may have a material adverse effect on our business. Further, any inability on our part to enforce non-compete
arrangements related to key personnel who have left our company or may leave our company in the future could have a material adverse
effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to manage our growth strategy could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to successfully implement our business plan and market and sell our surgical, wound and skin care products and services
requires an effective plan for managing our future growth. We plan to increase the scope of our operations at a rapid rate. Future
expansion efforts will be expensive and may strain our internal operating resources. To manage future growth effectively, we must
maintain and enhance our financial and accounting systems and controls, integrate new personnel and manage expanded operations.
If we do not manage growth properly, it could harm our operating results and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
operate in highly competitive markets and face competition from large, well-established medical device manufacturers and telehealth
providers as well as new market entrants, and if we are unable to compete within our markets or our products and services do not
gain market acceptance, our operating results and financial condition could suffer.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competition
from other medical device companies is significant and could be significantly affected by new product introductions and other
activities of market participants. We compete with other companies in acquiring rights to products or technologies from third-party
developers. Although our products have performed well in customer evaluations, we are a relatively unknown brand in a market dominated
by companies with extensive product lines and large customer bases. We may not, even with more efficacious products, be able to
secure contracts and achieve significant growth with large national accounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if we launch our wound and skin care virtual consult and other service offerings, we will face competition from other
telehealth providers. The public health emergency caused by the COVID-19 pandemic has led to the widespread adoption of telemedicine
for most health care clinical specialties, including wound care and dermatology. As such, any clinical wound care or dermatology
physician and/or provider group that has incorporated telemedicine into their practice could be considered competitive. If we
are unable to compete with other telehealth providers, our operating results and financial condition may suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
factors may limit the market acceptance of our products and services, including the timing of regulatory approvals and market
entry relative to competitive products and services, the availability of alternative products and services, the price of our products
and services relative to alternative products and services, the availability of third-party reimbursement and the extent of marketing
efforts by third-party distributors or agents that we retain. There can be no assurance that our products or services will receive
market acceptance in a commercially viable period of time, if at all. Furthermore, there can be no assurance that we can develop
products and services that are more effective or achieve greater market acceptance than competitive products and services, or
that our competitors will not succeed in developing or acquiring products and technologies that are more effective than those
being developed by us, that would render our products and technologies less competitive or obsolete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors enjoy several competitive advantages over us, including but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">large
                                         and established distribution networks in the U.S. and/or in international markets;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
                                         financial, managerial and other resources for products research and development, sales
                                         and marketing efforts and protecting and enforcing intellectual property rights;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
                                         name recognition;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">larger
                                         consumer bases;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">more
                                         expansive portfolios of products and intellectual property rights; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
                                         experience in obtaining and maintaining regulatory approvals and/or clearances from the
                                         FDA and other regulatory agencies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
presence of competition in our market may lead to pricing pressure which would make it more difficult to sell our products and
services at a profitable price or may prevent us from selling our products at all. Our failure to compete effectively would have
a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Security
breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and
reputation to suffer.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we use networks to collect and store sensitive data, including intellectual property, proprietary
business information and important information of our customers, suppliers and business partners, as well as personally identifiable
information of our customers and employees. The secure processing, maintenance and transmission of this information is critical
to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by
hackers or breached due to employee error, malfeasance or other disruptions. Any such breach could compromise our networks and
the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss
of information could result in the loss of existing customers, difficulty in attracting new customers, backlash from negative
public relations, legal claims or proceedings, liability under laws that protect the privacy of personal information, and regulatory
penalties. Further, such access, disclosure or loss may cause disruption of our operations and the services we provide to customers,
damage to our reputation, and cause a loss of confidence in our products and services, which could adversely affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have programs, processes and technologies in place to prevent, detect, contain, respond to and mitigate security related threats
and potential incidents. We undertake considerable ongoing improvements to our systems, connected devices and information-sharing
products in order to minimize vulnerabilities, in accordance with industry and regulatory standards. Because the techniques used
to obtain unauthorized access change frequently and can be difficult to detect, anticipating, identifying or preventing these
intrusions or mitigating them if and when they occur, may be challenging.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report
our financial results or prevent fraud and our business may be harmed and our stock price may be adversely impacted.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
internal controls over financial reporting are necessary for us to provide reliable financial reports and to effectively prevent
fraud. Any inability to provide reliable financial reports or to prevent fraud could harm our business. The Sarbanes-Oxley Act
of 2002 (the &ldquo;Sarbanes-Oxley Act&rdquo;) requires management to evaluate and assess the effectiveness of our internal control
over financial reporting. In order to comply with the requirements of the Sarbanes-Oxley Act, we are required to continuously
evaluate and, where appropriate, enhance our policies, procedures and internal controls. If we fail to maintain the adequacy of
our internal controls over financial reporting, we could be subject to litigation or regulatory scrutiny and investors could lose
confidence in the accuracy and completeness of our financial reports. We cannot provide any assurance that in the future we will
be able to fully comply with the requirements of the Sarbanes-Oxley Act or that management will conclude that our internal control
over financial reporting is effective. If we fail to fully comply with the requirements of the Sarbanes-Oxley Act, our business
may be harmed and our stock price may decline. In addition, because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
assessment, testing and evaluation of the design and operating effectiveness of our internal control over financial reporting
resulted in our conclusion that as of December 31, 2019, our internal control over financial reporting was not effective, due
to our small size and limited segregation of duties. As a result of such determination, we implemented additional controls, including
the hiring of an additional full-time accounting professional in January 2020, which enabled us to properly segregate duties,
and concluded that the material weakness was remediated as of June 30, 2020. While we have concluded that the material weakness
has been remediated, projections of any evaluation of the effectiveness of internal control over financial reporting for future
periods are subject to the risk that controls may become inadequate because of changes in conditions or if the degree of compliance
with the policies or procedures deteriorate over time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Loan Agreement governing our revolving line of credit includes restrictive terms, and our failure to comply with any of these
terms could result in a default, which would have an adverse effect on our business and prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement governing our revolving line of credit requires us to maintain compliance with certain financial covenants, including,
among others, a minimum liquidity of $1.0 million as of December 31, 2020 and March 31, 2021, a minimum Tangible Net Worth (as
defined in the Loan Agreement) of $1.0 million and, beginning with the fiscal quarter ending June 30, 2021, a minimum Interest
Coverage Ratio (as defined in the Loan Agreement) of 1.5 to 1.0. In addition, the Loan Agreement requires us to cause our shareholders
or other persons approved by Cadence to make an equity investment in the Company of at least $7.5 million by March 31, 2021. A
breach of these covenants could result in a default under the Loan Agreement. If amounts owed under the Loan Agreement are accelerated
because of a default and we are unable to pay such amounts, Cadence may have the right to assume control of substantially all
of our assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to refinance or repay amounts that we borrow under our revolving line of credit prior to its maturity date, our
cash flow would be directed to the repayment of our debt and would not be available for operating our business. No assurance can
be given that any refinancing or additional financing will be possible when needed or that we will be able to negotiate acceptable
terms. In addition, our access to capital is affected by prevailing conditions in the financial and capital markets and other
factors beyond our control. There can be no assurance that market conditions will be favorable at the times that we require new
or additional financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Products</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely on our research and development partners to design, manufacture and supply the products we have licensed for marketing. If
one of our partners fails to perform adequately or fulfill our needs, we may be required to incur significant costs. We may also
face significant delays in our product introductions and commercialization.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently own any facility that may be used as a manufacturing and processing facility, and we rely on our research and
development partners, from whom we license all of the products we currently commercialize, to design, manufacture and supply such
products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development partners responsible for manufacturing our products and their contract manufacturers are obliged to operate
in accordance with FDA&rsquo;s current good manufacturing practices (&ldquo;cGMP&rdquo;), current good tissue practices (&ldquo;cGTP&rdquo;),
and the Quality System Regulation (&ldquo;QSR&rdquo;), as applicable, as well as other regulations applicable to medical product
manufacturers. The manufacture of regulated medical products in compliance with cGMP, cGTP, and the QSR, as applicable, requires
significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls.
Manufacturers of medical products often encounter difficulties in production, including difficulties with production costs and
yields, quality control, including product stability and quality assurance testing, shortages of qualified personnel, as well
as compliance with strictly enforced regulatory requirements, other federal and state regulatory requirements and foreign regulations.
If our research and development partners or their contract manufacturers were to encounter any of these difficulties or otherwise
fail to comply with their obligations to us or under applicable regulations, our ability to commercialize our products would be
jeopardized. Any delay or interruption in the supply of products could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturers of our products may be unable to comply with applicable FDA, state and foreign regulatory requirements. The FDA
or similar foreign regulatory agencies may also implement new standards at any time, or change their interpretation and enforcement
of existing standards for manufacture, packaging or testing of regulated products. We have little control over the manufacturers&rsquo;
compliance with these regulations and standards. A failure of any of our current or future research and development partners or
their contract manufacturers to establish and follow cGMP, cCTP, and the QSR, as applicable, and to document their adherence to
such practices may lead to significant delays in obtaining marketing authorization of future products or the ultimate launch of
products. Failure by our current or future partners or manufacturers or us to comply with applicable regulations could also result
in sanctions being imposed on us or our partners, including fines, injunctions, civil penalties, failure of the government to
grant marketing authorization, delays, suspension or withdrawal of authorization, seizures or recalls of products, operating restrictions,
and criminal prosecutions. If the safety of any product supplied is compromised due to the manufacturers&rsquo; failure to adhere
to applicable laws or for other reasons, we may not be able to successfully commercialize our products. Any of these factors could
cause a delay of commercialization of our products, entail higher costs or impair our reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
future success will largely depend on our ability to maintain and further grow clinical acceptance and adoption of our products,
and we may be unable to adequately educate healthcare practitioners on the use and benefits of our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
practitioners play a significant role in determining the course of a patient&rsquo;s treatment and, ultimately, the type of products,
if any, that will be used to treat the patient. As a result, our commercial success is heavily dependent on our ability to educate
practitioners on the use of our products in both surgical and post-acute care settings. Acceptance and adoption of our products
in our markets depends on educating healthcare practitioners as to the distinctive characteristics, benefits, safety, clinical
efficacy and cost-effectiveness of our products, including potential comparisons to our competitors&rsquo; products, and on training
healthcare practitioners in the proper application of our products. If we are not successful in convincing healthcare practitioners
of the merits and advantages of our products compared to our competitors&rsquo; products, they may not use our products and we
will be unable to increase our sales and sustain growth or profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convincing
healthcare practitioners to dedicate the time and energy necessary to properly train to use new products and techniques is challenging,
and we may not be successful in these efforts. In particular, as healthcare resources are strained due to the ongoing COVID-19
pandemic, it may be more difficult to convince healthcare practitioners to commit their time and resources to learning to use
a new product. If healthcare practitioners are not properly trained, they may use our products ineffectively, resulting in unsatisfactory
patient outcomes, negative publicity or lawsuits against us. Accordingly, even if our products show superior benefits, safety
or efficacy, based on head-to-head clinical trials, in comparison to alternative treatments, our success will depend on our ability
to gain and maintain market acceptance for our products. If we fail to do so, our sales will not grow and our business, financial
condition and results of operations will be adversely affected. We may not have adequate resources to effectively educate the
medical community and our efforts may not be successful due to physician resistance or negative perceptions regarding our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
practitioners may be hesitant to change their medical treatment practices for the following reasons, among others:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
                                         or perceived lack of evidence supporting greater efficacy versus standard of care;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived
                                         liability risks generally associated with the use of new products and procedures;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
                                         or lack of availability of coverage and reimbursement within healthcare payment systems;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">existing
                                         sole-source supply contracts with purchasing entities, such as hospital systems and group
                                         purchasing organizations, that do not use our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pressure
                                         to contain costs and use lower cost alternatives to our products; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         time commitment that may be required for training to use new products or technologies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Competitors
could invent products superior to ours and cause our products and technologies to become obsolete.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
wound care sector of the medical products industry is characterized by a multitude of technologies and intense competition. Our
competitors currently manufacture and distribute a variety of products that are, in many respects, comparable to our products.
Many suppliers of competing products are considerably larger and have much greater resources than we have. In addition, many specialized
products companies have formed collaborations with large, established companies to support research, development and commercialization
of wound care products which may be competitive with ours. Academic institutions, government agencies and other public and private
research organizations are also conducting research activities and may commercialize wound care products on their own or through
joint ventures. It is possible that these competitors may develop technologies and products that are more effective than any we
currently have. If this occurs, any of our products and technology affected by these developments could become obsolete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Disruption
of, or changes in, our distribution model or customer base could harm our sales and margins.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to manage the distribution of our products properly, or if the financial condition or operations of our reseller channels
weaken, there may be a material adverse effect on our business. Furthermore, a change in the mix of our customers between service
provider and enterprise, or a change in the mix of direct and indirect sales, could adversely affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
factors could also result in disruption of or changes in our distribution model or customer base, which could harm our sales and
margins, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                         some instances, we compete with some of our resellers through our direct sales, which
                                         may lead these channel partners to use other suppliers that do not compete; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">some
                                         of our resellers may have insufficient financial resources and may not be able to withstand
                                         changes in business conditions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to manage product inventory in an effective and efficient manner, our profitability could be impaired.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
factors affect the efficient use and planning of product inventory, such as effectiveness of predicting demand, effectiveness
of preparing manufacturing to meet demand, efficiently meeting product mix and product demand requirements and product expiration.
Our products have a shelf life of between 18 months and three years. If we are unable to manage our product inventory efficiently
or within expected budget goals, or keep sufficient finished and in-process product on hand to meet demand, our operating margins
and long term growth prospects could be impaired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
place orders with our suppliers based on forecasts of demand and, in some instances, may acquire additional inventory to accommodate
anticipated demand. Our forecasts are based on management&rsquo;s judgment and assumptions, each of which may introduce error
into our estimates. If we overestimate customer demand, our excess or obsolete inventory may increase significantly, which would
reduce our gross margin and adversely affect our financial results. Conversely, if we underestimate customer demand or if insufficient
manufacturing capacity is available, we would miss revenue opportunities and potentially lose market share and damage our customer
relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
of any third-party assessments to demonstrate desired outcomes in proposed endpoints may result in adverse regulatory actions,
reduce physician usage or adoption of our products, or reduce the price, coverage and/or reimbursement for our products, which
could have a negative impact on our business performance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
collaborators regularly conduct clinical studies designed to test a variety of endpoints associated with product performance and
use across a number of applications. If a clinical study conducted by our collaborators fails to demonstrate statistically significant
results supporting performance, use benefits or compelling health economic outcomes from using our products, physicians may elect
not to use our products as a treatment for conditions that may benefit from them. Furthermore, in the event of an adverse clinical
study outcome, our products may not achieve &ldquo;standard-of-care&rdquo; designations, where they exist, for the conditions
in question, which could deter the adoption of our products. Also, if serious adverse events are reported during the conduct of
a study, it could affect continuation of the study, product marketing authorization by regulatory authorities and product adoption
by healthcare professionals or could cause regulatory authorities to impose other restrictions on the product or require additional
warning or precaution statements to appear on the product labeling. If our collaborators are unable to develop a body of statistically
significant evidence from our clinical studies, whether due to adverse results or the inability to complete properly designed
studies, public and private payors could refuse to cover our products, limit the manner in which they cover our products, or reduce
the price they are willing to pay or reimburse for our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may have exposure to product liability claims.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we have contractual indemnity from the manufacturers of our current products for certain liability claims related to their production,
we could face a product liability claim outside of the scope of the contractual indemnities. We do not have, and do not anticipate
obtaining, contractual indemnification from parties supplying raw materials or parties marketing the products we sell. In any
event, indemnification from the manufacturers of our products or from any other party is limited by the terms of the indemnity
and by the creditworthiness of the indemnifying party. A successful product liability claim or series of claims brought against
us could result in judgments, fines, damages and liabilities that could have a material adverse effect on our business. We may
incur significant expense investigating and defending these claims, even if they do not result in liability. Moreover, even if
no judgments, fines, damages or liabilities are imposed on us, our reputation could suffer as result of a product liability claim,
which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
liability insurance for the healthcare industry may become prohibitively expensive, to the extent it is available at all. We may
not be able to maintain such insurance on acceptable terms or be able to secure increased coverage as commercialization of our
products progresses, nor can we be sure that existing or future claims against us will be covered by our product liability insurance.
In the event that we do not have adequate insurance or contractual indemnification, product liability claims relating to defective
products could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interruptions
in the supply of our products or inventory loss may adversely affect our business, results of operations and financial condition.
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products are manufactured using technically complex processes requiring specialized facilities, highly specific raw materials
and other production constraints. The complexity of these processes, as well as strict company and government standards for the
manufacture and storage of our products, subjects us to production risks. In addition to ongoing production risks, process deviations
or unanticipated effects of approved process changes may result in non-compliance with regulatory requirements including stability
requirements or specifications. Most of our products must be stored and transported within a specified temperature range. For
example, if environmental conditions deviate from that range, our products&rsquo; remaining shelf-lives could be impaired or their
safety and efficacy could be adversely affected, making them unsuitable for use. These deviations may go undetected. The occurrence
of actual or suspected production and distribution problems can lead to lost inventories, and in some cases recalls, with consequential
reputational damage and the risk of product liability. The investigation and remediation of any identified problems can cause
production delays and result in substantial additional expenses. Any unforeseen failure in the storage of our products or loss
in supply could result in a loss of our market share and negatively affect our revenues and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Increased
prices for, or unavailability of, raw materials used in our products could adversely affect our business, results of operations
and financial condition. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
profitability is affected by the prices of the raw materials used in the manufacture of our products. These prices may fluctuate
based on a number of factors beyond our control, including changes in supply and demand, general economic conditions, labor costs,
fuel related delivery costs, competition, import duties, excises and other indirect taxes, currency exchange rates, and government
regulation. Due to the highly competitive nature of the healthcare industry and the cost containment efforts of our customers
and third-party payors, we may be unable to pass along cost increases for key components or raw materials through higher prices
to our customers. If the cost of key components or raw materials increases, and we are unable fully to recover these increased
costs through price increases or offset these increases through other cost reductions, we could experience lower margins and profitability.
Significant increases in the prices of raw materials that cannot be recovered through productivity gains, price increases or other
methods could adversely affect our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Planned Expansion into Wound and Skin Care Virtual Consult and Other Services</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
planned expansion into wound and skin care virtual consult and other services could have a material adverse effect on our business,
financial condition or results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently developing the capability to offer various services addressing chronic wound and skin care through our wholly owned
subsidiary UWSS. UWSS&rsquo;s services are expected to launch in 2021 and include an EMR software platform for both wound and
skin conditions through WounDerm, which we acquired in January 2021, skin and wound virtual consult services through our affiliations
with DirectDerm and MGroup, and diagnostic products and services for chronic wounds through our affiliation with Precision Healing.
Our planned expansion into wound and skin care virtual consult and other services subjects us to risks associated with the use
of new and novel technologies, operational, financial, regulatory, legal and reputational risks, as well as the risk that we may
be unable to timely or successfully launch our service offerings. The success of UWSS&rsquo;s operations depends upon our ability
to commercialize UWSS&rsquo;s service offerings, and our failure to do so could negatively affect our ability to generate revenue
from these activities. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
planned expansion into wound and skin care virtual consult and other services will require entrance into several markets in which
we have little or no experience, which may not be successful and could be costly.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of our planned expansion into wound and skin care virtual consult services, we will be required to enter into other markets
in which we have little to no experience, including EMR, telehealth and healthcare diagnostics. While we intend to expand our
staff with individuals with more experience in the EMR, telehealth and diagnostic markets and will closely scrutinize individuals
we engage, we cannot provide assurance that we will be able to retain or continue to hire well-qualified and experienced individuals
or that our assessment of individuals we retain will be accurate. As we enter new markets, we will face new technological and
operational risks and challenges with which we are unfamiliar and may incur significant costs. Entering new markets requires substantial
management efforts and skills to mitigate these risks and challenges. Our lack of experience with certain of these new markets
may result in unsuccessful new market entries. If we do not manage our entry into new markets properly, these costs and risks
could harm our business, financial condition or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
planned expansion into the telehealth business is dependent on our relationships with affiliated professional entities to provide
physician services, and our business would be adversely affected if those relationships were disrupted.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a risk that U.S. state authorities in some jurisdictions may find that any future contractual relationships we enter into with
our affiliated professional entities who provide telehealth services violate laws prohibiting the corporate practice of medicine
and professional fee-splitting laws. These laws generally prohibit the practice of medicine by lay persons or entities or sharing
of professional fees with lay persons and are intended to prevent unlicensed persons or entities from interfering with or inappropriately
influencing a physician&rsquo;s professional judgment. The corporate practice of medicine prohibition exists in some form, by
statute, regulation, board of medicine or attorney general guidance, or case law, in most states and is subject to change and
to evolving interpretations by state boards of medicine, state attorneys general and state courts. As such, we will be required
to continually monitor our compliance with laws in every jurisdiction in which we plan to operate, and we cannot guarantee that
subsequent interpretation of the corporate practice of medicine laws will not circumscribe our future business operations. State
corporate practice of medicine doctrines could also subject physicians to penalties for aiding the corporate practice of medicine,
which could discourage physicians from participating in our network of providers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the prevalence of the corporate practice of medicine doctrine, including in the states where we plan to conduct our telehealth
business, we expect to continue contracting with provider-entities through management services agreements. Although we expect
that these relationships will continue, we cannot guarantee that they will. A material change in our relationships with these
provider entities, whether resulting from a dispute among the parties, a change in government regulation, or the loss of these
affiliations, could impair our ability to provide services to our future clients and could have a material adverse effect on our
business, financial condition and results of operations. Any scrutiny, investigation or litigation with regard to our future arrangements
with these professional entities could have a material adverse effect on our business, financial condition, and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
and frequent state legislative and regulatory changes specific to telemedicine may present us with additional requirements and
state compliance costs, with potential operational impacts in certain jurisdictions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
state laws and regulations specific to telemedicine vary from state to state and are continually evolving. In some cases, these
laws and regulations target &ldquo;direct to consumer&rdquo; telehealth service offerings rather than specialty consultative services,
such as our planned acute telemedicine service offerings, and incorporate informed consent, modality, medical records and follow
up care and other requirements. Thus, where new legislation and regulations apply to our planned expansion into telemedicine services,
we may incur costs to monitor, evaluate, and modify operational processes for compliance. All such activities will increase our
costs and could, in certain circumstances, impact our ability to make telemedicine services available in a particular state.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to adequately protect our intellectual property rights, we may not be able to compete effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
of our success depends on our and our research development partners&rsquo; ability to protect proprietary rights to technologies
used in certain of our products. We and our research development partners rely on patents, copyrights, trademarks and trade secret
laws to establish and maintain proprietary rights in our technology and products. However, these legal means afford only limited
protection and may not adequately protect our or our research development partners&rsquo; rights or permit us to gain or keep
a competitive advantage. Patents and patent applications for the products we have may not be broad enough to prevent competitors
from introducing similar products into the market. Our or our research development partners&rsquo; patents or attempts to enforce
them may not be upheld by the courts. Efforts to enforce any of our or our research development partners&rsquo; proprietary rights
could be time-consuming and expensive, which could adversely affect our business and prospects and divert management&rsquo;s attention.
There can be no assurance that our or our research and development partners&rsquo; proprietary rights will not be challenged,
invalidated or circumvented or that such rights will in fact provide competitive advantages to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>CellerateRX
Surgical is not currently protected by any pending patent application nor any unexpired patent. Accordingly, CellerateRX Surgical
may be subject to competition from the sale of substantially equivalent products that could adversely affect our business and
operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CellerateRX
Surgical has no patent protection, and therefore, in order to continue to obtain commercial benefits from CellerateRX Surgical,
we will rely on product manufacturing trade secrets, know-how and related non-patent intellectual property. The effect of CellerateRX
Surgical&rsquo;s lack of patent protection depends, among other things, upon the nature of the market and the position of our
products in the market from time to time, the size of the market, the complexities and economics of manufacturing a competitive
product and applicable regulatory approval requirements. In the event that competition develops substantially equivalent products,
this competition could have a material adverse effect on our business, financial condition and operating results. The entrance
into the market of a product substantially equivalent to CellerateRX Surgical may erode our product&rsquo;s market share, which
may have a material adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are heavily dependent on technologies and products we have licensed from third parties, and we may need to license technologies
and products in the future, and if we fail to obtain licenses we need, or fail to comply with our payment obligations in the agreements
under which we in-license intellectual property and other rights from third parties, we could lose our ability to develop and
commercialize our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are heavily dependent on licenses from our research and development partners for all of our technologies and products and are
party to a sublicense agreement with CGI Cellerate RX, license agreements with Rochal and a marketing and distribution agreement
with Cook Biotech Inc. (&ldquo;Cook Biotech&rdquo;). Our sublicense agreement and license agreements require that we pay royalties
to the sublicensor or licensor, as applicable, based on our net sales of the sublicensed and licensed products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
assurance can be given that our existing sublicense agreement, license agreements or marketing and distribution agreement will
be extended on reasonable terms or at all. In addition, we expect we will need to license intellectual property, technology and
products from third parties in the future and that these licenses will be material to our business. No assurance can be given
that we will meet our minimum performance obligations or generate sufficient revenue or raise additional financing to meet our
payment obligations in our agreements with CGI Cellerate RX, Rochal and Cook Biotech or other license or marketing and distribution
agreements we enter into with third parties in the future. Any failure to meet our minimum performance obligations or make the
payments required by our agreements may permit the licensor or supplier to terminate the agreement. If we were to lose or otherwise
be unable to maintain these licenses or marketing and distribution agreements for any reason, it would halt our ability to commercialize
our pipeline products. Furthermore, such loss of these licenses or marketing and distribution agreements may enable development
of new products that may compete with our pipeline products, and our competitors may gain proprietary position. Any of the foregoing
could result in a material adverse effect on our business or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be found to infringe on intellectual property rights of others.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties, including customers, may in the future assert claims or initiate litigation related to exclusive patent, copyright, trademark
and other intellectual property rights to technologies and related standards that are relevant to us. These assertions may emerge
over time as a result of our growth and the general increase in the pace of patent claim assertions, particularly in the U.S.
Because of the existence of a large number of patents in the healthcare field, the secrecy of some pending patent applications
and the rapid rate of issuance of new patents, we believe that it is not economically practical or even possible to determine
in advance whether a product or any of its components infringes or will infringe the patent rights of others. The asserted claims
or initiated litigation can include claims against us or our manufacturers, suppliers or customers alleging infringement of their
proprietary rights with respect to our existing or future products or components of those products. Regardless of the merit of
these claims, they can be time-consuming, result in costly litigation and diversion of technical and management personnel, or
require us to develop a non-infringing technology or enter into license agreements. Where claims are made by customers, resistance
even to unmeritorious claims could damage customer relationships. There can be no assurance that licenses will be available on
acceptable terms and conditions, if at all, or that our indemnification by our suppliers will be adequate to cover our costs if
a claim were brought directly against us or our customers. Furthermore, because of the potential for high court awards that are
not necessarily predictable, it is not unusual to find even arguably unmeritorious claims settled for significant amounts. If
any infringement or other intellectual property claim made against us by any third party is successful, or if we fail to develop
non-infringing technology or license the proprietary rights on commercially reasonable terms and conditions, our business could
be materially and adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Regulations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business is affected by numerous regulations relating to the labeling, marketing and sale of our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
regulation by the FDA and similar agencies in other countries is a significant factor in the development, manufacturing and marketing
of our products and in the acquisition or licensing of new products. Complying with government regulations is often time consuming
and expensive and may involve delays or actions adversely impacting the marketing and sale of our current or future products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
initial regulatory approval or clearance of any products that we or our research and development partners may develop, we and/or
our research and development partners will be subject to continuing regulatory review, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
                                         registration and device listing requirements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QSR,
                                         which governs the methods used in, and the facilities and controls used for, the design,
                                         manufacture, packaging, labeling, storage, installation, and servicing of finished devices;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">labeling
                                         requirements, which mandate the inclusion of certain content in medical device labels
                                         and labeling, and when fully implemented, will generally require the label and package
                                         of medical devices to include a unique device identifier, and which also prohibit the
                                         promotion of products for uncleared or unapproved, i.e., &ldquo;off-label,&rdquo; indications;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         Medical Device Reporting regulation, which requires that manufacturers and importers
                                         report to the FDA if their device may have caused or contributed to a death or serious
                                         injury or malfunctioned in a way that would likely cause or contribute to a death or
                                         serious injury if it were to recur; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         Reports of Corrections and Removals regulation, which requires that manufacturers and
                                         importers report to the FDA recalls (i.e., corrections or removals) if undertaken to
                                         reduce a risk to health posed by the device or to remedy a violation of the Federal Food,
                                         Drug, and Cosmetic Act (&ldquo;FDCA&rdquo;) that may present a risk to health and that
                                         manufacturers and importers keep records of recalls that they determine to be not reportable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with applicable regulatory requirements can result in, among other things, the FDA or other governmental authorities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposing
                                         fines and penalties on us;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preventing
                                         us from manufacturing or selling our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delaying
                                         or denying pending applications for approval or clearance of our products or of new uses
                                         or modifications to our existing products, or withdrawing or suspending current approvals
                                         or clearances;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordering
                                         or requesting a recall of our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuing
                                         warning letters, untitled letters, or &ldquo;It has Come to Our Attention&rdquo; letters;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposing
                                         operating restrictions, including a partial or total shutdown of production or investigation
                                         of any or all of our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing
                                         to permit to import or export of our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">detaining
                                         or seizing our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                         injunctions preventing us from manufacturing or distributing any or all of our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencing
                                         criminal prosecutions or seeking civil penalties; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
                                         changes in our advertising and promotion practices.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing facilities we or our research and development partners use (and may use) to make any of our FDA-regulated products
are or may become subject to periodic review and inspection by the FDA. If a previously unknown problem with a product or a manufacturing
or laboratory facility used or contracted by us or one of our research and development partners is discovered, the FDA may impose
restrictions on that product or on the manufacturing facility, including requiring us and/or our research and development partner
to withdraw the product from the market. Any changes to an approved or cleared product, including the way it is manufactured or
promoted, often requires FDA review and separate approval or clearance before the product, as modified, may be marketed. In addition,
for products we develop in the future, we and our contract manufacturers may be subject to ongoing FDA requirements for submission
of safety and other post-market approval information. If we violate regulatory requirements at any stage, whether before or after
marketing approval or clearance is obtained, we may be fined, be forced to remove a product from the market or experience other
adverse consequences, which would materially harm our financial results. Additionally, due to limitations imposed on us by the
scope of the cleared or approved indications or intended use of our products and by FDA and Federal Trade Commission (&ldquo;FTC&rdquo;)
regulations relating to promotional claims, we may not be able to obtain the labeling claims necessary or desirable for product
promotion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution
of our products outside the United States is subject to extensive government regulation. These regulations, including the requirements
for marketing authorizations or product licenses necessary to bring a medical product to market, the time required for regulatory
review and the sanctions imposed for violations, vary from country to country. We do not know whether we will obtain the marketing
authorizations or product licenses necessary to market our products in such countries or that we will not be required to incur
significant costs in obtaining or maintaining these regulatory approvals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to obtain or experience significant delays in obtaining regulatory clearances or approvals to market future medical device
products, we will be unable to commercialize these products until such clearance or approval is obtained.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
developing, testing, manufacturing, marketing and selling of medical devices is subject to extensive regulation by governmental
authorities in the U.S. and other countries. The process of obtaining regulatory clearance and approval of certain medical technology
products is costly and time consuming. Inherent in the development of new medical products is the potential for delay because
product testing, including clinical evaluation, is typically required, especially for drugs, biologics and high-risk devices,
before such products can be approved for human use. With respect to medical devices, such as those that we currently market, before
a new medical device, or a new indicated use of, or claim for, an existing product can be marketed (unless it is a Class I device),
it must first receive either premarket clearance under Section 510(k) of the Federal Food, Drug and Cosmetic Act or approval of
a premarket approval application (&ldquo;PMA&rdquo;) from the FDA, or be reclassified and receive marketing authorization through
the de novo classification process, unless an exemption applies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the 510(k)-clearance process, the FDA must determine that the proposed device is &ldquo;substantially equivalent&rdquo; to a Class
I or II device legally on the market, known as a &ldquo;predicate&rdquo; device, with respect to intended use, technology, safety
and effectiveness to clear the proposed device for marketing. Clinical data is sometimes required to support substantial equivalence
for certain device types. The PMA pathway requires an applicant to demonstrate the safety and effectiveness of the device for
its intended use based, in part, on extensive data including, but not limited to, technical, preclinical, clinical trial, manufacturing
and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining,
life-supporting or implantable devices. If a device is novel and there is no appropriate predicate to which the applicant can
demonstrate substantial equivalence, the device will be automatically classified as a Class III device and require approval through
the PMA process prior to commercialization, unless the applicant submits a <I>de novo</I> classification request demonstrating
that the novel device should be reclassified into Class I or II. Demonstrating that a novel device should be reclassified to Class
I or II from Class III typically requires extensive information and data on the benefits and risks of the device, including performance
data and frequently data from one or more clinical studies. The 510(k), PMA and <I>de novo</I> classification approval processes
can be expensive and lengthy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with applicable regulatory requirements can result in, among other things, suspension or withdrawal of clearances or
approvals, seizure or recall of products, injunctions against the manufacture, holding, distribution, marketing and sale of a
product and civil and criminal sanctions. Furthermore, changes in existing regulations or the adoption of new regulations could
prevent us from obtaining, or affect the timing of, future regulatory clearances or approvals. Meeting regulatory requirements
and evolving government standards may delay marketing of any new products developed by us for a considerable period of time, impose
costly procedures upon our activities and result in a competitive advantage to larger companies that compete against us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that the FDA or other regulatory agencies will clear or approve any products developed by us on a timely basis,
if at all, or, if granted, that clearance or approval will not entail limiting the indicated uses for which we may market the
product, which could limit the potential market for any of these products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
to the FDA clearance and approval processes or ongoing regulatory requirements could make it more difficult for us to obtain FDA
clearance or approval of new products or comply with ongoing requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
government regulations may be enacted and changes in FDA policies and regulations and, their interpretation and enforcement, could
prevent or delay regulatory clearance or approval of new products. We cannot predict the likelihood, nature or extent of adverse
government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. Therefore,
we do not know whether we or our research and development partners will be able to continue to comply with such regulations or
whether the costs of such compliance will have a material adverse effect on our business. Changes could, among other things, require
different labeling, monitoring of patients, interaction with physicians, education programs for patients or physicians, curtailment
of necessary supplies, or limitations on product distribution. These changes, or others required by the FDA could have an adverse
effect on our business, and specifically, on the sales of affected products. The evolving and complex nature of regulatory science
and regulatory requirements, the broad authority and discretion of the FDA and the generally high level of regulatory oversight
results in a continuing possibility that from time to time, we will be adversely affected by regulatory actions despite ongoing
efforts and commitment to achieve and maintain full compliance with all regulatory requirements. If we or our research and development
partners are not able to maintain regulatory compliance, we may not be permitted to market our products and our business would
suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Modifications
to our current products may require new marketing clearances or approvals or require us to cease marketing or recall the modified
products until such clearances or approvals are obtained.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
modification to an FDA-cleared product that could significantly affect its safety or efficacy, or that would constitute a major
change or modification in its indicated use, requires a new FDA 510(k) clearance or, possibly, a PMA. In addition, any significant
modification to an FDA-approved product, such as a new indication for use, labeling changes, or manufacturing changes, requires
submission of a PMA supplement or 30-day notice for changes to manufacturing procedures or methods of manufacture that affect
the safety and effectiveness of the product. The FDA requires every manufacturer to make its own determination as to whether a
modification requires a new 510(k) clearance or PMA, but the FDA may review and disagree with any decision reached by the manufacturer.
In the future, we or our research and development partners may make additional modifications to our products after they have received
FDA clearance or approval and, in appropriate circumstances, determine that new clearance or approval is unnecessary. Regulatory
authorities may disagree with our or our research and development partners&rsquo; decisions not to seek new clearance or approval
and may require us or the research and development partner that controls the marketing authorization for the respective device
to obtain clearance or approval for previous modifications to our products. If that were to occur for a previously cleared or
approved product, we may be required to cease marketing or recall the modified device until we obtain, or our research and development
partner obtains, the necessary clearance or approval. Under these circumstances, we may also be subject to significant regulatory
fines or other penalties. If any of the foregoing were to occur, our financial condition and results of operations could be negatively
impacted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to obtain or maintain adequate reimbursement or insurance coverage for drugs, if any, could limit our ability to market those
drugs and decrease our ability to generate revenue. Changes in reimbursement policies and regulations by governmental or other
third-party payors may have an adverse impact on the use of our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pricing, coverage, and reimbursement of our products, if any, must be sufficient to support our commercial efforts and other development
programs, and the availability and adequacy of coverage and reimbursement by third-party payors, including governmental and private
insurers, are essential for most patients to be able to afford medical treatments. Sales of our products depend substantially,
both domestically and abroad, on the extent to which the costs of our products, if any, will be paid for or reimbursed by health
maintenance, managed care, and similar healthcare management organizations, or government payers and private payors. If coverage
and reimbursement are not available, or are available only in limited amounts, we may have to subsidize or provide medical products
for free or we may not be able to successfully commercialize our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
significant portion of our wound care products are purchased principally for the Medicare and Medicaid eligible population by
hospital outpatient clinics, wound care clinics, durable medical equipment (&ldquo;DME&rdquo;) suppliers and SNFs, which typically
bill various third-party payors, primarily state and federal healthcare programs (e.g., Medicare and Medicaid), and managed care
plans, for the products and services provided to their patients. Although the majority of our wound care products are currently
eligible for reimbursement under Medicare Part B, adjustments to our reimbursement amounts or a change in CMS&rsquo;s reimbursement
policies could have an adverse effect on our market opportunities in this area. The ability of our customers to obtain appropriate
reimbursement for products and services from third-party payors is critical to the success of our business because reimbursement
status affects which products our customers purchase. In addition, our ability to obtain reimbursement approval in foreign jurisdictions
may affect our ability to expand our product offerings internationally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payors have adopted, and are continuing to adopt, a number of policies intended to curb rising healthcare costs. These policies
include the imposition of conditions of payment by foreign, state and federal healthcare programs as well as private insurance
plans, and the reduction in reimbursement amounts applicable to specific products and services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in healthcare systems in the U.S. or internationally in a manner that significantly reduces reimbursement for procedures using
our products or denies coverage for these procedures would also have an adverse impact on the acceptance of our products and the
prices which our customers are willing to pay for them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
increasing efforts by governmental and private payors in the United States and abroad to limit or reduce healthcare costs may
result in restrictions on coverage and the level of reimbursement for new medical products and, as a result, they may not cover
or provide adequate payment for our products. We expect to experience pricing pressures in connection with our products due to
the increasing trend toward managed healthcare, including the increasing influence of health maintenance organizations and additional
legislative changes. The downward pressure on healthcare costs in general, and prescription drugs or biologics in particular,
has and is expected to continue to increase in the future. As a result, profitability of our current or future products, may be
more difficult to achieve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely on our research and development partners to comply with applicable laws and regulations relating to product classification
and FDA marketing authorization.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on our research and development partners, from whom we license all of the products we currently commercialize, to determine
the appropriate classification for each such product and to comply with applicable regulations related to obtaining the proper
marketing authorization. With respect to each medical device product we license, our respective research and development partner
designs the product and determines whether the device should be classified as a Class I, II, or III device and the appropriate
FDA marketing authorization pathway to pursue (i.e., 510(k), PMA or <I>de novo</I> classification). In addition, we rely on our
research and development partners to determine whether specific legal or regulatory definitions or exemptions apply to particular
medical products, which individually may be subject to FDA oversight as a device, drug, biologic or human cellular or tissue-based
product. The FDA has broad regulatory authority to interpret and enforce the laws and regulations that govern medical products
in commercial distribution, and any adverse determination by the FDA relating to one of our licensed products could require significant
cost and effort to comply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, our research and development partner, Cook Biotech, from whom we have the right to exclusively distribute three
biologic products for surgical and wound care applications, has determined that one such product, VIM Amnion Matrix, is intended
for homologous use as a wound covering or barrier. It is possible that the FDA, after evaluating the product, its intended use
and any promotional claims, may not agree with Cook Biotech&rsquo;s conclusion that the VIM Amnion Matrix product is intended
for homologous use, which would change the legal framework under which the product is regulated and may require Cook Biotech and
us to incur substantial costs and expend significant effort to bring the product into compliance with applicable regulations.
Such action by the FDA may also require us to cease marketing operations relating to the VIM Amnion Matrix product until the appropriate
corrections are complete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
and our employees and contractors are subject, directly or indirectly, to federal, state and foreign healthcare fraud and abuse
laws, including false claims laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial
penalties. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to various federal, state and foreign fraud and abuse laws. These laws may affect our operations, including
the financial arrangements and relationships through which we market, sell and distribute our products. U.S. federal and state
laws that affect our ability to operate include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         federal Anti-Kickback Statute, which prohibits, among other things, persons or entities
                                         from knowingly and willfully soliciting, receiving, offering or paying any remuneration
                                         (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly,
                                         in cash or in kind in return for, the purchase, recommendation, leasing or furnishing
                                         of an item or service reimbursable under a federal healthcare program, such as the Medicare
                                         and Medicaid programs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
                                         civil and criminal false claims laws and civil monetary penalty laws, which prohibit,
                                         among other things, individuals or entities from knowingly presenting, or causing to
                                         be presented, claims for payment or approval from Medicare, Medicaid, or other government
                                         payors that are false or fraudulent;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
                                         242 of the federal Health Insurance Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;)
                                         codified at 18 U.S.C. &sect; 1347, which created new federal criminal statutes that prohibit
                                         a person from knowingly and willfully executing a scheme or from making false or fraudulent
                                         statements to defraud any healthcare benefit program (i.e., public or private);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
                                         transparency laws, including the so-called federal &ldquo;sunshine&rdquo; law, which
                                         requires the tracking and disclosure to the federal government by pharmaceutical and
                                         medical device manufacturers of payments and other transfers of value to physicians and
                                         teaching hospitals as well as ownership and investment interests that are held by physicians
                                         and their immediate family members; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
                                         law equivalents of each of these federal laws, such as anti-kickback and false claims
                                         laws that may apply to items or services reimbursed by any third-party payer, including
                                         commercial insurers, state laws that require pharmaceutical and medical device companies
                                         to comply with their industry&rsquo;s voluntary compliance guidelines and the applicable
                                         compliance guidance promulgated by the federal government or otherwise restrict certain
                                         payments that may be made to healthcare providers and other potential referral sources,
                                         state laws that require drug and medical device manufacturers to report information related
                                         to payments and other transfers of value to physicians and other healthcare providers
                                         or marketing expenditures, state laws that prohibit giving gifts to licensed healthcare
                                         professionals and state laws governing the privacy and security of health information
                                         in certain circumstances, many of which differ from each other in significant ways and
                                         may not have the same effect, thus complicating compliance efforts in certain circumstances,
                                         such as specific disease states.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, activities and arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent
fraud, waste and other abusive practices. These laws and regulations may restrict or prohibit a wide range of activities or other
arrangements related to the development, marketing or promotion of products, including pricing and discounting of products, provision
of customer incentives, provision of reimbursement support, other customer support services, provision of sales commissions or
other incentives to employees and independent contractors and other interactions with healthcare practitioners, other healthcare
providers and patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrow scope of the statutory or regulatory exceptions and safe harbors available, our business
activities could be challenged under one or more of these laws. Relationships between medical product manufacturers and health
care providers are an area of heightened scrutiny by the government. We engage in various activities, including the conduct of
speaker programs to educate physicians, the provision of reimbursement advice and support to customers, and the provision of customer
and patient support services, that have been the subject of government scrutiny and enforcement action within the medical device
industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
expectations and industry best practices for compliance continue to evolve and past activities may not always be consistent with
current industry best practices. Further, there is a lack of government guidance as to whether various industry practices comply
with these laws, and government interpretations of these laws continue to evolve, all of which create compliance uncertainties.
Any non-compliance could result in regulatory sanctions, criminal or civil liability and serious harm to our reputation. Although
we have a comprehensive compliance program designed to ensure that our employees&rsquo; and commercial partners&rsquo; activities
and interactions with healthcare professionals and patients are appropriate, ethical, and consistent with all applicable laws,
regulations, guidelines, policies and standards, it is not always possible to identify and deter misconduct, and the precautions
we take to detect and prevent this activity may not be effective in preventing such conduct, mitigating risks, or reducing the
chance of governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a government entity opens an investigation into possible violations of any of these laws (which may include the issuance of subpoenas),
we would have to expend significant resources to defend ourselves against the allegations. Allegations that we, our officers,
or our employees violated any one of these laws can be made by individuals called &ldquo;whistleblowers&rdquo; who may be our
employees, customers, competitors or other parties. Government policy is to encourage individuals to become whistleblowers and
file a complaint in federal court alleging wrongful conduct. The government is required to investigate all of these complaints
and decide whether to intervene. If the government intervenes and we are required to pay damages, which in such cases are typically
set at three times the actual monetary damages, to the government, the whistleblower, as a reward, is awarded a percentage of
such damages or any settlement amount. If the government declines to intervene, the whistleblower may proceed on her own and,
if she is successful, she will receive a percentage of any judgment or settlement amount the company is required to pay. The government
may also initiate an investigation on its own. If any such actions are instituted against us, those actions could have a significant
impact on our business, including the imposition of significant fines, and other sanctions that may materially impair our ability
to run a profitable business. In particular, if our operations are found to be in violation of any of the laws described above
or if we agree to settle with the government without admitting to any wrongful conduct or if we are found to be in violation of
any other governmental regulations that apply to us, we, our officers and employees may be subject to sanctions, including civil
and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and
Medicaid, imprisonment, the curtailment or restructuring of our operations and the imposition of a corporate integrity agreement,
any of which could adversely affect our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
or our research and development partners&rsquo; use and disclosure of personally identifiable information, including health information,
is subject to federal and state privacy and security regulations, and our failure to comply with those regulations or to adequately
secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect
on our client base, business, financial condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
state and federal laws and regulations, including HIPAA, govern the collection, dissemination, use, privacy, confidentiality,
security, availability and integrity of personally identifiable information (&ldquo;PII&rdquo;), including protected health information.
HIPAA establishes a set of basic national privacy and security standards for the protection of protected health information (&ldquo;PHI&rdquo;)
by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business
associates with whom such covered entities contract for services, which likely includes us. HIPAA requires healthcare providers
and business associates to develop and maintain policies and procedures with respect to PHI that is used or disclosed, including
the adoption of administrative, physical, and technical safeguards to protect such information. HIPAA also implemented the use
of standard transaction code sets and standard identifiers that covered entities must use when submitting or receiving certain
electronic healthcare transactions, including activities associated with the billing and collection of healthcare claims. HIPAA
imposes mandatory penalties for certain violations. HIPAA also authorizes state attorneys general to file suit on behalf of their
residents. Courts will be able to award damages, costs and attorneys&rsquo; fees related to violations of HIPAA in such cases.
While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its
standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the
misuse or breach of PHI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, HIPAA mandates that the Secretary of Health and Human Services (&ldquo;HHS&rdquo;) conduct periodic compliance audits
of HIPAA covered entities or business associates for compliance with the HIPAA Privacy and Security Standards. HIPAA further requires
that patients be notified of any unauthorized acquisition, access, use or disclosure of their unsecured PHI that compromises the
privacy or security of such information, with certain exceptions related to unintentional or inadvertent use or disclosure by
employees or authorized individuals. HIPAA specifies that such notifications must be made without unreasonable delay and in no
case later than 60 calendar days after discovery of the breach. If a breach affects 500 patients or more, it must be reported
to HHS without unreasonable delay, and HHS will post the name of the breaching entity on its public web site. Breaches affecting
500 patients or more in the same state or jurisdiction must also be reported to the local media. If a breach involves fewer than
500 people, the covered entity must record it in a log and notify HHS at least annually.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
other federal and state laws protect the confidentiality, privacy, availability, integrity and security of PII, including PHI.
These laws in many cases are more restrictive than, and may not be preempted by, the HIPAA rules and may be subject to varying
interpretations by courts and government agencies, creating complex compliance issues for us and our clients and potentially exposing
us to additional expense, adverse publicity and liability. In addition, new health information standards, whether implemented
pursuant to HIPAA, congressional action or otherwise, could have a significant effect on the manner in which we must handle healthcare
related data, and the cost of complying with standards could be significant. If we do not comply with existing or new laws and
regulations related to PHI, we could be subject to criminal or civil sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the extreme sensitivity of the PII we or our partners may store and transmit, the security features of our technology platforms
are very important. If our security measures, some of which may be managed by third parties, are breached or fail, unauthorized
persons may be able to obtain access to sensitive client and patient data, including HIPAA-regulated PHI. As a result, our reputation
could be severely damaged, adversely affecting client or investor confidence. Clients may curtail their use of or stop using our
products and services, which would cause our business to suffer. In addition, we could face litigation, damages for contract breach,
penalties and regulatory actions for violation of HIPAA and other applicable laws or regulations and significant costs for remediation,
notification to individuals and for measures to prevent future occurrences. Any potential security breach could also result in
increased costs associated with liability for stolen assets or information, repairing system damage that may have been caused
by such breaches, incentives offered to client or other business partners in an effort to maintain our business relationships
after a breach and implementing measures to prevent future occurrences, including organizational changes, deploying additional
personnel and protection technologies, training employees and engaging third-party experts and consultants. While we maintain
insurance covering certain security and privacy damages and claim expenses, our coverage may not be sufficient to compensate for
all liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Government
regulation of healthcare creates risks and challenges with respect to our compliance efforts and our business strategies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
healthcare industry is highly regulated and is subject to changing political, legislative, regulatory, and other influences. Existing
and new laws and regulations affecting the healthcare industry could create unexpected liabilities for us, could cause us to incur
additional costs, and could restrict our operations. Many healthcare laws are complex, and their application to specific products
and services may not be clear. In particular, many existing healthcare laws and regulations, when enacted, did not anticipate
the services that we aim to provide. However, these laws and regulations may nonetheless be applied to our business. Our failure
to accurately anticipate the application of these laws and regulations, or other failure to comply, could create liability for
us, result in adverse publicity and materially affect its business, financial condition, and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with extensive healthcare laws and government regulations, we could suffer penalties or be required to make
significant changes to our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
healthcare industry is required to comply with extensive and complex laws and regulations at the federal, state and local government
levels relating to, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">licensure
                                         of health providers, certification of organizations and enrollment with government reimbursement
                                         programs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">necessity
                                         and adequacy of medical care;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">relationships
                                         with physicians and other referral sources and referral recipients;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">billing
                                         and coding for services;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">properly
                                         handling overpayments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">quality
                                         of medical equipment and services;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">qualifications
                                         of medical and support personnel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">confidentiality,
                                         maintenance, data breach, identity theft and security issues associated with health-related
                                         and personal information and medical records; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">communications
                                         with patients and consumers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
these laws are the federal Stark Law, the federal Anti-Kickback Statute, the False Claims Act (the &ldquo;FCA&rdquo;), and similar
state laws. If we fail to comply with applicable laws and regulations, we could suffer civil sanctions and criminal penalties,
including the loss of our ability to participate in the Medicare, Medicaid and other federal and state healthcare programs. While
we endeavor to ensure that our financial relationships with referral sources such as hospitals and physicians comply with the
applicable laws (including applicable safe harbors and exceptions), evolving interpretations or enforcement of these laws and
regulations could subject our current practices to allegations of impropriety or illegality or could require us to make changes
in our operations. A determination that we have violated these or other laws, or the public announcement that we are being investigated
for possible violations of these or other laws, could have a material adverse effect on our business, financial condition, results
of operations or prospects, and our business reputation could suffer significantly. In addition, other legislation or regulations
at the federal or state level may be adopted that adversely affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
officers, employees, independent contractors, principal investigators, consultants and commercial partners may engage in misconduct
or activities that are improper under other laws and regulations, which would create liability for us. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk that our officers, employees, independent contractors (including contract research organizations (&ldquo;CROs&rdquo;)),
principal investigators, consultants and commercial partners may engage in fraudulent conduct or other illegal activity and/or
may fail to disclose unauthorized activities to us. Misconduct by these parties could include, but is not limited to, intentional,
reckless and/or negligent failures to comply with:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         laws and regulations of the FDA and its foreign counterparts requiring, among other things,
                                         compliance with good manufacturing practice and/or quality system requirements, post-market
                                         vigilance reporting, product marketing authorization requirements, facility registration
                                         requirements, the reporting of true, complete and accurate information to such regulatory
                                         bodies, including but not limited to safety problems associated with the use of our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">laws
                                         and regulations of the FDA and its foreign counterparts concerning the conduct of clinical
                                         trials and the protection of human research subjects, including but not limited to good
                                         clinical practices;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                         laws and regulations of the FDA and its foreign counterparts relating to the manufacture,
                                         processing, packing, holding, investigating or distributing in commerce of medical devices,
                                         biological products and/or human cell, tissue, and cellular and tissue-based products
                                         (&ldquo;HCT/Ps&rdquo;);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
                                         standards we have established; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">healthcare
                                         fraud and abuse laws, including but not limited to, the Anti-Kickback Statute, the Stark
                                         Law, the FCA, and state law equivalents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, companies involved in the manufacture of medical products are subject to laws and regulations intended to ensure that
medical products that will be used in patients are safe and effective, and, specifically, that they are not adulterated or misbranded,
that they are properly labeled, and have the identity, strength, quality and purity that which they are represented to possess.
Further, companies involved in the research and development of medical products are subject to extensive laws and regulations
intended to protect research subjects and ensure the integrity of data generated from clinical trials and of the regulatory review
process. Any misconduct in any of these areas, whether by our own employees or by contractors, vendors, business associates, consultants,
or other entities acting as our agents, could result in regulatory sanctions, criminal or civil liability and serious harm to
our reputation. Although we have a comprehensive compliance program designed to ensure that our employees&rsquo;, CRO partners&rsquo;,
principal investigators&rsquo;, consultants&rsquo;, and commercial partners&rsquo; activities and interactions with healthcare
professionals and patients are appropriate, ethical, and consistent with all applicable laws, regulations, guidelines, policies
and standards, it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this
activity may not be effective in preventing such conduct, mitigating risks, or reducing the chance of governmental investigations
or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted
against us, or our CRO partners, principal investigators, consultants, or commercial partners, those actions could have a significant
impact on our business, including the imposition of significant fines, and other sanctions that may materially impair our ability
to run a profitable business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
could be adversely affected if healthcare reform measures substantially change the market for medical care or healthcare coverage
in the United States.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2010, President Obama signed the Patient Protection and Affordable Care Act (P.L. 111-148) and on March 30, 2010, the
signed the Health Care and Education Reconciliation Act (P.L. 111-152), collectively commonly referred to as the &ldquo;Healthcare
Reform Law.&rdquo; The Healthcare Reform Law included a number of new rules regarding health insurance, the provision of healthcare,
conditions to reimbursement for healthcare services provided to Medicare and Medicaid patients, and other healthcare policy reforms.
Through the law-making process, substantial changes have been and continue to be made to the system for paying for healthcare
in the United States, including changes made to extend medical benefits to certain Americans who lacked insurance coverage and
to contain or reduce healthcare costs (such as by reducing or conditioning reimbursement amounts for healthcare services and drugs,
and imposing additional taxes, fees, and rebate obligations on pharmaceutical and medical device companies). This legislation
was one of the most comprehensive and significant reforms ever experienced by the healthcare industry in the United States and
has significantly changed the way healthcare is financed by both governmental and private insurers. This legislation has impacted
the scope of healthcare insurance and incentives for consumers and insurance companies, among others. Additionally, the Healthcare
Reform Law&rsquo;s provisions were designed to encourage providers to find cost savings in their clinical operations. This environment
has caused changes in the purchasing habits of consumers and providers and resulted in specific attention to the pricing negotiation,
product selection and utilization review surrounding pharmaceuticals and medical devices. This attention may result in our current
commercial products, products we may commercialize or promote in the future, and our therapeutic candidates, being chosen less
frequently or the pricing being substantially lowered. At this stage, it is difficult to estimate the full extent of the direct
or indirect impact of the Healthcare Reform Law on us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
structural changes could entail further modifications to the existing system of private payors and government programs (such as
Medicare and Medicaid), creation of government-sponsored healthcare insurance sources, or some combination of both, as well as
other changes. Restructuring the coverage of medical care in the U.S. could impact the reimbursement for medical services and
procedures, prescribed drugs, biologics and medical devices, including our current commercial products, those we and our development
or commercialization partners are currently developing or those that we may commercialize or promote in the future. If reimbursement
for the products we currently commercialize or promote, any product we may commercialize or promote, or approved therapeutic candidates
is substantially reduced or otherwise adversely affected in the future, or rebate obligations associated with any pharmaceutical
product we commercialize or promote are substantially increased, it could have a material adverse effect on our reputation, business,
financial condition or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extending
medical benefits to those who currently lack coverage will likely result in substantial costs to the U.S. federal government,
which may force significant additional changes to the healthcare system in the United States. Much of the funding for expanded
healthcare coverage may be sought through cost savings. While some of these savings may come from realizing greater efficiencies
in delivering care, improving the effectiveness of preventive care and enhancing the overall quality of care, much of the cost
savings may come from reducing the cost of care and increased enforcement activities. Cost of care could be reduced further by
decreasing the level of reimbursement for medical services or products (including our current commercial products, our development
or commercialization partners or any product or medical service we may commercialize or promote), or by restricting coverage (and,
thereby, utilization) of medical services or products. In either case, a reduction in the utilization of, or reimbursement for
our current commercial products, any product we may commercialize or promote or for which we receive marketing approval or clearance
in the future, could have a material adverse effect on our reputation, business, financial condition, or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
states and private entities initially mounted legal challenges to the Healthcare Reform Law, and they continue to litigate various
aspects of the legislation. On July 26, 2012, the U.S. Supreme Court generally upheld the provisions of the Healthcare Reform
Law at issue as constitutional. However, the U.S. Supreme Court held that the legislation improperly required the states to expand
their Medicaid programs to cover more individuals. As a result, the states have a choice as to whether they will expand the number
of individuals covered by their respective state Medicaid programs. Some states have not expanded their Medicaid programs and
have chosen to develop other cost-saving and coverage measures to provide care to currently uninsured individuals. Many of these
efforts to date have included the institution of Medicaid-managed care programs. The manner in which these cost-saving and coverage
measures are implemented could have a material adverse effect on our reputation, business, financial condition or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the healthcare regulatory environment has seen significant changes in recent years and is still in flux. Legislative initiatives
to modify, limit, replace, or repeal the Healthcare Reform Law and judicial challenges continue. We cannot predict the impact
on our business of future legislative and legal challenges to the Healthcare Reform Law or other changes to the current laws and
regulations. The uncertainty around the future of the Healthcare Reform Law, and in particular the impact to reimbursement levels,
may lead to uncertainty or delay in the purchasing decisions of our customers, which may in turn negatively impact our product
sales. If there are not adequate reimbursement levels, our business and results of operations could be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial impact of U.S. healthcare reform legislation over the next few years will depend on a number of factors, including the
policies reflected in implementing regulations and guidance and changes in sales volumes for therapeutics affected by the legislation.
From time to time, legislation is drafted, introduced and passed in the U.S. Congress that could significantly change the statutory
provisions governing coverage, reimbursement, and marketing of medical products and services. In addition, third-party payor coverage
and reimbursement policies are often revised or interpreted in ways that may significantly affect our business and our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
in office, President Trump supported the repeal of all or portions of the Healthcare Reform Law. President Trump also issued an
executive order in which he stated that it is his administration&rsquo;s policy to seek the prompt repeal of the Healthcare Reform
Law and in which he directed executive departments and federal agencies to waive, defer, grant exemptions from, or delay the implementation
of the provisions of the Healthcare Reform Law to the maximum extent permitted by law. Congress has enacted legislation that repeals
certain portions of the Healthcare Reform Law, including but not limited to the Tax Cuts and Jobs Act, passed in December 2017,
which included a provision that eliminates the penalty under the Healthcare Reform Law&rsquo;s individual mandate, effective January
1, 2019, as well as the Bipartisan Budget Act of 2018, passed in February 2018, which, among other things, repealed the Independent
Payment Advisory Board (which was established by the Healthcare Reform Law and was intended to reduce the rate of growth in Medicare
spending).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
in December 2018, a district court in Texas held that the individual mandate is unconstitutional and that the rest of the Healthcare
Reform Law is, therefore, invalid. On appeal, the Fifth Circuit Court of Appeals affirmed the holding on the individual mandate
but remanded the case back to the lower court to reassess whether and how such holding affects the validity of the rest of the
Healthcare Reform Law. On March 2, 2020, the U.S. Supreme Court granted the petitions for writs of certiorari to review this case
and allocated one hour for oral arguments, which occurred on November 10, 2020. A decision from the Supreme Court is expected
to be issued in spring 2021. It is unclear how this litigation and other efforts to repeal and replace the Healthcare Reform Law
will impact the policies and programs implemented under the Healthcare Reform Law and the medical products industry more generally.
We also cannot predict the impact that this litigation against the Healthcare Reform Law will have on our business, and there
is uncertainty as to what healthcare programs and regulations may be implemented or changed at the federal and/or state level
in the United States or the effect of any future legislation or regulation. Furthermore, we cannot predict what actions the Biden
administration will implement in connection with the Healthcare Reform Law. However, it is possible that such initiatives could
have an adverse effect on our ability to obtain approval and/or successfully commercialize products in the United States in the
future. For example, any changes that reduce, or impede the ability to obtain, reimbursement for the type of products or services
we currently or intend to commercialize in the United States or that reduce medical procedure volumes could adversely affect our
operations and/or future business plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Defects,
failures or quality issues associated with our products could lead to product recalls or safety alerts, adverse regulatory actions,
litigation and negative publicity that could materially adversely affect our reputation, business, results of operations and financial
condition. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quality
is extremely important to us and our customers due to the serious and costly consequences of product failure. Quality and safety
issues may occur with respect to any of our products, and our future operating results will depend on our ability to maintain
an effective quality control system and effectively train and manage our workforce with respect to our quality system. The development,
manufacture and control of medical devices are subject to extensive and rigorous regulation by numerous government agencies, including
the FDA and similar foreign agencies. Compliance with these regulatory requirements, including but not limited to the FDA&rsquo;s
QSR, good manufacturing practices and adverse events/recall reporting requirements in the United States and other applicable regulations
worldwide, is subject to continual review and is monitored rigorously through periodic inspections by the FDA and foreign regulatory
authorities. The FDA and foreign regulatory authorities may also require post-market testing and surveillance to monitor the performance
of products cleared or approved for use in their jurisdictions. Our manufacturing facilities and those of our suppliers and independent
sales agencies are also subject to periodic regulatory inspections. If the FDA or other regulatory authority were to conclude
that we or our suppliers have failed to comply with any of these requirements, it could institute a wide variety of enforcement
actions, ranging from a public warning letter to more severe sanctions, such as product recalls or seizures, withdrawals, monetary
penalties, consent decrees, injunctive actions to halt the manufacture or distribution of products, import detentions of products
made outside the United States, export restrictions, restrictions on operations or other civil or criminal sanctions. Civil or
criminal sanctions could be assessed against our officers, employees, or us. Any adverse regulatory action, depending on its magnitude,
may restrict us from effectively manufacturing, marketing, and selling our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we cannot predict the results of future legislative activity or future court decisions, any of which could increase
regulatory requirements, subject us to government investigations or expose us to unexpected litigation. Any regulatory action
or litigation, regardless of the merits, may result in substantial costs, divert management&rsquo;s attention from other business
concerns and place additional restrictions on our sales or the use of our products. In addition, negative publicity, including
regarding a quality or safety issue, could damage our reputation, reduce market acceptance of our products, cause us to lose customers
and decrease demand for our products. Any actual or perceived quality issues may also result in issuances of physician&rsquo;s
advisories against our products or cause us to conduct voluntary recalls. Any product defects or problems, regulatory action,
litigation, negative publicity or recalls could disrupt our business and have a material adverse effect on our business, results
of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to this Offering and Ownership of Our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>You
may experience immediate and substantial dilution.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the price per share of common stock being offered may be substantially higher than the net tangible book value per share of our
common stock, you may experience substantial dilution to the extent of the difference between the offering price per share of
common stock you pay in this offering and the net tangible book value per share of our common stock immediately after this offering.
Our net tangible book value as of September 30, 2020, was $2.4 million, or $0.38 per share of common stock. Net tangible book
value per share is equal to our total tangible assets minus total liabilities, all divided by the number of shares of common stock
outstanding. Based on the public offering price of $25.00 per share of common
stock in this offering, and our historical net tangible book value per share as of September 30, 2020 described above, if you
purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of $21.29 per
share. See &ldquo;Dilution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
issuance of shares upon the exercise of derivative securities may cause immediate and substantial dilution to our existing shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 31, 2021, we had approximately 11,500 shares of common stock that were issuable upon the exercise of vested outstanding
stock options. The issuance of shares upon the exercise of these options may result in substantial dilution to the equity interest
and voting power of holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may also issue additional shares of common stock or other securities convertible into or exchangeable for shares
of common stock. For instance, certain of the product license agreements we have entered into with third parties require us to
make payments to such third parties upon the occurrence of certain events. Pursuant to these product license agreements, we may
choose to make such payments in shares of our common stock. The issuance of additional shares of our common stock may substantially
dilute the ownership interests of our existing shareholders. Furthermore, sales of a substantial amount of our common stock in
the public market, or the perception that these sales may occur, could reduce the market price of our common stock. This could
also impair our ability to raise additional capital through the sale of our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Management
will have broad discretion as to the use of the net proceeds from this offering, and we may not use these proceeds effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in
ways that do not improve our results of operations or enhance the value of our common stock. Accordingly, you will be relying
on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part
of your investment decision, to assess whether the proceeds are being used appropriately. Our failure to apply these funds effectively
could have a material adverse effect on our business, delay the development of our products and cause the price of our common
stock to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>It
is possible that we will require additional capital to meet our financial obligations and support business growth, and this capital
might not be available on acceptable terms or at all; new investors face possible future dilution.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to continue to make significant investments to support our business growth and expect to require additional funds to respond
to business challenges. Accordingly, we may need to engage in equity or debt financings to secure additional funds. If we raise
additional funds through future issuances of equity or convertible debt securities, our existing shareholders could suffer significant
dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of
our common stock. Any debt financing that we secure in the future could involve restrictive covenants relating to our capital
raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital
and to pursue business opportunities, including potential acquisitions. We may not be able to obtain additional financing on terms
favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when and if
we require it, our ability to continue to support our business growth and to respond to business challenges could be significantly
impaired, and our business may be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
trading price of the shares of our common stock is highly volatile, and purchasers of our common stock could incur substantial
losses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock has been and is likely to continue to be highly volatile and could fluctuate widely in response
to various factors, many of which are beyond our control, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">technological
                                         innovations or new products and services by us or by our competitors, including announcements
                                         by us or our competitors of significant contracts, acquisitions, strategic partnerships
                                         or capital commitments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
                                         or departures of key personnel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in expectations as to our future financial performance;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         continued impact of the COVID-19 pandemic on our business operations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
                                         of our common stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to execute our business plan;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
                                         of any strategic relationship;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">industry
                                         developments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in financial estimates by any securities analysts who follow our common stock, our failure
                                         to meet these estimates or failure of those analysts to initiate or maintain coverage
                                         of our common stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                         market conditions, including market volatility;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
                                         in stock market prices and trading volumes of similar companies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic,
                                         political and other external factors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">period-to-period
                                         fluctuations in our financial results;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applicable
                                         regulatory developments in the United States and foreign countries, both generally or
                                         specific to us and our products; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">intellectual
                                         property, product liability or other litigation against us.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
publicly traded securities are subject to price and volume fluctuations, it is likely that our common stock will experience these
fluctuations to a greater degree than the securities of more established and better capitalized organizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
common stock does not have a vigorous trading market, and you may not be able to sell your securities at or near ask prices, or
at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
there is a public market for our common stock, trading volume has been historically low, which could impact our stock price and
your ability to sell shares of our common stock at or near ask prices, or at all. We can give no assurance that a more active
and liquid public market for the shares of our common stock will develop in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
potential sale of large amounts of common stock may have a negative effect upon the market value of our shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a significant number of shares of our common stock in the public market could harm the market price of our common stock and
make it more difficult for us to raise funds through future offerings of common stock. As additional shares of our common stock
become available for resale in the public market, the supply of our common stock will increase, which could decrease the price
of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have not paid, and we are unlikely to pay, cash dividends on our securities in the near future. Because we have no current plans
to pay cash dividends on our common stock for the foreseeable future, you may not receive any return on investment unless you
sell your common stock for a price greater than that which you paid for it.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid and do not currently intend to pay dividends on our common stock, which may limit the current return available on
an investment in our stock. Future dividends on our stock, if any, will depend on our future earnings, capital requirements, financial
condition and such other factors as our management may consider relevant. Currently, we intend to retain earnings, if any, to
increase our net worth and reserves. Consequently, shareholders will only realize an economic gain on their investment in our
common stock if the price appreciates. Shareholders should not purchase our common stock expecting to receive cash dividends.
Because we currently do not pay dividends, and there may be limited trading in our common stock, shareholders may not have any
manner to liquidate or receive any payment on their common stock. Therefore, our failure to pay dividends may cause shareholders
to not see any return on their common stock even if we are successful in our business operations. In addition, because we do not
pay dividends, we may have trouble raising additional funds, which could affect our ability to expand our business operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
few of our existing shareholders own a large percentage of our voting stock and have control over matters requiring shareholder
approval and may delay or prevent a change in control or otherwise lead to actual or potential conflicts of interest.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 31, 2021, our directors owned, and through their affiliates controlled, 70.5% of our outstanding common stock. As a
result, our directors and their affiliates could have the ability to exert substantial influence over all matters requiring approval
by our shareholders, including (i) the election and removal of directors, (ii) any proposed merger, consolidation or sale of all
or substantially all of our assets as well as other corporate transactions and (iii) any amendment to our Certificate of Formation,
as amended (the &ldquo;Certificate of Formation&rdquo;). This concentration of control could be disadvantageous to other shareholders
having different interests. This significant concentration of share ownership may adversely affect the trading price for our common
stock because investors sometimes perceive disadvantages in owning stock in companies with controlling shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our Certificate of Formation contains a provision which under the Texas Business Organizations Code (the &ldquo;TBOC&rdquo;)
could allow the shareholders who own a majority of our common stock to approve certain major transactions without the approval
of other shareholders that otherwise would be required under Texas corporation law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Certificate of Formation includes provisions limiting the personal liability of our directors for breaches of fiduciary duties
under Texas law.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Formation contains a provision eliminating a director&rsquo;s personal liability to the fullest extent permitted
under Texas law. Pursuant to the TBOC, a corporation has the power to indemnify its directors and officers against judgments and
certain expenses other than judgments that are actually and reasonably incurred in connection with a proceeding, provided that
there is a determination that the individual acted in good faith and in a manner reasonably believed to be in or not opposed to
the best interests of the corporation and, with respect to any criminal proceeding, had no reasonable cause to believe the individual&rsquo;s
conduct was unlawful. However, no indemnification may be made in respect of any proceeding in which such individual is liable
to the corporation or improperly received a personal benefit and is found liable for willful misconduct, breach of the duty of
loyalty owned to the corporation, or an act or omission deemed not to be committed in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal effect of the limitation on liability provision is that a shareholder will be unable to prosecute an action for monetary
damages against a director unless the shareholder can demonstrate a basis for liability for which indemnification is not available
under the TBOC. This provision, however, should not limit or eliminate our rights or any shareholder&rsquo;s rights to seek non-monetary
relief, such as an injunction or rescission, in the event of a breach of a director&rsquo;s fiduciary duty. This provision will
not alter a director&rsquo;s liability under federal securities laws. The inclusion of this provision in our Certificate of Formation
may discourage or deter shareholders or management from bringing a lawsuit against directors for a breach of their fiduciary duties,
even though such an action, if successful, might otherwise have benefited us and our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Texas
law and our Certificate of Formation and bylaws contain anti-takeover provisions that could delay or discourage takeover attempts
that shareholders may consider favorable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our Certificate of Formation, our board of directors can authorize the issuance of preferred stock, which could diminish the rights
of holders of our common stock and make a change of control of the Company more difficult even if it might benefit our shareholders.
The board of directors is authorized to issue shares of preferred stock in one or more series and to fix the voting powers, preferences
and other rights and limitations of the preferred stock. Accordingly, we may issue shares of preferred stock with a preference
over our common stock with respect to dividends or distributions on liquidation or dissolution, or that may otherwise adversely
affect the voting or other rights of the holders of common stock. Issuances of preferred stock, depending upon the rights, preferences
and designations of the preferred stock, may have the effect of delaying, deterring or preventing a change of control, even if
that change of control might benefit our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, provisions of our Certificate of Formation and bylaws may delay or discourage transactions involving an actual or potential
change in our control or change in our management, including transactions in which shareholders might otherwise receive a premium
for their shares, or transactions that our shareholders might otherwise deem to be in their best interests. For example, our Certificate
of Formation and bylaws (i) do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares
of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should
so choose), (ii) require that special meetings of the shareholders be called by the Chairman of the board of directors, the President
or the board of directors, or by the holders of not less than ten percent (10%) of all the shares issued, outstanding and entitled
to vote, (iii) permit our board of directors to alter, amend or repeal our bylaws or to adopt new bylaws, and (iv) enable our
board of directors to increase the number of persons serving as directors and to fill vacancies created as a result of the increase
by a majority vote of the directors present at a meeting of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we are subject to the provisions of Title 2, Chapter 21, Subchapter M of the TBOC, which provides that a Texas corporation that
qualifies as an &ldquo;issuing public corporation&rdquo; (as defined in the TBOC) may not engage in specified types of business
combinations, including mergers, consolidations and asset sales, with a person, or an affiliate or associate of that person, who
is an &ldquo;affiliated shareholder,&rdquo; the restrictions in Title 2, Chapter 21, Subchapter M of the TBOC do not apply to
us because we have elected, in the manner provided under the TBOC, not to be subject to such provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares of common stock are currently listed for trading on The Nasdaq Capital Market under the symbol &ldquo;SMTI.&rdquo; If we
fail to satisfy the continued listing requirements of The Nasdaq Stock Market, LLC (&ldquo;Nasdaq&rdquo;), such as the corporate
governance requirements, the shareholder&rsquo;s equity requirement or the minimum closing bid price requirement, Nasdaq may take
steps to delist our common stock. Such a delisting or even notification of failure to comply with such requirements would likely
have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when
you wish to do so. In the event of a delisting, we expect that we would take actions to restore our compliance with Nasdaq&rsquo;s
listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become
listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping
below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&rsquo;s listing requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_005"></A>CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus and the documents incorporated herein and therein contain forward-looking
statements within the meaning of the federal securities laws. Forward-looking statements generally relate to future events or
our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain
words such as &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;continue,&rdquo; &ldquo;contemplates,&rdquo; &ldquo;could,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predicts,&rdquo; &ldquo;projects,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo; &ldquo;will&rdquo; or &ldquo;would&rdquo;
or the negative of these words, variations of these words or other similar terms or expressions that concern our expectations,
strategy, plans, or intentions. Such forward-looking statements are subject to certain risks, uncertainties and assumptions relating
to factors that could cause actual results to differ materially from those anticipated in such statements, including, without
limitation, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         impact of the COVID-19 pandemic on our business, financial condition and results of operations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shortfalls
                                         in forecasted revenue growth;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to implement our comprehensive wound and skin care strategy through acquisitions
                                         and investments and our ability to realize the anticipated benefits of such acquisitions
                                         and investments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to meet our future capital requirements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to retain and recruit key personnel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         intense competition in the markets in which we operate and our ability to compete within
                                         our markets;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         failure of our products to obtain market acceptance;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         effect of security breaches and other disruptions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to maintain effective internal controls over financial reporting;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to comply with the restrictive covenants set forth in the Loan Agreement governing
                                         our revolving credit facility;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to maintain and further grow clinical acceptance and adoption of our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         impact of competitors inventing products that are superior to ours;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions
                                         of, or changes in, our distribution model, consumer base or the supply of our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to manage product inventory in an effective and efficient manner;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         failure of third-party assessments to demonstrate desired outcomes in proposed endpoints;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to successfully expand into wound and skin care virtual consult and other services;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability and the ability of our research and development partners to protect the proprietary
                                         rights to technologies used in certain of our products and the impact of any claim that
                                         we have infringed on intellectual property rights of others;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         dependence on technologies and products that we license from third parties;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         effects of current and future laws, rules, regulations and reimbursement policies relating
                                         the labeling, marketing and sale of our products and our planned expansion into wound
                                         and skin care virtual consult and other services and our ability to comply with the various
                                         laws, rules and regulations applicable to our business; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         effect of defects, failures or quality issues associated with our products.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
caution you that the foregoing list may not contain all of the risk factors that may impact the forward-looking statements made
in this prospectus supplement and the accompanying prospectus and the documents incorporated herein and therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not rely upon forward-looking statements as predictions of future events. We have based the forward-looking statements
contained in this prospectus supplement and the accompanying prospectus and the documents incorporated by reference herein and
therein primarily on our current expectations and projections about future events and trends that we believe may affect our business,
financial condition, results of operations, and prospects. The outcome of the events described in these forward-looking statements
is subject to risks, uncertainties and other factors described in the section titled &ldquo;Risk Factors&rdquo; in this prospectus
supplement and the accompanying prospectus and in the documents incorporated by reference herein and therein. Moreover, we operate
in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible
for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this prospectus
supplement and the accompanying prospectus and the documents incorporated by reference herein and therein. We cannot assure you
that the results, events, and circumstances reflected in the forward-looking statements will be achieved or occur, and actual
results, events, or circumstances could differ materially from those described in the forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements made, or incorporated by reference, in this prospectus supplement and the accompanying prospectus relate
only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements
made, or incorporated by reference, in this prospectus supplement and the accompanying prospectus to reflect events or circumstances
after the date of this prospectus supplement, the accompanying prospectus or the documents incorporated by reference herein or
therein or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually
achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions,
mergers, dispositions, joint ventures, or investments we may make.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, statements that &ldquo;we believe&rdquo; and similar statements reflect our beliefs and opinions on the relevant subject.
These statements are based upon information available to us as of the date of this prospectus supplement and the accompanying
prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited
or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review
of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not
to unduly rely upon these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_006"></A>USE
OF PROCEEDS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We estimate that the net
proceeds from the issuance and sale of our common stock in this offering will be approximately $25.0 million (or approximately
$28.8 million if the underwriters exercise their option to purchase additional shares of common stock) after deducting underwriting
discounts and commissions and estimated offering expenses payable by us.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently intend to use the net proceeds we receive from this offering to expand our salesforce and for further development of
our products, services and technologies pipeline, clinical studies, a $600,000 investment in Precision Healing that is required
to be made in February 2021 and general corporate purposes, including working capital. In addition, pursuant to our product license
agreement with Rochal, dated July 7, 2019, we are required to pay Rochal a $750,000 Capital Raise Payment, which, at our option,
may be paid in cash or shares of our common stock, or a combination of cash and shares of our common stock, if we sell shares
of our common stock for gross proceeds in the amount of at least $10 million on or prior to December 31, 2022. Accordingly, we may use a portion of the proceeds from this offering to
pay Rochal the Capital Raise Payment pursuant to the product license agreement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected use of the net proceeds from this offering and our existing cash and our cash equivalents and short-term investments
represents our intentions based upon our current plans and business conditions, which could change in the future as our plans
and business conditions evolve. As of the date of this prospectus supplement, we cannot predict with certainty all of the particular
uses for the proceeds to be received upon the closing of this offering or the actual amounts that we will spend on the uses set
forth above. Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital
preservation investments, including short-term, investment-grade, interest-bearing instruments.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_007"></A>MARKET
INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our common stock currently
trades on The Nasdaq Capital Market under the symbol &ldquo;SMTI.&rdquo; On February 11, 2021, the last reported sale price of
our common stock on The Nasdaq Capital Market was $41.00 per share. As of February 11, 2021, we had 219 holders of record of our
common stock. This does not reflect the number of persons or entities who held stock in nominee or street name through various
brokerage firms.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_008"></A>DIVIDEND
POLICY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future
earnings for use in the operation of our business and do not anticipate paying any cash dividends in the foreseeable future. Any
decision to declare and pay dividends in the future will be made at the discretion of our board of directors and will depend on,
among other things, our results of operations, cash requirements, financial condition, contractual restrictions, and other factors
that our board of directors may deem relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_009"></A>DILUTION</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock, your interest will be diluted immediately to the extent of the difference between the offering
price per share you will pay in this offering and the as adjusted net tangible book value per share of our common stock after
this offering. As of September 30, 2020, our historical net tangible book value was $2.4 million, or $0.38 per share of our common
stock. Our historical net tangible book value is the amount of our total tangible assets less our liabilities. Historical net
tangible book value per share is our historical net tangible book value divided by the number of shares of common stock outstanding
as of September 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our as adjusted net tangible
book value as of September 30, 2020, which is our net tangible book value at that date, after giving effect to the sale of 1,100,000
shares of common stock in this offering by us at a public offering price of $25.00 per share, and after deducting the underwriting
discounts and commissions and estimated offering expenses payable by us, would have been $27.4 million, or $3.71 per share. This
amount represents an immediate increase in net tangible book value of $3.33 per share to our existing shareholders and
an immediate dilution of $21.29 per share to investors participating in this offering. Dilution per share to investors participating
in this offering is determined by subtracting as adjusted net tangible book value per share after this offering from the public
offering price per share paid by investors in this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table illustrates this dilution on a per share basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    offering price per share</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.00</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical
    net tangible book value per share as of September 30, 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.38</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in net tangible book value per share attributable to new investors purchasing shares of common stock in this offering</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">3.33</P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    adjusted net tangible book value per share after giving effect to this offering</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.71</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution
    per share to investors participating in this offering</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">21.29</P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the underwriters exercise
their option to purchase additional securities in full, the as adjusted net tangible book value will increase to $4.13 per share,
representing an immediate increase in as adjusted net tangible book value to existing shareholders of $3.75 per share and immediate
dilution of $20.87 per share to investors participating in this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above discussion and table is based on 6,279,610 outstanding shares of common stock as of September 30, 2020. This number excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,500
                                         shares of common stock issuable upon the exercise of outstanding stock options at a weighted
                                         average exercise price of $6.00 per share as of September 30, 2020;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">1,769,122
                                         shares of common stock reserved for future issuance under the 2014 Plan as of September
                                         30, 2020; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,536
                                         shares of common stock issued in January 2021 pursuant to an equity exchange agreement
                                         whereby we acquired all of the issued and outstanding equity interests of WounDerm;
                                         and</FONT></TD></TR>                                                                                                                                                                                                   <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&#9679;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">30,000 shares of common stock that we may issue to Rochal upon the
completion of this offering for purposes of the Capital Raise Payment.</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, except as otherwise indicated, all information above assumes no exercise by the underwriters of their option to purchase
165,000 additional
shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that any outstanding options are exercised, new options or restricted stock units are issued under our stock-based
compensation plans or we issue additional shares of common stock or other equity or convertible debt securities in the future,
there will be further dilution to investors participating in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations is intended to provide a reader of
our financial statements with a narrative from the perspective of our management on our financial condition, results of operations,
liquidity and certain other factors that may affect our future results. You should read the following discussion and analysis
of our financial condition and results of operations in conjunction with the audited and unaudited consolidated financial statements
and related notes included elsewhere in this prospectus. The following discussion contains forward-looking statements that are
subject to risks and uncertainties. See &ldquo;Special Note Regarding Forward-Looking Statements&rdquo; for a discussion of the
uncertainties, risks, and assumptions associated with those statements. Actual results could differ materially from those discussed
in or implied by forward-looking statements as a result of various factors, including those discussed below and elsewhere in this
prospectus, particularly in &ldquo;Risk Factors.&rdquo; References in this discussion and analysis to our &ldquo;Company,&rdquo;
&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo; or &ldquo;ours&rdquo; or similar words are to Sanara MedTech Inc. and its
direct and indirect subsidiaries.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes
and reduce healthcare expenditures in the surgical and chronic wound and skin care markets. Our portfolio of products and services
will allow us to deliver comprehensive wound and skin care solutions for patients in all care settings, including acute (hospitals
and long-term acute care hospitals (&ldquo;LTACHs&rdquo;)) and post-acute (wound care clinics, physician offices, skilled nursing
facilities (&ldquo;SNFs&rdquo;), home health, hospice, and retail). Each of our products, services, and technologies contributes
to our overall goal of achieving better clinical outcomes at a lower overall cost for patients regardless of where they receive
care. We strive to be one of the most innovative and comprehensive providers of effective wound and skin care products and technologies
and are continually seeking to expand our offerings for patients requiring wound and skin care treatments across the entire continuum
of care in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently market seven products across chronic and surgical wound care applications and have multiple products in our pipeline.
We license our products from research and development partners Applied Nutritionals, LLC (&ldquo;AN&rdquo;) (through a sublicense
with CGI Cellerate RX, LLC (&ldquo;CGI Cellerate RX&rdquo;), an affiliate of The Catalyst Group, Inc. (&ldquo;Catalyst&rdquo;))
and Rochal Industries, LLC (&ldquo;Rochal&rdquo;) and have the right to exclusively distribute certain products under development
by Cook Biotech Inc. (&ldquo;Cook Biotech&rdquo;). In 2021, we intend to begin marketing three biologic products for surgical
and wound care applications pursuant to our marketing and distribution agreement with Cook Biotech.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2020, we formed a subsidiary, United Wound and Skin Solutions LLC (&ldquo;UWSS&rdquo;), to hold certain investments and operations
in wound and skin care virtual consult services. We anticipate that our various service offerings will allow clinicians/physicians
utilizing our technologies to collect and analyze large amounts of data on patient conditions and outcomes that will improve treatment
protocols and ultimately lead to more evidence-based formulary to improve patient outcomes. We intend to launch our initial virtual
consult service offerings in 2021. Through a combination of our UWSS services and our Sanara products, we believe we will be able
to offer patient care solutions at every step in the continuum of wound and skin care from diagnosis through healing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impact
of the COVID-19 Pandemic</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
in March 2020, many states issued orders suspending elective surgeries in order to free-up hospital resources to treat COVID-19
patients. This resulted in a reduction in demand for our surgical products beginning in the second half of March 2020.
Additionally, most states limited access to SNFs to only resident caregivers, which impeded our ability to provide education and
product training to the clinicians who use our products in these facilities. These restrictions resulted in an overall decline
in sales for the second quarter of 2020. During the third quarter of 2020, we saw a strong rebound in product sales as restrictions
on elective surgeries eased in our primary markets in Texas, Florida, and the southeastern United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
for the three months ended September 30, 2020 was $4.3 million, a $1.3 million increase from the three months ended June 30, 2020
and represented a record high sales quarter for our Company. With certain states recently experiencing a spike in COVID-19 cases,
the Company may again experience swings in monthly sales if more stringent restrictions are imposed on elective surgeries. For
example, Texas Governor Greg Abbott has issued a standing executive order requiring that hospitals in any Trauma Service Area
(as defined in the executive order) that has had seven consecutive days in which the number of COVID-19 hospitalized patients
as a percentage of total hospital capacity exceeds 15 percent postpone all surgeries and procedures that are not medically necessary
to diagnose or correct a serious medical condition of, or to preserve the life of, a patient, until such time as the Trauma Service
Area reaches seven consecutive days in which the number of COVID-19 hospitalized patients as a percentage of total hospital capacity
is 15 percent or less.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the COVID-19 pandemic, we significantly reduced costs in areas such as payroll, consulting, business travel, and other
discretionary spending. The duration of the pandemic is uncertain; however, management believes that elective surgical procedures
will continue to be performed with the exception of certain geographic COVID-19 hotspots. We will continue to closely monitor
the COVID-19 pandemic in order to ensure the safety of our people and our ability to serve our customers and patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cellerate
Acquisition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
August 28, 2018, we consummated definitive agreements that continued operations to market our principal product, CellerateRX,
through a 50% ownership interest in a newly formed entity, Cellerate, LLC (&ldquo;Cellerate&rdquo;), which began operations on
September 1, 2018. The remaining 50% ownership interest was held by an affiliate of Catalyst, which acquired the exclusive license
to CellerateRX products. Cellerate conducted operations with an exclusive sublicense from the Catalyst affiliate to distribute
CellerateRX products in the United States, Canada and Mexico (which sublicense was subsequently amended to include worldwide distribution
rights). In connection with the formation of Cellerate, we issued a convertible promissory note to an affiliate of Catalyst in
the original principal amount of $1.5 million, which was convertible into shares of our common stock at a conversion price of
$9.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2019, we acquired Catalyst&rsquo;s 50% interest in Cellerate in exchange for the issuance of 1,136,815 shares of our
newly created Series F Convertible Preferred Stock (the &ldquo;Cellerate Acquisition&rdquo;). Each share of Series F Convertible
Preferred Stock was convertible at the option of the holder, at any time, into two shares of common stock. Additionally, each
holder of Series F Convertible Preferred Stock was entitled to vote on all matters submitted for a vote of our shareholders with
votes equal to the number of shares of common stock into which such holder&rsquo;s shares of Series F Convertible Preferred Stock
could then be converted. Following the closing of the Cellerate Acquisition, Mr. Ronald T. Nixon, Founder and Managing Partner
of Catalyst, was elected to our board of directors, effective March 15, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Cellerate Acquisition was accounted for as a reverse merger and recapitalization because, immediately following the completion
of the transaction, Catalyst could obtain effective control of the Company upon conversion of its convertible preferred stock
and convertible promissory note, both of which could occur at Catalyst&rsquo;s option. Additionally, Cellerate&rsquo;s officers
and senior executive positions continued on as management of the combined entity after consummation of the Cellerate Acquisition.
For accounting purposes, Cellerate was deemed to be the acquirer in the transaction and, consequently, the Cellerate Acquisition
was treated as a recapitalization of Sanara MedTech. As part of the reverse merger and recapitalization, the net liabilities existing
in the Company as of the date of the Cellerate Acquisition totaling approximately $1,666,537, which included $508,973 of cash,
were converted to equity as part of the Cellerate Acquisition. No step-up in basis or intangible assets or goodwill was recorded
in this transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the reverse merger, Cellerate&rsquo;s assets, liabilities and results of operations are the historical financial statements
of the registrant, and Cellerate&rsquo;s assets, liabilities and results of operations have been combined with Sanara MedTech
effective as of the date of the closing of the Cellerate Acquisition. The consolidated financial statements incorporated by reference
herein identify Cellerate as &ldquo;Successor&rdquo; for the twelve-month period ended December 31, 2019, and on the balance sheet
date of December 31, 2018. Upon its formation on August 28, 2018, Cellerate succeeded to the business and operations of Sanara
MedTech. As a result, Sanara MedTech is identified as &ldquo;Predecessor&rdquo; for the periods preceding August 28, 2018. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
provide a meaningful presentation and comparison of our results of operations, this discussion and analysis combines the period
of January 1, 2018 through August 27, 2018 (Predecessor) with the period of August 28, 2018 through December 31, 2018 (Successor).
In the consolidated financial statements incorporated herein by reference, a black line separates the Predecessor and Successor
financial statements to highlight the lack of comparability between these two periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Successor financials for the twelve months ended December 31, 2019 do not include revenues and expenses related to the Predecessor
for the period January 1, 2019 through March 15, 2019. During this period, the Predecessor&rsquo;s revenues were approximately
$34,000 and expenses were approximately $348,000, which are not reflected in the Company&rsquo;s results of operations during
the twelve months ended December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reverse
Stock Split </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
May 10, 2019, we effected a reverse stock split of the issued and outstanding shares of our common stock at a ratio of one share
for every 100 shares. All share and per share information in this discussion and analysis has been adjusted to reflect the reverse
stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Components
of Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sources
of Revenues</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenue is derived primarily from sales of our surgical wound care products to hospitals and other acute care facilities, and
sales of our chronic wound care products to customers across the post-acute continuum of care. Our revenue is driven by direct
orders shipped by us to our customers, and to a lesser extent, direct sales to customers through delivery at the time of procedure
by one of our sales representatives. We generally recognize revenue when our product is received by the customer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
streams from product sales and royalties are summarized below for the nine months ended September 30, 2020 and 2019. All revenue
was generated in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Nine Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify">Surgical</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">9,978,134</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">7,552,708</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Wound Care</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">668,954</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">752,084</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Royalty revenue</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">150,750</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">108,875</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Total Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,797,838</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,413,667</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize royalty revenue from a development and licensing agreement with BioStructures, LLC. We record revenue each calendar
quarter as earned per the terms of the agreement which stipulates that we will receive quarterly royalty payments of at least
$50,250. Under the terms of the development and license agreement, royalties of 2.0% are recognized on sales of products containing
our patented resorbable bone hemostasis. The minimum annual royalty due to our Company is $201,000 per year throughout the life
of the patent which expires in 2023. These royalties are payable in quarterly installments of $50,250. To date, royalties related
to this development and licensing agreement have not exceeded the annual minimum of $201,000 ($50,250 per quarter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cost
of Goods Sold</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of goods sold consists of the acquisition costs from the manufacturers of our licensed products, raw material costs for certain
components sourced directly by our Company, and all royalties related due as a result of the sale of our products. Our gross profit
represents total revenue less the cost of goods sold, and gross margin is gross profit expressed as a percentage of total revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Operating
Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
general and administrative expenses (&ldquo;SG&amp;A&rdquo;) consist primarily of salaries, sales commissions, benefits, bonuses,
and stock-based compensation. SG&amp;A also includes outside legal counsel, audit fees, insurance premiums, rent, and other corporate
expenses. We expense all SG&amp;A expenses as incurred. We expect our SG&amp;A expenses to increase in absolute dollars and decrease
as a percent of revenue as we grow our commercial organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Income (Expense)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income (expense) is primarily comprised of interest income, interest expense and other non-operating activities. Interest expense
during 2020 consisted primarily of interest expense associated with our unsecured promissory note under the Paycheck Protection
Program (the &ldquo;PPP&rdquo;) pursuant to the Coronavirus Aid, Relief and Economic Security Act, and for 2019, consisted primarily
of interest on amounts due on our revolving line of credit that matured in June 2020. Interest income consists of interest earned
on our cash and cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Three
and Nine Months Ended September 30, 2020 Compared to Three and Nine Months Ended September 30, 2019</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Revenues</I>.
We generated record high revenue of $4,306,324 for the three months ended September 30, 2020, compared to revenue of $2,909,282
for the three months ended September 30, 2019, representing a 48% increase in revenue from the comparable prior year period. During
the third quarter of 2020, many restrictions on elective surgeries were eliminated or relaxed in our primary markets which facilitated
a return to pre-COVID pandemic sales levels. For the nine months ended September 30, 2020, revenue totaled $10,797,838, compared
to revenue of $8,413,667 for the nine months ended September 30, 2019, yielding a 28% increase from the comparable prior year
period. The higher revenue in 2020 was due to the strong rebound in third quarter 2020 sales and the continued execution of our
strategy to expand our sales force and independent distribution network in both new and existing U.S. geographic markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cost
of goods sold</I>. Cost of goods sold for the three months ended September 30, 2020, was $447,935, compared to costs of goods
sold of $285,164 for the three months ended September 30, 2019. Cost of goods sold for the nine months ended September 30, 2020,
was $1,126,798, compared to costs of goods sold of $909,333 for the nine months ended September 30, 2019. The increase over the
prior year was primarily due to higher sales volume.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Selling,
general and administrative expenses</I>. SG&amp;A expenses for the three months ended September 30, 2020 were $5,083,424, as compared
to $3,315,575 for the three months ended September 30, 2019. SG&amp;A expenses for the nine months ended September 30, 2020, were
$13,613,989, as compared to $8,649,186 for the nine months ended September 30, 2019. The higher SG&amp;A expenses in 2020 were
primarily due to increased payroll costs resulting from sales force expansion and operational support, higher sales commission
expense as a result of higher product sales, and higher costs related to the expansion of our comprehensive wound and skin care
strategy including the development of electronic imagery and data sharing technology to support virtual consultation and diagnostics.
Direct selling costs represented the majority of the increase in total SG&amp;A costs as we increased the size of our field sales
organization from fourteen in September 2019 to twenty in September of 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
higher SG&amp;A expenses are consistent with our strategy of building out a larger sales force and the expansion of our comprehensive
wound and skin care strategy. New sales representatives generally take six to twelve months to begin generating sales.
We expect SG&amp;A expenses to decline as a percentage of revenue in the next two years as revenue generated by new sales representatives
begins to offset the cost of the sales force expansion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interest
expense</I>. Interest expense was $1,458 for the three months ended September 30, 2020, as compared to $46,014 for the three months
ended September 30, 2019. Interest expense was $10,913 for the nine months ended September 30, 2020, as compared to $80,925 for
the nine months ended September 30, 2019. The lower interest expense was primarily due to declines in draws on our revolving line
of credit that matured in June 2020 and the conversion of an interest-bearing promissory note to common stock in early 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Net
income / loss</I>. We had a net loss of $1,208,123 for the three months ended September 30, 2020, compared to net loss of $843,233
for the three months ended September 30, 2019. We had a net loss of $4,178,692 for the nine months ended September 30, 2020, compared
to net loss of $1,358,276 for the nine months ended September 30, 2019. The increase in net loss was due to higher SG&amp;A costs
described above, which were driven by our strategy to grow top-line revenue through significant investments in sales force expansion,
operational support, and the expansion of our comprehensive wound and skin care strategy. We expect SG&amp;A expenses to decline
as a percentage of revenue in the next two years as the revenue generated by our new sales force begins to offset the sales force
expansion expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Year
Ended December 31, 2019 Compared to Year Ended December 31, 2018</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Revenues</I>.
For the year ended December 31, 2019, we generated revenues of $11,766,763 compared to revenues of $8,779,872 for the year ended
December 31, 2018 as reported for the combined Predecessor and Successor periods, or a 34% increase from prior year. The higher
revenues in 2019 were primarily due to the continued execution of our strategy to expand our sales force and independent distribution
network in both new and existing U.S. geographic markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cost
of goods sold</I>. Cost of goods sold for the year ended December 31, 2019, was $1,209,300, compared to costs of goods sold of
$852,124 for the year ended December 31, 2018 as reported for the combined Predecessor and Successor periods. The increase over
prior year was due to higher sales volume and non-cash obsolescence charges related to certain raw materials and finished goods
inventory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>SG&amp;A</I>.
SG&amp;A expenses for the year ended December 31, 2019, were $13,067,569 compared to SG&amp;A expenses of $7,646,119
for the year ended December 31, 2018 as reported for the combined Predecessor and Successor periods. The higher SG&amp;A expenses
in 2019 were primarily due to increased payroll costs resulting from sales force expansion and operational support, higher sales
commission expense as a result of higher product sales, and increased marketing costs related to promotional activities for new
and existing product lines. Direct selling costs represented the vast majority of the increase in total SG&amp;A costs as we more
than doubled the size of our field sales organization from eight to eighteen in 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
higher SG&amp;A costs are consistent with our strategy of building out a larger sales force and independent distribution network.
New sales representatives generally take six to twelve months on average to begin generating significant revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interest
expense</I>. Interest expense was $105,919 for the year ended December 31, 2019, as compared to $60,608 for the year ended December
31, 2018 as reported for the combined Predecessor and Successor periods. The higher interest expense was primarily due to the
use of our line of credit in 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Net
income / loss</I>. For the year ended December 31, 2019, we had a net loss of $2,814,088, compared to net income of $175,464 for
the year ended December 31, 2018 as reported for the combined Predecessor and Successor periods. The net loss in 2019 was due
to higher SG&amp;A costs described above, which were driven by our strategy to grow top-line revenue through significant investments
in sales force expansion and related sales support infrastructure as well as other areas of administrative support. As mentioned
above, the Successor financials for the year ended December 31, 2019 do not include revenues and expenses related to the Predecessor
for the period January 1, 2019 through March 15, 2019. During this period, Predecessor&rsquo;s revenues were approximately $34,000
and expenses were approximately $348,000, which are not reflected in our results of operations during the year ended December
31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
we have financed our operations primarily from the sale of equity securities. During 2019 and 2020, our principal sources of liquidity
have been cash generated from operations, utilization of our bank line of credit that matured in June 2020, cash provided by an
unsecured promissory note in the principal amount of $583,000 (&ldquo;the PPP Loan&rdquo;) to Cadence Bank, N.A. (&ldquo;Cadence&rdquo;)
pursuant to the PPP, and $10,000,000 in proceeds received from a private placement of our common stock in October 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 15, 2021, we entered into a new loan agreement with Cadence (the &ldquo;Loan Agreement&rdquo;), providing for a $2.5 million
revolving line of credit. The revolving line of credit matures on January 13, 2023, and is secured by substantially all of our
assets. Any amounts outstanding will bear interest of 0.75% plus the &ldquo;Prime Rate&rdquo; designated in the &ldquo;Money Rates&rdquo;
section of the Wall Street Journal. Proceeds from the line of credit are to be used to provide additional working capital in support
of current assets and for other general corporate purposes and may not be used for acquisitions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
line of credit contains customary representations and warranties and requires us to maintain compliance with certain financial
covenants, including, among others, a minimum liquidity of $1,000,000 as of December 31, 2020 and March 31, 2021, a minimum Tangible
Net Worth (as defined in the Loan Agreement) of $1,000,000 and, beginning with the fiscal quarter ending June 30, 2021, a minimum
Interest Coverage Ratio (as defined in the Loan Agreement) of 1.5 to 1.0. In addition, the Loan Agreement requires us to cause
our shareholders or other persons approved by Cadence to make an equity investment in our Company of at least $7,500,000 by March
31, 2021. The Loan Agreement also contains customary events of default. If such an event of default occurs, Cadence would be entitled
to take various actions, including the acceleration of amounts due under the Loan Agreement. We generally may (and must, under
certain circumstances) prepay all or a portion of the principal outstanding on the revolving line of credit prior to its contractual
maturity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the COVID-19 pandemic, beginning in March 2020, we significantly reduced costs in areas such as payroll, consulting,
business travel, and other discretionary spending. We are continuing to monitor our cash flow and plan to make additional expenditure
adjustments as necessary. In November 2020, we were informed that the full amount of the PPP Loan was forgiven. If appropriate,
we may pursue additional financing including issuing additional stock and incurring additional debt to support our strategic initiatives.
If we are unable to obtain additional funding for operations at any time in the future, we may not be able to continue expanding
the business as currently planned which would require us to modify various aspects of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2020, our subsidiary, UWSS, entered into agreements to purchase shares of Series A Convertible Preferred Stock (the
&ldquo;Series A Stock&rdquo;) of Precision Healing Inc. (&ldquo;Precision Healing&rdquo;) for an aggregate purchase price of $600,000.
The Series A Stock is convertible into 150,000 shares of common stock of Precision Healing and has a senior liquidity preference
relative to the common shareholders. UWSS also agreed to invest an additional $600,000 in February 2021 for 150,000 additional
shares of Series A Stock. The additional shares of Series A Stock will convert into shares of common stock of Precision Healing
at a ratio based on the date Precision Healing delivers a development milestone related to a wound diagnostic tool currently under
development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 7, 2019, we executed a license agreement with Rochal whereby we acquired an exclusive world-wide license to market, sell
and further develop antimicrobial products for the prevention and treatment of microbes on the human body utilizing certain Rochal
patents and pending patent applications (the &ldquo;BIAKO&#772;S License Agreement&rdquo;). Under the terms of the BIAKO&#772;S
License Agreement, we agreed to pay Rochal $750,000 upon the completion of a capital raise, on or before December 31, 2022, of
at least $10,000,000 through the sale of our common stock or assets. At our option, the $750,000 payment may be paid in any combination
of cash and our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nine
Months Ended September 30, 2020 Compared to Nine Months Ended September 30, 2019</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2020, net cash used in operating activities was $3,443,449 compared to $1,333,878 used in
operating activities during the first nine months of 2019. The higher use of cash in 2020 was primarily due to our investment
in sales force expansion, corporate infrastructure, and start-up costs related to telehealth services including the development
of electronic imagery and data sharing technology to support virtual consultation and diagnostics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2020, net cash used in investing activities was $1,657,456 compared to $681,832 used in investing
activities during the first nine months of 2019. The increase in cash used in investing activities during the first nine months
of 2020 was primarily due to our entry into a product license agreement with Rochal in May 2020, which included an initial cash
payment of $600,000, along with a $500,000 milestone payment made to Rochal during the first quarter of 2020 as a result of U.S.
Food and Drug Administration (&ldquo;FDA&rdquo;) clearance of BIAKO&#772;S Antimicrobial Wound Gel. In addition, during the third
quarter of 2020, a $500,000 long-term investment was made to purchase a minority interest in Direct Dermatology Inc (&ldquo;DirectDerm&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2020, net cash provided by financing activities was $609,220 as compared to $2,000,000 provided
by financing activities for the nine months ended September 30, 2019. The cash provided by financing activities in 2020 was primarily
related to funds received from the PPP Loan. Cash provided by financing activities for the nine months ended September 30, 2019
was due to a $2,000,000 draw on a credit facility with Cadence, which was subsequently repaid and expired in the second quarter
of 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Year
Ended December 31, 2019 Compared to Year Ended December 31, 2018</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2019, net cash used in operating activities was $2,167,401 as reported for Successor, compared to
$517,079 provided by operating activities for the year ended December 31, 2018 as reported for the combined Predecessor and Successor
periods. The higher use of cash in 2019 was due to investments in our sales force expansion and related sales support infrastructure,
higher inventory purchases, and an increase in prepaid items related to inventory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2019, net cash used in investing activities was $1,197,097 as reported for Successor, compared to
$27,770 used in investing activities during the year ended December 31, 2018 as reported for the combined Predecessor and Successor
periods. The cash used in 2019 investing activities was primarily related to new product licenses whereby we paid $1,500,000 for
the exclusive worldwide rights to market and sell certain FDA-cleared products developed by Rochal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2019, net cash provided by financing activities was $9,800,005 as reported for Successor, compared
to $0 for the year ended December 31, 2018 as reported for the combined Predecessor and Successor periods. The cash provided by
financing activities was funded by the October 15, 2019 private placement offering discussed above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Material
Transactions with Related Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>CellerateRx
Sublicense Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have an exclusive,
world-wide sublicense to distribute CellerateRX products into the wound care and surgical markets from an affiliate of Catalyst,
CGI Cellerate RX, which licenses the rights to CellerateRX from AN. Sales of CellerateRX have comprised the majority of our sales
during 2018, 2019 and the nine months ended September 30, 2020. On January 26, 2021, we amended the term of the sublicense agreement
to an initial termination date of May 17, 2050, with automatic one-year renewals so long as annual net sales of CellerateRX exceed
$1,000,000. We pay royalties based on our annual net sales of CellerateRX consisting of 3% of all collected net sales each
year up to $12,000,000, 4% of all collected net sales each year that exceed $12,000,000 up to $20,000,000, and 5% of all collected
net sales each year that exceed $20,000,000. Minimum royalties of $400,000 per year are payable for the first five years of the
sublicense agreement, which was entered on August 27, 2018. For the nine-month periods ended September 30, 2020 and 2019, royalties
due under the terms of this agreement totaled $300,000 and $337,549, respectively.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
T. Nixon, our Executive Chairman, is the founder and managing partner of Catalyst. Mr. Nixon and Catalyst, collectively
with their affiliates, including CGI Cellerate RX, beneficially owned 3,418,996 shares of our common stock as of
December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Convertible
Notes Payable </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Cellerate Acquisition, we issued a 30-month convertible promissory note to Catalyst in the principal amount
of $1,500,000, bearing interest at a 5% annual interest rate, compounded quarterly. Interest on the promissory note was payable
quarterly but could have been deferred at our election to the maturity of the promissory note. Outstanding principal and interest
were convertible at Catalyst&rsquo;s option into shares of our common stock at a conversion price of $9.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 7, 2020, Catalyst converted its $1,500,000 promissory note, including accrued interest of $111,911, into 179,101 shares
of our common stock. As of September 30, 2020, there were no related party promissory notes or accrued interest outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Payables
and Prepaid Items</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had outstanding payables to related parties totaling $94,807 on September 30, 2020, and $68,668 on December 31, 2019. In the normal
course of business, we may advance payments to our suppliers, inclusive of Rochal, a related party. As of September 30, 2020,
we prepaid $50,970 to Rochal for a finished goods inventory order. On December 31, 2019, there were no prepaid balances to related
parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Manufacturing
and Technical Services Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 9, 2020, we executed a manufacturing agreement with Rochal. Under the terms of the manufacturing agreement, Rochal agreed
to manufacture, package, and label products we licensed from Rochal. The manufacturing agreement includes customary terms and
conditions. The term of the agreement is for a period of five years unless extended by the mutual consent of the parties. As of
September 30, 2020, we had not incurred any costs under this agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 9, 2020, we executed a technical services agreement with Rochal. Under the terms of the technical services agreement,
Rochal will provide its expertise and services on technical service projects identified by us for wound care, skin care and surgical
site care applications. The technical services agreement includes customary terms and conditions for our industry. We may terminate
this agreement at any time. As of September 30, 2020, we had incurred $174,200 of costs under this agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
T. Nixon, our Executive Chairman, is also a director of Rochal, and indirectly a significant shareholder of Rochal, and through
the potential exercise of warrants a majority shareholder of Rochal. Ann Beal Salamone, a director, is a significant shareholder,
the former president and current Chairman of the Board of Rochal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impact
of Inflation and Changing Prices</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
and changing prices have not had a material impact on our historical results of operations. We do not currently anticipate that
inflation and changing prices will have a material impact on our future results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements,
which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these consolidated
financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and
expenses. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under
the circumstances. The results of these assumptions form the basis for making judgments about the carrying values of assets and
liabilities that are not readily apparent from other sources. Under different assumptions or conditions, actual results may differ
from these estimates. We have identified certain significant accounting policies which involve a higher degree of judgment and
complexity in making certain estimates and assumptions that affect amounts reported in our consolidated financial statements,
as summarized below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revenue
Recognition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize revenue in accordance with Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 606, Revenue from Contracts with
Customers, which we adopted on January 1, 2018 using the modified retrospective method. Revenues are recognized when control of
the promised goods or services is transferred to the customer in an amount that reflects the consideration we expect to be entitled
to receive in exchange for transferring those goods or services. Revenue is recognized based on the following five step model:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
Identification of the contract with a customer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
Identification of the performance obligations in the contract</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
Determination of the transaction price</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
Allocation of the transaction price to the performance obligations in the contract</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
Recognition of revenue when, or as, we satisfy a performance obligation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Impairment
of Long-Lived Assets</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets, including certain identifiable intangibles held and to be used by our Company, are reviewed for impairment whenever events
or changes in circumstances, including the COVID-19 pandemic, indicate that the carrying amount of such assets may not be recoverable.
We continuously evaluate the recoverability of our long-lived assets based on estimated future cash flows and the estimated liquidation
value of such long-lived assets and provide for impairment if such undiscounted cash flows are insufficient to recover the carrying
amount of the long-lived assets. If impairment exists, an adjustment is made to write the asset down to its fair value, and a
loss is recorded as the difference between the carrying value and fair value. Fair values are determined based on quoted market
values, undiscounted cash flows or internal and external appraisals, as applicable. Assets to be disposed of are carried at the
lower of carrying value or estimated net realizable value. No impairment was recorded during the nine months ended September 30,
2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Investment
in Equity Securities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investments consist of non-marketable equity securities in a privately held company without readily determinable fair values,
and are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions
for the identical or similar investment of the same issuer. We have reviewed the carrying value of our investment and have
determined there was no impairment or observable price changes as of September 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Inventories</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at the lower of cost or net realizable value, with cost computed on a first-in, first-out basis. Inventories consist
of finished goods and related packaging components. We recorded inventory obsolescence expense of $258,585 for the nine months
ended September 30, 2020, compared to $88,438 for the nine months ended September 30, 2019. The allowance for obsolete and slow-moving
inventory had a balance of $231,342 at September 30, 2020, and $43,650 at December 31, 2019. We considered the impact of COVID-19
on our recorded value of inventory and determined no adjustment was necessary as of September 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19
pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and
subject to change. We considered the potential impact of the COVID-19 pandemic on our estimates and assumptions and determined
there was not a material impact on our estimates and assumptions used in preparing our consolidated financial statements as of
and for the nine months ended September 30, 2020; however, actual results could differ from those estimates and there may be changes
to our estimates in future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Income
Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic No. 740, &ldquo;Income Taxes.&rdquo; This standard requires us to provide
a net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between
book and tax accounting and any available operating loss or tax credit carry forwards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
applying the provisions of Section 382 of the Internal Revenue Code, the unexpired net operating loss carry forward as of December
31, 2019 was approximately $8,934,000, with a portion expiring every year from 2020 through the 2038 tax year if not used.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a limited liability company in 2018, the Successor (Cellerate, LLC) was taxed as a partnership for federal income tax purposes
and therefore had no federal tax asset or liability as of December 31, 2018. The non-current deferred tax asset is summarized
below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019 Successor</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018 Successor</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%">Net operating loss carry forwards, (21% as of December 31, 2019)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">1,876,114</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,876,114</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net non-current deferred tax asset</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
100% valuation allowance has been provided for all deferred tax assets, as the ability of the Company to generate sufficient taxable
income in the future is uncertain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not have any off-balance sheet arrangements as of December 31, 2019 or September 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_011"></A>BUSINESS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes
and reduce healthcare expenditures in the chronic and surgical wound and skin care markets. Our portfolio of products and services
will allow us to deliver comprehensive wound and skin care solutions for patients in all care settings, including acute (hospitals
and LTACHs) and post-acute (wound care clinics, physician offices, SNFs, home health, hospice, and retail). Each of our products,
services, and technologies contribute to our overall goal of achieving better clinical outcomes at a lower overall cost for patients
regardless of where they receive care. We strive to be one of the most innovative and comprehensive providers of effective wound
and skin care products and technologies and are continually seeking to expand our offerings for patients requiring wound and skin
care treatments across the entire continuum of care in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently market seven products across chronic and surgical wound care applications and have multiple products in our pipeline.
We license our products from research and development partners AN (through a sublicense with CGI Cellerate RX, an affiliate of
Catalyst) and Rochal and have the right to exclusively distribute certain products under development by Cook Biotech. In 2021,
we intend to begin marketing three biologic products for surgical and wound care applications pursuant to our marketing and distribution
agreement with Cook Biotech. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2020, we formed a subsidiary, UWSS, to hold certain investments and operations in wound and skin care virtual consult services.
We anticipate that our various service offerings will allow clinicians/physicians utilizing our technologies to collect and analyze
large amounts of data on patient conditions and outcomes that will improve treatment protocols and ultimately lead to more evidence-based
formulary to improve patient outcomes. We intend to launch our initial virtual consult service offerings in 2021. Through a combination
of our UWSS services and our Sanara products, we believe we will be able to offer patient care solutions at every step in the
continuum of wound and skin care from diagnosis through healing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Scale</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
study by a physician at the Department of Surgery for the Indiana University Health Comprehensive Wound Center found that approximately
8.2 million patients suffer from surgical and chronic wounds each year in the United States. Furthermore, according to an article
published by the <I>American College of Surgeons and Surgical Infection Society</I>, in the United States, the annual treatment
cost projections for all wounds is approximately $28 billion with the estimated annual cost of surgical site infections ranging
from $3.5 billion to $10 billion. The U.S. teledermatology market alone is estimated to grow from $5 billion in 2019 to $45 billion
by 2027 according to a research report by Fortune Business Insights. In addition to our surgical wound and chronic wound divisions,
the Company is planning to launch virtual consult services through UWSS for both virtual wound and virtual skin (dermatology)
consultations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
of our Product &amp; Service Offerings and Development Programs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are committed to developing and commercializing innovative products that address the challenges physicians face in diagnosing
and treating wound and skin care ailments. The following table sets forth our product and service portfolio:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="new_004.jpg" ALT="" STYLE="height: 363px; width: 645px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
surgical wound care products, CellerateRX Surgical Powder and Gel, are used in a wide range of surgical specialties to help promote
patient healing and reduce the risk of complications. The product is used in specialties including cardiothoracic, colorectal,
general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, oncology, orthopedic (hip
and knee, sports, spine, joint, foot and ankle, ortho trauma and ortho oncology), plastic/reconstructive, podiatric,
urology, and vascular. Currently, substantially all of our revenue is derived from the sale of surgical wound care products. We
anticipate that chronic wound care products and UWSS technology-based services will become meaningful drivers of revenue in the
future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
chronic wound care products, HYCOL Powder and Gel, BIAKO&#772;S AWC and BIAKO&#772;S Skin and Wound Gel, are used across the post-acute
continuum of care, including home health, hospice, physician offices, podiatrists, retail, SNFs, and wound care centers. Our chronic
wound care products can be used on stage I-IV pressure ulcers, DFUs, venous stasis, arterial, post-surgical wounds, first- and
second-degree burns and donor sites. BIAKO&#772;S AWC is also available in an irrigation bottle (BIAKO&#772;S Antimicrobial Skin
and Wound Irrigation Solution) that can be used in conjunction with NPWTi-d and other wound irrigation needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have a robust pipeline of products under development for both the chronic and surgical wound care and virtual consult
markets. We believe our pipeline efforts will deepen our comprehensive portfolio of offerings as well as allow us to address additional
clinical applications. Wound care products in our pipeline include an over-the-counter hand and skin cleanser, an antimicrobial
skin protectant, a debrider product that leverages the body&rsquo;s own enzymes and moisture, a new wound bed preparation device
for use with BIAKO&#772;S AWC, next generation CellerateRX and HYCOL, a novel dressing that delivers oxygen to the wound bed,
and a sterile BIAKO&#772;S product for use in surgical settings. Additionally, Sanara expects to commercialize three products
with Cook Biotech in the second half of 2021. The first two, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular
Matrix, are currently 510(k) cleared for use in the surgical wound care segment, and VIM Amnion Matrix is categorized by the FDA
as an HCT/P, subject to regulation under Section 361 of the Public Health Service Act (&ldquo;PHSA&rdquo;) (for which no premarket
approval or clearance is required).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
UWSS technology-based services we expect to launch in 2021 include: an EMR software platform for both wound and skin conditions
(WounDerm), skin and wound virtual consult services (DirectDerm and MGroup), and diagnostic products and services for chronic
wounds (Precision Healing). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
detailed below, following the anticipated launch of UWSS&rsquo;s service offerings, we expect to be able to provide wound treatment
solutions for patients across the entire acute and post-acute continuum of care:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="new_003.jpg" ALT="" STYLE="height: 357px; width: 635px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strategy
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Drive
                                         additional market penetration as well as geographic expansion for our products.</I></B>
                                         We intend to leverage our comprehensive product and technology-based services portfolio
                                         and relationships with key constituents to deepen our presence in the surgical and chronic
                                         wound and skin care markets. We believe the breadth and flexibility of the products we
                                         offer allow us to address a wide variety of wound types and sizes and offer significant
                                         new opportunities for sales growth. In addition, we believe that as we continue to offer
                                         new products and technology-based services, our salesforce&rsquo;s ability to reach additional
                                         customers in new and existing geographic regions while penetrating further in existing
                                         customer accounts will be enhanced.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Expand
                                         into new markets for our products and services. </I></B>In 2020 we made significant investments
                                         in virtual consult technologies and services. The COVID-19 pandemic has dramatically
                                         increased demand for these services with expanded reimbursements and patients being more
                                         comfortable seeing their care provider virtually. We believe that the virtual consult
                                         technologies and services that we will offer, when combined with our innovative and highly
                                         efficacious products, will offer a differentiated comprehensive wound and skin care solution
                                         for patients and care givers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Launch
                                         new innovative products.</I></B> We are actively working with third-party research and
                                         development partners to develop additional proprietary products for the chronic and surgical
                                         wound and skin care markets. We expect these products and services to deepen our portfolio
                                         of technologies to treat chronic wounds as well as improve surgical site outcomes. We
                                         are focused on offering additional products and services that are more efficacious than
                                         competing products and services and provide a stronger value proposition (lower total
                                         cost to heal and less time to heal leading to reduced costs to the healthcare system).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Capture
                                         patients throughout the entire continuum of care.</I></B> We intend to continue expanding
                                         our platform to aid in treating wound and skin care patients as they progress through
                                         the healing process in all care settings. As discussed above, in June 2020, we formed
                                         a subsidiary, UWSS, to hold certain investments in technologies and operations in wound
                                         and skin care virtual consult services. We believe our service offerings will allow us
                                         to collect and analyze large amounts of data on patient conditions and outcomes that
                                         will improve treatment protocols and ultimately lead to more evidence-based healing formularies
                                         to improve outcomes in the future. We anticipate that this data will also enable us to
                                         participate in the creation of new standards of care that promote patient compliance
                                         and enable direct dialogue between patients, clinicians and payors, resulting in greater
                                         satisfaction for patients, their caregivers, clinicians and payors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Seek
                                         and establish partnerships and product, technology, and/or services acquisitions.</I></B>
                                         We plan to continue to seek and establish partnerships in the United States and internationally
                                         to provide innovative products, services, and technologies. We believe that partnerships
                                         will be a key driver of our growth in the future. We also intend to selectively pursue
                                         acquisitions of businesses and technologies that complement our existing strategy and
                                         footprint.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Achieve
                                         meaningful operating margin improvement.</I></B> We expect to increase our margins through
                                         a dual-pronged approach. First, as we scale the sales of our products, the leverage on
                                         salaries and infrastructure costs (legal, finance, commercial operations support and
                                         rent) as a percentage of revenue should decrease, increasing our operating margin. Second,
                                         we expect to achieve higher gross and operating margins as our UWSS services are commercialized
                                         and reach sufficient scale.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competitive
Strengths </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comprehensive
                                         solution for improved wound care outcomes.</I></B> We are dedicated to offering a comprehensive
                                         portfolio of products and services to improve wound care treatment outcomes. We are currently
                                         developing the capability to provide telehealth services for the diagnosis and treatment
                                         of wound and skin care patients. Our product offerings are able to disinfect wounds and
                                         accelerate the body&rsquo;s healing process for acute and chronic wounds and allow clinicians
                                         to provide a consistent plan of care for a patient from diagnosis through treatment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Wound
                                         care products for all care settings.</I></B> Our wound care product portfolio allows
                                         clinicians to personalize solutions to meet the needs of individual wound care patients
                                         in all care settings including acute (hospitals and LTACHs) and post-acute (wound care
                                         clinics, physician offices, SNFs, home health, hospice, and retail). Our experienced
                                         wound care sales force is highly trained to assist clinicians to effectively deploy the
                                         full complement of our product portfolio to effectively treat wounds.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Innovative
                                         pipeline and proven clinical performance.</I></B> We have a robust pipeline of chronic
                                         and surgical wound and skin care products that we expect to market in the near term.
                                         We believe the efficacy of our offerings, will be proven via statistically significant
                                         collected and analyzed clinical and health economic outcomes data, resulting in expanded
                                         adoption of our products at a lower overall cost to payors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Attractive
                                         markets for acute and chronic wound care.</I></B> We believe the acute and chronic wound
                                         care markets will continue to see accelerated growth given favorable global tailwinds
                                         that include an aging population, increasing costs of health care, recognition of difficult-to-treat
                                         infection threats such as biofilms, and the increasing prevalence of diabetes and obesity.
                                         We believe there will be growing adoption of our products due to their clinical efficacy
                                         and cost effectiveness for all key constituents compared to traditional wound care products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Proven
                                         executive leadership team with a long-term track record of value creation.</I></B> We
                                         are led by a dedicated and seasoned management team with significant industry experience
                                         who have successfully executed our strategic implementation to date by launching new
                                         products and technologies through investment in new areas of growth. We believe our management
                                         has the vision and experience to implement our future growth strategy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Opportunities for our Products and Technology-Based Services </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, CMS&rsquo;s reimbursement methodology for home health agencies and SNFs (PDGM and PDPM, respectively) created unique
opportunities to provide efficacious wound healing inside of those sites of care in unprecedented fashion. With those payment
models now focused on a patient&rsquo;s characteristics (including number of wounds and skin conditions) rather than the volume
of services provided, greater remuneration is provided to home health agencies and SNFs for the treatment of wound care patients.
As a result, the incentive to transfer patients with both acute and chronic wounds to more burdensome and costly care settings,
such as inpatient or outpatient wound-care centers, has been discouraged or eliminated. This shift in vertical economics provides
us with a unique opportunity, in adjunctive fashion with home health agencies and SNFs, to deliver highly technical and comprehensive
wound care where this most vulnerable patient population resides thus achieving CMS&rsquo;s desired results: better patient outcomes
at a lower total cost of care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Chronic
and Other Hard-to-Heal Wounds </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to a study published by the <I>Value in Health</I> journal, roughly 15% of the Medicare beneficiary population has chronic nonhealing
wounds. Chronic wounds do not advance through the phases of healing in a normal progression and do not show significant progress
toward healing in 30 days. Factors contributing to the chronicity of the wound may include pressure / friction, trauma; insufficient
blood flow and oxygenation in locations such as the lower extremities; increased bacterial load; excessive proteases; degraded
growth factors; MMPs; senescent / aberrant cells; or inappropriate treatment. Examples of chronic wounds include DFUs, VLUs, arterial
ulcers, pressure ulcers and hard-to-heal surgical/traumatic wounds. In each of the various wound types, the presence of biofilms
is a frequent cause for chronification of wounds and the removal of biofilms is a crucial step to commence healing. Biofilms need
to be eradicated to prevent further deterioration of the wound that may result in additional negative patient outcomes. If not
effectively treated, these wounds can lead to potentially severe complications, including further infection, osteomyelitis, fasciitis,
amputation and increased mortality. Chronic wounds are primarily seen in the elderly population. For example, a 2019 study published
in <I>Advances in Wound Care</I> reported that in the United States, 3% of the population over the age of 65 had open wounds.
According to the same study, in 2020, the U.S. government estimated that the elderly population totaled 55 million people, suggesting
that chronic wounds will continue to be an increasingly persistent problem in this population. Four common chronic and other hard-to-heal
wounds are: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Diabetic
                                         Foot Ulcers.</I> Diabetes can lead to a reduction in blood flow, which can cause patients
                                         to lose sensation in their feet and may prevent them from noticing injuries, sometimes
                                         leading to the development of DFUs, which are open sores or ulcers on the feet that may
                                         take several weeks to heal, if ever. According to the 2020 National Diabetes Statistics
                                         Report by the Center for Disease Control and Prevention, in the United States alone,
                                         over 34 million people, or approximately 10% of the population, suffer from diabetes,
                                         a chronic, life-threatening disease. Of those that suffer from diabetes, approximately
                                         1.7 million people (or 5% of diabetics in the United States) will develop DFUs on a yearly
                                         basis, according to the CEO of Corstrata, a digital healthcare and wound management firm
                                         specializing in the treatment of foot ulcers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Venous
                                         Leg Ulcers.</I> VLUs develop as a result of vascular insufficiency, or the inability
                                         for the vasculature of the leg to return blood back toward the heart properly and, according
                                         to a 2013 report published by the <I>International Journal of Tissue Repair and Regeneration</I>,
                                         VLUs affect approximately 600,000 people per year in the United States alone. These ulcers
                                         usually form on the sides of the lower leg, above the ankle and below the calf, and are
                                         slow to heal and often recur if preventative steps are not taken. The risk of venous
                                         ulcers can be increased as a result of a blood clot forming in the deep veins of the
                                         legs, obesity, smoking, lack of physical activity or work that requires many hours of
                                         standing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pressure
                                         Ulcers.</I> Pressure ulcers, also known as decubitus ulcers or bed sores, are injuries
                                         to skin and underlying tissue resulting from prolonged pressure, or pressure in combination
                                         with shear or friction. Constant pressure on an area of skin reduces blood supply to
                                         the area and over time can cause the skin to break down and form an open ulcer. These
                                         often occur in patients who are hospitalized or confined to a chair or bed and most often
                                         form on the skin over bony areas, where there is little cushion between the bone and
                                         the skin, such as heels, ankles, hips and the tailbone. Annually, 2.5 million pressure
                                         ulcers are treated in the United States in acute care facilities alone, according to
                                         a 2006 study published in the <I>Journal of the American Medical Association</I>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Surgical/traumatic
                                         wounds.</I> Surgical wounds form as a result of various types of surgical procedures
                                         such as investigative or corrective, minor or major, open (traditional) or minimal access
                                         surgery, elective or emergency, and incisions (simple cuts) or excision (removal of tissue),
                                         among others. Traumatic wounds form as a result of cuts, lacerations or puncture wounds,
                                         which have caused damage to the skin and underlying tissue. Severe traumatic wounds may
                                         require surgical intervention to close the wound and stabilize the patient. Surgical/traumatic
                                         hard-to-heal wounds develop for various reasons, such as local surgical complications,
                                         suboptimal closure techniques, presence of foreign materials, exposed bones or tendons
                                         and infection. In the United States, millions of people receive post-surgical wound care
                                         annually, and the typical operative patient has comorbidities that create challenges
                                         with post-operative wound healing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sanara
Products</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
market and distribute wound and skin care products and services to physicians, hospitals, clinics, and post-acute care settings.
Our products are primarily sold in the U.S. advanced wound care and surgical tissue repair markets. We are actively seeking to
expand within our six focus areas of wound and skin care for the acute, post-acute, and surgical markets: (1) debridement, (2)
biofilm removal, (3) hydrolyzed collagen, (4) advanced biologics, (5) negative pressure wound therapy adjunct products, and (6)
the oxygen delivery system segment of the wound and skin care market. The table below summarizes how we believe our current products
and product pipeline address our six focus areas:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="new_005.jpg" ALT="" STYLE="height: 335px; width: 630px"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara&rsquo;s
current product offerings include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following products licensed from AN:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CellerateRX
                                         Surgical Powder and Gel (through a sublicense with CGI Cellerate RX, an affiliate
                                         of Catalyst);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HYCOL
                                         Powder and Gel; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following products licensed from Rochal:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIAKO&#772;S
                                         AWC;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIAKO&#772;S
                                         Antimicrobial Skin and Wound Irrigation Solution; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIAKO&#772;S
                                         Antimicrobial Skin and Wound Gel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collagen
is important in all phases of wound healing: hemostasis, inflammation, proliferation and remodeling. Collagen promotes the development
of granulation (the formation of new tissue from the bottom of the wound bed), angiogenesis/vascularization, and re-epithelialization
(the migration of cells across granulation tissue to close the wound). A healthy body produces native collagen as the first step
in the healing process. Native collagen is an insoluble, rigidly coiled helical molecule that is critical to wound healing and
one of the first tissue structures deposited into the wound base by fibroblasts. Native collagen must then be hydrolyzed by proteases
(e.g. collagenase or MMPs) into its soluble component amino acid peptides in order to realize additional biological benefits.
Hydrolyzed collagen results from the conversion of the coiled collagen helix into peptides which support the cellular activities
and migration associated with granulation, angiogenesis and re-epithelialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CellerateRX
Surgical is a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial-
and full-thickness wounds as well as first- and second-degree burns. It is manufactured in what we believe to be a trade secret
process and the powder is further processed for use in a sterile, surgical environment. The gel is typically applied post-operatively.
CellerateRX Surgical products are primarily purchased by hospitals and ambulatory surgical centers for use by surgeons on surgical
wounds. The predominance of CellerateRX Surgical is used in foot and ankle, neuro/spinal, orthopedic/hip and knee replacement,
ortho trauma, and ortho oncology surgeries. Additional specialties benefiting from the use of CellerateRX Surgical include cardiothoracic,
colorectal, general, general trauma, gynecologic oncology, hand, head and neck, mohs, obstetrics and gynecology (including caesarian
deliveries), plastic/reconstructive, urologic, and vascular.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CellerateRX
Surgical is used in operative cases where patients might have trouble healing normally due to underlying health complications.
There is always a risk of complication with surgical incisions. This is especially true in patients with certain comorbidities,
including obesity, diabetes and hypertension. These complications can include surgical site infections, dehiscence (where an incision
opens after primary closure) and necrosis. Surgeons use CellerateRX Surgical to compliment the body&rsquo;s normal healing process.
By helping the body heal normally without complications, improved patient outcomes are achieved, thereby reducing downstream costs
related to complications (such as re-operation, longer hospitalization, re-admittance, extended rehabilitative care and other
additional treatments). Wound infections have become increasingly problematic due to the high rates of surgical patient comorbidities
and the financial strain on insurance carriers as well as hospitals who suffer exorbitant costs for readmission of these patients
within 30 days of surgery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a prospective study published by SciMedCentral in 2017, of 102 consecutive neurosurgery cases in which a mixture of 5 grams of
CellerateRX Surgical powder and 1-gram Vancomycin powder was applied at closure, there were no cases of wound dehiscence, infection,
complication or allergic reaction to the product. This compares to neurosurgery infection rates ranging from as high as 24% for
cranioplasty surgery to 6.3% for spine surgery patients. Two similar retrospective studies are underway using CellerateRX powder
in ortho/spine surgeries and general/colorectal surgeries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HYCOL
Hydrolyzed Collagen products are a medical hydrolysate of Type I bovine collagen intended for the management of full and partial
thickness wounds including pressure ulcers, venous and arterial leg ulcers and DFUs. HYCOL is primarily used in SNFs, wound care
centers and physician offices and is currently approved for reimbursement under Medicare Part B. HYCOL provides the benefit of
hydrolyzed collagen fragments directly in the wound bed. Therefore, unlike with the body&rsquo;s own native collagen or native
collagen products, the body does not have to break HYCOL down before use, which is extremely beneficial when treating elderly
and otherwise compromised patients with comorbidities such as diabetes and cardiovascular disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our CellerateRX and HYCOL products are unique in composition, superior to other products in clinical performance, demonstrate
the ability to reduce costs associated with the standards of care for their intended uses and have been safely used on over seventy-five
thousand patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIAKO&#772;S
AWC is an FDA 510(k) cleared, patented product that laboratory tests show effectively disrupts extracellular polymeric substances
to eradicate mature biofilm microbes. BIAKO&#772;S AWC is indicated for the mechanical removal of debris, dirt, foreign materials,
and microorganisms from wounds including stage I-IV pressure ulcers, DFUs, post-surgical wounds, first and second-degree burns
as well as grafted and donor sites. BIAKO&#772;S AWC is effective in killing free-floating microbes, immature, and mature bacterial
biofilms and fungal biofilms. In addition, safety studies demonstrated that BIAKO&#772;S AWC is biocompatible and supports the
wound healing process. Initial sales of BIAKO&#772;S AWC occurred in July 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIAKO&#772;S
AWC is also available in an irrigation bottle (BIAKO&#772;S Antimicrobial Skin and Wound Irrigation Solution) that can be used
in conjunction with NPWTi-d and other wound irrigation needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIAKO&#772;S
Antimicrobial Wound Gel is an antimicrobial hydrogel wound dressing that can be used alone or in combination with BIAKO&#772;S
AWC. In February 2020, we received notification of FDA 510(k) clearance for BIAKO&#772;S Antimicrobial Wound Gel and launched
the product in November 2020 to complement BIAKO&#772;S AWC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIAKO&#772;S
AWC and BIAKO&#772;S Antimicrobial Wound Gel are effective against planktonic microbes as well as immature and mature biofilms.
When used together, the cleanser can be used initially to clean a wound and disrupt biofilms (removing 99% in 10 minutes). The
gel can then be applied and remains in the wound for up to 72 hours helping to continue disrupting biofilm microbes. In a study
conducted in 2020, BIAKO&#772;S Antimicrobial Wound Gel, in combination with BIAKO&#772;S AWC, was compared to a number of wound
cleansers to treat chronic wounds such as pressure, diabetic, and venous ulcers in the inflammatory phase of wound healing. The
BIAKO&#772;S system reduced the biofilm burden by 7.5 logs (&gt;99.99% reduction) by the 24-hour time point and eradicated it
by the 48-hour time point while the remaining commercial controls reduced the Methicillin-resistant Staphylococcus aureus (&ldquo;MRSA&rdquo;)
biofilms by less than 1 log. Below is a graphic summarizing the efficacy of the use of BIAKO&#772;S Antimicrobial Wound Gel in
combination with BIAKO&#772;S AWC when reducing the MRSA mature biofilm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_007.jpg" ALT="" STYLE="height: 357px; width: 632px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara
MedTech recently executed a marketing and distribution agreement with Cook Biotech to purchase, market, and distribute three advanced
biologics products:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORTIFY
                                         TRG Tissue Repair Graft;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORTIFY
                                         FLOWABLE Extracellular Matrix; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIM
                                         Amnion Matrix.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORTIFY
TRG Tissue Repair Graft is a freeze-dried, multi-layer small intestinal submucosa (SIS) extracellular matrix (ECM) sheet. The
graft is used for implantation to reinforce soft tissue, has a thin profile, is available in multiple sizes, and can be
cut to size to accommodate the patient&rsquo;s anatomy. FORTIFY TRG Tissue Repair Graft is provided sterile and can be hydrated
with autologous blood fluid. It is a FDA 510(k) cleared product and terminally sterilized. The Company expects first sales of
this product to occur in the second half of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORTIFY
FLOWABLE Extracellular Matrix is an advanced wound care device that presents the SIS ECM technology in a way that can fill irregular
wound shapes and depths. FORTIFY FLOWABLE Extracellular Matrix is indicated for the management of wounds including: partial and
full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical
wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations,
second-degree burns, and skin tears) and draining wounds. FORTIFY FLOWABLE Extracellular Matrix is provided sterile and is intended
for one-time use. It is a 510(k) cleared product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIM
Amnion Matrix is a single layer sheet of amnion tissue that is minimally processed to decellularize the material while maintaining
the structure and components of the extracellular matrix environment. All tissues are collected from consenting donors, tested
for infectious diseases, and determined eligible for transplantation by a licensed Medical Director. It is provided in multiple
sizes and terminally sterilized. The VIM Amnion Matrix is intended for homologous use as a wound covering or barrier in
surgical, orthopedic, ophthalmic, and wound applications. It is air-dried for off-the-shelf room temperature storage with no product
preparation. The graft is supplied sterile and is intended for one-time use in a single patient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have the right to exclusively distribute PULSAR II Advanced Wound Irrigation System (&ldquo;PULSAR II&rdquo;), a portable,
no touch, painless, selective hydro-mechanical debridement system that effectively removes bacteria and necrotic tissue from wounds
without disrupting healthy tissue. While undergoing product evaluations, it came to our attention that the pump component of the
Pulsar II could potentially overheat. As a result, we suspended our plans for a full-scale product launch while we performed an
investigation. As a result of the investigation, we determined that a simple design change was appropriate and our supplier, Wound
Care Solutions, Limited, agreed to credit us for our existing inventory against any future purchases and implement a design enhancement
for future units. Pulsar II is a single patient use product, and there currently are no Pulsar II units in the market. If we receive
an enhanced product that meets our quality standards, we intend to relaunch the product, which we expect to occur, if at all,
in late 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sanara
Technology-Based Services</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently developing the capability to offer various services addressing chronic wound and skin care through our subsidiary
UWSS. UWSS was formed in June 2020, and we expect to report its operations as a separate business division in 2021. UWSS currently
owns WounDerm and has investment interests in, or has exclusive affiliations with, three companies, which include DirectDerm,
MGroup, and Precision Healing. We intend to begin launching UWSS&rsquo;s service offerings in 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our various service offerings will allow us to collect large amounts of data on patient conditions and outcomes
that will improve treatment protocols and ultimately lead to more evidence-based treatments to improve outcomes in the future.
We believe our planned service offerings through UWSS are complemented by our existing product portfolio to complete the comprehensive
wound strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UWSS
plans to offer the following services:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>EMR
                                         software platform for both wound and skin conditions</I></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2020, we, through UWSS, made a minority investment in WounDerm to fund further development of WounDerm&rsquo;s imagery and data
sharing platform designed to meet our specified virtual environment. In January 2021, we acquired the remaining interest of WounDerm.
WounDerm developed a software system that combines the documentation functionality of wound care and dermatology EMRs with a Health
Insurance Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;)-secure online platform for provider and caregiver collaboration.
The software is expected to include a complete wound and skin care specialty specific collaboration platform that will allow for
interoperability with client facing EMRs, reduce the burden of duplicate documentation, and improve the accuracy of assessments
and treatment plans. Additionally, the collaboration platform is expected to have the ability to import images from any third
party &ldquo;wound tool&rdquo; application or EMR, as well as gather images and clinical information through an Apple or Android
based mobile app. We anticipate that the proprietary software will provide for the correction of inaccurate initial measurements
performed by caregivers, as well as adjustments for light and photo quality. We plan to have this technology commercially available
in mid-2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Virtual
                                         consultation services for both wound and skin care conditions </I></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DirectDerm
is a telemedicine company based in Palo Alto, California and has an exclusive network of dermatologists licensed across 23 states
who have trained and/or teach at top U.S. medical institutions, and whose service is covered by many of the major health plans
in the United States. UWSS is working to integrate its collaboration platform into DirectDerm&rsquo;s platform to provide virtual
consultations through DirectDerm&rsquo;s network of board-certified dermatologists to patients in all of UWSS&rsquo;s healthcare
markets. DirectDerm plans to expand coverage to all 50 states in 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MGroup
is a physician-owned and physician-led multispecialty wound care group focused on utilizing telehealth and associated technologies
to build high-quality, cost-effective care delivery systems. MGroup currently holds active medical licenses in 40 states with
plans to expand coverage to all 50 states in 2021. Our affiliation with MGroup will provide us with the ability to offer wound
care telehealth services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Diagnostic
                                         products and services for chronic wounds</I></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Precision Healing product platform is a diagnostic imaging and smart pad for assessing a patient&rsquo;s wound and skin conditions.
This comprehensive skin and wound assessment technology is designed to quantify biochemical markers to determine the trajectory
of a wound&rsquo;s condition to enable better diagnosis and treatment protocol. Precision Healing was formed by executives and
imaging specialists at Lumicell Corporation as well as experienced wound care scientists and physicians. Precision Healing expects
to have its imaging device and smart pad commercially available in 2021 and is currently being integrated into the WounDerm EMR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sales
and Marketing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently employ seventeen surgical division regional sales managers (&ldquo;RSMs&rdquo;) and five wound care division RSMs. Our
RSMs are recruited based on their previous industry experience and professional performance and are required to have a minimum
of three years of experience successfully selling into similar markets. We constantly evaluate new markets and sales opportunities
to add to our sales teams as warranted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSMs
are initially trained through an internal learning management system, SanaraU, which gives them further product and surgical specialty
training including wound etiology, operating room etiquette and credentialing requirements. After completing their internal training,
new hire RSMs participate in field training with experienced RSM field trainers to get insights into best practice as well as
real world training. The initial training period lasts approximately five weeks. RSMs are supported by regular updated training
modules on product information and best practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key component of our sales and marketing efforts involves working with physicians and clinicians to champion our products in their
facilities. Our surgical division works closely with surgeons and health system stakeholders to demonstrate the efficacy and beneficial
impact of our products and successfully navigate the hospital value analysis committee, (more commonly known as the &ldquo;VAC&rdquo;),
approval process, allowing our products to be sold in those facilities. Similarly, our wound care division works with clinicians
to demonstrate the efficacy of our products in their respective care settings. If our sales and marketing efforts are successful,
the clinicians then advocate for the use of our products when medically necessary and push for their suppliers to carry our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
surgical division markets and distributes CellerateRX Surgical. CellerateRX Surgical is primarily purchased by hospitals and ambulatory
surgical centers for use by surgeons in their facilities. CellerateRX Surgical is sold through a growing network of independent
surgical specialty sales agencies and Company representatives who sell and support the products in surgical settings. Over 750
hospitals and ambulatory surgical centers currently have approval to use CellerateRX Surgical, with more locations being consistently
added. The current efforts of our sales teams involve deeper penetration into these approved locations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
chronic wound division markets and distributes the following products: BIAKO&#772;S AWC, BIAKO&#772;S Antimicrobial Skin and Wound
Gel, BIAKO&#772;S Antimicrobial Skin and Wound Irrigation Solution, and HYCOL powder and gel. Our chronic wound division primarily
distributes to post-acute care settings, including long-term care facilities, home health, wound care centers, and professional
medical offices. Products are sold by Company representatives supplemented by major medical-surgical distributors, independent
distributors, and DME distributors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manufacturing,
Supply, and Production</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate and do not intend to establish our own manufacturing facilities. We rely on, and plan to continue relying
on, contract manufacturing for our products. Our contract manufacturing strategy is intended to drive cost leverage and scale
and avoid the high capital outlays and fixed costs associated with constructing and operating manufacturing facilities. Our manufacturing
partners have internal compliance processes to maintain the high quality and reliability of our products. They utilize annual
internal audits, combined with external audits by regulatory agencies and commercial partners to monitor their quality control
practices. We believe our contract manufacturers are well-positioned to support future expansion of our product sales. We do source
some packaging and marketing materials separate from our licensing partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reimbursement,
Clinical Validation, and Clinical Utility</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not promote our products based on their reimbursement status, however, we are mindful of the benefits of a favorable reimbursement
coverage status to increase patient access and support our research and development efforts to supply the highest efficacy solutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
of our chronic wound care products (BIAKO&#772;S Antimicrobial Skin and Wound Gel, HYCOL Hydrolyzed Collagen Powder, and HYCOL
Hydrolyzed Collagen Gel) have HCPCS A codes and are eligible for reimbursement through Medicare Part B. There is currently no
reimbursement for BIAKO&#772;S AWC or BIAKO&#772;S Antimicrobial Skin and Wound Irrigation Solution. CellerateRX Surgical is currently
captured as part of the cost of the surgical procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently collaborating with a pricing, reimbursement, and market access consultant to demonstrate the clinical utility of
our products versus the standard of care, impact on patient management decisions, patient reported outcomes and health economics.
We anticipate that our UWSS services, once launched, will provide a wealth of patient data to help us measure our products&rsquo;
effectiveness on improving patient outcomes while simultaneously reducing healthcare costs. We believe our reimbursement strategy,
including establishing the clinical validation, clinical utility and health economics of our products, will allow us to drive
improved reimbursement coverage for our products and technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
wound care market is served by a number of large, multi-product line companies as well as a number of small companies. Our products
compete with primary dressings, advanced wound care products, collagen matrices and other biopharmaceutical products. Manufacturers
and distributors of competitive products include Smith &amp; Nephew plc, Medline Industries, Inc., ConvaTec Group plc, M&ouml;lnlycke
Health Care AB, 3M Company, Integra LifeSciences Holdings Corporation (which acquired ACell Inc. on January 20, 2021) and numerous
others. Many of our competitors are significantly larger than we are and have greater financial and personnel resources. We believe,
however, that our products outperform our competitors&rsquo; currently available equivalent products for the specific application
in which they are intended by providing improved efficacy, better outcomes, and reduced cost of patient care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UWSS
plans to offer a comprehensive wound care and dermatology strategy to expand cost-effective, high quality wound and skin care
to all patients throughout the care setting continuum. Although novel in its comprehensive offerings and solutions, there are
existing competitors for each of the verticals in which UWSS plans to offer services and solutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing
wound care imaging technology competitors include MolecuLight, Wound-Vision, HyperMed Imaging, Inc., SpectralMD, Inc., Kent and
Tissue Analytics. However, we do not believe that any of these existing platforms offer a bioassay evaluation in combination with
their imaging solution. In addition, there are existing wound care-specific EMR documentation and telemedicine communication platforms
such as NetHealth, Swift Medical Inc., Corstrata, LLC and Intellicure, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public health emergency caused by the COVID-19 pandemic has led to the widespread adoption of telemedicine for all health care
clinical specialties, including wound care and dermatology. As such, any clinical wound care or dermatology physician and/or provider
group that has incorporated telemedicine into their practice could be considered competitive. However, the majority of these groups
are local or regional and do not incorporate the comprehensive national care delivery platform that UWSS expects to offer. Examples
of large wound care specialty practices include Vohra Physician Group, Healogics Specialty Physicians and WoundTech.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensing
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own the patents for the products we market, sell, and distribute. We in-license the rights to market, sell, and distribute
our products from third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>CellerateRX
Activated Collagen</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 0; text-align: justify; text-indent: 0.5in">On August 27,
2018, we entered into an exclusive, world-wide sublicense agreement with CGI Cellerate RX to distribute CellerateRX Surgical and
HYCOL products into the wound care and surgical markets. We pay royalties of 3-5% of annual collected net sales of CellerateRX
Surgical and HYCOL. As amended, the term of the sublicense extends through May 2050, with automatic year-to-year renewal terms
thereafter so long as our Net Sales (as defined in the sublicense agreement) each year are equal to or in excess of $1,000,000.
If our Net Sales fall below $1,000,000 for any year after the initial expiration date, CGI Cellerate RX will have the
right to terminate the sublicense agreement upon written notice. Minimum royalties of $400,000 per year are payable for the first
five years of the sublicense agreement. For the nine-month periods ended September 30, 2020 and 2019, royalties due under the
terms of this agreement totaled $300,000 and $337,549, respectively.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.05pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.05pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>BIAKO&#772;S
Antimicrobial Wound Gel and BIAKO&#772;S Antimicrobial Skin and Wound Cleanser</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.05pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 7, 2019, we a license agreement with Rochal, whereby we acquired an exclusive world-wide license to market, sell and further
develop antimicrobial products for the prevention and treatment of microbes on the human body utilizing certain Rochal patents
and pending patent applications (the &ldquo;BIAKOS License Agreement&rdquo;). Currently, the products covered by the BIAKOS License
Agreement are BIAKO&#772;S Antimicrobial Wound Gel and BIAKO&#772;S Antimicrobial Skin and Wound Cleanser. Both products are 510(k)
approved. Our Executive Chairman is also a director of Rochal, and indirectly a significant shareholder of Rochal, and through
the potential exercise of warrants, a majority shareholder of Rochal. Another one of our directors is also a director and significant
shareholder of Rochal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.05pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.05pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
commitments under the terms of the BIAKOS License Agreement include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.05pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                         to the occurrence of specified Company financing conditions by the end of 2022, we will
                                         pay Rochal $750,000, which at our option, may be paid in any combination of cash and
                                         our common stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         will pay Rochal a royalty of 2-4% of net sales. The minimum annual royalty due to Rochal
                                         was $100,000 in 2020 and will increase by 10% each subsequent calendar year up to a maximum
                                         amount of $150,000.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         will pay additional royalty annually based on specific net profit targets from sales
                                         of the licensed products, subject to a maximum of $1,000,000 during any calendar year.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
previously terminated by the parties, the BIAKOS License Agreement will expire with the related patents in December 2031. For
the nine-month periods ended September 30, 2020 and September 30, 2019, royalty expense recognized under BIAKOS License Agreement
was $75,000 and $275, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>CuraShield
Antimicrobial Barrier Film and No Sting Skin Protectant</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2019, we executed a license agreement with Rochal whereby we acquired an exclusive world-wide license to market, sell
and further develop certain antimicrobial barrier film and skin protectant products for use in the human health care market utilizing
certain Rochal patents and pending patent applications (the &ldquo;ABF License Agreement&rdquo;). Currently, the products covered
by the ABF License Agreement are CuraShield Antimicrobial Barrier Film and a no sting skin protectant product. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
commitments under the terms of the ABF License Agreement include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31.5pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Company will pay Rochal a royalty of 2-4% of net sales. The minimum annual royalty due
                                         to Rochal will be $50,000 beginning with the first full calendar year following the year
                                         in which first commercial sales of the products occur. The annual minimum royalty will
                                         increase by 10% each subsequent calendar year up to a maximum amount of $75,000.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 49.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31.5pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         will pay additional royalties annually based on specific net profit targets from sales
                                         of the licensed products, subject to a maximum of $500,000 during any calendar year.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 49.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
previously terminated or extended by the parties, the ABF License Agreement will terminate upon expiration of the last U.S. patent
in October 2033. No commercial sales or royalty payments had been made under ABF License Agreement as of September 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Debrider
License Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 4, 2020, we executed a product license agreement with Rochal, whereby we acquired an exclusive world-wide license to market,
sell and further develop a debrider for human medical use to enhance skin condition or treat or relieve skin disorders, excluding
uses primarily for beauty, cosmetic, or toiletry purposes (the &ldquo;Debrider License Agreement&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
commitments under the terms of the Debrider License Agreement include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31.5pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
                                         the time Rochal issues a purchase order to its contract manufacturer for the first good
                                         manufacturing practice run of the licensed products, we will pay Rochal $600,000 in cash.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31.5pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                         FDA clearance of the licensed products, we will pay Rochal $500,000 in cash and $1,000,000,
                                         which at our option may be paid in any combination of cash and our common stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31.5pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         will pay Rochal a royalty of 2-4% of net sales. The minimum annual royalty due to Rochal
                                         will be $100,000 beginning with the first full calendar year following the year in which
                                         first commercial sales of the licensed products occur and increase by 10% each subsequent
                                         calendar year up to a maximum amount of $150,000.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31.5pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         will pay additional royalty annually based on specific net profit targets from sales
                                         of the licensed products, subject to a maximum of $1,000,000 during any calendar year.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
previously terminated or extended by the parties, the Debrider License Agreement will expire in October 2034. No commercial sales
or royalties had been recognized under the Debrider License Agreement as of September 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cook
Biotech</I></B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I> Marketing and Distribution Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 17, 2020, we entered into a marketing and distribution agreement with Cook Biotech whereby the we were appointed as the
exclusive distributor in the United States of three Cook advanced biologic products. The first two products, FORTIFY TRG Tissue
Repair Graft and FORTIFY FLOWABLE Extracellular Matrix, are for use in the surgical wound care segment, and VIM Amnion Matrix
is for use in the chronic wound care and surgical wound care segments. We expect to commercialize these products in the second
half of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the agreement, we will purchase the products from Cook Biotech at initial transfer prices stipulated in the agreement.
Cook Biotech may update the transfer prices annually based on changes in the US Producer&rsquo;s Price Index. Minimum annual order
quantities will be agreed upon by both parties after the first year of the contract term. The agreement will terminate on the
third anniversary of the date on which the first commercial sale to us from Cook Biotech is made, with automatic two-year renewal
terms unless notice of non-renewal is given by one party at least one year prior to the end of the initial term or renewal term
that is then in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Resorbable
Bone Hemostat </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
acquired a patent in 2009 for a resorbable bone hemostat and delivery system for orthopedic bone void fillers. This patent is
not part of our long-term strategic focus. We subsequently licensed the patent to a third party to market a bone void filler product
for which we receive a 3% royalty on product sales over the life of the patent, which expires in 2023, with annual minimum royalties
of $201,000. We pay two unrelated third parties a combined royalty equal to eight percent (8%) of our net revenues and royalties
generated from products that utilize the acquired patented bone hemostat and delivery system. To date, royalties received by us
related to this licensing agreement have not exceeded the annual minimum of $201,000 ($50,250 per quarter). Therefore, our annual
royalty obligation under the terms of the license agreement has been $16,080 ($4,020 per quarter). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to comprehensive federal, state, and local laws and regulations in the jurisdictions in which we or our
research and development partners or affiliates do business. The laws and regulations governing our business and interpretations
of those laws and regulations and are subject to frequent change. Our ability to operate profitably will depend in part upon our
ability, and that of our research and development partners and affiliates, to operate in compliance with applicable laws and regulations.
The laws and regulations relating to medical products and healthcare services that apply to our business and that of our partners
and affiliates continue to evolve, and we must, therefore, devote significant resources to monitoring developments in legislation,
enforcement, and regulation in such areas. As the applicable laws and regulations change, we are likely to make conforming modifications
in our business processes from time to time. We cannot provide assurance that a review of our business by courts or regulatory
authorities will not result in determinations that could adversely affect our operations or that the regulatory environment will
not change in a way that restricts our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>FDA
Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
medical products and operations are regulated by the FDA and other federal and state agencies. The products we currently market
are regulated as medical devices in the United States under the FDCA, as implemented and enforced by the FDA. The FDA regulates
the development, testing, manufacturing, labeling, packaging, storage, installation, servicing, advertising, promotion, marketing,
distribution, import, export, and market surveillance of our medical devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have entered into an agreement to market and distribute VIM Amnion Matrix for use in the chronic wound care and surgical
wound care segments. VIM Amnion Matrix is a tissue-based product regulated by FDA under Section 361 of the PHSA (42 U.S.C. &sect;
264) and 21 C.F.R. Part 1271.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Device
Premarket Regulatory Requirements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
being introduced into the U.S. market, each medical device must obtain marketing clearance or approval from FDA through the 510(k)
premarket notification process, the <I>de novo</I> classification process (summarized below under <I>De Novo Classification Process</I>),
or PMA process, unless they are determined to be Class I devices or to otherwise qualify for an exemption from one of these available
forms of premarket review and authorization by the FDA. Under the FDCA, medical devices are classified into one of three classes&mdash;Class
I, Class II or Class III&mdash;depending on the degree of risk associated with each medical device and the extent of control needed
to provide reasonable assurance of safety and effectiveness. Classification of a device is important because the class to which
a device is assigned determines, among other things, the necessity and type of FDA review required prior to marketing the device.
Class I devices are those for which reasonable assurance of safety and effectiveness can be assured by adherence to general controls
that include compliance with the applicable portions of the FDA&rsquo;s Quality System Regulation (&ldquo;QSR&rdquo;), as well
as regulations requiring facility registration and product listing, reporting of adverse medical events, and appropriate, truthful
and non-misleading labeling, advertising, and promotional materials. The Class I designation also applies to devices for which
there is insufficient information to determine that general controls are sufficient to provide reasonable assurance of the safety
and effectiveness of the device or to establish special controls to provide such assurance, but that are not life-supporting or
life-sustaining or for a use which is of substantial importance in preventing impairment of human health, and that do not present
a potential unreasonable risk of illness of injury.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
II devices are those for which general controls alone are insufficient to provide reasonable assurance of safety and effectiveness
and there is sufficient information to establish &ldquo;special controls.&rdquo; These special controls can include performance
standards, post-market surveillance requirements, patient registries and FDA guidance documents describing device-specific special
controls. While most Class I devices are exempt from the 510(k) premarket notification requirement, most Class II devices require
a 510(k) premarket notification prior to commercialization in the United States; however, the FDA has the authority to exempt
Class II devices from the 510(k) premarket notification requirement under certain circumstances. As a result, manufacturers of
most Class II devices must submit 510(k) premarket notifications to the FDA under Section 510(k) of the FDCA (21 U.S.C. &sect;
360(k)) in order to obtain the necessary clearance to market or commercially distribute such devices. To obtain 510(k) clearance,
manufacturers must submit to the FDA adequate information demonstrating that the proposed device is &ldquo;substantially equivalent&rdquo;
to a predicate device already on the market. A predicate device is a legally marketed device that is not subject to PMA, meaning,
(i) a device that was legally marketed prior to May 28, 1976 (&ldquo;preamendments device&rdquo;) and for which a PMA is not required,
(ii) a device that has been reclassified from Class III to Class II or I, or (iii) a device that was found substantially equivalent
through the 510(k) process. If the FDA agrees that the device is substantially equivalent to a predicate device currently on the
market, it will grant 510(k) clearance to commercially market the device. If there is no adequate predicate to which the manufacturer
can compare its proposed device, the proposed device is automatically classified as a Class III device. In such cases, the device
manufacturer must then fulfill the more rigorous PMA requirements or can request a risk-based classification determination for
the device in accordance with the <I>de novo</I> classification process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<I>de novo</I> classification process allows a manufacturer whose novel device is automatically classified into Class III to request
down-classification of its device to Class I or Class II on the basis that the device presents low or moderate risk, rather than
requiring the submission and approval of a PMA application. Under the Food and Drug Administration Safety and Innovation Act of
2012 (&ldquo;FDASIA&rdquo;), the FDA is required to classify a device within 120 days following receipt of the <I>de novo</I>
classification request. If the manufacturer seeks reclassification into Class II, the classification request must include a draft
proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical
device. The FDA may reject the classification request if it identifies a legally marketed predicate device that would be appropriate
for a 510(k) or determines that the device is not low to moderate risk or that general controls would be inadequate to control
the risks and special controls cannot be developed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices
that are intended to be life sustaining or life supporting, devices that are implantable, devices that present a potential unreasonable
risk of harm or are of substantial importance in preventing impairment of health, and devices that are not substantially equivalent
to a predicate device are placed in Class III and generally require FDA approval through the PMA process, unless the device is
a preamendments device not yet subject to a regulation requiring premarket approval. The PMA process is more demanding than the
510(k) premarket notification process. For a PMA, the manufacturer must demonstrate through extensive data, including data from
preclinical studies and clinical trials, that the device is safe and effective. The PMA must also contain a full description of
the device and its components, a full description of the methods, facilities and controls used for manufacturing, and proposed
labeling. Following receipt of a PMA, the FDA determines whether the application is sufficiently complete to permit a substantive
review. If the FDA accepts the application for review, it has 180 days under the FDCA to complete its review of a PMA, although
in practice, the FDA&rsquo;s review often takes significantly longer, and can take up to several years. Before approving a PMA,
the FDA generally also performs an on-site inspection of manufacturing facilities for the product to ensure compliance with the
QSR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thus
far, all of the medical devices that we currently market and distribute have been cleared through 510(k) premarket notifications
filed by our third-party research and development partners, who are the manufacturers of such devices. We also are continuing
to work through the development process for a number of products in our pipeline. We are currently working on final formulation
and the development of a retail marketing strategy for an over-the-counter hand and skin cleanser. Our debrider product, as well
a novel dressing that delivers oxygen to the wound bed and a sterile BIAKO&#772;S product, are currently under development at
Rochal, and we are in discussions concerning the best path for seeking clearance and approval for these products. We are also
exploring new indications of use and improved formulas for a next generation CellerateRX and a next generation HYCOL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials are almost always required to support PMAs and are sometimes required to support 510(k) submissions. All clinical investigations
of devices to determine safety and effectiveness must be conducted in accordance with the FDA&rsquo;s investigational device exemption
(&ldquo;IDE&rdquo;), regulations that govern investigational device labeling, prohibit promotion of the investigational device,
and specify recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device
presents a &ldquo;significant risk,&rdquo; as defined by the FDA, the agency requires the device sponsor to submit an IDE application
to the FDA, which must become effective prior to commencing human clinical trials. The IDE will automatically become effective
30 days after receipt by the FDA, unless the FDA denies the application or notifies the company that the investigation is on hold
and may not begin until the sponsor provides supplemental information about the investigation that satisfies FDA&rsquo;s concerns.
If the FDA determines that there are deficiencies or other concerns with an IDE that require modification of the study, the FDA
may permit a clinical trial to proceed under a conditional approval. In addition, the study must be approved by, and conducted
under the oversight of, an institutional review board (&ldquo;IRB&rdquo;), for each clinical site. If the device presents a non-significant
risk to the patient according to criteria established by FDA as part of the IDE regulations, a sponsor may begin the clinical
trial after obtaining approval for the trial by one or more IRBs without separate authorization from the FDA, but must still comply
with abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent,
and labeling and record-keeping requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Device
Post-market Regulatory Requirements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a device is cleared or approved for commercialization, and prior to marketing, numerous regulatory requirements apply to the various
entities responsible for preparing a device for distribution, including the manufacturer (including specification developer),
contract manufacturers, relabelers/repackagers, sterilizers and initial importer, as applicable. These include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
    registration and device listing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">development
    of a quality management system, including establishing and implementing procedures to design and manufacture devices in compliance
    with the QSR (unless a device category is exempt from this requirement by the FDA, such as in the case of many Class I devices);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">labeling
    regulations that prohibit the promotion of products for uncleared or unapproved uses (known as off-label uses), as well as
    requirements to provide accurate and non-misleading information and adequate information on both risks and benefits of the
    device;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA&rsquo;s
    unique device identification requirements that call for a unique device identifier (&ldquo;UDI&rdquo;) on device labels, packages,
    and in some cases, on the device itself, and submission of data to the FDA&rsquo;s Global Unique Device Identification Database
    (&ldquo;GUDID&rdquo;);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">medical
                                         device reporting regulations that require manufacturers to report to the FDA if a device
                                         may have caused or contributed to a death or serious injury or malfunctioned in a way
                                         that would likely cause or contribute to a death or serious injury if it were to recur;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">corrections
    and removal reporting regulations that require manufacturers report to the FDA field corrections and product recalls or removals
    if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk
    to health; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-market
    surveillance regulations, which apply to Class II or III devices if the FDA has issued a post-market surveillance order and
    the failure of the device would be reasonably likely to have serious adverse health consequences, the device is expected to
    have significant use in the pediatric population, the device is intended to be implanted in the human body for more than one
    year, or the device is intended to be used to support or sustain life and to be used outside a user facility;.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development partners and their contract manufacturers may be subject to periodic scheduled or unscheduled inspections
by the FDA. If we are required to register with the FDA, by becoming the manufacturer or specification developer of any medical
device for instance, then we also may be subject to such inspections by FDA. If the FDA believes we or any of our research and
development partners or their contract manufacturers are not in compliance with the QSR, or other post-market requirements, it
has broad authority to that significant enforcement actions to compel compliance. Specifically, if the FDA determines that we
or our research and development partners or their contract manufacturers failed to comply with applicable regulatory requirements,
the agency can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled
    letters, warning letters, fines, injunctions, consent decrees and civil penalties;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer
    notifications or repair, replacement or refunds;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandatory
    recalls, withdrawals, or administrative detention or seizure of our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    restrictions or partial suspension or total shutdown of production;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing
    or delaying requests for 510(k) marketing clearance or approval of pre-market approval applications relating to new products
    or modified products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reclassifying
    a 510(k)-cleared device or withdrawing PMA approval;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to grant export approvals for our products; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursuing
    criminal prosecution.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such enforcement action by the FDA would have a material adverse effect on our business. In addition, these regulatory controls,
as well as any changes in FDA policies, can affect the time and cost associated with the development, introduction, and continued
availability of new products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>HCT/P
Regulatory Requirements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
cells, tissues, and cellular and tissue-based products (&ldquo;HCT/Ps&rdquo;) are regulated by FDA&rsquo;s Center for Biologics
Evaluation and Research (&ldquo;CBER&rdquo;) or Center for Devices and Radiological Health (&ldquo;CDRH&rdquo;) depending of the
type of product, how it is manufactured and its intended uses. HCT/Ps that meet all of the criteria described in 21 C.F.R. &sect;
1271.10(a) are regulated by CBER under Section 361 of the PHSA (42 U.S.C. &sect; 264) and 21 C.F.R. Part 1271 only (&ldquo;361
products&rdquo;). Although 361 products do not require premarket review by FDA prior to commercialization, manufacturers of 361
products must register with FDA, submit a list of HCT/Ps manufactured, and comply with current good tissue practices (&ldquo;cGTP&rdquo;),
among other things.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an agreement to market and distribute VIM<SUP>TM</SUP> Amnion Matrix, which is manufactured from amniotic membrane
and will be marketed as a 361 product. Cook Biotech, as the manufacturer, must comply with all requirements of Section 361 of
the PHSA and 21 C.F.R. Part 1271 that are applicable to the products and may be subject to periodic scheduled or unscheduled inspections
by the FDA to ensure compliance with cGTP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Federal
Trade Commission Regulatory Oversight</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
advertising for our products and services is subject to federal truth-in-advertising laws enforced by the Federal Trade Commission,
or FTC, as well as comparable state consumer protection laws. Under the Federal Trade Commission Act (&ldquo;FTC Act&rdquo;),
the FTC is empowered, among other things, to (a) prevent unfair methods of competition and unfair or deceptive acts or practices
in or affecting commerce; (b) seek monetary redress and other relief for conduct injurious to consumers; and (c) gather and compile
information and conduct investigations relating to the organization, business, practices, and management of entities engaged in
commerce. The FTC has very broad enforcement authority, and failure to abide by the substantive requirements of the FTC Act and
other consumer protection laws can result in administrative or judicial penalties, including civil penalties, injunctions affecting
the manner in which we would be able to market services or products in the future, or criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fraud
and Abuse and Transparency Laws and Regulations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business activities (and the business activities of our research and development partners and affiliates), including, but not
limited to, research, sales, promotion, distribution and medical education, are subject to regulation by numerous federal and
state regulatory and law enforcement authorities in the United States, including the Department of Justice, the Department of
Health and Human Services and its various divisions, CMS, the Health Resources and Services Administration, the Department of
Veterans Affairs, the Department of Defense, and state and local governments. Our business activities must comply with numerous
healthcare laws, including, but not limited to, anti-kickback and false claims laws and regulations as well as data privacy and
security laws and regulations, which are described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying,
soliciting, or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return
for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, furnishing, or order of any item or service
reimbursable under Medicare, Medicaid, or other federal healthcare programs, in whole or in part. The term &ldquo;remuneration&rdquo;
has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements
between pharmaceutical manufacturers on one hand and prescribers, purchasers, formulary managers, and beneficiaries on the other.
There are certain statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions
and safe harbors are drawn narrowly, and practices that involve remuneration that may be alleged to be intended to induce prescribing,
purchases, or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet
all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per
se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis
based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statute&rsquo;s intent
requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare
covered business, the statute has been violated. The Patient Protection and Affordable Care Act, of 2010, as amended (the &ldquo;ACA&rdquo;),
modified the intent requirement under the Anti-Kickback Statute to a stricter standard, such that a person or entity no longer
needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition,
the ACA also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a whistleblower to
assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for
purposes of the federal civil FCA. The ACA further created new federal requirements for reporting, by applicable manufacturers
of covered drugs, payments and other transfers of value to physicians and teaching hospitals, and ownership and investment interests
held by physicians and other healthcare providers and their immediate family members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal civil FCA, prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented,
a false or fraudulent claim for payment to, or approval by, the federal government, knowingly making, using, or causing to be
made or used a false record or statement material to a false or fraudulent claim to the federal government, or avoiding, decreasing,
or concealing an obligation to pay money to the federal government. A claim includes &ldquo;any request or demand&rdquo; for money
or property presented to the U.S. government. The civil FCA has been used to assert liability on the basis of kickbacks and other
improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, or submission
of inaccurate information required by government contracts, improper use of Medicare provider or supplier numbers when detailing
a provider of services, improper promotion of off-label uses not expressly approved by the FDA in a drug&rsquo;s label, and allegations
as to misrepresentations with respect to the products supplied or services rendered. Several pharmaceutical and other healthcare
companies have further been sued under these laws for allegedly providing free product to customers with the expectation that
the customers would bill federal programs for the product. Intent to deceive is not required to establish liability under the
civil FCA; however, a change in Department of Justice policy now prohibits enforcement actions for knowing violations of law based
on non-compliance with agency subregulatory guidance. Civil FCA actions may be brought by the government or may be brought by
private individuals on behalf of the government, called &ldquo;qui tam&rdquo; actions. If the government decides to intervene
in a qui tam action and prevails in the lawsuit, the individual will share in the proceeds from any fines or settlement funds.
If the government declines to intervene, the individual may pursue the case alone. Since 2004, these FCA lawsuits against pharmaceutical
companies have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements, as
much as $3.0 billion, regarding certain sales practices and promoting off label drug uses. Civil FCA liability may be imposed
for Medicare or Medicaid overpayments, for example, overpayments caused by understated rebate amounts, that are not refunded within
60 days of discovering the overpayment, even if the overpayment was not caused by a false or fraudulent act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
government may further prosecute conduct constituting a false claim under the criminal FCA. The criminal FCA prohibits the making
or presenting of a claim to the government knowing such claim to be false, fictitious, or fraudulent and, unlike the civil FCA,
requires proof of intent to submit a false claim. The civil monetary penalties statute is another potential statute under which
drug and device companies may be subject to enforcement. Among other things, the civil monetary penalties statue imposes fines
against any person who is determined to have presented, or caused to be presented, claims to a federal healthcare program that
the person knows, or should know, is for an item or service that was not provided as claimed or is false or fraudulent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
also created federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to
defraud or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned
by, or under the custody or control of, a healthcare benefit program, regardless of whether the payor is public or private, knowingly
and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health
care offense, and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making
any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items, or services relating
to healthcare matters. The ACA, as amended, modified the intent requirement under the certain portions of these federal criminal
statutes such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ACA further created federal requirements for reporting, by applicable manufacturers of covered therapeutics, payments and other
transfers of value to physicians and teaching hospitals, and ownership and investment interests held by physicians and other healthcare
providers and their immediate family members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services
reimbursed by any third-party payor, including commercial insurers, and some have transparency laws that require reporting price
increases and related information. Certain state laws also regulate manufacturers&rsquo; use of prescriber-identifiable data.
Certain states also require implementation of commercial compliance programs and compliance with the pharmaceutical industry&rsquo;s
voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict
payments or the provision of other items of value that may be made to healthcare providers and other potential referral sources;
impose restrictions on marketing practices; or require drug manufacturers to track and report information related to payments,
gifts, and other items of value to physicians and other healthcare providers. These laws may affect our future sales, marketing,
and other promotional activities by imposing administrative and compliance burdens.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any of the laws or regulations described above or any other laws that apply to
us, we may be subject penalties or other enforcement actions, including criminal and significant civil monetary penalties, damages,
fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, corporate integrity agreements,
debarment from receiving government contracts or refusal of new orders under existing contracts, reputational harm, diminished
profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability
to operate our business and our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Telemedicine
Standards, and Related Laws and Guidelines</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into management agreements with DirectDerm, a telemedicine company based in California, which has an exclusive network
of dermatologists licensed across 23 states, as well as MGroup, which is a physician-owned multispecialty wound care group with
active medical licenses in 40 states. Through these partnerships, we expect to make available coordinated telemedicine services
on our platform. In connection with these arrangements, we expect to administer non-clinical services to support our partners
and their delivery of telemedicine services, including billing, scheduling and a wide range of other administrative and support
services, and they pay us a pre-determined, fair market value amount for those services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
delivery of telemedicine services directly or through contractual relationships is subject to various federal, state, and local
laws, regulations and approvals, relating to, among other things, the health provider licensure, adequacy and continuity of medical
care, medical practice standards (including specific requirements when providing healthcare utilizing telemedicine technologies
and consulting services among providers), medical records maintenance, personnel supervision, and prerequisites for the prescription
of medication. The application of some of these laws to telemedicine is unclear and subject to differing interpretation. Further,
laws and regulations specific to delivering medical services utilizing telemedicine technologies continues to evolve with some
states incorporating modality and consent requirements for certain telemedicine encounters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telemedicine
services also implicate state corporate practice of medicine and fee-splitting laws which vary from state to state and are not
always consistent among states. In addition, these requirements are subject to broad powers of interpretation, enforcement discretion
by state regulators, and, in some cases, dated (yet still valid) case law. Some of these requirements may apply to us or our partners,
even if we do not have a physical presence in the state, based solely on the engagement of a provider licensed in the state or
the provision of telemedicine to a resident of the state. However, regulatory authorities or other parties, including providers
in our affiliated provider network, may assert that, despite these arrangements, we are engaged in the corporate practice of medicine
or that our contractual arrangements with affiliated physician groups constitute unlawful fee-splitting. In this event, failure
to comply could lead to adverse judicial or administrative action against us and/or our providers, civil or criminal penalties,
receipt of cease-and-desist orders from state regulators, loss of provider licenses, or the need to make changes to the arrangements
with our affiliated provider network; each of which could interfere with our business or prompt other materially adverse consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
Federal and State Health Information Privacy and Security Laws</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are numerous U.S. federal and state laws and regulations related to the privacy and security of PII, including health information.
In particular, HIPAA as amended by the Health Information Technology for Economic and Clinical Health Act, and its respective
implementing regulations establishes privacy and security standards that limit the use and disclosure of PHI, and require the
implementation of administrative, physical, and technical safeguards to ensure the confidentiality, integrity and availability
of individually identifiable health information in electronic form. Our affiliated network providers and our hospital, health
system and other provider clients are all regulated as covered entities under HIPAA. Since the effective date of the HIPAA Omnibus
Final Rule on September 23, 2013, HIPAA&rsquo;s requirements are also directly applicable to the independent contractors, agents
and other &ldquo;business associates&rdquo; of covered entities that create, receive, maintain or transmit PHI in connection with
providing services to covered entities. We are a business associate under HIPAA when we are working on behalf of our affiliated
providers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violations
of HIPAA may result in civil and criminal penalties. The civil penalties range from $119 to $59,522 per violation, with a cap
of $1.8 million per year for violations of the same standard during the same calendar year. However, a single breach incident
can result in violations of multiple standards. We must also comply with HIPAA&rsquo;s breach notification rule. Under the breach
notification rule, covered entities must notify affected individuals without unreasonable delay in the case of a breach of unsecured
PHI, which may compromise the privacy, security or integrity of the PHI. In addition, notification must be provided to the HHS
and the local media in cases where a breach affects more than 500 individuals. Breaches affecting fewer than 500 individuals must
be reported to HHS on an annual basis. The regulations also require business associates of covered entities to notify the covered
entity of breaches by the business associate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
attorneys general also have the right to prosecute HIPAA violations committed against residents of their states. While HIPAA does
not create a private right of action that would allow individuals to sue in civil court for a HIPAA violation, its standards have
been used as the basis for the duty of care in state civil suits, such as those for negligence or recklessness in misusing personal
information. In addition, HIPAA mandates that HHS conduct periodic compliance audits of HIPAA covered entities and their business
associates for compliance. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of
breaches of unsecured PHI may receive a percentage of the Civil Monetary Penalty fine paid by the violator. In light of the HIPAA
Omnibus Final Rule, recent enforcement activity, and statements from HHS, we expect increased federal and state HIPAA privacy
and security enforcement efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
also required HHS to adopt national standards establishing electronic transaction standards that all healthcare providers must
use when submitting or receiving certain healthcare transactions electronically.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states in which we or our research and development partners may operate also have laws that protect the privacy and security of
sensitive and personal information, including health information. These laws may be similar to or even more protective than HIPAA
and other federal privacy laws. For example, the laws of the State of California are more restrictive than HIPAA. Where state
laws are more protective than HIPAA, we must comply with the state laws to which we are subject, in addition to HIPAA. In certain
cases, it may be necessary to modify our planned operations and procedures to comply with these more stringent state laws. Not
only may some of these state laws impose fines and penalties upon violators, but also some, unlike HIPAA, may afford private rights
of action to individuals who believe their personal information has been misused. In addition, state laws are changing rapidly,
and there is discussion of a new federal privacy law or federal breach notification law, to which we may be subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to HIPAA, state health information privacy laws, we may be subject to other state and federal privacy laws, including
laws that prohibit unfair privacy and security practices and deceptive statements about privacy and security and laws that place
specific requirements on certain types of activities, such as data security and texting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, there have been a number of well-publicized data breaches involving the improper use and disclosure of PII and PHI.
Many states have responded to these incidents by enacting laws requiring holders of personal information to maintain safeguards
and to take certain actions in response to a data breach, such as providing prompt notification of the breach to affected individuals
and state officials. In addition, under HIPAA and pursuant to the related contracts that we enter into with our business associates,
we must report breaches of unsecured PHI to our contractual partners following discovery of the breach. Notification must also
be made in certain circumstances to affected individuals, federal authorities and others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 31, 2021, we had a staff of 40, consisting of 39 full-time employees and 1 part-time employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Properties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own any buildings or other real property. We have one material operating lease which consists of an office space lease
with a remaining lease term of 42 months as of December 31, 2020. Our leased office consists of 5,877 square feet of rentable
space located in Summit Office Park, a twin-building, mid-rise, 242,000 square foot office park located on the perimeter of the
Fort Worth, Texas central business district. The monthly base rental payments for our office lease are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Monthly</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">From</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Through</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Base Rental</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 30%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
                                         1, 2020</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 30%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
                                         30, 2021</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 30%; text-align: right">12,488.63</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
                                         1, 2021</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
                                         30, 2022</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,488.63</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
                                         1, 2022</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
                                         30, 2023</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,733.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
                                         1, 2023</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
                                         30, 2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,978.38</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, our operating lease has a remaining lease term of 3.5 years and a discount rate of 6.25%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be from time to time subject to or involved in litigation and other proceedings. To our knowledge, there are no pending lawsuits
or claims that may, individually or in the aggregate, have a material adverse effect on our business, financial condition or results
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in Texas on December 14, 2001. On March 15, 2019, we entered into a Share Exchange Agreement with CGI Cellerate
RX, an affiliate of Catalyst, pursuant to which we acquired Catalyst&rsquo;s 50% equity interest in Cellerate in exchange for
1,136,815 shares of our newly created Series F Convertible Preferred Stock. Prior to the consummation of the Cellerate Acquisition,
we and Catalyst each owned a 50% equity interest in Cellerate. The Cellerate Acquisition was accounted for as a reverse merger,
and Cellerate was deemed to be the accounting acquirer. In May 2019, we changed our name to Sanara MedTech Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 1200 Summit Ave, Suite 414, Fort Worth, Texas 76102, telephone number (817) 529-2300.
Our website address is www.sanaramedtech.com. Information accessed through our website is not incorporated into this prospectus
supplement and is not a part of this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_012"></A>MANAGEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officers and Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table and biographies that follow sets forth the name, age, position and description of the business experience of individuals
who serve as our executive officers and directors as of the date of this prospectus supplement and brief statements of those aspects
of our directors&rsquo; backgrounds that led us to conclude that they should serve as directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Executive
    Officers</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.
    Michael Carmena</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    Chairman and Principal Executive Officer</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    D. McNeil</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shawn
    M. Bowman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Chief
    Operating Officer and President, Wound Care</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zachary
    B. Fleming</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Chief
    Operating Officer and President, Surgical</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris
    Morrison</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Telehealth Services</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Non-Employee
    Directors</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
    T. Nixon</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Chairman</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    A. DeSutter</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sara
    Ortwein</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ann
    Beal Salamone</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    W. Stuckert</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth
    E. Thorpe</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
are elected by our shareholders and hold office until their successors are elected and qualified or until their earlier resignation
or removal. Officers are appointed by our board of directors and serve at the discretion of the board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biographies
of Executive Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>J.
Michael Carmena</I>, age 65, has served as Vice Chairman of the board of directors and Principal Executive Officer of the Company
since May 2019, and served as Chief Executive Officer from February 2018 to May 2019. He served as Chief Financial Officer from
December 2016 to April 2018. Prior to joining the Company, Mr. Carmena served as Senior Director, Business &amp; Sales Operations
of Smith and Nephew plc (successor to Healthpoint Biotherapeutics) from 2010 to 2013. He served as Senior Director, Finance &amp;
Administration of Healthpoint Biotherapeutics from 2008 to 2010 and as Controller from 1998 to 2008. Mr. Carmena began his professional
career in 1978 with Arthur Andersen &amp; Co. and became a CPA in 1981. Mr. Carmena earned a Bachelor of Business Administration
degree from Texas Christian University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Michael
D. McNeil</I>, age 56, has served as Chief Financial Officer since April 2018. Prior to joining the Company, Mr. McNeil
served as Controller for Smith and Nephew&rsquo;s U.S. Advanced Wound Management Division from 2012 to 2018. Mr. McNeil previously
served as Controller and Assistant Controller with Healthpoint Biotherapeutics from 1999 to 2012. Prior to his employment at Healthpoint,
Mr. McNeil held several finance and internal audit positions with Burlington Resources, Snyder Oil Corporation, and Union Pacific
Corporation. Mr. McNeil earned his Bachelor of Science in Business Administration from the University of Nebraska and is a Texas
certified public accountant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shawn
M. Bowman</I>, age 45, has served as President, Wound Care Division since May 2019, and was named Co-Chief Operating Officer on
January 28, 2020. Mr. Bowman previously served as the Company&rsquo;s Vice President and General Manager, Wound Care since September
2018. Mr. Bowman will be responsible for leading the strategic expansion of the Company&rsquo;s wound care division. Mr. Bowman
has over eighteen years of experience in the medical device, biologics and pharmaceutical industries. Prior to joining Sanara
MedTech, Mr. Bowman built two successful teams as Senior Vice President of Wellsense, and as a National Sales Director for Smith
&amp; Nephew&rsquo;s Advanced Wound Management Division. Mr. Bowman earned a Bachelor of Science in Marketing from the University
of Connecticut<I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Zachary
B. Fleming</I>, age 46, was appointed to the position of President, Surgical Division on May 28, 2019, and was named Co-Chief
Operating Officer on January 28, 2020. Mr. Fleming joined the Company as Vice President of Sales in November 2017 and was promoted
to Vice President, Surgical in September 2018. Mr. Fleming will be responsible for the continued expansion and management of the
surgical sales force as well as new product introductions. Mr. Fleming has spent over fifteen years in the medical industry
with Healthpoint Biotherapeutics, Smith &amp; Nephew and Sanara MedTech. Mr. Fleming earned a Bachelor of Science from Indiana
University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chris
Morrison</I>, age 50, has served as the President of Telehealth Services since October 2020. Dr. Morrison is board-certified by
both the American Board of Family Medicine and the American Board of Preventive Medicine. Dr. Morrison is the founder and former
CEO of Nautilus Health Care Group, where he served in such capacity from 2000 until Nautilus Health Care Group was acquired by
Healogics, Inc. in 2012, where he then served as President and Executive Medical Director of Healogics Specialty Physicians. In
2018, Dr. Morrison founded MGroup Strategies, an investment and consulting firm focused on helping health care service and technology
companies build innovative and market-leading strategies with a focus on the complexities of multi-state corporate practice of
medicine requirements and the positive influence of telemedicine in the future of health care. Dr. Morrison earned a Bachelor
of Science degree in Biology and a Medical Doctorate degree from Indiana University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biographies
of Non-Employee Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Ronald
T. Nixon</I>, age 65, has been a director of the Company since March 2019 and has served as Executive Chairman of the board of
directors since May 2019. As Executive Chairman, he has been involved in strategy planning, execution and identifying prospective
partnerships and acquisitions opportunities for the Company. Mr. Nixon is the Founder and Managing Partner of The Catalyst Group,
Inc., a private investment firm that provides growth capital and strategic advisory services to private companies. Mr. Nixon serves
on the board of directors of LHC Group, Inc. as well as a number of private companies, including Trilliant Surgical, LLC, Rochal,
and Triad Life Sciences, Inc. Mr. Nixon also serves on the Engineering Advisory Board for the Cockrell School of Engineering at
the University of Texas at Austin, where he was the previous vice chairman. Mr. Nixon holds a Bachelor&rsquo;s degree in Mechanical
Engineering from the University of Texas at Austin and is a registered professional engineer (inactive) in Texas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Robert
A. DeSutter</I>, age 52, is a managing director in Piper Sandler healthcare investment banking. Mr. DeSutter has 28 years of investment
banking experience. He served as healthcare global group head from 2003 to 2018. Mr. DeSutter has decades of medical technology
transaction experience on numerous buy and sell-side, friendly and hostile, strategic and financial buyer and public and private
deals on a global basis. Mr. DeSutter has completed financing transactions involving public and private equity, convertible debt
and senior/sub debt. Mr. DeSutter was an investor and Board member for his family&rsquo;s sporting goods business, Great Plains
Sporting Goods LLC, from 2002 to 2009, which ultimately sold to a public company. Mr. DeSutter is a graduate of the University
of Minnesota Carlson School of Management and the University of Virginia&rsquo;s Darden Graduate School of Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sara
Ortwein</I>, age 62, retired from ExxonMobil in March 2019, after a thirty-eight-year career. Prior to retiring, she was president
of XTO Energy, a subsidiary of ExxonMobil, from November 2016 through February 2019 and was responsible for ExxonMobil&rsquo;s
unconventional oil and gas business. Ms. Ortwein also served in various roles including president of ExxonMobil Upstream Research
Company, senior manager within ExxonMobil&rsquo;s U.S. production operations, and corporate upstream advisor to senior management
at ExxonMobil&rsquo;s headquarters in Irving, Texas. Ms. Ortwein earned a Bachelor of Science degree in civil engineering at the
University of Texas at Austin before joining Exxon Company, U.S.A. in 1980.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Ann
Beal Salamone</I>, M.S., age 70, has been a director of the Company since August 2019. Ms. Salamone is a co-founder of Rochal
and has served as its chairman since September 2019, prior to which she served as its president from 1986 to September 2019. She
is one of the principal inventors of Rochal&rsquo;s liquid bandages, antimicrobial compositions and skin regeneration products
for burn and wound treatment, and she has participated in the development of products for electronics, water purification, personal
care and healthcare. Ms. Salamone has co-founded six companies and invested in and served on the board of directors of several
private entrepreneurial companies. Ms. Salamone is a member of the National Academy of Engineering and The Academy of Medicine,
Engineering &amp; Science of Texas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>James
W. Stuckert</I>, age 82, has been a director of the Company since September 2015. He has been engaged in personal investing activities
from 2004 to 2019. Mr. Stuckert served as Chairman and Chief Executive Officer of J.J.B. Hilliard, W.L. Lyons, LLC from December
1995 until December 2003, prior to which he served in executive and broker positions from 1963. J.J.B. Hilliard, W.L. Lyons, LLC
is a full-service financial asset management firm headquartered in Louisville, Kentucky. Mr. Stuckert was an initial investor
and served 24 years on the board of directors of Royal Gold, Inc. He previously has served as chairman of SenBanc Fund; a director
of DataBeam, Inc.; a board member of the Securities Industry Association and chairman of its regional firms committee; and a past
member of the nominating committee of the New York Stock Exchange. Mr. Stuckert has served as a member of the board of trustees
of the University of Kentucky and as chairman of its Finance Committee and as chairman of its Presidential Search Committee. He
has also served as chairman of a local hospital&rsquo;s investment committee. Mr. Stuckert earned a Bachelor&rsquo;s degree in
Mechanical Engineering and a Master of Business Administration degree from the University of Kentucky.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Kenneth
E. Thorpe, Ph.D.</I>, age 63, has been a director of the Company since August 2019. He has been the Robert W. Woodruff Professor
and Chair of the Department of Health Policy &amp; Management of the Rollins School of Public Health of Emory University in Atlanta,
Georgia since 1999. From 1983 to 1999 he held faculty positions in the public health departments at Tulane University, the University
of North Carolina at Chapel Hill, Harvard University and Columbia University. Since 2007 Dr. Thorpe has served as Chairman of
the Partnership to Fight Chronic Disease. He served on the Board of Directors of LHC Group, Inc. in 2010; was a consultant in
the Governor&rsquo;s Office and Legislature of West Virginia in 2011; and was Co-Chair of the Partnership for the Future of Medicare
in 2013. From 1993 to 1995, Dr. Thorpe served as Deputy Assistant Secretary for Health Policy in the U.S. Department of Health
and Human Services where he coordinated all financial estimates and program impacts of the Clinton administration&rsquo;s healthcare
reform proposals. In 1991 he was awarded the Young Investigator Award as the most promising health services researcher in the
country under age 40 by the Association for Health Services Research. He has authored multiple articles and books on healthcare
financing, insurance and healthcare reform. Dr. Thorpe received his Bachelor of Arts degree from the University of Michigan, Master
of Arts degree from Duke University, and Ph.D. from the Rand Graduate School.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Composition </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors currently consists of seven directors, six of which are non-employee directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our officers or executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the rules of Nasdaq, independent directors must comprise a majority of a listed company&rsquo;s board of directors, subject to
specified exceptions and certain phase-in periods available to companies that do not yet have a class of common stock registered
under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). In addition, Nasdaq rules require that,
subject to specified exceptions, each member of a listed company&rsquo;s audit, compensation and nominating and corporate governance
committees be independent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has undertaken a review of the composition of our board of directors, our committees and the independence of
each director. Based upon information requested from and provided by each director concerning their background, employment and
affiliations, including family relationships, the board of directors has determined that Robert A. DeSutter, Sara Ortwein, James
W. Stuckert and Kenneth E. Thorpe are &ldquo;independent&rdquo; as that term is defined under applicable Nasdaq rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Committees
of the Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Audit
Committee</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee consists of Mr. DeSutter, Mr. Stuckert and Mr. Thorpe, with Mr. Stuckert serving as chairman. Our board of directors
has determined that each of Mr. DeSutter, Mr. Stuckert and Mr. Thorpe are independent under Nasdaq listing standards and Rule
10A-3(b)(1) of the Exchange Act. Our board of directors has also determined that each member of our audit committee can read and
understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, the
board of directors has examined each audit committee member&rsquo;s scope of experience and the nature of their current and prior
employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functions of the audit committee include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting
                                         a qualified firm to serve as the independent registered public accounting firm to audit
                                         our financial statements and prepare or issue an audit report;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">helping
                                         to ensure the independence and performance of the independent registered public accounting
                                         firm;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing
                                         the scope and results of the audit with the independent registered public accounting
                                         firm, and reviewing, with management and the independent accountants, our annual and
                                         quarterly financial statements, as well as all internal control reports;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                         and overseeing procedures for employees to submit concerns confidentially and anonymously
                                         about questionable accounting or auditing matters;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                         our policies on risk assessment and risk management, including our major financial risk
                                         exposures and cybersecurity risks;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                         and approving related-party transactions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                         and reviewing a report by the independent registered public accounting firm that describes
                                         our internal quality-control procedures, any material issues with such procedures, and
                                         any steps taken to deal with such issues when required by applicable law; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
                                         (or, as permitted, pre-approving) all audit and all permissible non-audit services, to
                                         be provided by the independent registered public accounting firm.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has designated Mr. DeSutter as an &ldquo;audit committee financial expert&rdquo; as defined under the applicable
SEC rules and determined that he has accounting or related financial management expertise as required under Nasdaq rules. A copy
of the audit committee charter is available on our website at <I>https://sanaramedtech.com/corporate-governance/</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Compensation
Committee</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee consists of Mr. DeSutter and Mr. Thorpe, with Mr. Thorpe serving as the chairman. Our board of directors
has determined that each of Mr. DeSutter and Mr. Thorpe are independent under Nasdaq listing standards and &ldquo;non-employee
directors&rdquo; as defined in Rule 16b-3 promulgated under the Exchange Act. The compensation committee, with input from our
Principal Executive Officer, reviews and approves, or recommends that our board of directors approve, the compensation of our
executive officers. Prior to the formation of the compensation committee, our board of directors reviewed and approved both director
and executive officer compensation, and our board of directors continues to review and approve director compensation. A copy of
the compensation committee charter is available on our website at <I>https://sanaramedtech.com/corporate-governance/</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functions of the compensation committee include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                         and approving our goals and objectives applicable to the compensation of our executive
                                         officers;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
                                         and approving the compensation of our executive officers;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                         and approving and, when appropriate, recommending that our board of directors approve
                                         any employment agreements and any severance arrangements for our executive officers;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
                                         administering and making recommendations to our board of directors with respect to our
                                         incentive equity plans;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                         our incentive compensation arrangements to determine whether they encourage excessive
                                         risk-taking and evaluating compensation policies and practices that could mitigate any
                                         such risk; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
                                         and approving plans, policies, programs and arrangements relating to compensation and
                                         benefits of our employees.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nominating
and Corporate Governance Committee</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and corporate governance committee consists of Mr. DeSutter, Mr. Stuckert and Mr. Thorpe, with Mr. DeSutter serving
as chairman. A copy of the nominating and corporate governance committee charter is available on our website at <I>https://sanaramedtech.com/corporate-governance/</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functions of the nominating and corporate governance committee include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying
                                         individuals qualified to serve on our board of directors and its committees consistent
                                         with criteria approved by our board of directors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                         a slate of director nominees for approval by our board of directors for election by the
                                         shareholders of the Company at the annual meeting;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                         director nominees to fill any vacancies on our board of directors, in accordance with
                                         our Certificate of Formation, bylaws and Texas law;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                         and making recommendations regarding the structure and composition of the committees
                                         of our board of directors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                         and making recommendations to our board of directors with regard to our corporate governance
                                         guidelines applicable to us; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                         and recommending to our board of directors for approval the Principal Executive Officer
                                         succession plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted a Code of Ethics and Business Conduct (the &ldquo;Code of Ethics&rdquo;) applicable to all directors, officers
and employees. The Code of Ethics addresses, among other things, honest and ethical conduct, conflicts of interest, proper use
of Company assets, corporate opportunities, discrimination and harassment and disciplinary measures. The Code of Ethics can be
found on the Company&rsquo;s website at <I>https://sanaramedtech.com/code-of-conduct/</I>. We intend to disclose any future amendments
to certain provisions of the Code of Ethics, or waivers of such provisions granted to executive officers and directors, on this
website within four business days following the date of any such amendment or waiver.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_013"></A>MATERIAL
U.S. FEDERAL INCOME AND ESTATE TAX CONSIDERATIONS FOR NON-U.S. HOLDERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the material U.S. federal income tax considerations related to the purchase, ownership and disposition
of our common stock by a non-U.S. holder (as defined below) who holds our common stock as a &ldquo;capital asset&rdquo; within
the meaning of Section 1221 of the Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;) (generally, property held
for investment). This summary is based on provisions of the Code, U.S. Treasury regulations, administrative rulings and judicial
decisions, all as in effect of the date hereof, and all of which are subject to change, possibly with retroactive effect. We have
not sought any ruling from the Internal Revenue Service (the &ldquo;IRS&rdquo;) with respect to the statements made and the conclusions
reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary does not address all aspects of U.S. federal income taxation that may be relevant to non-U.S. holders in light of their
personal circumstances. In addition, this summary does not address the net investment income tax on certain investment income,
U.S. federal gift or estate tax laws, any state, local or non-U.S. tax laws or any tax treaties. In addition, this discussion
does not address tax considerations applicable to investors that may be subject to special treatment under the U.S. federal income
tax laws, such as (without limitation):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks,
                                         insurance companies or other financial institutions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt
                                         or governmental organizations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">qualified
                                         foreign pension funds (or any entities all of the interests of which are held by a qualified
                                         foreign pension fund);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers
                                         or dealers in securities or foreign currencies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">traders
                                         in securities that use the mark-to-market method of accounting for U.S. federal income
                                         tax purposes;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                         subject to the alternative minimum tax;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">partnerships
                                         or other pass-through entities for U.S. federal income tax purposes or holders of interests
                                         therein;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                         that acquired our common stock through the exercise of employee stock options or otherwise
                                         as compensation or through a tax-qualified retirement plan;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
                                         former citizens or residents of the United States;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">real
                                         estate investment trusts or regulated investment companies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                         that hold our common stock as part of a straddle, constructive sale transaction, synthetic
                                         security, hedge, conversion transaction or other integrated investment or risk reduction
                                         transaction;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shareholders
                                         that own, or are deemed to own, more than five percent (5%) of our outstanding common
                                         stock (except to the extent specifically set forth below); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;controlled
                                         foreign corporations,&rdquo; &ldquo;passive foreign investment companies&rdquo; or corporations
                                         that accumulate earnings to avoid U.S. federal income tax.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-U.S.
Holder Defined</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this discussion, a &ldquo;non-U.S. holder&rdquo; is a beneficial owner of our common stock that is not a &ldquo;U.S.
person&rdquo; or an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                         individual who is a citizen or resident of the United States;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         corporation (including any entity treated as a corporation for U.S. federal income tax
                                         purposes) created or organized in or under the laws of the United States, any state thereof
                                         or the District of Columbia;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                         estate the income of which is subject to U.S. federal income taxation regardless of its
                                         source; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         trust (i) the administration of which is subject to the primary supervision of a U.S.
                                         court and which has one or more U.S. persons who have the authority to control all substantial
                                         decisions of the trust or (ii) which has made a valid election under applicable U.S.
                                         Treasury regulations to be treated as a U.S. person.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #222720; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a partnership (including an entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds our common
stock, the U.S. federal income tax treatment of a partner in the partnership generally will depend upon the status of the partner,
upon the activities of the partnership and upon certain determinations made at the partner level. Accordingly, we urge partners
in partnerships (including entities or arrangements treated as partnerships for U.S. federal income tax purposes) considering
the purchase of our common stock to consult their tax advisors regarding the U.S. federal income tax considerations of the purchase,
ownership and disposition of our common stock by such partnership.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #222720; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Distributions
on our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #222720; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributions
of cash or property on our common stock will constitute dividends for U.S. federal income tax purposes to the extent paid from
our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent any such
distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a non-taxable return of capital
to the extent of the non-U.S. holder&rsquo;s tax basis in our common stock and thereafter as capital gain from the sale or exchange
of such common stock. See &ldquo;&mdash;Gain on Disposition of our Common Stock&rdquo; below. Subject to the discussion below
under &ldquo;&mdash;Additional Withholding Requirements under FATCA,&rdquo; dividends paid to a non-U.S. holder with respect to
our common stock that are not effectively connected with the non-U.S. holder&rsquo;s conduct of a trade or business within the
United States generally will be subject to U.S. withholding tax at a rate of 30% unless an applicable income tax treaty provides
for a lower rate. To receive the benefit of a reduced treaty rate, a non-U.S. holder must provide the applicable withholding agent
with an IRS Form W-8BEN or IRS Form W-8BEN-E (or other applicable or successor form) certifying qualification for the reduced
rate. Non-U.S. holders that do not timely provide us or our withholding agent with the required certification, but that qualify
for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund
with the IRS. Non-U.S. holders should consult their tax advisors regarding their entitlement to benefits under an applicable income
tax treaty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
paid to a non-U.S. holder that are effectively connected with the non-U.S. holder&rsquo;s conduct of a trade or business in the
United States (and, if required by an applicable income tax treaty, are treated as attributable to a permanent establishment maintained
by the non-U.S. holder in the United States) generally will be taxed on a net income basis at the rates and in the manner generally
applicable to U.S. persons (as defined under the Code). Such effectively connected dividends will not be subject to U.S. withholding
tax if the non-U.S. holder satisfies certain certification requirements by providing the applicable withholding agent a properly
executed IRS Form W-8ECI certifying eligibility for exemption. If the non-U.S. holder is a non-U.S. corporation, it may also be
subject to a branch profits tax (at a 30% rate or such lower rate as specified by an applicable income tax treaty) on its effectively
connected earnings and profits (as adjusted for certain items), which will include effectively connected dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gain
on Disposition of our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below under &ldquo;&mdash;Additional Withholding Requirements under FATCA,&rdquo; a non-U.S. holder generally
will not be subject to U.S. federal income tax or withholding tax on any gain realized upon the sale or other disposition of our
common stock unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         non-U.S. holder is an individual who is present in the U.S. for a period or periods aggregating
                                         183 days or more during the calendar year in which the sale or disposition occurs and
                                         certain other conditions are met;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         gain is effectively connected with the non-U.S. holder&rsquo;s conduct of a trade or
                                         business in the United States (and, if required by an applicable income tax treaty, is
                                         attributable to a permanent establishment maintained by the non-U.S. holder in the United
                                         States); or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         common stock constitutes a U.S. real property interest by reason of our status as a U.S.
                                         real property holding corporation (&ldquo;USRPHC&rdquo;) for U.S. federal income tax
                                         purposes and the non-U.S. holder held, at any time during the five-year period ending
                                         on the date of disposition, more than 5% of the common stock and such non-U.S. holder
                                         is not eligible for an exemption under an applicable income tax treaty.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-U.S. holder described in the first bullet point in the list immediately above will be subject to U.S. federal income tax at
a rate of 30% (or such lower rate as specified by an applicable income tax treaty) on the amount of such gain, which generally
may be offset by U.S. source capital losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-U.S. holder whose gain is described in the second bullet point in the list immediately above generally will be taxed on a
net income basis at the rates and in the manner generally applicable to U.S. persons (as defined in the Code) unless an applicable
income tax treaty provides otherwise. If the non-U.S. holder is a corporation, it may also be subject to a branch profits tax
(at a 30% rate or such lower rate as specified by an applicable income tax treaty) on its effectively connected earnings and profits
(as adjusted for certain items).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the third bullet, we believe that we have not been, are not currently, and do not anticipate becoming in the future,
a USRPHC for U.S. federal income tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Backup
Withholding and Information Reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
dividends paid to a non-U.S. holder must be reported annually to the IRS and to the non-U.S. holder. Copies of these information
returns may be made available to the tax authorities in the country in which the non-U.S. holder resides or is established. Payments
of dividends to a non-U.S. holder generally will not be subject to backup withholding if the non-U.S. holder establishes an exemption
by properly certifying its non-U.S. status on an IRS Form W-8BEN, IRS Form W-8BEN-E or other appropriate version of IRS Form W-8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #222720"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #222720"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
of the proceeds from a sale or other disposition by a non-U.S. holder of our common stock effected by or through a U.S. office
of a broker generally will be subject to information reporting and backup withholding (at the applicable rate) unless the non-U.S.
holder establishes an exemption by properly certifying its non-U.S. status on an IRS Form W-8BEN, IRS Form W-8BEN-E or other appropriate
version of IRS Form W-8 and certain other conditions are met. Information reporting and backup withholding generally will not
apply to any payment of the proceeds from a sale or other disposition of our common stock effected outside the United States by
a non-U.S. office of a broker. However, unless such broker has documentary evidence in its records that the holder is not a U.S.
person and certain other conditions are met, or the non-U.S. holder otherwise establishes an exemption, information reporting
will apply to a payment of the proceeds of the disposition of our common stock effected outside the United States by such a broker
if it has certain relationships within the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #222720"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #222720"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax. Rather, the U.S. income tax liability (if any) of persons subject to backup withholding
will be reduced by the amount of tax withheld. If backup withholding results in an overpayment of taxes, a refund may be obtained,
provided that the required information is timely furnished to the IRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #222720"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222720"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Withholding Requirements under FATCA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222720"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #222720"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sections
1471 through 1474 of the Code, and the Treasury regulations and administrative guidance issued thereunder (&ldquo;FATCA&rdquo;),
impose a 30% withholding tax on any dividends paid on our common stock if paid to a &ldquo;foreign financial institution&rdquo;
or a &ldquo;non-financial foreign entity&rdquo; (each as defined in the Code) (including, in some cases, when such foreign financial
institution or non-financial foreign entity is acting as an intermediary), unless (i) in the case of a foreign financial institution,
such institution enters into an agreement with the U.S. Treasury to, among other things, undertake to identify accounts held by
certain U.S. persons or U.S.-owned foreign entities, annually report certain information about such accounts, and withhold 30%
on payments to account holders whose actions prevent it from complying with these reporting and other requirements, (ii) in the
case of a non-financial foreign entity, such entity certifies that it does not have any &ldquo;substantial United States owners&rdquo;
(as defined in the Code) or provides the applicable withholding agent with a certification identifying the direct and indirect
substantial United States owners of the entity (in either case, generally on an IRS Form W-8BEN-E), or (iii) the foreign financial
institution or non-financial foreign entity otherwise qualifies for an exemption from these rules and provides appropriate documentation
(such as an IRS Form W-8BEN-E). Foreign financial institutions located in jurisdictions that have an intergovernmental agreement
with the United States governing these rules may be subject to different rules. The FATCA withholding tax will apply to all withholdable
payments without regard to whether the beneficial owner of the payment would otherwise be entitled to an exemption from imposition
of withholding tax pursuant to an applicable tax treaty with the United States or U.S. domestic law, though, under certain circumstances,
a holder might be eligible for refunds or credits of such taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #222720"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #222720"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
SUMMARY OF MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS ABOVE IS INCLUDED FOR GENERAL INFORMATION PURPOSES ONLY AND SHOULD
NOT VIEWED AS TAX ADVICE. PROSPECTIVE INVESTORS ARE ENCOURAGED TO CONSULT THEIR OWN TAX ADVISORS REGARDING THE APPLICATION OF
THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATION, AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND
DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL GIFT AND ESTATE TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL
OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE TAX TREATY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_014"></A>UNDERWRITING</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms and conditions set forth in the underwriting agreement, dated February 12, 2021, between us and Cantor Fitzgerald &amp; Co., 499 Park Avenue, New York, New York 10022, as representative of the underwriters
named below and the sole book-running manager of this offering, we have agreed to sell to Cantor Fitzgerald &amp; Co., and Cantor
Fitzgerald &amp; Co. has agreed to purchase from us, the shares of common stock shown opposite its name below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 71%; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Underwriter</TD><TD STYLE="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 25%; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                         of Shares</B></FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cantor Fitzgerald &amp; Co.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">1,100,000</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">1,100,000</P></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriting agreement provides that the obligations of Cantor Fitzgerald &amp; Co. are subject to certain conditions precedent
such as the receipt by Cantor Fitzgerald &amp; Co. of officers&rsquo; certificates and legal opinions and approval of certain
legal matters by their counsel. The underwriting agreement provides that Cantor Fitzgerald &amp; Co. will purchase all of the
shares of common stock if any of them are purchased. We have agreed to indemnify Cantor Fitzgerald &amp; Co. and certain of its
controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments
that Cantor Fitzgerald &amp; Co. may be required to make in respect of those liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
Fitzgerald &amp; Co. is offering the shares of common stock subject to its acceptance of the shares of common stock from us and
subject to prior sale. Cantor Fitzgerald &amp; Co. reserves the right to withdraw, cancel or modify offers to the public and to
reject orders in whole or in part. In addition, Cantor Fitzgerald &amp; Co. has advised us that it does not intend to confirm
sales to any account over which it exercises discretionary authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option
to Purchase Additional Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted to Cantor Fitzgerald &amp; Co. an option, exercisable 30 days from the date of this prospectus supplement, to purchase,
from time to time, in whole or in part, up to an aggregate of 165,000 shares
from us at the public offering price set forth on the cover page of this prospectus supplement, less underwriting discounts and
commissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
and Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
Fitzgerald &amp; Co. has advised us that it proposes to offer the shares of common stock to the public at the public offering
price set forth on the cover page of this prospectus supplement and to certain dealers, which may include the underwriters, at
that price less a concession not in excess of $1.05 per share of
common stock. After the initial offering, Cantor Fitzgerald &amp; Co. may change the offering price and other selling terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the public offering price, the underwriting discounts and commissions that we are to pay Cantor Fitzgerald
&amp; Co. and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise
and full exercise of Cantor Fitzgerald &amp; Co.&rsquo;s option to purchase additional shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Without<BR> Option to Purchase Additional Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">With<BR> Option to Purchase Additional Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Without<BR> Option to Purchase Additional Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">With<BR> Option to Purchase Additional Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-size: 10pt">Public offering price</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">25.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">25.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">27,500,000.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">31,625,000.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Underwriting discounts and commissions</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.75</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.75</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,925,000.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,213,750.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Proceeds to us, before expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">23.25</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">23.25</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">25,575,000.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">29,411,250.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred
to above, will be approximately $374,365. We have also agreed to reimburse the underwriters for up to $250,000 of certain of their counsels&rsquo; fees and expenses,
which reimbursed fee is deemed underwriting compensation for this offering by FINRA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the trading symbol &ldquo;SMTI.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
Sales of Similar Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed,
subject to certain specified exceptions, not to directly or indirectly, without prior written consent of Cantor Fitzgerald &amp;
Co. (which consent may be withheld in its sole discretion) for a period of 90 days after the date of the underwriting agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -4.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.3in"><FONT STYLE="font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">sell, offer to sell, contract to sell or lend any shares
    or Related Securities (as defined below);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">effect any short sale, or establish or increase any &ldquo;put
    equivalent position&rdquo; (as defined in Rule 16a-1(h) under the Exchange Act) or liquidate or decrease any &ldquo;call equivalent
    position&rdquo; (as defined in Rule 16a 1(b) under the Exchange Act) of any shares or Related Securities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">pledge, hypothecate or grant any security interest in any
    shares of common stock or Related Securities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in any other way transfer or dispose of any shares or Related
    Securities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">enter into any swap, hedge or similar arrangement or agreement
    that transfers, in whole or in part, the economic risk of ownership of any shares or Related Securities, regardless of whether
    any such transaction is to be settled in securities, in cash or otherwise;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">announce the offering of any shares or Related Securities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(vii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">file any registration statement under the Securities Act
    in respect of any shares or Related Securities (other than as contemplated by the underwriting agreement with respect to the
    offered shares); or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(viii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">publicly announce the intention to do any of the foregoing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">provided, however, that the Company may (A) sell the offered shares,
(B) issue shares of common stock, options to purchase shares of common stock, restricted stock units or other similar equity securities,
or issue shares of common stock upon exercise or conversion of options, restricted stock units or similar equity securities, pursuant
to any stock option, stock bonus or other stock plan or arrangement described in the registration statement, the time of sale prospectus
and the prospectus, but only if the holders of such shares or options agree in writing with the Cantor Fitzgerald &amp; Co. not
to sell, offer, dispose of or otherwise transfer any such shares or options during the lock-up period without the prior written
consent of Cantor Fitzgerald &amp; Co. (which consent may be withheld in its sole discretion), (C) issue shares of its capital
stock or Related Securities in connection with a transaction that includes a commercial relationship (including joint ventures,
marketing or distribution arrangements, collaboration agreements or intellectual property license agreements) or any acquisition
of assets or not less than a majority or controlling portion of the equity of another entity, provided that (x) the aggregate number
of securities issued pursuant to this clause (C) shall not represent more than 5.0% of the total number of then-outstanding common
stock and (y) the recipient of any such securities issued pursuant to this clause (C) during the lock-up period shall enter into
a lock-up agreement, and (D) issue up to a number of shares of common stock equal to $750,000 divided by the price to the public
in this offering to Rochal pursuant to that certain Exclusive License Agreement, dated July 7, 2019, by and between the Company
and Rochal, as amended, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144)
and carry no registration rights that require or permit the filing of any registration statement in connection therewith during
the lock-up period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of the
foregoing, &ldquo;Related Securities&rdquo; shall mean any options or warrants or other rights to acquire shares or any securities
exchangeable or exercisable for or convertible into shares, or to acquire other securities or rights ultimately exchangeable or
exercisable for, or convertible into, shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
officers and directors and certain of our stockholders have agreed, subject to certain specified exceptions, not to directly or
indirectly, for a period of 90 days after the date of the underwriting agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell,
                                         offer, contract or grant any option to sell (including any short sale), pledge, transfer,
                                         establish an open &ldquo;put equivalent position&rdquo; within the meaning of Rule 16a-l(h)
                                         under the Securities Exchange Act of 1934, as amended, or otherwise dispose of, any shares
                                         of common stock, options or warrants to acquire shares of common stock, or securities
                                         exchangeable or exercisable for or convertible into shares of common stock currently
                                         or hereafter owned either of record or beneficially,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
                                         into any swap, hedge or other agreement or transaction that transfers, in whole or in
                                         part, the economic consequence of ownership of common stock, or securities exchangeable
                                         or exercisable for or convertible into shares of common stock, or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicly
                                         announce an intention to do any of the foregoing for a period of 90 days after the date
                                         of this prospectus supplement without the prior written consent of Cantor Fitzgerald
                                         &amp; Co.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, each such person has agreed that, without the prior written consent of Cantor Fitzgerald &amp; Co., such person will
not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares
of common stock or any security convertible into or exercisable or exchangeable for common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
restrictions in the immediately preceding paragraph do not apply in certain circumstances, including transfers:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                         a bona fide gift or gifts;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                         any trust for the direct or indirect benefit of the locked-up party or the immediate
                                         family of the locked-up party;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursuant
                                         to a qualified domestic order or in connection with a divorce settlement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                         will or intestate succession to the legal representative, heir, beneficiary or immediate
                                         family of the locked-up party upon the death of the locked-up party;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         establishment of a trading plan pursuant to Rule 10b5-1 promulgated under the Exchange
                                         Act, provided that (i) such plan does not provide for the transfer of securities during
                                         the lock-up period and (ii) no filing or public announcement under the Exchange Act or
                                         otherwise is required or voluntarily made by or on behalf of the locked-up party or us
                                         in connection with the establishment of such plan;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfers
                                         of shares of common stock acquired in open market transactions after the completion of
                                         this offering;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursuant
                                         to a bona fide third-party tender offer, merger, consolidation or other similar transaction
                                         made to all holders of common stock and involving a change of control of the Company,
                                         provided that in the event that such tender offer, merger, consolidation or other similar
                                         transaction is not completed, the common stock owned by the locked-up party shall remain
                                         subject to the restrictions contained in the applicable lock-up agreement; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                         us for the sole purpose of paying taxes (including estimated taxes) due as a result of
                                         the exercise, vesting or settlement of outstanding options, warrants, restricted stock,
                                         restricted stock units or other equity interests granted pursuant to employee benefit
                                         plans disclosed, or incorporated by reference, in this prospectus supplement relating
                                         to the offering, provided that if the locked-up party is required to file a report under
                                         Section 16(a) of the Exchange Act during the lock-up period regarding such transfer,
                                         the locked-up party shall include a statement in any such report to the effect that such
                                         transfer was solely pursuant to the circumstances described in this clause (viii).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
Fitzgerald &amp; Co. may, in its sole discretion and at any time or from time to time before the termination of the 90-day period
release all or any portion of the securities subject to lock-up agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Making, Stabilization and Other Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
Fitzgerald &amp; Co. may make a market in the common stock as permitted by applicable laws and regulations. However, Cantor Fitzgerald
&amp; Co. is not obligated to do so, and Cantor Fitzgerald &amp; Co. may discontinue any market-making activities at any time
without notice in its sole discretion. Accordingly, no assurance can be given as to the liquidity of the trading market for the
common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you
receive when you sell will be favorable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter has advised us that it, pursuant to Regulation M under the Exchange Act and certain persons participating in the offering,
may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty
bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of
the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may
involve either &ldquo;covered&rdquo; short sales or &ldquo;naked&rdquo; short sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Covered&rdquo;
short sales are sales made in an amount not greater than the underwriter&rsquo;s option to purchase additional shares of our common
stock in this offering. The underwriter may close out any covered short position by either exercising its option to purchase additional
shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of shares to
close out the covered short position, the underwriter will consider, among other things, the price of shares available for purchase
in the open market as compared to the price at which its may purchase shares through the option to purchase additional shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Naked&rdquo;
short sales are sales in excess of the option to purchase additional shares of our common stock. The underwriter must close out
any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriter
is concerned that there may be downward pressure on the price of the shares of our common stock in the open market after pricing
that could adversely affect investors who purchase in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriter for the purpose of fixing or
maintaining the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common
stock on behalf of the underwriter to reduce a short position incurred by the underwriter in connection with the offering. Similar
to other purchase transactions, the underwriter&rsquo;s purchases to cover the syndicate short sales may have the effect of raising
or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock.
As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty
bid is an arrangement permitting the underwriter to reclaim the selling concession otherwise accruing to a syndicate member in
connection with the offering if the common stock originally sold by such syndicate member are purchased in a syndicate covering
transaction and therefore have not been effectively placed by such syndicate member.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we, nor the underwriter make any representation or prediction as to the direction or magnitude of any effect that the transactions
described above may have on the price of our common stock. The underwriter is not obligated to engage in these activities and,
if commenced, may end any of these activities at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Passive
Market Making</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter may also engage in passive market making transactions in our common stock on the NASDAQ in accordance with Rule 103
of Regulation M during a period before the commencement of offers or sales of shares of our common stock in this offering and
extending through the completion of distribution. A passive market maker must display its bid at a price not in excess of the
highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&rsquo;s
bid, that bid must then be lowered when specified purchase limits are exceeded. Passive market making may cause the price of our
common stock to be higher than the price that otherwise would exist in the open market in the absence of those transactions. The
underwriter is not required to engage in passive market making and, if commenced, may end passive market making activities at
any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available by e-mail or on the web sites or through online services maintained by one
or more of the underwriters, selling group members (if any) or their affiliates. The underwriter may agree with us to allocate
a specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for online distributions
will be made by the underwriter on the same basis as other allocations. Other than the prospectus in electronic format, the information
on the underwriter&rsquo;s web site and any information contained in any other web site maintained by the underwriter is not part
of this prospectus supplement, has not been approved and/or endorsed by us or the underwriter and should not be relied upon by
investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Activities and Relationships </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cantor
Fitzgerald &amp; Co. and certain of its affiliates are full service financial institutions engaged in a wide range of activities
for their own accounts and the accounts of customers, which may include, among other things, corporate finance, mergers and acquisitions,
merchant banking, equity and fixed income sales, trading and research, derivatives, foreign exchange, futures, asset management,
custody, clearance and securities lending. Cantor Fitzgerald &amp; Co. and certain of its affiliates have, from time to time,
performed, and may in the future perform, various investment banking and financial advisory services for us and our affiliates,
for which it received or will receive customary fees and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in the ordinary course of its business, Cantor Fitzgerald &amp; Co. and its affiliates may, directly or indirectly,
hold long or short positions, trade and otherwise conduct such activities in or with respect to debt or equity securities and/or
bank debt of, and/or derivative products. Such investment and securities activities may involve our securities and instruments.
Cantor Fitzgerald &amp; Co. and its affiliates may also make investment recommendations or publish or express independent research
views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or
short positions in such securities and instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stamp
Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you purchase shares of common stock offered in this prospectus supplement, you may be required to pay stamp taxes and other charges
under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus
supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
TO INVESTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Canada</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement constitutes an &ldquo;exempt offering document&rdquo; as defined in and for the purposes of applicable Canadian
securities laws. No prospectus has been filed with any securities commission or similar regulatory authority in Canada in connection
with the offer and sale of the common stock. No securities commission or similar regulatory authority in Canada has reviewed or
in any way passed upon this prospectus supplement or on the merits of the common stock and any representation to the contrary
is an offence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Canadian
investors are advised that this prospectus supplement has been prepared in reliance on section 3A.3 of National Instrument 33-105
<I>Underwriting Conflicts</I> (&ldquo;NI 33-105&rdquo;). Pursuant to section 3A.3 of NI 33-105, this prospectus supplement is
exempt from the requirement that the Company and the underwriter(s) provide investors with certain conflicts of interest disclosure
pertaining to &ldquo;connected issuer&rdquo; and/or &ldquo;related issuer&rdquo; relationships that may exist between the Company
and the underwriter(s) as would otherwise be required pursuant to subsection 2.1(1) of NI 33-105.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Resale
Restrictions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offer and sale of the common stock in Canada is being made on a private placement basis only and is exempt from the requirement
that the Company prepares and files a prospectus under applicable Canadian securities laws. Any resale of the common stock acquired
by a Canadian investor in this offering must be made in accordance with applicable Canadian securities laws, which may vary depending
on the relevant jurisdiction, and which may require resales to be made in accordance with Canadian prospectus requirements, pursuant
to a statutory exemption from the prospectus requirements, in a transaction exempt from the prospectus requirements or otherwise
under a discretionary exemption from the prospectus requirements granted by the applicable local Canadian securities regulatory
authority. These resale restrictions may under certain circumstances apply to resales of the common stock outside of Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representations
of Purchasers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Canadian investor who purchases the common stock will be deemed to have represented to the Company and the underwriter(s) that
the investor (i) is purchasing the common stock as principal, or is deemed to be purchasing as principal in accordance with applicable
Canadian securities laws, for investment only and not with a view to resale or redistribution; (ii) is an &ldquo;accredited investor&rdquo;
as such term is defined in section 1.1 of National Instrument 45-106 <I>Prospectus Exemptions </I>(&ldquo;NI 45-106&rdquo;) or,
in Ontario, as such term is defined in section 73.3(1) of the <I>Securities Act </I>(Ontario); and (iii) is a &ldquo;permitted
client&rdquo; as such term is defined in section 1.1 of National Instrument 31-103 <I>Registration Requirements, Exemptions and
Ongoing Registrant Obligations</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Taxation
and Eligibility for Investment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
discussion of taxation and related matters contained in this prospectus supplement does not purport to be a comprehensive description
of all of the tax considerations that may be relevant to a Canadian investor when deciding to purchase the common stock and, in
particular, does not address any Canadian tax considerations. No representation or warranty is hereby made as to the tax consequences
to a resident, or deemed resident, of Canada of an investment in the common stock or with respect to the eligibility of the common
stock for investment by such investor under relevant Canadian federal and provincial legislation and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rights
of Action for Damages or Rescission</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
legislation in certain of the Canadian jurisdictions provides certain purchasers of securities pursuant to an offering memorandum
(such as this prospectus supplement), including where the distribution involves an &ldquo;eligible foreign security&rdquo; as
such term is defined in Ontario Securities Commission Rule 45-501 <I>Ontario Prospectus and Registration Exemptions</I> and in
Multilateral Instrument 45-107 <I>Listing Representation and Statutory Rights of Action Disclosure Exemptions</I>, as applicable,
with a remedy for damages or rescission, or both, in addition to any other rights they may have at law, where the offering memorandum,
or other offering document that constitutes an offering memorandum, and any amendment thereto, contains a &ldquo;misrepresentation&rdquo;
as defined under applicable Canadian securities laws. These remedies, or notice with respect to these remedies, must be exercised
or delivered, as the case may be, by the purchaser within the time limits prescribed under, and are subject to limitations and
defences under, applicable Canadian securities legislation. In addition, these remedies are in addition to and without derogation
from any other right or remedy available at law to the investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Language
of Documents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
receipt of this document, each Canadian investor hereby confirms that it has expressly requested that all documents evidencing
or relating in any way to the sale of the securities described herein (including for greater certainty any purchase confirmation
or any notice) be drawn up in the English language only. <I>Par la r&eacute;ception de ce document, chaque investisseur Canadien
confirme par les pr&eacute;sentes qu&rsquo;il a express&eacute;ment exig&eacute; que tous les documents faisant foi ou se rapportant
de quelque mani&egrave;re que ce soit &agrave; la vente des valeurs mobili&egrave;res d&eacute;crites aux pr&eacute;sentes (incluant,
pour plus de certitude, toute confirmation d&rsquo;achat ou tout avis) soient r&eacute;dig&eacute;s en anglais seulement.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Australia</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement is not a disclosure document for the purposes of Australia&rsquo;s Corporations Act 2001 (Cth) of Australia,
or Corporations Act, has not been lodged with the Australian Securities &amp; Investments Commission and is only directed to the
categories of exempt persons set out below. Accordingly, if you receive this prospectus supplement in Australia:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
confirm and warrant that you are either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         &ldquo;sophisticated investor&rdquo; under section 708(8)(a) or (b) of the Corporations
                                         Act;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         &ldquo;sophisticated investor&rdquo; under section 708(8)(c) or (d) of the Corporations
                                         Act and that you have provided an accountant&rsquo;s certificate to the Company which
                                         complies with the requirements of section 708(8)(c)(i) or (ii) of the Corporations Act
                                         and related regulations before the offer has been made; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         &ldquo;professional investor&rdquo; within the meaning of section 708(11)(a) or (b) of
                                         the Corporations Act.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor or professional investor under
the Corporations Act any offer made to you under this prospectus supplement is void and incapable of acceptance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
warrant and agree that you will not offer any of the shares issued to you pursuant to this prospectus supplement for resale in
Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue
a disclosure document under section 708 of the Corporations Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>European
Economic Area</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
relation to each Member State of the European Economic Area, no offer of any securities which are the subject of the offering
contemplated by this prospectus supplement has been or will be made to the public in that Member State other than any offer where
a prospectus has been or will be published in relation to such securities that has been approved by the competent authority in
that Member State or, where appropriate, approved in another Member State and notified to the relevant competent authority in
that Member State in accordance with the Prospectus Directive, except that an offer of such securities may be made to the public
in that Member State:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                         any legal entity which is a &ldquo;qualified investor&rdquo; as defined in the Prospectus
                                         Directive;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                         fewer than 150, natural or legal persons (other than qualified investors as defined in
                                         the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining
                                         the prior consent of the representatives of the underwriters for any such offer; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                         any other circumstances falling within Article 3(2) of the Prospectus Directive,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
that no such offer of securities shall require the Company or any of the underwriters to publish a prospectus pursuant to Article
3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of this provision, the expression an &ldquo;offer to the public&rdquo; in relation to any securities in any Member
State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities
to be offered so as to enable an investor to decide to purchase or subscribe the securities, as the same may be varied in that
Member State by any measure implementing the Prospectus Directive in that Member State and the expression &ldquo;Prospectus Directive&rdquo;
means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive), and includes any relevant implementing
measure in the Member State and the expression &ldquo;2010 PD Amending Directive&rdquo; means Directive 2010/73/EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hong
Kong</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other
than to persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to &ldquo;professional
investors&rdquo; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance;
or in other circumstances which do not result in the document being a &ldquo;prospectus&rdquo; as defined in the Companies Ordinance
(Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap.32)
of Hong Kong. No document, invitation or advertisement relating to the securities has been issued or may be issued or may be in
the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at,
or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities
laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong
Kong or only to &ldquo;professional investors&rdquo; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong
and any rules made under that Ordinance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus supplement
may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of
the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities,
to confirm that he is aware of the restriction on offers of the securities described in this prospectus supplement and the relevant
offering documents and that he is not acquiring, and has not been offered any securities in circumstances that contravene any
such restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Japan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering has not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948
of Japan, as amended), or FIEL, and the Initial Purchaser will not offer or sell any securities, directly or indirectly, in Japan
or to, or for the benefit of, any resident of Japan (which term as used herein means, unless otherwise provided herein, any person
resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering
or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption from the registration requirements
of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and ministerial guidelines of Japan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Singapore</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement has not been and will not be lodged or registered with the Monetary Authority of Singapore. Accordingly,
this prospectus supplement and any other document or material in connection with the offer or sale, or the invitation for subscription
or purchase of the securities may not be issued, circulated or distributed, nor may the securities be offered or sold, or be made
the subject of an invitation for subscription or purchase, whether directly or indirectly, to the public or any member of the
public in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289
of Singapore, or the SFA, (ii) to a relevant person as defined under Section 275(2), or any person pursuant to Section 275(1A)
of the SFA, and in accordance with the conditions, specified in Section 275 of the SFA, or (iii) otherwise pursuant to, and in
accordance with the conditions of any other applicable provision of the SFA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
the securities are subscribed or purchased under Section 275 of the SFA by a relevant person which is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         corporation (which is not an accredited investor as defined under Section 4A of the SFA)
                                         the sole business of which is to hold investments and the entire share capital of which
                                         is owned by one or more individuals, each of whom is an accredited investor; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         trust (where the trustee is not an accredited investor) whose sole purpose is to hold
                                         investments and each beneficiary is an accredited investor,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares,
debentures and units of shares and debentures of that corporation or the beneficiaries&rsquo; rights and interest in that trust
shall not be transferable for six months after that corporation or that trust has acquired the Offer Shares under Section 275
of the SFA except:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                         an institutional investor under Section 274 of the SFA or to a relevant person defined
                                         in Section 275(2) of the SFA, or to any person pursuant to an offer that is made on terms
                                         that such shares, debentures and units of shares and debentures of that corporation or
                                         such rights and interest in that trust are acquired at a consideration of not less than
                                         $200,000 (or its equivalent in a foreign currency) for each transaction, whether such
                                         amount is to be paid for in cash or by exchange of securities or other assets, and further
                                         for corporations, in accordance with the conditions, specified in Section 275 of the
                                         SFA;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                         no consideration is given for the transfer; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                         the transfer is by operation of law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Switzerland</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other
stock exchange or regulated trading facility in Switzerland. This prospectus supplement has been prepared without regard to the
disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure
standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange
or regulated trading facility in Switzerland. Neither this prospectus supplement nor any other offering or marketing material
relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
this prospectus supplement nor any other offering or marketing material relating to the offering, the Company or the securities
have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed
with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, or FINMA,
and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes,
or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend
to acquirers of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been
filed with or approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to,
and is directed only at, and any offer of the shares is directed only at, investors listed in the first addendum, or the Addendum,
to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies,
banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities
with equity in excess of NIS 50 million and &ldquo;qualified individuals&rdquo;, each as defined in the Addendum (as it may be
amended from time to time), collectively referred to as qualified investors (in each case purchasing for their own account or,
where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors
will be required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same
and agree to it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>United
Kingdom</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified
investors (as defined in the Prospectus Directive) that are also (i) investment professionals falling within Article 19(5) of
the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, referred to herein as the &ldquo;Order&rdquo;,
and/or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order and other persons to whom it may lawfully
be communicated or caused to be communicated. Each such person is referred to herein as a &ldquo;Relevant Person&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and its contents are confidential and should not be distributed, published or reproduced (in whole or in
part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a Relevant
Person should not act or rely on this document or any of its contents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets
Act 2000 (the &ldquo;FSMA&rdquo;)) may only be communicated or caused to be communicated in connection with the issue or sale
of the securities in circumstances in which Section 21(1) of the FSMA does not apply. All applicable provisions of the FSMA must
be complied with in respect of anything done by any person in relation to the securities in, from or otherwise involving the United
Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_015"></A>LEGAL
MATTERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the securities offered hereby will be passed upon for us by Haynes and Boone, LLP, Dallas, Texas. Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C., Boston, Massachusetts, is acting as counsel for the underwriters in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_016"></A>EXPERTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements as of December 31, 2019 and 2018 and for the years then ended incorporated by reference in this prospectus
supplement have been audited by MaloneBailey, LLP, an independent registered public accounting firm, as stated in its report,
which is incorporated by reference in this prospectus supplement, and is incorporated by reference in reliance upon the
report of such firm given upon its authority as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_017"></A>WHERE
YOU CAN FIND MORE INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the informational requirements of the Exchange Act, and in accordance therewith file annual, quarterly and current
reports, proxy statements and other information with the SEC. The SEC maintains an internet website at <I>www.sec.gov</I> that
contains periodic and current reports, proxy and information statements and other information regarding registrants that are filed
electronically with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
documents are also available, free of charge, through the Investor Relations section of our website, which is located at <I>www.sanaramedtech.com</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement under the Securities Act relating to the offering of these securities. The registration
statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus
supplement does not contain all of the information set forth in the registration statement. You can obtain a copy of the registration
statement for free at <I>www.sec.gov</I>. The registration statement and the documents referred to below under &ldquo;Incorporation
of Documents by Reference&rdquo; are also available on our website, <I>www.sanaramedtech.com</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not incorporated by reference into this prospectus supplement the information on our website, and you should not consider
it to be a part of this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_018"></A>INCORPORATION
OF DOCUMENTS BY REFERENCE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to &ldquo;incorporate by reference&rdquo; the information we have filed with it, which means that we can disclose
important information to you by referring you to those documents. The information we incorporate by reference is an important
part of this prospectus supplement, and later information that we file with the SEC will automatically update and supersede this
information. We specifically are incorporating by reference the following documents and any future documents we file with the
SEC (excluding those portions of any Current Report on Form 8-K that are furnished and not deemed &ldquo;filed&rdquo; pursuant
to the General Instructions of Form 8-K):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420003345/smti_10k.htm" STYLE="-sec-extract: exhibit">Annual
                                         Report on Form 10-K</A> for the fiscal year ended December 31, 2019, filed on March 26,
                                         2020;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         portions of our <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420006958/smti_def14a.htm" STYLE="-sec-extract: exhibit">Definitive
                                         Proxy Statement on Schedule 14A</A>, filed with the Commission on June 25, 2020, that
                                         were deemed to be filed with the SEC;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         Quarterly Reports on Form 10-Q <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420005225/smti_10q.htm" STYLE="-sec-extract: exhibit">for
                                         the quarter ended March 31, 2020</A>, filed with the SEC on May 12, 2020, <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420009006/smti_10q.htm" STYLE="-sec-extract: exhibit">for
                                         the quarter ended June 30, 2020</A>, filed with the SEC on August 13, 2020, and <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420012356/smti_10q.htm" STYLE="-sec-extract: exhibit">for
                                         the quarter ended September 30, 2020</A>, filed with the SEC on November 13, 2020;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         Current Reports on Form 8-K filed on <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420001419/smti_8k.htm" STYLE="-sec-extract: exhibit">February
                                         13, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420004644/smti_8k.htm" STYLE="-sec-extract: exhibit">April
                                         29, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420005087/smti_8k.htm" STYLE="-sec-extract: exhibit">May
                                         8, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420005876/smti_8k.htm" STYLE="-sec-extract: exhibit">May
                                         21, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420007672/smti_8k.htm" STYLE="-sec-extract: exhibit">July
                                         14, 2020</A> (as amended on <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420011158/smti_8ka.htm" STYLE="-sec-extract: exhibit">October
                                         14, 2020</A>), <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420011236/smti_8k.htm" STYLE="-sec-extract: exhibit">October
                                         16, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420013880/smti_8k.htm" STYLE="-sec-extract: exhibit">December
                                         23, 2020</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495421000724/smti_8k.htm" STYLE="-sec-extract: exhibit">January
                                         22, 2021</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495421001031/smti_8k.htm" STYLE="-sec-extract: exhibit">February
                                         1, 2021</A>; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         description of our securities contained in our registration statement on <A HREF="https://www.sec.gov/Archives/edgar/data/714256/000165495420011574/smti_8ka.htm" STYLE="-sec-extract: exhibit">Form
                                         8-A</A>, filed with the SEC on October 29, 2020, including all amendments and reports
                                         filed for the purpose of updating such description.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
statement contained herein or in any document incorporated or deemed to be incorporated by reference shall be deemed to be modified
or superseded for purposes of this prospectus supplement to the extent that a statement contained in any other subsequently filed
document which also is or is deemed to be incorporated by reference modifies or supersedes such statement. Any such statement
so modified or superseded shall not be deemed to constitute a part of this prospectus supplement, except as so modified or superseded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide without charge to each person to whom a copy of this prospectus supplement is delivered, upon written or oral request,
a copy of any or all of the information that has been incorporated by reference in this prospectus supplement but not delivered
with this prospectus supplement (other than an exhibit to these filings, unless we have specifically incorporated that exhibit
by reference in this prospectus supplement). Any such request should be addressed to us at 1200 Summit Ave, Suite 414, Fort Worth,
Texas 76102 (telephone: 817-529-2300).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may also access the documents incorporated by reference in this prospectus through our website at <I>www.sanaramedtech.com</I>.
Except for the specific incorporated documents listed above, no information available on or through our website shall be deemed
to be incorporated in this prospectus supplement or the registration statement of which it forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV><DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Prospectus</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><IMG SRC="smti_s3000.jpg" STYLE="width: 208px; height: 69px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B></B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 16px"><B>Sanara
MedTech Inc.</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>$150,000,000</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Common
Stock</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Preferred
Stock</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Warrants</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Units</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: auto; margin-right: auto; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--line--><BR></DIV>
<DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 1px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
may offer and sell from time to time, in one or more series or issuances and on terms that we will determine at the time of the
offering, any combination of the securities described in this prospectus, up to an aggregate amount of $150,000,000.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
will provide specific terms of any offering in a supplement to this prospectus. Any prospectus supplement may also add, update,
or change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement
as well as the documents incorporated or deemed to be incorporated by reference in this prospectus before you purchase any of
the securities offered hereby.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">These
securities may be offered and sold in the same offering or in separate offerings; to or through underwriters, dealers, and agents;
or directly to purchasers. The names of any underwriters, dealers, or agents involved in the sale of our securities, their compensation
and any over-allotment options held by them will be described in the applicable prospectus supplement. See &#x201C;Plan of Distribution.&#x201D;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Our
common stock is listed on The Nasdaq Capital Market under the symbol &#x201C;SMTI.&#x201D; On December 22, 2020, the last reported
sale price of our common stock was $52.42 per share as reported on The Nasdaq Capital Market. We recommend that you obtain current
market quotations for our common stock prior to making an investment decision. We will provide information in any applicable prospectus
supplement regarding any listing of securities other than shares of our common stock on any securities exchange.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>You
should carefully read this prospectus, any prospectus supplement relating to any specific offering of securities, and all information
incorporated by reference herein and therein.</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Investing
in our securities involves a high degree of risk. These risks are discussed in this prospectus under &#x201C;Risk Factors&#x201D;
beginning on page 4 and in the documents incorporated by reference in this prospectus.</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Neither
the Securities and Exchange Commission (the &#x201C;SEC&#x201D;) nor any state securities commission has approved or disapproved
of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal
offense.</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">The
date of this prospectus is January 4, 2021.</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>TABLE
OF CONTENTS</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: left"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 13px Times New Roman; margin: 0px auto 0px 0px; text-align: left; width: 100%">
<TR><TD STYLE="vertical-align: top; width: 90%"><DIV><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</TD>
<TD STYLE="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top; width: 10%"><DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Page</B></FONT></DIV>
</TD>
</TR><TR STYLE="background-color: #cceeff">
<TD STYLE="vertical-align: top; width: 90%"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><A HREF="#about">
                                         About This Prospectus</A></FONT></DIV>
</TD>
<TD STYLE="vertical-align: top; width: 10%"><DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">ii<BR>
                                         </FONT></DIV>
</TD>
</TR><TR>
<TD STYLE="vertical-align: top; width: 90%"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><A HREF="#cautionary"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Cautionary
                                         Statement Regarding Forward-Looking Statements</FONT></A></DIV>
</TD>
<TD STYLE="vertical-align: top; width: 10%"><DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">iii<BR>
                                         </FONT></DIV>
</TD>
</TR><TR STYLE="background-color: #cceeff">
<TD STYLE="vertical-align: top; width: 90%"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><A HREF="#propsectsum"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Prospectus
                                         Summary</FONT></A></DIV>
</TD>
<TD STYLE="vertical-align: top; width: 10%"><DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">1<BR></FONT></DIV>
</TD>
</TR><TR>
<TD STYLE="vertical-align: top; width: 90%"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><A HREF="#riskfactor"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Risk
                                         Factors</FONT></A></DIV>
</TD>
<TD STYLE="vertical-align: top; width: 10%"><DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">4<BR></FONT></DIV>
</TD>
</TR><TR STYLE="background-color: #cceeff">
<TD STYLE="vertical-align: top; width: 90%"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><A HREF="#useofproceed"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Use
                                         of Proceeds</FONT></A></DIV>
</TD>
<TD STYLE="vertical-align: top; width: 10%"><DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">5<BR></FONT></DIV>
</TD>
</TR><TR>
<TD STYLE="vertical-align: top; width: 90%"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><A HREF="#descriptionofcapstock"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Description
                                         of Capital Stock</FONT></A></DIV>
</TD>
<TD STYLE="vertical-align: top; width: 10%"><DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">6<BR></FONT></DIV>
</TD>
</TR><TR STYLE="background-color: #cceeff">
<TD STYLE="vertical-align: top; width: 90%"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><A HREF="#decofwarrants"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Description
                                         of Warrants</FONT></A></DIV>
</TD>
<TD STYLE="vertical-align: top; width: 10%"><DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">10<BR>
                                         </FONT></DIV>
</TD>
</TR><TR>
<TD STYLE="vertical-align: top; width: 90%"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><A HREF="#descofunits"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Description
                                         of Units</FONT></A></DIV>
</TD>
<TD STYLE="vertical-align: top; width: 10%"><DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">12<BR>
                                         </FONT></DIV>
</TD>
</TR><TR STYLE="background-color: #cceeff">
<TD STYLE="vertical-align: top; width: 90%"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><A HREF="#planofdistro"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Plan
                                         of Distribution</FONT></A></DIV>
</TD>
<TD STYLE="vertical-align: top; width: 10%"><DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">13<BR>
                                         </FONT></DIV>
</TD>
</TR><TR>
<TD STYLE="vertical-align: top; width: 90%"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><A HREF="#legalmatter"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Legal
                                         Matters</FONT></A></DIV>
</TD>
<TD STYLE="vertical-align: top; width: 10%"><DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">16<BR>
                                         </FONT></DIV>
</TD>
</TR><TR STYLE="background-color: #cceeff">
<TD STYLE="vertical-align: top; width: 90%"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><A HREF="#experts"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Experts</FONT></A></DIV>
</TD>
<TD STYLE="vertical-align: top; width: 10%"><DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">16<BR>
                                         </FONT></DIV>
</TD>
</TR><TR>
<TD STYLE="vertical-align: top; width: 90%"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><A HREF="#whereyoucanfind"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Where
                                         You Can Find More Information</FONT></A></DIV>
</TD>
<TD STYLE="vertical-align: top; width: 10%"><DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">16<BR>
                                         </FONT></DIV>
</TD>
</TR><TR STYLE="background-color: #cceeff">
<TD STYLE="vertical-align: top; width: 90%"><DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><A HREF="#incorpbyref"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Incorporation
                                         of Documents by Reference</FONT></A></DIV>
</TD>
<TD STYLE="vertical-align: top; width: 10%"><DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">16<BR>
                                         </FONT></DIV>
</TD>
</TR></TABLE>
</DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV>&#xA0;</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">i</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>ABOUT
THIS PROSPECTUS</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">This
prospectus is part of a registration statement on Form S-3 that we filed with the SEC using a &#x201C;shelf&#x201D; registration
process. Under this shelf process, we may, from time to time, sell any combination of the securities described in this prospectus
in one or more offerings up to a total amount of $150,000,000.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">This
prospectus provides you with a general description of the securities we may offer. Each time we sell securities under this prospectus,
we will provide a prospectus supplement that will contain specific information about the terms of that offering. The prospectus
supplement may also add to, update or change information contained in the prospectus and, accordingly, to the extent inconsistent,
information in this prospectus is superseded by the information in the prospectus supplement.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">This
prospectus may not be used to sell securities unless it is accompanied by a prospectus supplement that describes those securities.
The prospectus supplement to be attached to the front of this prospectus may describe, as applicable: the terms of the securities
offered; the public offering price; the price paid for the securities; net proceeds; and the other specific terms related to the
offering of the securities.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><A NAME="about"></A></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">You
should only rely on the information contained or incorporated by reference in this prospectus and any prospectus supplement or
issuer free writing prospectus relating to a particular offering. No person has been authorized to give any information or make
any representations in connection with this offering other than those contained or incorporated by reference in this prospectus,
any accompanying prospectus supplement and any related issuer free writing prospectus in connection with the offering described
herein and therein, and, if given or made, such information or representations must not be relied upon as having been authorized
by us. Neither this prospectus nor any prospectus supplement nor any related issuer free writing prospectus shall constitute an
offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person
to make such an offering or solicitation. This prospectus does not contain all of the information included in the registration
statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement,
including its exhibits.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">You
should read the entire prospectus and any prospectus supplement and any related issuer free writing prospectus, as well as the
documents incorporated by reference into this prospectus or any prospectus supplement or any related issuer free writing prospectus,
before making an investment decision. Neither the delivery of this prospectus or any prospectus supplement or any issuer free
writing prospectus nor any sale made hereunder shall under any circumstances imply that the information contained or incorporated
by reference herein or in any prospectus supplement or issuer free writing prospectus is correct as of any date subsequent to
the date hereof or of such document incorporated by reference, prospectus supplement or issuer free writing prospectus, as applicable.
You should assume that the information appearing in this prospectus, any prospectus supplement, any issuer free writing prospectus,
or any document incorporated by reference is accurate only as of the date of the applicable documents, regardless of the time
of delivery of this prospectus or any sale of securities. Our business, financial condition, results of operations and prospects
may have changed since that date.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Sanara,
Sanara MedTech, our logo and other trademarks or service marks appearing in this prospectus and the documents incorporated by
reference herein are the property of Sanara MedTech Inc. Trade names, trademarks and service marks of other companies appearing
in this prospectus and the documents incorporated by reference herein are the property of their respective owners. Solely for
convenience, the trademarks, service marks and trade names included in this prospectus and the documents incorporated by reference
herein are without the &#xAE;, &#x2122; or other applicable symbols, but such references are not intended to indicate, in any
way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors
to these trademarks, service marks and trade names.<B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">ii</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B><A NAME="cautionary">C</A>AUTIONARY
STATEMENT REGARDING FORWARD LOOKING STATEMENTS</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">This
prospectus and the documents incorporated by reference herein contain forward-looking statements within the meaning of the federal
securities laws. Forward-looking statements generally relate to future events or our future financial or operating performance.
In some cases, you can identify forward-looking statements because they contain words such as &#x201C;anticipates,&#x201D; &#x201C;believes,&#x201D;
&#x201C;continue,&#x201D; &#x201C;contemplates,&#x201D; &#x201C;could,&#x201D; &#x201C;estimates,&#x201D; &#x201C;expects,&#x201D;
&#x201C;intends,&#x201D; &#x201C;may,&#x201D; &#x201C;plans,&#x201D; &#x201C;potential,&#x201D; &#x201C;predicts,&#x201D; &#x201C;projects,&#x201D;
&#x201C;should,&#x201D; &#x201C;target,&#x201D; &#x201C;will&#x201D; or &#x201C;would&#x201D; or the negative of these words,
variations of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions.
Such forward-looking statements are subject to certain risks, uncertainties and assumptions relating to factors that could cause
actual results to differ materially from those anticipated in such statements, including, without limitation, the following:</FONT></DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">unanticipated
changes in the markets for the Company&#x2019;s business;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">unanticipated
downturns in business relationships with customers or their purchases from us;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the potential
effects on our businesses from natural disasters;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the availability
of credit to customers and suppliers;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">competitive
pressures on sales and pricing;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">unanticipated
changes in the cost of inventory and other operating costs;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the introduction
of competing products;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">unexpected technical
or marketing difficulties;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">unexpected claims,
charges, litigation or dispute resolutions;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">new laws and
governmental regulations;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">stock market
and currency fluctuations;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">war, civil or
political unrest or terrorism;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the course of
the COVID-19 pandemic and government responses thereto; and</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">unanticipated
deterioration of economic and financial conditions in the United States and around the world.</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
caution you that the foregoing list may not contain all of the risk factors that may impact the forward-looking statements made
in this prospectus and the documents incorporated herein.</FONT></DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">You
should not rely upon forward-looking statements as predictions of future events. We have based the forward-looking statements
contained in this prospectus primarily on our current expectations and projections about future events and trends that we believe
may affect our business, financial condition, results of operations, and prospects. The outcome of the events described in these
forward-looking statements is subject to risks,&#xA0;uncertainties and other factors described in the section titled &#x201C;Risk
Factors&#x201D; in this prospectus<I>&#xA0;</I>and in the documents incorporated by reference in this prospectus. Moreover, we
operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is
not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained
in this prospectus. We cannot assure you that the results, events, and circumstances reflected in the forward-looking statements
will be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking
statements.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">iii</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">The
forward-looking statements made, or incorporated by reference, in this prospectus relate only to events as of the date on which
the statements are made. We undertake no obligation to update any forward-looking statements made, or incorporated by reference,
in this prospectus to reflect events or circumstances after the date of this prospectus or the documents incorporated by reference
herein or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually
achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions,
mergers, dispositions, joint ventures, or investments we may make.</FONT></DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">In
addition, statements that &#x201C;we believe&#x201D; and similar statements reflect our beliefs and opinions on the relevant subject.
These statements are based upon information available to us as of the date of this prospectus, and while we believe such information
forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be
read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.
These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">iv</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B><A NAME="propsectsum">P</A>ROSPECTUS
SUMMARY</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>This
summary provides an overview of selected information contained elsewhere or incorporated by reference in this prospectus and does
not contain all of the information you should consider before investing in our securities. You should carefully read the prospectus,
the information incorporated by reference and the registration statement of which this prospectus is a part in their entirety
before investing in our securities, including the information discussed under &#x201C;Risk Factors&#x201D; in this prospectus
and the documents incorporated by reference and our financial statements and notes thereto that are incorporated by reference
in this prospectus. Some of the statements in this prospectus and the documents incorporated by reference herein constitute forward-looking
statements that involve risks and uncertainties. See information set forth under the section &#x201C;Cautionary Statement Regarding
Forward-Looking Statements.&#x201D; In this prospectus, unless the context otherwise requires, references to &#x201C;we,&#x201D;
&#x201C;us,&#x201D; &#x201C;our,&#x201D; the &#x201C;Company&#x201D; and &#x201C;Sanara MedTech&#x201D; refer to Sanara MedTech
Inc. and its subsidiaries.</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>&#xA0;</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Overview</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
develop, market and distribute wound and skin care products to physicians, hospitals, clinics and post-acute care settings. Our
products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech products
include CellerateRX Surgical Activated Collagen Adjuvant (&#x201C;CellerateRX&#x201D;), HYCOL Hydrolyzed Collagen (&#x201C;HYCOL&#x201D;),
BIAK&#x14C;S Antimicrobial Skin &amp; Wound Cleanser (&#x201C;BIAK&#x14C;S AWC&#x201D;), BIAK&#x14C;S Antimicrobial Skin and Wound
Irrigation Solution and BIAK&#x14C;S Antimicrobial Wound Gel.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">CellerateRX
products are primarily purchased by hospitals and ambulatory surgical centers for use by surgeons on surgical wounds. HYCOL products
are used in skilled nursing facilities, wound care clinics and other medical facilities, and are intended for the management of
full and partial thickness wounds including pressure ulcers, venous and arterial leg ulcers and diabetic foot ulcers. HYCOL is
currently approved for reimbursement under Medicare Part B. We believe CellerateRX and HYCOL products are unique in composition,
superior to other products in clinical performance, and demonstrate the ability to reduce costs associated with the standards
of care for their intended uses.</FONT></DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">BIAK&#x14C;S
AWC is an FDA cleared, patented product that effectively disrupts extracellular polymeric substances to eradicate biofilm microbes.
BIAK&#x14C;S AWC also provides mechanical removal of debris, dirt, foreign materials, and microorganisms from wounds including
stage I-IV pressure ulcers, diabetic foot ulcers, post-surgical wounds, first and second-degree burns as well as grafted and donor
sites. BIAK&#x14C;S AWC is effective in killing free-floating microbes, immature, and mature bacterial biofilms and fungal biofilms.
In addition, safety studies demonstrated that BIAK&#x14C;S AWC is biocompatible and supports the wound healing process. Initial
sales of BIAK&#x14C;S AWC occurred in July 2019. BIAK&#x14C;S AWC is also available in an irrigation bottle (BIAK&#x14C;S Antimicrobial
Skin and Wound Irrigation Solution) that can be used in conjunction with negative pressure wound therapy installation and dwell
(NPWTi-d) and other wound irrigation needs.</FONT></DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">BIAKO&#x304;S
Antimicrobial Wound Gel is an antimicrobial hydrogel wound dressing that can be used alone or in combination with BIAKO&#x304;S
AWC. Based on laboratory studies, when used in conjunction, the products can work together to enhance effectiveness. The cleanser
is applied initially to clean a wound and disrupts biofilm microbes (removing 99% in 10 minutes). The gel can then be applied
and will remain in the wound for up to 72 hours helping to continue to disrupt biofilm microbes. When used in clinical settings,
BIAKO&#x304;S Antimicrobial Wound Gel is indicated for the management of partial and full thickness wounds, such as diabetic foot
ulcers, post-surgical wounds, pressure ulcers, first and second-degree burns, grafts and donor sites.</FONT></DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Corporate
Information</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
were incorporated in Texas on December 14, 2001. On March 15, 2019, we entered into a Share Exchange Agreement with CGI Cellerate
RX, LLC, an affiliate of The Catalyst Group, Inc. (&#x201C;Catalyst&#x201D;), pursuant to which we acquired Catalyst&#x2019;s
50% equity interest in Cellerate, LLC (&#x201C;Cellerate&#x201D;) in exchange for 1,136,815 shares of our newly created Series
F Convertible Preferred Stock (the &#x201C;Cellerate Acquisition&#x201D;). Prior to the consummation of the Cellerate Acquisition,
we and Catalyst each owned a 50% equity interest in Cellerate. The Cellerate Acquisition was accounted for as a reverse merger,
and Cellerate was deemed to be the accounting acquirer. In May 2019, we changed our name to Sanara MedTech Inc.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">1</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Our
principal executive offices are located at 1200 Summit Ave, Suite 414, Fort Worth, Texas 76102, telephone number (817) 529-2300.
Our website address is www.sanaramedtech.com. Information accessed through our website is not incorporated into this prospectus
and is not a part of this prospectus.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Offerings
Under This Prospectus</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 12px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
may offer up to $150,000,000 of common stock, preferred stock, warrants and/or units in one or more offerings and in any combination.
This prospectus provides you with a general description of the securities we may offer. A prospectus supplement, which we will
provide each time we offer securities, will describe the specific amounts, prices and terms of these securities.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 12px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>Common
Stock</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 12px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
may issue shares of our common stock from time to time. The holders of common stock are entitled to one vote per share. Our Certificate
of Formation, as amended (the &#x201C;Certificate of Formation&#x201D;), does not provide for cumulative voting. All of our directors
hold office for one-year terms until the election and qualification of their successors. The holders of our common stock are entitled
to receive ratably such dividends, if any, as may be declared by the board of directors out of legally available funds. Upon liquidation,
dissolution or winding-up, the holders of our common stock are entitled to share ratably in all assets that are legally available
for distribution. The holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights,
preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the
holders of any series of preferred stock, which may be designated solely by action of the board of directors and issued in the
future.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>Preferred
Stock</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 12px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
may issue shares of our preferred stock from time to time, in one or more series. Our board of directors will determine the rights,
preferences, privileges and restrictions of the preferred stock, including dividend rights, conversion rights, voting rights,
terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation
of such series, without any further vote or action by shareholders. Convertible preferred stock will be convertible into our common
stock or exchangeable for our other securities. Conversion may be mandatory or at your option or both and would be at prescribed
conversion rates.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 12px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">If
we sell any series of preferred stock under this prospectus and applicable prospectus supplements, we will fix the rights, preferences,
privileges and restrictions of the preferred stock of such series in the certificate of designation relating to that series. We
will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from
reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred
stock we are offering before the issuance of the related series of preferred stock. We urge you to read the applicable prospectus
supplement related to the series of preferred stock being offered, as well as the complete certificate of designation that contains
the terms of the applicable series of preferred stock.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>Warrants</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 12px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
may issue warrants for the purchase of common stock or preferred stock in one or more series. We may issue warrants independently
or together with common stock or preferred stock, and the warrants may be attached to or separate from these securities. We will
evidence each series of warrants by warrant certificates that we will issue under a separate agreement. We may enter into warrant
agreements with a bank or trust company that we select to be our warrant agent. We will indicate the name and address of any such
warrant agent in the applicable prospectus supplement relating to a particular series of warrants.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">2</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">In
this prospectus, we have summarized certain general features of the warrants. We urge you, however, to read the applicable prospectus
supplement related to the particular series of warrants being offered, as well as the warrant agreements and warrant certificates
that contain the terms of the warrants. We will file as exhibits to the registration statement of which this prospectus is a part,
or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement or warrant certificate
containing the terms of the warrants we are offering before the issuance of the warrants.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>Units</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 12px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
may issue units consisting of common stock, preferred stock and/or warrants for the purchase of common stock or preferred stock
in one or more series. In this prospectus, we have summarized certain general features of the units. We urge you, however, to
read the applicable prospectus supplement related to the series of units being offered, as well as the unit agreements that contain
the terms of the units. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate
by reference from reports that we file with the SEC, the form of unit agreement and any supplemental agreements that describe
the terms of the series of units we are offering before the issuance of the related series of units.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">3</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B><A NAME="riskfactor">R</A>ISK
FACTORS</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>An
investment in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider
carefully the specific factors discussed under the heading &#x201C;Risk Factors&#x201D; in the applicable prospectus supplement,
together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or
incorporated by reference in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under
Item 1A, &#x201C;Risk Factors,&#x201D; in our most recent Annual Report on Form 10-K and any updates in our Quarterly Reports
on Form 10-Q or in other documents that are filed after the date hereof and incorporated by reference into this prospectus and
any prospectus supplement related to a particular offering. The risks and uncertainties we have described are not the only ones
we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our
operations. Past financial performance may not be a reliable indicator of future performance, and historical trends should not
be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, business prospects,
financial condition or results of operations could be seriously harmed. This could cause the trading price of our common stock
to decline, resulting in a loss of all or part of your investment. Please also read carefully the section above entitled &#x201C;Cautionary
Statement Regarding Forward-Looking Statements.&#x201D;</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>&#xA0;</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">4</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B><A NAME="useofproceed">U</A>SE
OF PROCEEDS</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
cannot assure you that we will receive any proceeds in connection with securities which may be offered pursuant to this prospectus.
Unless otherwise indicated in the applicable prospectus supplement, we intend to use any net proceeds from the sale of securities
under this prospectus for our operations and for other general corporate purposes, including, but not limited to, general working
capital and possible future acquisitions. We have not determined the amounts we plan to spend on any of the areas listed above
or the timing of these expenditures. As a result, our management will have broad discretion to allocate the net proceeds, if any,
we receive in connection with securities offered pursuant to this prospectus for any purpose. Pending application of the net proceeds
as described above, we may initially invest the net proceeds in investment-grade, interest-bearing securities such as money market
funds, certificates of deposit, or direct or guaranteed obligations of the U.S. government, hold the net proceeds as cash or apply
the net proceeds to the reduction of short-term indebtedness.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">5</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B><A NAME="descriptionofcapstock">D</A>ESCRIPTION
OF CAPITAL STOCK</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">The
following description of common stock and preferred stock summarizes the material terms and provisions of the common stock and
preferred stock that we may offer under this prospectus, but is not complete. For the complete terms of our common stock and preferred
stock, please refer to our Certificate of Formation, any certificates of designation for our preferred stock and our bylaws. While
the terms we have summarized below will apply generally to any future common stock or preferred stock that we may offer, we will
describe the specific terms of any series of preferred stock in more detail in the applicable prospectus supplement. If we so
indicate in a prospectus supplement, the terms of any preferred stock we offer under that prospectus supplement may differ from
the terms we describe below.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
have authorized 22,000,000 shares of capital stock, 20,000,000 of which are designated as common stock, par value $0.001 per share,
and 2,000,000 of which are designated as &#x201C;blank check&#x201D; preferred stock, par value $10.00 per share, none of which
are currently designated as an outstanding series. On December 21, 2020, there were 6,293,968 shares of common stock issued and
outstanding and no shares of preferred stock outstanding.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Common
Stock</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>Voting
Rights</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>&#xA0;</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Holders
of shares of common stock are entitled to one vote for each share held of record on all matters to be voted on by shareholders.
Except as otherwise provided by law, matters other than the election of directors require the affirmative vote of the holders
of a majority of shares entitled to vote thereon. Holders of our common stock do not have any cumulative voting rights, which
means that a plurality of the shares voted can elect all of the directors then standing for election. Holders of common stock
vote together as a single class.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>Dividend
Rights</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>&#xA0;</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Subject
to preferential dividend rights of any other class or series of stock, the holders of shares of common stock are entitled to receive
dividends, including dividends of equity, as and when declared by our board of directors, subject to any limitations applicable
by law and to the rights of the holders, if any, of our preferred stock. Our board of directors is not obligated to declare a
dividend.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>Liquidation
Rights</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>&#xA0;</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Upon
our liquidation, dissolution or winding-up, the holders of our common stock are entitled to share equally, identically and ratably
in all assets remaining, subject to the prior satisfaction of all outstanding debt and liabilities and the preferential rights
and payment of liquidation preferences, if any, on any outstanding shares of preferred stock.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>Other
Rights and Preferences</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>&#xA0;</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Subject
to the preferential rights of any other class or series of stock, all shares of common stock have equal dividend, distribution,
liquidation and other rights, and have no preference, appraisal or exchange rights, except for any appraisal rights provided by
Texas law. Furthermore, holders of common stock have no conversion, sinking fund or redemption rights, or preemptive rights to
subscribe for any of our securities.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">The
rights, powers, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the rights
of holders of shares of any series of preferred stock which we may designate and issue in the future.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>Transfer
Agent and Registrar</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">The
transfer agent and registrar for our common stock is Securities Transfer Corporation, Plano, Texas.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">6</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><I>Listing</I></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Our
common stock is listed on The Nasdaq Capital Market under the symbol &#x201C;SMTI.&#x201D;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Preferred
Stock</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Our
board of directors is authorized, subject to limitations prescribed by Texas law, to issue up to 2,000,000 shares of preferred
stock in one or more series, to establish from time to time the number of shares to be included in each series, and to fix the
designation, powers, preferences, and rights of the shares of each series and any of its qualifications, limitations, or restrictions,
in each case without further vote or action by our shareholders. Our board of directors can also increase or decrease the number
of shares of any series of preferred stock, but not below the number of shares of that series then outstanding, without any further
vote or action by our shareholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion
rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred
stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things,
have the effect of delaying, deferring, or preventing a change in control of our company and might adversely affect the market
price of our common stock and the voting and other rights of the holders of our common stock.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">If
we offer shares of preferred stock, we will file as an exhibit to the registration statement of which this prospectus forms a
part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that
describes the terms of the series of preferred stock we are offering. This description and the applicable prospectus supplement
will include:</FONT></DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the title and
stated value;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the number of
shares authorized;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the liquidation
preference per share;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the purchase
price;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the dividend
rate, period and payment date, and method of calculation for dividends;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">whether dividends
will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the procedures
for any auction and remarketing, if any;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the provisions
for a sinking fund, if any;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the provisions
for redemption or repurchase, if applicable, and any restrictions on our ability to exercise such redemption and repurchase rights;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">any listing
of the preferred stock on any securities exchange or market;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">whether the
preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be calculated,
and the conversion period;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">voting rights,
if any, of the preferred stock;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">preemptive rights,
if any;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">restrictions
on transfer, sale or other assignment, if any;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">7</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">a discussion
of any material United States federal income tax considerations applicable to the preferred stock;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the relative
ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">any limitations
on issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to
dividend rights and rights if we liquidate, dissolve or wind up our affairs; and</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">any other specific
terms, preferences, rights or limitations of, or restrictions on, the preferred stock.&#xA0;&#xA0;<B>&#xA0;</B></FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">The
transfer agent, registrar, and dividend disbursement agent, if any, for a series of preferred stock will be named in a prospectus
supplement. The registrar for shares of preferred stock will send notices to stockholders of any meetings at which holders of
the preferred stock have the right to elect directors or to vote on any other matter.</FONT></DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Texas
Anti-Takeover Law and Provisions of our Certificate of Formation and Bylaws</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">A
number of provisions of Texas law, our Certificate of Formation and our bylaws could have an anti-takeover effect and make more
difficult the acquisition of the Company by means of a tender offer, a proxy contest or otherwise and the removal of our directors
or management. These provisions are intended to discourage coercive takeover practices and inadequate takeover bids and to encourage
persons seeking to acquire control of the Company to negotiate first with our board of directors.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
are subject to the provisions of Title 2, Chapter 21, Subchapter M of the Texas Business Organizations Code (the &#x201C;TBOC&#x201D;),
which provides that a Texas corporation that qualifies as an &#x201C;issuing public corporation&#x201D; (as defined in the TBOC)
may not engage in specified types of business combinations, including mergers, consolidations and asset sales, with a person,
or an affiliate or associate of that person, who is an &#x201C;affiliated shareholder.&#x201D; The restrictions in Title 2, Chapter
21, Subchapter M of the TBOC do not apply to corporations that have elected, in the manner provided under the TBOC, not to be
subject to such provisions. Our Certificate of Formation affirmatively states that the Company elects not to be governed by such
provisions, and neither our Certificate of Formation nor bylaws provide a similar restriction on business combinations.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; text-indent: 48px; margin-right: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">However,
provisions of our Certificate of Formation and bylaws may delay or discourage transactions involving an actual or potential change
in our control or change in our management, including transactions in which shareholders might otherwise receive a premium for
their shares, or transactions that our shareholders might otherwise deem to be in their best interests. Therefore, these provisions
could adversely affect the price of our common stock. Among other things, for example, our Certificate of Formation and bylaws:</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">do not provide
for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any
election of directors to elect all of the directors standing for election, if they should so choose);</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">empower our
board of directors, without shareholder approval, to issue our preferred stock, the terms of which, including voting power, are
set by our board of directors;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">require that
special meetings of the shareholders be called by the Chairman of the board of directors, the President or the board of directors,
or by the holders of not less than ten percent (10%) of all the shares issued, outstanding and entitled to vote;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">permit our board
of directors to alter, amend or repeal our bylaws or to adopt new bylaws; and</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">enable our board
of directors to increase the number of persons serving as directors and to fill vacancies created as a result of the increase
by a majority vote of the directors present at a meeting of directors.</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">8</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Indemnification
of Directors and Officers</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Pursuant
to the TBOC, a corporation has the power to indemnify its directors and officers against judgments and certain expenses other
than judgments that are actually and reasonably incurred in connection with a proceeding, provided that there is a determination
that the individual acted in good faith and in a manner reasonably believed to be in or not opposed to the best interests of the
corporation and, with respect to any criminal proceeding, had no reasonable cause to believe the individual&#x2019;s conduct was
unlawful. Such determination will be made, in the case of an individual who is a director or officer at the time of such determination:</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">by a majority
of the disinterested and independent directors, even though less than a quorum;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">by a majority
vote of a committee of the directors if the committee is designated by a majority vote of the directors, who at the time of the
vote are disinterested and independent, even though less than a quorum, and is composed solely of one or more directors who are
disinterested and independent;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">by special legal
counsel selected by the directors, or selected by a committee of the directors as described in the preceding two subparts above;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">by the owners
or members of the corporation in a vote that excludes the ownership or membership interests held by each director who is not disinterested
and independent; or</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">by a unanimous
vote of the owners or members of the corporation.&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">No
indemnification may be made in respect of any proceeding in which such individual is liable to the corporation or improperly received
a personal benefit and is found liable for willful misconduct, breach of the duty of loyalty owned to the corporation, or an act
or omission deemed not to be committed in good faith.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">The
TBOC requires indemnification of directors and officers for reasonable expenses relating to a wholly successful defense on the
merits or otherwise in defense of a proceeding.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">The
TBOC permits a corporation to advance expenses relating to the defense of any proceeding to directors and officers, contingent
upon, among other things, such individuals&#x2019; commitment to repay any advances unless it is determined ultimately that such
individuals are entitled to be indemnified.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Our
Certificate of Formation and bylaws provide for indemnification by us of our directors and officers to the fullest extent permitted
by Texas Law.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Limitation
of Personal Liability of Directors</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Our
Certificate of Formation provides that our directors will not be personally liable to us or any of our shareholders for monetary
damages for an act or omission in the director&#x2019;s capacity as a director to the fullest extent permitted by Texas law.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">The
TBOC provides that a corporation&#x2019;s certificate of formation may include a provision limiting the personal liability of
a director to the corporation or its shareholders for monetary damages for an act or omission as a director. However, no such
provision can eliminate or limit the liability of a director for:</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">any breach of
the director&#x2019;s duty of loyalty to the corporation or its shareholders;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">acts or omissions
not in good faith or that constitute a breach of a duty owed to the corporation or involve intentional misconduct or a knowing
violation of the law;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">violation of
certain provisions of the Texas Law; or</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">any transaction
from which the director received an improper benefit.</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">9</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B><A NAME="decofwarrants">D</A>ESCRIPTION
OF WARRANTS</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
may issue warrants for the purchase of common stock or preferred stock in one or more series. We may issue warrants independently
or together with common stock or preferred stock, and the warrants may be attached to or separate from these securities.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
will evidence each series of warrants by warrant certificates that we may issue under a separate agreement. We may enter into
a warrant agreement with a warrant agent. Each warrant agent may be a bank that we select which has its principal office in the
United States. We may also choose to act as our own warrant agent. We will indicate the name and address of any such warrant agent
in the applicable prospectus supplement relating to a particular series of warrants.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
will describe in the applicable prospectus supplement the terms of the series of warrants, including:</FONT></DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the offering
price and aggregate number of warrants offered;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">if applicable,
the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such
security or each principal amount of such security;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">if applicable,
the date on and after which the warrants and the related securities will be separately transferable;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">in the case
of warrants to purchase common stock or preferred stock, the number or amount of shares of common stock or preferred stock, as
the case may be, purchasable upon the exercise of one warrant and the price at which and currency in which these shares may be
purchased upon such exercise;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the manner of
exercise of the warrants, including any cashless exercise rights;&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">any warrant
agreement under which the warrants will be issued;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the effect of
any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">anti-dilution
provisions of the warrants, if any;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the terms of
any rights to redeem or call the warrants;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">any provisions
for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the dates on
which the right to exercise the warrants will commence and expire or, if the warrants are not continuously exercisable during
that period, the specific date or dates on which the warrants will be exercisable;&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the manner in
which any warrant agreement and warrants may be modified;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the identities
of any warrant agent and any calculation or other agent for the warrants;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">federal income
tax consequences of holding or exercising the warrants;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the terms of
the securities issuable upon exercise of the warrants;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">any securities
exchange or quotation system on which the warrants or any securities deliverable upon exercise of the warrants may be listed or
quoted; and</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">any other specific
terms, preferences, rights or limitations of or restrictions on the warrants.</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">10</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Before
exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such
exercise, including, in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any,
or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Exercise
of Warrants</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Each
warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise
price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement,
holders of the warrants may exercise the warrants at any time up to 5:00 P.M. eastern time, the close of business, on the expiration
date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised
warrants will become void.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Holders
of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together
with specified information, and paying the required exercise price by the methods provided in the applicable prospectus supplement.
We will set forth on the reverse side of the warrant certificate, and in the applicable prospectus supplement, the information
that the holder of the warrant will be required to deliver to the Company or any warrant agent.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Upon
receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office
of the warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities
purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we
will issue a new warrant certificate for the remaining amount of warrants.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Enforceability
of Rights by Holders of Warrants</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Any
warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship
of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue
of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement
or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us.
Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate
legal action the holder&#x2019;s right to exercise, and receive the securities purchasable upon exercise of, its warrants in accordance
with their terms.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Warrant
Agreement Will Not Be Qualified Under Trust Indenture Act</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">No
warrant agreement will be qualified as an indenture, and no warrant agent will be required to qualify as a trustee, under the
Trust Indenture Act of 1939. Therefore, holders of warrants issued under a warrant agreement will not have the protection of the
Trust Indenture Act of 1939 with respect to their warrants.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>Governing
Law</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Unless
we provide otherwise in the applicable prospectus supplement, each warrant agreement and any warrants issued under the warrant
agreements will be governed by New York law.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">11</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B><A NAME="descofunits">D</A>ESCRIPTION
OF UNITS</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
may issue units comprised of one or more of the other securities described in this prospectus or any prospectus supplement in
any combination. Each unit will be issued so that the holder of the unit is also the holder, with the rights and obligations of
a holder, of each security included in the unit. The unit agreement under which a unit is issued may provide that the securities
included in the unit may not be held or transferred separately, at any time or at any times before a specified date or upon the
occurrence of a specified event or occurrence.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">The
applicable prospectus supplement will describe:</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the designation
and the terms of the units and of the securities comprising the units, including whether and under what circumstances those securities
may be held or transferred separately;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">any unit agreement
under which the units will be issued;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">any provisions
for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">whether the
units will be issued in fully registered or global form.&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">12</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B><A NAME="planofdistro">P</A>LAN
OF DISTRIBUTION</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
may sell the securities offered pursuant to this prospectus from time to time in one or more transactions, including, without
limitation:</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">to or through
underwriters;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">through broker-dealers
(acting as agent or principal);</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">through agents;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">directly by
us to one or more purchasers (including our affiliates and shareholders), through a specific bidding or auction process, a rights
offering or otherwise;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">through a combination
of any such methods of sale; or</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">through any
other methods described in a prospectus supplement or free writing prospectus.</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">The
distribution of securities may be effected, from time to time, in one or more transactions, including:</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">block transactions
(which may involve crosses) and transactions on The Nasdaq Capital Market or any other organized market where the securities may
be traded;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">purchases by
a broker-dealer as principal and resale by the broker-dealer for its own account pursuant to a prospectus supplement or free writing
prospectus;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">ordinary brokerage
transactions and transactions in which a broker-dealer solicits purchasers;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">sales &#x201C;at
the market&#x201D; to or through a market maker or into an existing trading market, on an exchange or otherwise; and</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">sales in other
ways not involving market makers or established trading markets, including direct sales to purchasers.</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 36px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">The
applicable prospectus supplement or free writing prospectus will describe the terms of the offering of the securities, including:</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the name or
names of any underwriters, and if required, any dealers or agents;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the purchase
price of the securities and the proceeds we will receive from the sale;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">any underwriting
discounts and other items constituting underwriters&#x2019; compensation;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">any discounts
or concessions allowed or re-allowed or paid to dealers; and</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">any securities
exchange or market on which the securities may be listed or traded.</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
may distribute the securities from time to time in one or more transactions at:</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">a fixed price
or prices, which may be changed;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">market prices
prevailing at the time of sale;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">prices related
to such prevailing market prices; or</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">negotiated prices.</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">13</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Only
underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">If
underwriters are used in an offering, we will execute an underwriting agreement with such underwriters and will specify the name
of each underwriter and the terms of the transaction (including any underwriting discounts and other terms constituting compensation
of the underwriters and any dealers) in a prospectus supplement. The securities may be offered to the public either through underwriting
syndicates represented by managing underwriters or directly by one or more investment banking firms or others, as designated.
If an underwriting syndicate is used, the managing underwriter(s) will be specified on the cover of the prospectus supplement.
If underwriters are used in the sale, the offered securities will be acquired by the underwriters for their own accounts and may
be resold from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or
at varying prices determined at the time of sale. Any public offering price and any discounts or concessions allowed or reallowed
or paid to dealers may be changed from time to time. Unless otherwise set forth in the prospectus supplement, the obligations
of the underwriters to purchase the offered securities will be subject to conditions precedent, and the underwriters will be obligated
to purchase all of the offered securities, if any are purchased.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
may grant to the underwriters options to purchase additional securities to cover over-allotments, if any, at the public offering
price, with additional underwriting commissions or discounts, as may be set forth in a related prospectus supplement. The terms
of any over-allotment option will be set forth in the prospectus supplement for those securities.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">If
we use a dealer in the sale of the securities being offered pursuant to this prospectus or any prospectus supplement, we will
sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to
be determined by the dealer at the time of resale. The names of the dealers and the terms of the transaction will be specified
in a prospectus supplement.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
may sell the securities directly or through agents we designate from time to time. We will name any agent involved in the offering
and sale of securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus
supplement states otherwise, any agent will act on a best-efforts basis for the period of its appointment.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
may authorize agents or underwriters to solicit offers by institutional investors to purchase securities from us at the public
offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery
on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation
of these contracts in the prospectus supplement.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">In
connection with the sale of the securities, underwriters, dealers or agents may receive compensation from us or from purchasers
of the securities for whom they act as agents, in the form of discounts, concessions or commissions. Underwriters may sell the
securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions
from the underwriters or commissions from the purchasers for whom they may act as agents. Underwriters, dealers and agents that
participate in the distribution of the securities, and any institutional investors or others that purchase securities directly
for the purpose of resale or distribution, may be deemed to be underwriters, and any discounts or commissions received by them
from us and any profit on the resale of the common stock by them may be deemed to be underwriting discounts and commissions under
the Securities Act of 1933, as amended.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
may provide agents, underwriters and other purchasers with indemnification against particular civil liabilities, including liabilities
under the Securities Act, or contribution with respect to payments that the agents, underwriters or other purchasers may make
with respect to such liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the
ordinary course of business.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">14</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">To
facilitate the public offering of a series of securities, persons participating in the offering may engage in transactions that
stabilize, maintain, or otherwise affect the market price of the securities. This may include over-allotments or short sales of
the securities, which involves the sale by persons participating in the offering of more securities than have been sold to them
by us. In addition, those persons may stabilize or maintain the price of the securities by bidding for or purchasing securities
in the open market or by imposing penalty bids, whereby selling concessions allowed to underwriters or dealers participating in
any such offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The
effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might
otherwise prevail in the open market. Such transactions, if commenced, may be discontinued at any time. We make no representation
or prediction as to the direction or magnitude of any effect that the transactions described above, if implemented, may have on
the price of our securities.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Unless
otherwise specified in the applicable prospectus supplement, any common stock sold pursuant to a prospectus supplement will be
eligible for listing on The Nasdaq Capital Market, subject to official notice of issuance. Any underwriters to whom securities
are sold by us for public offering and sale may make a market in the securities, but such underwriters will not be obligated to
do so and may discontinue any market making at any time without notice.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">In
order to comply with the securities laws of some states, if applicable, the securities offered pursuant to this prospectus will
be sold in those states only through registered or licensed brokers or dealers. In addition, in some states securities may not
be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or
qualification requirement is available and complied with.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">15</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B><A NAME="legalmatter">L</A>EGAL
MATTERS</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">The
validity of the securities offered by this prospectus will be passed upon for us by Haynes and Boone, LLP, Dallas, Texas. If legal
matters in connection with offerings made by this prospectus are passed on by counsel for the underwriters, dealers or agents,
if any, that counsel will be named in the applicable prospectus supplement.</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B><A NAME="experts">E</A>XPERTS</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Our
financial statements as of December 31, 2019 and 2018 and for the years then ended incorporated in this prospectus by reference
to our Annual Report on Form 10-K for the year ended December 31, 2019 have been audited by MaloneBailey, LLP, an independent
registered public accounting firm, as stated in its report appearing in the registration statement, and are incorporated in reliance
upon the report of such firm given upon its authority as experts in accounting and auditing.</FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B><A NAME="whereyoucanfind">W</A>HERE
YOU CAN FIND MORE INFORMATION</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
are subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the &#x201C;Exchange Act&#x201D;),
and in accordance therewith file annual, quarterly and current reports, proxy statements and other information with the SEC. The
SEC maintains an internet website at www.sec.gov that contains periodic and current reports, proxy and information statements
and other information regarding registrants that are filed electronically with the SEC.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">These
documents are also available, free of charge, through the Investor Relations section of our website, which is located at www.sanaramedtech.com.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
have filed with the SEC a registration statement under the Securities Act relating to the offering of these securities. The registration
statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus
does not contain all of the information set forth in the registration statement. You can obtain a copy of the registration statement
for free at www.sec.gov. The registration statement and the documents referred to below under &#x201C;Incorporation of Documents
by Reference&#x201D; are also available on our website, www.sanaramedtech.com.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a
part of this prospectus.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;<B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>I<A NAME="incorpbyref">N</A>CORPORATION
OF DOCUMENTS BY REFERENCE</B></FONT></DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px"><B>&#xA0;</B></FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">The
SEC allows us to &#x201C;incorporate by reference&#x201D; the information we have filed with it, which means that we can disclose
important information to you by referring you to those documents. The information we incorporate by reference is an important
part of this prospectus, and later information that we file with the SEC will automatically update and supersede this information.
We specifically are incorporating by reference the following documents filed with the SEC (excluding those portions of any Current
Report on Form 8-K that are furnished and not deemed &#x201C;filed&#x201D; pursuant to the General Instructions of Form 8-K):</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">our <A HREF="http://www.sec.gov/Archives/edgar/data/714256/000165495420003345/smti_10k.htm">
<U>Annual Report on Form 10-K</U></A> for the fiscal year ended December 31, 2019, filed with the SEC on March 26, 2020;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the portions
of our <A HREF="http://www.sec.gov/Archives/edgar/data/714256/000165495420006958/smti_def14a.htm"> <U>Definitive Proxy Statement
on Schedule 14A</U></A>, filed with the SEC on June 25, 2020, that were deemed to be filed with the SEC;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">our Quarterly
Reports on Form 10-Q <A HREF="http://www.sec.gov/Archives/edgar/data/714256/000165495420005225/smti_10q.htm"> <U>for the quarter
ended March 31, 2020</U></A>, filed with the SEC on May 12, 2020, <A HREF="http://www.sec.gov/Archives/edgar/data/714256/000165495420009006/smti_10q.htm">
<U>for the quarter ended June 30, 2020</U></A>, filed with the SEC on August 13, 2020, and <A HREF="http://www.sec.gov/Archives/edgar/data/714256/000165495420012356/smti_10q.htm">
<U>for the quarter ended September 30, 2020</U></A>, filed with the SEC on November 13, 2020;</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">16</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">our Current
Reports on Form 8-K filed on <A HREF="http://www.sec.gov/Archives/edgar/data/714256/000165495420001419/smti_8k.htm"> <U>February
13, 2020</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/714256/000165495420004644/smti_8k.htm"> <U>April 29, 2020</U></A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/714256/000165495420005087/smti_8k.htm"> <U>May 8, 2020</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/714256/000165495420005876/smti_8k.htm">
<U>May 21, 2020</U></A><U>,</U>&#xA0;<A HREF="http://www.sec.gov/Archives/edgar/data/714256/000165495420007672/smti_8k.htm"><U>July
14, 2020</U></A> (as amended on <A HREF="http://www.sec.gov/Archives/edgar/data/714256/000165495420011158/smti_8ka.htm"> <U>October
14, 2020</U></A>), <A HREF="http://www.sec.gov/Archives/edgar/data/714256/000165495420011236/smti_8k.htm"> <U>October 16, 2020</U></A>
and <A HREF="http://www.sec.gov/Archives/edgar/data/714256/000165495420013880/smti_8k.htm"> December 23, 2020</A>; and</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="margin-left: 48px; display: table"><DIV STYLE="display: table-row"><DIV STYLE="text-align: left; display: table-cell; width: 24px"><FONT STYLE="font-size: 13px">&#x25CF;</FONT></DIV>
<DIV STYLE="text-align: justify; display: table-cell"><FONT STYLE="font-family: Times New Roman; font-size: 13px">the description
of our securities contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/714256/000165495420011574/smti_8ka.htm">
<U>Form 8-A</U></A>, filed with the SEC on October 29, 2020, including all amendments and reports filed for the purpose of updating
such description.</FONT></DIV>
</DIV>
</DIV>
<DIV><FONT STYLE="font-family: Times New Roman; font-size: 10">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; text-indent: 48px; margin-right: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">All
reports and definitive proxy or information statements subsequently filed after the date of the initial registration statement
of which this prospectus forms a part and prior to effectiveness of such registration statement by the Company pursuant to Sections
13(a), 13(c), 14 and 15(d) of the Exchange Act, but excluding information furnished to, rather than filed with, the SEC, shall
be deemed to be incorporated by reference herein and to be a part hereof from the date such documents are filed.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">Any
statement contained herein or in any document incorporated or deemed to be incorporated by reference shall be deemed to be modified
or superseded for purposes of the registration statement of which this prospectus forms a part to the extent that a statement
contained in any other subsequently filed document which also is or is deemed to be incorporated by reference modifies or supersedes
such statement. Any such statement so modified or superseded shall not be deemed to constitute a part of the registration statement
of which this prospectus forms a part, except as so modified or superseded.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">You
should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone else
to provide you with different information. You should not assume that the information in this prospectus is accurate as of any
date other than the date of this prospectus or the date of the documents incorporated by reference in this prospectus.</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">We
will provide without charge to each person to whom a copy of this prospectus is delivered, upon written or oral request, a copy
of any or all of the information that has been incorporated by reference in this prospectus but not delivered with this prospectus
(other than an exhibit to these filings, unless we have specifically incorporated that exhibit by reference in this prospectus).
Any such request should be addressed to us at 1200 Summit Ave, Suite 414, Fort Worth, Texas 76102 (telephone: 817-529-2300).</FONT></DIV>
<DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV STYLE="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">You
may also access the documents incorporated by reference in this prospectus through our website at www.sanaramedtech.com. Except
for the specific incorporated documents listed above, no information available on or through our website shall be deemed to be
incorporated in this prospectus or the registration statement of which it forms a part.</FONT></DIV>
<DIV STYLE="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pgbrk" STYLE="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px"><DIV ID="ftr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
<DIV ID="pn" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 13px">17</FONT></DIV>
</DIV>
<DIV ID="pb" STYLE="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000"><!--page break--></DIV>
<DIV ID="hdr"><DIV STYLE="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</DIV>
</DIV>
<DIV><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 13px Times New Roman; width: 100%"> <TR><TD STYLE="vertical-align: top; width: 100%"><DIV><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</TD>
</TR><TR>
<TD STYLE="vertical-align: top; width: 100%"><DIV><FONT STYLE="font-family: Times New Roman; font-size: 13px">&#xA0;</FONT></DIV>
</TD>
</TR></TABLE>
</DIV>
<DIV STYLE="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"></DIV>
</DIV>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt">1,100,000
Shares of Common Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_008.jpg" ALT="https:||sanaramedtech.com|wp-content|uploads|2019|08|logo-footer.png" STYLE="height: 66px; width: 198px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>Sanara
MedTech Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Cantor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>February 12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
2021</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img_001.jpg
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ +$# 2(  A$! Q$!_\0
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M,HZJ^XGGZ@@_C61\;+RTB\'0VLK*;F:Y5H5[C:#N;Z8./QJ_J'PXBCUF74=
MURZT2XN23+%#RCGJ2%R/KW_"HKKX4V>H:=<)J&K7EWJ,[+NOY\.RJ#G:H/W1
M6B<%/GN9-3=/DL5/BC&LMEX3C=0R/J,2L#W!%>CW2/):3)$<2-&P4^AQQ6'X
MB\)P^(H]*26ZDA_L^X2X7:H.\KV-=#6<I)Q2]36,6I-OK8\[^#4T(\&RV7"W
M=M=2+<1G[P8]"?PX_ U;^+EY:6_P_O(KDKYEPR) A/)<,#D?0 T_6?AW#=ZT
M^LZ-JMUHVH2_ZY[?E)#ZE<CFJ\OPO@O[.Z_M?6;W4=0FC\M+J?GR!D$[$S@9
MQBKO!SY[F?+-0Y+'B=%>N_\ "FK+_H,W7_?I:*Z/;P[G/]7J=CTF:9((V=R<
M*"V ,D@>@')KB]0\/VMV^KV9LXH/[2NXI-]]/O6ZP,G8H.5(/&*[.=I5C/DH
MKRX^4,<+^)[5EW5@Y8['%S>^8\UM+=1[DM^GRY7&!CI_]:N2F[.YTUTVK+^O
M^#_3.>^SKX3\5+/I]M?7]MJD@AGVRCR;!4 [8XP.><8 KJK'7=)U*WBGL]0M
MY8IG,<;"0#>PZ@9ZFN,U#PI8-J;7-I9R6=W!>_:(5EN=L-_*_+<$\\+T';CU
MI(/!R7D$TMJNEA].E>32A:N?+AGZD28ZX8+P<]/3BM'"+5V_Z_K^KF<:LE+E
MC'3^OZ^[H:'B#Q!!K=K'I.DQ7&H6U],UG=7=A( ;0\<GCW)[ @'FL/P?IWVB
M^@O;BR6PA-L^F.;UR;JZQP&5A@=,#CTQSQ1;>%2UK8W-[%:M+:"2[":1.$-[
M<_Q)CH>% XQCGL:ZO2;%%L].D?2UMK5$5H;5U+S6\S-DDGTY%5[L59?U_7]:
MD\TIN]OZ_P M_P#AC0MM-AMF2VM+BZB%M;F-5R2GS=&Y&&88K3165<,^X\<X
MQVJ*S@DM;2.&6XDN'7.99,;FY[XXJ>N>3NSIIP45HK'/>+X9;FRL8()FAEDO
M$5)%_A.&P?SQ56ZUB;5M%MK& F&_O"T-P!U@"?ZT_P!!_O"M[4;#[<UF?,V?
M9[A9^F=V,\?K3(M&L[?4;S4(TVW%TH61B>!@=O3/&?I6L9Q44GNCGJ4:DJDG
M'9V3]+=//I\_(YVPUYK31M&L8Y;:*:2S69YKM\(J]![DD_RJY%XH=K2=%CM[
MB^2=((_(DS%(S\J<]AP<CVJ5/#;V]O8?9;Q$O+2W%N7>(.DJ=<%<\<\@@U9D
MT26YTTV]S>9N!*)HYX8E3RF'W<#N![DYR:J4J3=_ZW9E"&)2MV7Z+\=_^&,S
M4&U4:GHD>H):LAO0RR6^X 'RW^4@_7@^QJ.Y\/:4OBFQMA: 0RV\KNF]L%@5
MP>ON:TCHNH7-[8W-]J:2FTE\Q8XX-BM\I!SR>>?PY]:OS:<9=:MM0\W AB>/
M9CKN(.<_A2]I:UGT>Q7L'.[E&^JWLW;J<\OB-HXY5L)=+@MK5FBC@N)B)) G
M!_W<XXSFM!=;O-3FAATB* ;K9+F66Y)P@?.U0!U/!_*E_L"ZMY9EL+Z*&VFD
M:39);"1HV8Y;:<]"<G!!Q4]UI-Q]N6]T^^6WN3$(I1)&'251T) (P1D\CUH;
MI]/Z]0C&NEK?Y?/;\/\ AS-U674EOM!9[>W:_P#.E4*CGR_N$;LD9 QSBM'3
MM0U#^UI=-U*.W\T0B>.2W)VLN<$$'H0:<NDW#W&G7%S?>?+:R2.S>6%W[E(P
M .@&?>K!L,:V-2,H %L8-F/]K=G-2Y1:MY/\RX4ZBES:[KMM;6Y>HHSFBL3L
M"BBB@ HHHH *:T:.KJR@AQAO>G44 41IUA'!;PFUC,=EAX#(,B,@$ @GH0,\
M^]9VEZ3!:VMFT-G';&2=[B5;.?\ =,S _,<_?!&./Z"MNX)6WE(ZA"?TI8U7
MRT^4# &,#IQ5J3L9.";M_7]:&59Z6+:W*I8VEM]GG9K8QKYA"'&3SC#$9%7(
MK5;6[DE@C54N#OFZEF?@ ]< 8%7**3FWN.-*,;6Z?U_P HHHJ30S-72:7[.D
M4;LJN78JN[H#@8SW)_2H&MKU%>)%?R!,@1 5.4.TMG/8<C\:VJ*=Q6.=2/57
MF:9HY8Y9-J&3"DJN&)VCTW$#GL*F/]K)+*<S,C=,!<JN_''OM&?Q]JW**+A8
MR[4WZ-<R3F1_+4K'&0OSX P<CN?RYK-BM]3M;4^1%+O90N1@$D*3R#_M'KW
MKIJ*+A8Q7_M1Y"H:5(VD"[L+E5"^G^]WHM!>_:KF[N+>0R+"5C!V\G<3@8[<
M+6U11<+'.I::A L80.6CB2/>%Y&XDN1D\G@#\33YDU2;SX)(Y7B9#'SMP1N4
M9_[YW'\?:M^BBX6,%QJ,7[T"6*-7+.!MY7>,?@$'ZBK>CRS7 FGFD<L6 \MA
9@)WX['@BM.@  8 Q1<+!1112&%%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img_007.jpg
<TEXT>
begin 644 img_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %E G@# 2(  A$! Q$!_\0
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MQ7/_ $%+K_OB+_XBC[%<_P#04NO^^(O_ (BKM%',PL4OL5S_ -!2Z_[XB_\
MB*/L5S_T%+K_ +XB_P#B*NT4<S"Q2^Q7/_04NO\ OB+_ .(H^Q7/_04NO^^(
MO_B*NT4<S"Q2^Q7/_04NO^^(O_B*/L5S_P!!2Z_[XB_^(J[11S,+%+[%<_\
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M1_T_PH ?13-A_P">C_I_A1L/_/1_T_PH ?13-A_YZ/\ I_A1L/\ ST?]/\*
M'T4S8?\ GH_Z?X4;#_ST?]/\* 'T4S8?^>C_ *?X4;#_ ,]'_3_"@!]%,V'_
M )Z/^G^%&P_\]'_3_"@!]%,V'_GH_P"G^%&P_P#/1_T_PH ?13-A_P">C_I_
MA1L/_/1_T_PH ?13-A_YZ/\ I_A1L/\ ST?]/\* 'T4S8?\ GH_Z?X4;#_ST
M?]/\* 'T4S8?^>C_ *?X4;#_ ,]'_3_"@!]%,V'_ )Z/^G^%&P_\]'_3_"@!
M]%,V'_GH_P"G^%&P_P#/1_T_PH ?13-A_P">C_I_A1L/_/1_T_PH ?13-A_Y
MZ/\ I_A1L/\ ST?]/\* 'T4S8?\ GH_Z?X4;#_ST?]/\* 'T4S8?^>C_ *?X
M4;#_ ,]'_3_"@!]%,V'_ )Z/^G^%&P_\]'_3_"@!]%,V'_GH_P"G^%&P_P#/
M1_T_PH ?13-A_P">C_I_A1L/_/1_T_PH ?13-A_YZ/\ I_A1L/\ ST?]/\*
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M]?SI=J_W1^5&U?[H_*@# \:.I\)WP# G"]_]H5Y RJPPR@CW%>O^-% \)WV
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MXB/52<#)Z5#;7=O>1F2VF25 <%D.1FO%M=\8^(K7Q!J5O!JLR117,B(H5<*
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MZMP:#I5LUPT-C"IN%*RC&05/48/ !]!Q4VGZ79:7$T5E;K$K'<V"26/N3R:
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M)^C/)NU2VW_'W!_UT7^8J+M4MM_Q]P?]=%_F*Z'L9H]+^,O_ !YZ/_UUD_\
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M\_5FU7:/H6]*_P"0S8?]?,?_ *$*^@]<W?N-V.^,?A7SYI/_ "&K#_KYC_\
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MGQ%QV&?O?]C]:/WO^Q^M/HJ!C/WO^Q^M'[W_ &/UI]% #/WO^Q^M9?B/S/\
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M\A74O^N"?^A&O/Z] ^%'_(5U+_K@G_H1K7&?P)&=#^(CB/$G_(TZM_U^2_\
MH1K,K3\2?\C3JW_7Y+_Z$:S*N'PKT1,MV>J6O_)#9_\ KA+_ .C#7D5>NVO_
M "0V?_KA+_Z,->15RX?>?JS:KM'T+>D_\AJP_P"OF/\ ]"%?0FN_\L/^!?TK
MY[TG_D-6'_7S'_Z$*^A-=_Y8?\"_I6&,^./S-</\+,>M+1/^/Q_]P_S%9M:6
MB?\ 'X_^X?YBN6?PLW6YOT445S&@4444 %%%% %>^_Y!]S_UR;^1KRD=!7JU
M]_R#[G_KDW\C7E(Z"N[";,PK;H#T-=/X]_Y%BP_ZZI_Z":Y@]#73^/?^18L/
M^NJ?^@FMI?Q8>I"^"1YQ71>!O^1LM?\ <?\ ]!-<[71>!O\ D;+7_<?_ -!-
M==?^%+T,*?QHI_$C_D<IO^N$?\C7)5UOQ(_Y'*;_ *X1_P C7)5IAOX,?0RJ
M_P 1GJ/PO_Y &J?]=?\ V2O)#]X_6O6_A?\ \@#5/^NO_LE>2'[Q^M84OX]3
MY&L_X<!&^Z?I7K7CK_DE5A]+;_T&O)6^Z?I7K7CK_DE5A]+;_P!!I8GXZ?J.
MC\,O0\=KH? O_(\Z1_UV/_H)KGJZ'P+_ ,CSI'_78_\ H)K6K_#EZ,B'Q(]G
MUK_C_'^X/YFLZM'6O^/\?[@_F:SJ\F'PH[WN;6A?=G^J_P!:UZR-"^[/]5_K
M6O6%3XBX[!1114#"BBB@ K*\2?\ (O7G^X/YBM6LKQ)_R+UY_N#^8JZ?QKU%
M+9GF]36?_'];_P#75/YBH:FL_P#C^M_^NJ?S%>J]CD6YJ?$O_CXTW_=D_FM<
M)7=_$O\ X^--_P!V3^:UPE7A/X,2*WQL[+X;_P#(<N_^O;_V85QOBK_D;=6_
MZ^GKLOAO_P AR[_Z]O\ V85QOBK_ )&W5O\ KZ>JI?[S+T1-3^$O4R*]/T'_
M ))!J'_7*X_F:\PKT_0?^20:A_URN/YFGC?@CZHG#_$_1GDW:I;;_C[@_P"N
MB_S%1=JEMO\ C[@_ZZ+_ #%=#V,T>E_&7_CST?\ ZZR?^@BO)J]9^,O_ !YZ
M/_UUD_\ 017DU<>#_@KYF]?^(SM_A3_R.G_;K)_,5Z7J7_(1F^H_E7FGPI_Y
M'3_MUD_F*]+U+_D(S?4?RKEQ/\;Y&]'^&5*Z#1?^/$_[YKGZZ#1?^/$_[YKG
MJ?":QW-&BBBN<T*%U_R&;#_<E_DM%%U_R&;#_<E_DM%-[(2%3_D/3_\ 7M'_
M .A/4>ORR0:#>R1221R+&=K1_>S[>GIGMUJ1/^0]/_U[1_\ H3TS5;6\N8FC
M@^RS0.A26VN%(#@_[0Z?D:)#16T2&>*9S-8WMME!S<7OG@GT W'!]ZVJP-*%
MGI]T(CI$UA/*-@8 R1M[!QD#\<5OT@*FIQ"?39XC9+>JRX-NS "0>F3Q^=9&
MDV%Y96D\2V/D074^%MA.#]EC*8)]#EAG:/6NBHH XJ30=6O]/M[*:VCMSI]J
MT,4AE#"=_EP1CE5PG.>>>E;NE07DNIW>I7MK]D:6..%(3('.%W$DD<<EOTK8
MHH *9Y?_ $T?\Z?10 SR_P#IH_YT>7_TT?\ .GT4 ,\O_IH_YT>7_P!-'_.G
MT4 >3W/_ !]S_P#71OYFHJEN?^/N?_KHW\S45>PMCC9U6JK_ ,6V)W-_JDX[
M?>%>:5Z;JO\ R30_]<4_]"%>94\'\,O5BK[KT+^B<Z]I_P#U\Q_^A"M?XJC;
MK&G<D_Z.W7_>K(T/_D/Z=_U\Q_\ H0K9^*__ "&=._Z]V_\ 0JM_[S#T9#_@
MOU1P%=_\*5W:KJ7)'[A.G^\:X"O0/A1_R%=2_P"N"?\ H1K7&?P)&=#^(CB/
M$?'BC5N_^F2_^A&LRM/Q)_R-.K?]?DO_ *$:S*N'PKT1,MV>IVJ_\6/G.YO]
M1+QV_P!8:\CKUVU_Y(;/_P!<)?\ T8:\BKEP^\_5FU7:/H6]*_Y#-A_U\Q_^
MA"OH/7%V^1\Q/7K^%?/FD_\ (:L/^OF/_P!"%?0FN_\ +#_@7]*PQGQQ^9KA
M_A9CUHZ,-UVXR1\G;ZBLZM+1/^/Q_P#</\Q7+/X6;K<W/+_Z:/\ G1Y?_31_
MSI]%<QH,\O\ Z:/^='E_]-'_ #I]% #/+_Z:/^='E_\ 31_SI]% %2^CQ87/
MSO\ ZIN_L:\L'05ZM??\@^Y_ZY-_(UY2.@KNPFS,*VZ ]#73>/%QX9L3N8_O
M4Z_[IKF3T-=/X]_Y%BP_ZZI_Z":VE_%AZD+X)'G%=#X(&?%=L,D?(_(_W37/
M5T7@;_D;+7_<?_T$UUU_X4O0PI_&BE\1QCQC,,D_N8^OT-<G76_$C_D<IO\
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M"I[\T :]%%-\V/\ OK^= #J*;YL?]]?SH\V/^^OYT .HIOFQ_P!]?SH\V/\
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MQRZGX5V # G%MQG_ &:6)^.GZCH_#+T/'ZZ'P+_R/.D?]=C_ .@FN>KH/ Q
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MMW^GQW$\UM'%#(OG2F1D=MV1DDGD ''O0!NT44SS#_SS?]* 'T4SS#_SS?\
M2CS#_P \W_2@!]%,\P_\\W_2CS#_ ,\W_2@#RJY_X^Y_^NC?S-15+<_\?<__
M %T;^9J*O86QQLZS5?\ DFA_ZXI_Z$*\RKTS56/_  K8C:W^J3GM]X5YG3P?
MPR]6*ONO0OZ'_P A_3O^OF/_ -"%;/Q7_P"0SIW_ %[M_P"A5C:)QKVG]_\
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MUZ%_0_\ D/Z=_P!?,?\ Z$*V?BO_ ,AG3O\ KW;_ -"K&T3/]O:?CK]IC_\
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MJH_X4?.W.?(E[_\ 30UY'7+A]Y^K-JNT?0MZ3_R&K#_KYC_]"%?0FN_\L/\
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MI\2/^1RF_P"N$?\ (UR5=9\1P%\8S ?\\8^_L:Y.M,-_!CZ&57^(SU'X7_\
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M#_$_1GE':I;;_C[@_P"NB_S%1=JEMO\ C[@_ZZ+_ #%=#V,T>E_&7_CST?\
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M[(2%3_D/3_\ 7M'_ .A/5ZJ*?\AZ?_KVC_\ 0GJ]0P04444AF?K5]+I^F--
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MS! ?*&U2@79NSC#'G.<U/IF@26%U!/)=B9HUG#?N]NXR2!\]>,8Q0!MT444
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MH''I]*DHI 0O:6TD:1O;Q,D?W%* A?H.U M;=9Q.+>(2A=HD"#<!Z9]*FHH
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M!_92?\_E[_X$-1_92?\ /Y>_^!#444<S"R#^RD_Y_+W_ ,"&H_LI/^?R]_\
M AJ**.9A9!_92?\ /Y>_^!#4?V4G_/Y>_P#@0U%%',PL@_LI/^?R]_\  AJ/
M[*3_ )_+W_P(:BBCF860?V4G_/Y>_P#@0U']E)_S^7O_ ($-111S,+(/[*3_
M )_+W_P(:C^RD_Y_+W_P(:BBCF860?V4G_/Y>_\ @0U']E)_S^7O_@0U%%',
MPL@_LI/^?R]_\"&H_LI/^?R]_P# AJ**.9A9#H=-BAN5G,MQ*Z A?-E+ 9Z\
)?A1110W<9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img_008.jpg
<TEXT>
begin 644 img_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !" ,8# 2(  A$! Q$!_\0
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M)99P&P$R<YZ  <<G-3"2EHT:5(..J9OV=L+.WDT:!?[(TZ.1!8W"3@F8L2Q
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MX'/08QBI=.*5[FJQ$VU&R3\]M%?U_JYH6^L:G=VLTEKI\,[QW<T!4S>7A4;
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MHE4H"N[Y\_+@>N:M50U*SEO&MPFPQQN796<J2<$#D#MG-"&U=%F*[@EC\Q7
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MWJ$Z-<_:FDWP.A#@ @AB"H4#(Z8 /3UI?,JR6R+=MI&D6UR+BVLK2.9LE71
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..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>new_002.jpg
<TEXT>
begin 644 new_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,Y!;L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYO"WA"SN_$=LBZY<*RI8P'.]P> ""V!@KDY/7\*Q(?$OQ3\L7TGA.R:TQN,
M;;+M^A<G/_ ?PI*E)Z@ZL5H>H45YUH_Q+DUSQU8:+;6:Q6T]NSW"SHPG@E4/
ME#SCC:.W>O1:F4'#1E1FI:H****DH**** /BRBBBO</#"BBB@ HHHH ****
M"BBB@"YIFEW^LWJ6>G6LMS</TCC7)QZGT'N:[*7X2:W9VB7&JZGHFE*_ 6]O
M-ASZ9"D9^AKUGX2^'[;1_!5K>+&/M>H+YTLF.2,G:OT _4FO'/BK-J$GQ U%
M;\R;48"W5N@BQQM]CS^.:YO;2E5]G'2QTJC&-+VDM1FH_#'Q+96BWEM;PZI:
M,,B?3I1,I'J .2/H*P=;\/:KX<NX[75K0VT\D8D5"ZME22,_*3CH>*Z#X<>,
MI_"OB*%))C_9ERX2YC)^49X#^Q'\LUT'QVVGQ9I[#'-D.1W^=JKGG&I&#U3$
MH4YTY26C1@+\)_&SJ&71,@C(/VJ'_P"+I?\ A4OC@?\ ,$_\FH?_ (NMOX*Z
MY?Q>+!I)N96L9H'/D,Q*JP^;('8]>GK7M?AK6DUS2WG# RP7$MO*!V9'(Y^H
MP?QK.M6J4W;3^M"Z-&G45]?Z5SY&EC>&5XI%*R(Q5E/4$=12 %B !DG@5W7Q
M;T'^Q?'%Q-&I$%^/M*<<;CPP_/G\:H?#?0CKWC>QB=<V]NWVF<GIM3G'XG _
M&NBG44H*;_KN85*;C4<%_78L#X3>-R 1HG!_Z>H?_BZ;+\*O&L$+S2:+MC12
MS'[5"< <G^.OHKPWK2:_I3:A%CR7N)4C([JKE0?QQG\:\3^-U_>'QA'8FYE^
MR+:QL(-YV;B6YQTSP*Y88BI*?)HCJGAZ<(.>K.;L/AGXOU.P@OK/2/-MIT$D
M;_:8EW*>AP7!%6?^%2^./^@)_P"3</\ \77<Z]XPE\-_"/P_96,ICO[^S55=
M3@QQ@#<P]^0!]?:N6^##M)\1%=V+.UM*68G))XYK55*CYGI97_ Q=.FN5:W=
MOQ,__A4OCC_H"?\ DW#_ /%T?\*E\<?] 3_R;A_^+KV[XI?\DWUC_<3_ -#6
MO#?AWXRN/"GB&#?,W]F7#A+F(GY0#QO ]1_+BIHU:E5-JUT76HTZ35[ZC(OA
MCXPGN;BVCT?=+;E1*OVF$;=PR.=_/'I4_P#PJ7QQ_P! 3_R;A_\ BZT?BQ?W
M=A\2[BXL;J:WE\B+$D,A4XP#U'X5] ://)<Z)83RMNDEMXW<^I*@FIE7J*G&
M>FHXT*;J.GKI_P  ^9-1^&OB[2=/GO[W2?*MH%WR/]IB;:/7 8DURE=;\2=0
MO+OQUJT-Q=32Q0W#+%&[DJ@'' Z"N2KHI2E**E+J<]:,8S<8]#0T;1-0\0:B
MFGZ7;_:+IU++'O5,@#)Y8@5TO_"I?''_ $!/_)N'_P"+KC(Y'BD62-V1U(96
M4X(([@U]*_"'4;S4O D4E[<RW$D<\D:O*Q9MHQ@9/)ZU-><H1YHE4(1G+ED>
M._\ "I?''_0$_P#)N'_XNH;GX7>-+6(R2:%*R@$XBECD/Y*Q-=7\>"5\1Z2R
MD@BU)!';YS73?!3Q+?ZQI>H:??W$EPUFR-%)*Q9MK9^4D]<%>/K62JU'2]HK
M?T[&KHTU5]F[G@EQ;3VD[P7,,D,R'#1R*593[@\BHJ^@?C=HMI<>%XM7\M5N
M[694$@'+(W&T_C@_G7A-MI>H7L1EM;"ZGC!QNBA9AGTR!6M&LJD>9Z&5:C[.
M5EK<J45<OM(U+3!$=0T^[M!*,QFXA:/?],@9ZBI9_#^M6MG]LN-(OX;7&?.D
MMG5/^^B,5KS+N9<K[&=116A9:#K&IQ^98:3?74?]Z"W>0?F!3;MN))O8SZ*O
M7VBZKI:AM0TR]M > ;B!H\_F!5&A-/8&FMPK0T6ST^_U-+?4]4&FVK YN3 T
MNT]AM'//K6?6M%X6\0SPB:'0=4DB(R'2SD*D?4"DVDM6"3>QZUI7P6\-ZG8P
MW5MXBN+R%N#+;[-K$=<=<?3G%<'\2O"%AX-UNULM/FN98IK<2L;AE9@=Q'&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVYDX^?\ 5SF:35^5J7E_5C'^(6KQ^)=-\"7DL9BL;^XWSH3D+R@(S[9>O:
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M%S=32%YY?F48.?NCV!/2K'QV_P"11L/^OT?^@-6$W:O%I6V_4VIJ]"2;OO\
MH<Q\'O&NI1ZS9^%YBDNGR+)Y0V -$V"_4=0>>N>M>K^.I=,@\'WTVL0R3V,>
MQY(8S@R$,"%SV!. ?:O _A/_ ,E+TG_MK_Z*:O:_BO\ \DVU7Z1_^C%IXN*5
M2+77_,>#DW!I]/\ (Y'P1\6KC5O$]KHDNDV=I83?NK9;8$&+ R ><$<8X KJ
M/BQH5MJW@>\NGC7[38KY\4F.0 ?F'T(S^E>'_#?_ )*)HG_7Q_0U]$>/?^1!
MUW_KSD_E4XF"ISBX_P!:AAIN<9*7]:,^??ASX/'C#Q(+><LMC;KYMR5."1G
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M["V>.6);@17$;H,2JI."#U!P3T]>]:\/QP\16T$<$&F:+%%&H5(T@D55 Z
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M176)9]2NH+%8+J-+6.:+9)C>S,X(W<C'RCM52'7]6GU&YL4T./SK=4:3-Z,
M-G&/E]C46B+IZ^+]6&G>7Y7V>$MY7W-^Y\XQQ^7?-26WF_\ "5^(O)_UOV:W
MV?[VU\4<L5=6Z(2G4DD^;>36EO/:Z\C9DU33XKH6LE];)<$X$32J&S],YJ2Z
MO;6QC$EW<PP(3@-*X4$_C7!Z7 +CPNZ74VCH9-WVHW:L)EDR<ER3D-G^E:<,
M<2^+!'KDD<ICL8A:23?ZMFQ^\*YXW$X]\4.BDWKL$<7.23LM;?*]]_Z6NAKZ
MIK0M[;3Y[&2">*YO8K=G!W+M8X)!!ZU?MM3L+R5HK6^MIY%^\D<JL1^ -<OX
M@MM*FTZSMM/$ @EU>!9A;$ ;CP>G0XQ5_4--L;#6-#GL[6&WD^TF$M$@7*&)
MS@XZ]!2Y(\J[Z_TRE6JJ;>C2Y>_7M_P3HZ***P.T**** "BBB@ HHHH ****
M /BRBBBO</#"BBB@ HHHH **** "BBB@#Z<U"ST#Q!X'TG1-6OH+>6[LXGM=
M\BJX<(,,H/7KT[Y->(ZW\-/%6BWC0_V5<7L6<)-9QF56'KA1D?B*Y&M.U\2:
M[8PB&SUK4;>(# 2&Z=%'X UA&E*$FXO<WE5C.*C);(]>^%'@R_\ #,]WXAU]
M5T^,P&*-)G"D*2"6;^[T YYZUS'Q6\<6_BK4;;2]*;S+&U<GS>@FD/&1[#IG
MODUP5]K&IZIC^T-1N[O!R/M$[28/XDU2H5%NI[2;V!UDJ;IP6Y[S\+OAMJWA
MO6'UC6##$_D&..!'WL"V,EB..,=B>M<Q\1OAEJEC?ZIX@LVAGTYW:XD&_;)%
MDY;@\$9/8Y]J\MHH]E/GY^;\ 56')R<OXGOWP[\?Z7:_#L)J>HV\5WIRNBPR
MS*LDJJ,KM!.3P=O'I7D6GZ1K?CWQ%=M8PB>[E9IYBTBJ%!;D\GH,CIDUSU%5
M&DHSE-;LEUG*"@]D?6'@70+CPQX0LM*NY(WN(MS.8SE068M@?3-<!\6/A_K6
MN:R=<TU89X8[8))$9 CC:221G@C!]>U>'45E]7DI^TYM?0U^L1</9N.GJ%>W
M?"SX>:_H/B$:QJL,5M"('18_-#NQ;&#\N0!^/X5XC1714BY1LG8YX2497:N?
M6_C#1)O$7A/4-*MY$CFN(P$:3.W(((SCMQ7S'XF\)ZMX2O([;588T:52T;1R
M!E<#J1CD?B!6)16-&@Z3T>AM6KJJM5L=%X:\$:[XL5Y-*MD>"-]DDLDJJJ'&
M>03D_@#7U/IMJUEI=I:.P9H(4C+#H2J@?TKXVHIUJ+JZ7T)HU53UMJ>H_$OX
M>:Y#K.K>(H4BGTYW,[LL@#1KCG*G&>?3->7445I2@X1Y6[V)JS4Y<R5KFAHN
MB:AXAU)-/TN#S[IP6";U7@<GEB!7TO\ #KPU>>%/"<>G7[Q-<F9Y6\ILJ,XP
M,X'I7RQ14UJ;J+EO9#I5%3ES-79]!?%?P%K'BJ[L[[21#*;>%HWA=]C'G(P3
MQ^9%> 2Q/#,\4@PZ,589Z$=:9111INFN6]T.M551\UK,*^A_A!X0U7PS9:A<
MZK&D+7OEF.(.&("[N21D<[AWKYXHJJD'./*G:Y%.:A+F:N?1GQ8\%ZMXLM-/
MDTE8I);0R;HG<(6# =">.W<CK7SO/#);7$D$J[9(V*.N<X(."*CHJ*-)TURW
MNBZU557>UF>M?"+X@6FBQOH.KSB&UDD\RWG<X6-CU5CV!ZY^M;/QC\'ZAK<M
MCKFCVKWNV+RID@&]BN<JP Y(Y/3VKPRM"RU[6-,B\JPU:_M(_P"Y!<O&/R!I
M3H7FJD79CA7M!TY*Z/<?A'X8N?"NC:AJVMJ+%KG;A)R$,<:Y.6S]W)/0^E<-
M\5_'D'BB]ATW3)"^G6K%C)C EDZ9'L!T^IKA+[6=4U0 :AJ5Y=@'(^T3M)C\
MR:I4*A>I[2;U&Z]J?LX(]^^$'CBUO=&A\/7TZQWUK\MOO('G1]0![CICTQ[U
M-\0_A5+XIU0:MI5U!;W;J%FCGR$?' ;(!(...G85\]@D'(.#6J_B?Q!);FW?
M7=3: C!C:[D*X],9Q4SP[Y_:0=F.&(7)[.:NCZ(^'&A6?A;0+NQ358+V:.X+
M7<D9_=Q2;5^4'V&/S[5S'Q:\-6NOSVVJP^(-*M7AA,1BN[@() "6^4C.3STQ
M7A-%+ZO+GY^;7T&L3%0Y.73U/9_@3KEM"=1T2:14GE<3P!CC?@88#WX!Q]:Z
MSXE_#VY\:+97%A=0PW5L&3;/D(ZD@]0"01CTKYN1WCD62-F1U(*LIP0?4&M.
M;Q1X@N;=K>?7=3E@8;6C>[D92/0@G%.I0<JBJ1=F*G748.G)71[W\,-&TGPW
M#JMA;:FE]>Q-&U]-'Q$APV$4^V#D^_X54^*^@67B:QLKF/7],LY;0N +NX")
M)NP<;NQ^7TYKYZHI/#MSY^;7T''$14'#ET]3V#X/^/+33(F\.ZM.L,32%[29
MSA 3U0GMD\@^Y]J]"\>^ [;QOI\)6<6][!DP3[=RD'JI]CZ]J^7:TK/Q#K>G
M0B&QUC4+6(=$@N71?R!IU</S2YXNS%2Q'+'DDKH]'M/A);^'?^)IXQUFRCT^
M [C#;LQ,V/X<L >?0 D^U<QHWB'2X/BG:ZS#:1Z?IGVKY8D&!&A!7)].N3CB
MN7O=2OM3E$M_>W-W(. \\K2$?B356M(PE>\W<SE.-K05CZ_U[2XO$7AR]TWS
M@J7<)195^8#/0^_:OGO7OAMJ_@V.VU*]O=.EC^THB)%(Y=CGK@J/3GFN7M/$
M>N:?;B"RUK4;:$=(X;IT4?@#BJ=U>75].9[RYFN)CP9)G+L?Q-9T:$Z4KIZ&
ME:O"K&THZGN'Q.\"Q^)]1DOM#G@DUJ"-1=6(D4.Z8^5L$\''KU'TKG/A9X;\
M7:9XSBD>POK&P3<+OST,:2#!P,'[W..F<5Y?#/+;3+-!*\4J\JZ,58?0BM.7
MQ7XBFB,4NOZI)&>JM>2$?EFG&E.,.1.Z\Q2JPG)3:L_(]@^-/BS3QHG_  CM
MO,DUY+*KS*ASY2J<\^Y../2O"***NC25*-D16JNK*YU?PWU&STOQ]I=U?,J0
M!V0NQP$+*5!/XD5])>)='_X2+PU?:6LPB^U1%5DQD ]0?IQ7R%6I;^)M>L[9
M;:VUO4H(%&%BBNY%4#T !Q45Z'M;-.UBZ%?V5TU>Y[1\._"$/@;Q+)!JFLV4
MFK7L!2&T@8GY 0Q8D@'/' QZ]>VU\5_"VJ>*?#MM#I,2S7%O<"0Q%PA8;2."
M2!W[FOFYKF=[G[2TTC3[MWFEB6W>N>N:T9?%/B&> P2Z]JDD1&#&]Y(5(^F:
MF>'G*2GS:HN&(A&+ARZ,]"^%7@;7(/%<&M7,"06=F\T3$R*Q9P&0J ">A[]/
M3->M>.-$N?$7@^_TNS9!<3*NSS#@$A@<9_"ODVBG5H2J23;V\B:6(5--);^9
MZ1\-O!NM_P#"=17+VRI#I5T4NV,JG8X!^4 ')^HX]Z]V\3:9-K/AC4]-MV19
MKFW>-"YP,D<9KY!HHJT'4:;>WD%*O&G>RW\ST3P=JEW\,?'DMAKB>5#*HBN0
MC!PH/*.,=AGZX)XSQ7M?BCP_8>.O"QM%N4,<N);:YCPX5AT8>HY(_&OE"K]A
MKFKZ7&T>GZI>VB,<E;>X>,$_0$4ZM!SM*^J"EB%3NK:,]@\&_#-_"7C"QO=8
MUFR\[>ZV=M 27F.TYSD#  R>,_6O0_%]G9Z[X:U#1Y=2M[1YDP7=Q\A!#<C/
M3BOE.ZO+J^G,]Y<S7$S=9)G+L?Q/-0U,\/*I9REJO(J&)C3NHQT]31UO21HN
MHFS&H6%^ H83V,WFQG/;..OM6=1174DTM3E;3>A].:A9Z!X@\#Z3HFK7T%O+
M=V<3VN^15<.$&&4'KUZ=\FO$=;^&GBK1;QH?[*N+V+.$FLXS*K#UPHR/Q%<C
M6G:^)-=L81#9ZUJ-O$!@)#=.BC\ :PC2E"3<7N;2JQG%1DMD>O?"CP9?^&9[
MOQ#KZKI\9@,4:3.%(4D$LW]WH!SSUKE_BSXZMO$]]!IVF/YFGV;%C+VED/&1
M[ <9[Y-<'?:QJ>J8_M#4;N[P<C[1.TF#^)-4J%1;J>TF]@]LHT_9P6Y[M\)/
MB!8OI$/AW5+A;>ZM_EMI)6 65">%R?XAG&.XQ6S\0?A?'XONDU*QNDM-05-C
M^8I*2@=,XY!'KSQVKYPK4MO$VO64*PVNMZE!$HP$BNY%4?@#4SP[<^>#LRJ>
M(2AR35T>BVOPEM/#@_M/QGK5G'8PG=Y-LS$S8_AR0#^ !/N*YBU\/W'C_P 6
MWLGAO3(;.Q60,4WA5A0\ D9ZG!.%%<K>7]YJ,WG7UW/=2]-\\A=OS)JO6L(S
M3YI/7\#.4X6Y8QT_$^T-G[K9G^'&:^5_%_@;6?"4PEU".(VTTA6*>.0$,>3C
M'4<>U<O165+#NG*Z?X&E7$*I'E:_$*[+X8^(SX=\:6KR/MM;L_9I^> &/!_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *='(\4BR1NR2(0RLIP5(Z$&FT4 >E^'/C3KNE(D&J1)JD"\!G;9*!_O
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M_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\
M$T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O
M_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X
M R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_
M /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N
M:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\
M]"YJ_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$
M_P#T+FK_ /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$
M.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_
M (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^
M1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H
M]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!
M]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[
M+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*
M/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZ
MYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P# &7_X
MFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG_P"A<U?_ , 9
M?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\
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M+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\
M^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ
M_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T
M+FK_ /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_
M /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[
MQ/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\
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M^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P#
M&7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG_P"A<U?_
M , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S
M5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\
MH7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG
M_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PA
MWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'
M_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\
M$T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O
M_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X
M R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_
M /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N
M:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\
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M?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\
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M+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\
M^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ
M_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T
M+FK_ /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_
M /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[
MQ/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\
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M^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P#
M&7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG_P"A<U?_
M , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S
M5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\
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M?_$T?\+.\9_]!Z?_ +X3_P")H^IS[H/KD.S/J:BOEG_A9WC/_H/3_P#?"?\
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M -_W_P :0S2HK-\A?^>D_P#W_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\
M]_W_ ,:/(7_GI/\ ]_W_ ,: -*BLWR%_YZ3_ /?]_P#&CR%_YZ3_ /?]_P#&
M@#2HK-\A?^>D_P#W_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\ ]_W_ ,:/
M(7_GI/\ ]_W_ ,: -*BLWR%_YZ3_ /?]_P#&CR%_YZ3_ /?]_P#&@#2HK-\A
M?^>D_P#W_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\ ]_W_ ,:/(7_GI/\
M]_W_ ,: -*BLWR%_YZ3_ /?]_P#&CR%_YZ3_ /?]_P#&@#2HK-\A?^>D_P#W
M_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\ ]_W_ ,:/(7_GI/\ ]_W_ ,:
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M7_P%1W^2+=0SJ&EP=K%21M8]1]* +=%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])
M_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])
M_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])
M_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])
M_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])
M_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])
M_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])
M_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C5NR9GL+=F)+&)223R3@4 3T5 [,+^%<
MG:8G)&>,Y3_$T7K,EA<,I(81,00>0<&@">BLWR%_YZ3_ /?]_P#&CR%_YZ3_
M /?]_P#&@#2HK-\A?^>D_P#W_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\
M]_W_ ,:/(7_GI/\ ]_W_ ,: -*BLWR%_YZ3_ /?]_P#&CR%_YZ3_ /?]_P#&
M@#2HK-\A?^>D_P#W_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\ ]_W_ ,:/
M(7_GI/\ ]_W_ ,: -*BLWR%_YZ3_ /?]_P#&CR%_YZ3_ /?]_P#&@#2HK-\A
M?^>D_P#W_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\ ]_W_ ,:/(7_GI/\
M]_W_ ,: -*BLWR%_YZ3_ /?]_P#&CR%_YZ3_ /?]_P#&@#2HK-\A?^>D_P#W
M_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\ ]_W_ ,:/(7_GI/\ ]_W_ ,:
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M;3EF6/;C!5A*H.X9'(X.:[^P^'>BVNG7]I=RW^JM?QB*XN=1N3+,R+RJAN,
M'D8[TMIX"M+?1=2TN?6M=OH;^$P.U[?&5HD(QA 1M'UP34M737D5%VL_,X72
M+^72_$;ZA J-+;>"H9D#@E25Y&<8XXKKXO&5]*W@A?+M/^)]&SW.%;Y<1;_D
M^;CGCG-:5IX'TJTU#[6)+F5O[,72S'(Z[6A7N<*#N/KG'M6=I/POT?2-2TV^
MCU'6+B336<VJ75WYB1JR[=@4C 4#IC!]2:TDTY>7_!E_FB(JT?/_ ($5^:9S
MOA+4]1TSX?SMI4VDQWLNL7,<?]IRNJ']X3A50%G;CH,=SVJ1?B1XAD\,PSQZ
M=IYU<:XNDRQL)4A<D?>4-AT[?>!QZ5T,WPST>32(=/2]U2!H+R2]ANK>X$<T
M<CG+88+C'..F<=ZDA^'.C6]ND$4]\(TU--4 :8,?.4 <LRDD'&3DY))YJ8VZ
M^7X6_P""4_+S_'F_X WQ9_:7_"J-9_MC[)_:']G3>=]DW>5G!^[NYQC'6O*/
M,)\#+X$,C;EN3<D9()MO(^TCU_BXKWK6-+@UO1KS2[EY$@NX6AD:,@, PP<9
M!&?PK!_X5[HW]JG4M]U]H.F?V9G>N/+QMW?=^_CC/3VJ7K?S_1.WXV&M+>7_
M  /TN<_8:QK6F_#KPK#H4NBBZEL$8IJ+2L[JJ#_5QQ*6;KU[<>M9K^-/%NO2
M>";O2CI]I'J<DR3P2[]KR1[@V<#.W R!USUXKKKGX;Z1<P:/&M[JML^E0"VB
MFM;LQ/+%QE'*@9!QSC!H/PXT@:7IEA!=ZC;+IER]S:RV\X21-Y)9-P7[O./7
M'>M&TYN7G^K_ $Z$V]VWE^G^9A-XE\2:U:^+?/L=(;0]--Y:N&,HFFVIE1@-
MC'J<@G/&,4B>,Y_"?@?PSJ;V-J-'N+!(O)A+!XIRF8P"[G*'!!SDCJ377VWA
M&PM=-UNQ2:Y,6L3337!9EW*TB[6V?+P,=,YJH/A_HKP:?;79N+VTT^S-G!;W
M+*T8!&TN0%&7(XSV[ 5"VMZ?D[_\#[_6VU^+_2W_  ?ZMO:2U^^DVKZI]G^W
M-&&F%L"(PQ[+DDX'KGFKE4-%TI-$TBVTV.YN;F.W38DERP9]HZ D 9P..G:K
M]-VOH0KVU"G6/WKK_KK_ .R+3:=8_>NO^NO_ +(M(9;HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *^<_C;_R/R_]><?\VKZ,KYS^-O\ R/R_]><?\VKI
MPG\0YL7_  SSBBBBO3/,"O?/@-_R+.I_]?G_ +(M>!U[Y\!O^19U/_K\_P#9
M%KGQ?\,Z,)_$#X\_\BSIG_7Y_P"R-7@=>^?'G_D6=,_Z_/\ V1J\#HPG\,,7
M_$"BBBN@YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /K'P%_R(
M.A?]><?\JW)K:*=E:0-E00"KE>N,]#["L/P%_P B#H7_ %YQ_P JZ*O%G\3/
M:A\**O\ 9\'_ $V_[_O_ (T?V?!_TV_[_O\ XU:HJ2BK_9\'_3;_ +_O_C1_
M9\'_ $V_[_O_ (U:HH J_P!GP?\ 3;_O^_\ C1_9\'_3;_O^_P#C5JB@"K_9
M\'_3;_O^_P#C1_9\'_3;_O\ O_C5JB@"K_9\'_3;_O\ O_C1_9\'_3;_ +_O
M_C5JB@"K_9\'_3;_ +_O_C1_9\'_ $V_[_O_ (U:HH JFQME&290/4SO_C3?
MLEIC.^3_ ,"'_P :??OY=HQ-<Z]PTC8*<=@#3L!T/V"W/0R_]_W_ ,:/[/@_
MZ;?]_P!_\:QK!&-U'@D?,,UT?04@*O\ 9\'_ $V_[_O_ (T?V?!_TV_[_O\
MXU:HH J_V?!_TV_[_O\ XT?V?!_TV_[_ +_XU:HH J_V?!_TV_[_ +_XT?V?
M!_TV_P"_[_XU:HH IFSMA(L9,VY@6 \Y^@QGO[BG?V?!_P!-O^_[_P"-.?\
MY",/_7*3^:58H J_V?!_TV_[_O\ XT?V?!_TV_[_ +_XU:HH J_V?!_TV_[_
M +_XT?V?!_TV_P"_[_XU:HH J_V?!_TV_P"_[_XT?V?!_P!-O^_[_P"-6J*
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M>K2LXFE@";5#-)'G>JKLRV,'IFI;J6VL=)EU2ZO[J&SBA,\CO$ RH!DDKLW
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M[E2W[L';@-P,5"U_#] 9ZE>M;Z>L+76H3QB:9((SL4Y=CA1PO<]^E6?L+?\
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M92\*-('.W."6)^4@@]\<4[:V$W8]"N(H;2,27.I/"A94#2-&H+,<*,E>I)
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M[NZE33/+C"Q-';SX1<#?D8PVXGD\8Z4>H+5V/3_L+?\ /W/^2?\ Q-'V%O\
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MVX 7(( &5!.$T+PCK%GJ&G6MX-3>*PN9IQ<&:T6V;>'Y7;'Y[%MW*L0.OS'
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M\;?^1^7_ *\X_P";5TX3^(<V+_AGG%%%%>F>8%>^? ;_ )%G4_\ K\_]D6O
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M$;W$AED.XG<QZGD\?A6T*MH2B^MOS,)TN:<)+HW^5B[1116!N%%%% !1110
M4444 5W_ .0C#_URD_FE6*KO_P A&'_KE)_-*L4 %%%% !1110 4'...M%%
M&49W?[_WAP:H7J07"O!/&DD+C+(Z@C(Y'!X]ZVWLHI)2Y+ 'D@=Z#I]JS!C"
M"0,=33N(X^WMKV[ $*$<8VQIM4 9P/\ ')(.#P,\:MOX:<R[YY$1<D[4Y/)Y
M_/\ &NC5510J*%4#  & !2T@2L4H-(L;?E+="W]YQDFK@  P!@>U+10,****
M "BBB@ HHHH **** "BBB@"NG_(1F_ZY1_S>K%5T_P"0C-_URC_F]6* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *%OK-A=:Q>:3#<;K
MZS1'GBV,-@?.TY(P<X/0U?KQ7Q3=75IXY\3M9W=Q:RO/H\9E@D*-M:0@C([$
M'ITJ]J6IZM8/XKL+;4+X6%IJMDLDS7#R2VUM(JF8J[$L!UYS\H)(QBFE=)_U
M_6HVK.QZ'<^*]$M+B\MY[W9+9RPPSKY3G8\Q C' YSD=.G?%;->(O>I:ZIXK
MGT74[B2 ZAHZ1W*7+.SH2H(\S.74@D9).1W-=3INI)+XGO5UW6=0L]8CU4QV
M=A!,^)+;C9^Y *LAY)DVY!S\PQ0EHA/2YZ+5!]9T^._L[$W2FXO1(;=5!8/L
M^_R!@8SW->1Q:U?:CXJT^./4KQ%U"YOK2]L9+V5Y(P%?RU95(2$_*"NU0V/X
MCR3+X0N[JQTCP5::7=3/*;*_\^U-R[J;A$&$=23C!_AXQGH,TNE_ZZC:L['L
MU%>4Z5JUZZ:0UCJ=W=ZA-9RMKT,MR[_96$602A.(&#X 50N1G@XR*OAW4=3A
M_P"$,D.KZC))JFBW+W33323AG1%9'"'/S D]!D]\TVK?UZ_Y;B_K\O\ ,]@H
MKR7P)J]Z]_?6.HZI)>1#3WEGO[+4I+B-&!Y9HY%+P2X)^0$#@_+QQZ5H3V\F
M@:>]I>3WELUNABN;@DR3+M&&8D DD<G(%#7]??\ Y"3-"BBBD,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@"N__ "$8?^N4G\TJQ5=_^0C#_P!<
MI/YI5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY*R,P9$897=A"3V5:R?">MWGB/7O!6JWYC-U/I-[YC1X 8B2-<\=,XHBKO\
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MWLEQ:2SW$-LELD$MK(5#%(@RD2QRC;\V[<N<CCC">@+4]#9E12S,%51DDG
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M#@\BLJBJA24'=>?XNY,ZTIJS\OP5@HHHK0R"BBB@#ZQ\!?\ (@Z%_P!><?\
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MG:S2"-5WX$6V3SBXVC(8'/S<+BNFO]8GM/%HLVN5CM/[*FN2K!1\ZNHW9//
M)]J3T5_ZT5PZV_K>QO+<P/=/;+/&;B-0[Q!QO53D D=0#@X/L:EKQVS\1:H7
MBU$702]U'3-'BGO#&I\KS990TFW&W//'&,D<8KH-5UC6[._T_0[+5+K4WE>X
M\Z[L([1;E#'L(B82L(MV'R?E!P.%'6JE'E=OZZ@>A45YWIFM>(=7O]/BGU-=
M/5;">XG$7V>02M',$4LPWJH(^\%/'(!&*N>#]9U:355L=:OIYI[BS^TQ@QP/
M!)@@,\$L.#Y?S#"R+NY!R>:5A7.XHHHI#"BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KI_R$9O^N4?\WJQ5=/\
MD(S?]<H_YO5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF%[;48[.*:>V8L_E!@1CS#PQRI'4GCGK5.-F_(E.Z3-:BBBI*"BBB@ HHHH
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M23S'50&?&-QQR<4^J5KK.EWUY/9VFI6=Q=6_^NAAG5WC_P!Y0<C\:NTO,-M
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MTDC7[SH[ *ZCN5) S7.1^!KR58Y)E@MY7ODFG']H7-XWEK$Z?ZV;EF^?@;5
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MG9",=0H?VQBNEU/PS>7MUJ<L4EN!=:+_ &='N8Y$F7Y/'W?F'O[4W9+3^O\
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M %%%% !1110 4444 %%%% 'UCX"_Y$'0O^O./^5=%7.^ O\ D0="_P"O./\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %=_\
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MV]SI5C-#*5,D<MNC*Y484D$8.  !Z8I!H&C!44:18!4E$ZC[,F%D P'''#8
M&>N!3>K;_KK_ )DVT2_KI_D<'8>(O$%IHNAZC/J,VHS7VD7-]);M!$JETB1D
M5=B@XR3W.<_05U/A6>ZEBCDO/$46I/=6D5T+<Q1H\6[J5V8)C/0;@3P?F/:[
MJ4FE>']-AO7L(Q%:;((5@A7,2NRIA.FT<KD#L*23PMHK6LEM#IMK:QRW$=S*
M+:!(_,='#@M@<G('/7WIW3;:V_K]!O9%3Q?KDGANS@U0R$6B,\<R;0<LR'RS
MG&?OA5_X%7&Q>,?$46ER0W%W']OTPQVFI2F%=BRRSA%E.   L8+X&!\PS7J%
MS:V]Y"8;J"*>(D$I*@920<@X/H0#^%,^P6?^D_Z)!_I1S<?NQ^^XV_/_ 'N
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M^19TS_K\_P#9&KP.M<)_#,<7_$"BBBN@YPHHHH **** "BBB@ HHHH ****
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M=EK$B2PSP6R2KFV=PK,F8W)&1N7:-K] P!KT]M,T]X;F%[&V:*ZYN$,2E9N
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M^?\ XFC_ (4EXL_O:?\ ]_S_ /$UM_\ "_;S_H 0?^!)_P#B:/\ A?MY_P!
M"#_P)/\ \31S8GM^0<N&[_F8G_"DO%G][3_^_P"?_B:/^%)>+/[VG_\ ?\__
M !-;?_"_;S_H 0?^!)_^)H_X7[>?] "#_P "3_\ $T<V)[?D'+AN_P"9B?\
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M'_XJCS;S_GK!_P!^C_\ %4 7J*H^;>?\]8/^_1_^*H\V\_YZP?\ ?H__ !5
M%ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_ 'Z/_P 50!>HJCYMY_SU@_[]'_XJCS;S
M_GK!_P!^C_\ %4 7J*H^;>?\]8/^_1_^*H\V\_YZP?\ ?H__ !5 %ZBJ/FWG
M_/6#_OT?_BJ/-O/^>L'_ 'Z/_P 50!>HJCYMY_SU@_[]'_XJCS;S_GK!_P!^
MC_\ %4 7J*H^;>?\]8/^_1_^*H\V\_YZP?\ ?H__ !5 %ZBJ/FWG_/6#_OT?
M_BJ/-O/^>L'_ 'Z/_P 50!>HJCYMY_SU@_[]'_XJCS;S_GK!_P!^C_\ %4 7
MJ*H^;>?\]8/^_1_^*H\V\_YZP?\ ?H__ !5 %ZBJ/FWG_/6#_OT?_BJ/-O/^
M>L'_ 'Z/_P 50!>HJCYMY_SU@_[]'_XJCS;S_GK!_P!^C_\ %4 7J*H^;>?\
M]8/^_1_^*H\V\_YZP?\ ?H__ !5 %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_ 'Z/
M_P 50!>HJCYMY_SU@_[]'_XJCS;S_GK!_P!^C_\ %4 7J*H^;>?\]8/^_1_^
M*H\V\_YZP?\ ?H__ !5 %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_ 'Z/_P 50!>H
MJCYMY_SU@_[]'_XJCS;S_GK!_P!^C_\ %4 7J*H^;>?\]8/^_1_^*H\V\_YZ
MP?\ ?H__ !5 %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_ 'Z/_P 50!>HK-FN;R*"
M23S(#L4MCRCS@?[U:5 $2QL+J27(VLBJ/7(+?XBI:A5V-[+&3\JQHP'N2V?Y
M"DNY7AMR\>W=N51N&1RP']: )Z*H^;>?\]8/^_1_^*H\V\_YZP?]^C_\50!>
MHJCYMY_SU@_[]'_XJCS;S_GK!_WZ/_Q5 %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'
M_?H__%4 7J*H^;>?\]8/^_1_^*H\V\_YZP?]^C_\50!>HJCYMY_SU@_[]'_X
MJCS;S_GK!_WZ/_Q5 %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_?H__%4 7J*H^;>?
M\]8/^_1_^*H\V\_YZP?]^C_\50!>HJCYMY_SU@_[]'_XJCS;S_GK!_WZ/_Q5
M %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_?H__%4 7J*H^;>?\]8/^_1_^*H\V\_Y
MZP?]^C_\50!>HJCYMY_SU@_[]'_XJCS;S_GK!_WZ/_Q5 %ZBJ/FWG_/6#_OT
M?_BJ/-O/^>L'_?H__%4 7J*H^;>?\]8/^_1_^*H\V\_YZP?]^C_\50!>HJCY
MMY_SU@_[]'_XJCS;S_GK!_WZ/_Q5 %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_?H_
M_%4 7J*H^;>?\]8/^_1_^*H\V\_YZP?]^C_\50!>HJCYMY_SU@_[]'_XJCS;
MS_GK!_WZ/_Q5 %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_?H__%4 7J*H^;>?\]8/
M^_1_^*H\V\_YZP?]^C_\50!>HJCYMY_SU@_[]'_XJCS;S_GK!_WZ/_Q5 %ZB
MJ/FWG_/6#_OT?_BJ/-O/^>L'_?H__%4 7J*H^;>?\]8/^_1_^*H\V\_YZP?]
M^C_\50!>HJCYMY_SU@_[]'_XJI[25YK</)MW;F4[1@<,1_2@!S1L;J.7(VJC
M*?7)*_X&I:A9V%[%&#\K1NQ'N"N/YFEN9&AM9I5 +(C,,],@4 2T51\V\_YZ
MP?\ ?H__ !5'FWG_ #U@_P"_1_\ BJ +U%4?-O/^>L'_ 'Z/_P 51YMY_P ]
M8/\ OT?_ (J@"]15'S;S_GK!_P!^C_\ %4>;>?\ /6#_ +]'_P"*H O451\V
M\_YZP?\ ?H__ !5'FWG_ #U@_P"_1_\ BJ +U%4?-O/^>L'_ 'Z/_P 51YMY
M_P ]8/\ OT?_ (J@"]15'S;S_GK!_P!^C_\ %4>;>?\ /6#_ +]'_P"*H O4
M51\V\_YZP?\ ?H__ !5'FWG_ #U@_P"_1_\ BJ .3\2>";[6==OKR&:!8+B*
MT*YGDB=9+>1G R@R P8C<&!4@$ TD'A?7[*UEGL&MK:\GN$>>%M4N9S+$JL
MIN959@<G/RQCICG.:ZWS;S_GK!_WZ/\ \51YMY_SU@_[]'_XJCR!ZNYR6@^#
M-4T[4[:ZNIK5UBU*XO#B>25MLD(0#<XR2&SU/3\A+8^'=3TSQ"=1+V6GZ?%)
M+-<?9+N;R[E2"?FMV&R-@3N+JQ)(/K74>;>?\]8/^_1_^*H\V\_YZP?]^C_\
M51=]!61C>%K*]3PA,T;BVN[Z6YNXF=,^4979TR.^ RY%<S>>!O$NJ-<37ES9
M^?+I%QIY+WTTP+OLVO@QJJC*G(5<].6XQW_FWG_/6#_OT?\ XJCS;S_GK!_W
MZ/\ \53O9W15V<WK7A*_U#5UU"VFMD:"WM1"LA;#2PRF3#8'"D'&1DCKCBM'
MP[I>J6FI:SJ&J"S234)HY$BM9&D$86-4P695R<CKC\JT_-O/^>L'_?H__%4>
M;>?\]8/^_1_^*I7_ *]1?\#\#E(O"NMPS:99*^G'3=/U-[U9C(_G2*WF':4V
MX!!DZ[CG':I8?#WB'3_#>B:=8W5MNM%9+N(7#PK+GH5D$;,,=<8&<]1BNF\V
M\_YZP?\ ?H__ !5'FWG_ #U@_P"_1_\ BJ!W//[;X=:Q#I%Q9O<V3-):W4"L
M99&R9+D2J26!)XR"22<^O6MS7/"5_J6MW5[#+;+%+_9^T.S C[/.TCYP.X(Q
M[]<5TGFWG_/6#_OT?_BJ/-O/^>L'_?H__%52DT[DVU;[G*R>#;MM"MK*:> "
M+5KF^E:,L3Y4AF("_+DOB0<>QYK'\*WLM_XF\.VL-QI]Y;Z5I\\#RV3NS+Q&
MJ^<K*/)<[?\ 5G)X//%>A>;>?\]8/^_1_P#BJ/-O/^>L'_?H_P#Q5).S_KM8
M;=_Z\[G/>)_!TOB'6K>8SQ+ISV[QWD+ [I&"L(B./X3(Y//I5/3_  IKVE+I
M.II/8WNM6\4Z7BS2/%%,9F5B5<(Q&W8H&5Y''%=;YMY_SU@_[]'_ .*H\V\_
MYZP?]^C_ /%4EIL#=]SC+;P7K>DB=["?3[B:^M)H;DSN\:Q/)*\NY %;< 9"
M-IV] <]JE7P3J(\/:U8>=:>=?:1;V$;;FVAXXF0EOESMRPQC)]JZ[S;S_GK!
M_P!^C_\ %4>;>?\ /6#_ +]'_P"*IIV#K<Y+4?">N/!J%A9/IS6=]>0WC2SR
M.LD90Q[D"A"&!\O(;(QG&.]6+7PSJ]OXJ%]";.RM?M#RS/:74P%TASA7MF!C
M5LG)D#$G'09P.E\V\_YZP?\ ?H__ !5'FWG_ #U@_P"_1_\ BJ+]0Z6+U%4?
M-O/^>L'_ 'Z/_P 51YMY_P ]8/\ OT?_ (JD!>HJCYMY_P ]8/\ OT?_ (JC
MS;S_ )ZP?]^C_P#%4 7J*H^;>?\ /6#_ +]'_P"*H\V\_P">L'_?H_\ Q5 %
MZBJ/FWG_ #U@_P"_1_\ BJ/-O/\ GK!_WZ/_ ,50!>HJCYMY_P ]8/\ OT?_
M (JCS;S_ )ZP?]^C_P#%4 7J*H^;>?\ /6#_ +]'_P"*J6TFDE$HE*%D?;E5
M(!&T'U/K0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^<_C;_R/R_]
M><?\VKZ,KYS^-O\ R/R_]><?\VKIPG\0YL7_  P^'FI^&)$M=#U#PRNHZG<W
M)5)V"X .,9)YP.371:EXE^&FF:]-I<OA,,()C#),MNN 0<$@$Y(!KR'3-0N=
M*U.VO[-MMS;R"2,XSR#Z=Z]\@N]:OK1=;N/AA9R:G@.LKS1+(W'WL,NX'V/-
M=-:*C)2>WK8YJ$G*+@M_2YY+\2M/M],\;W=O:6*65L$C:**/[I!4?,/KS7I_
MP&_Y%G4_^OS_ -D6O&_%.LZCKWB*[OM5C\J[+;&AVE?* X"X//%>R? ;_D6=
M3_Z_/_9%J:J:PZ3\BZ33Q#:_K8/CS_R+.F?]?G_LC5X'7OGQY_Y%G3/^OS_V
M1J\#K3"?PS+%_P 0****Z#G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ^L? 7_ "(.A?\ 7G'_ "K5NO\ C]@_ZYR?S2LKP%_R(.A?]><?\JU;
MK_C]@_ZYR?S2O%G\3/:A\*"BBBI*"BBB@ HHHH #P#7BT/Q3\4/8RZD;KP:T
M44SH-,^T2I?2!7*[53<?F../K7M!Z&O"[;P=X@30+O1)OAGID]S</,%UF:]M
MPZ;W)5\ %_E!'0YX_"DOB_KN/2W]=CTM/$UZ_P 0K70#;Q1VLVE&];<I\U7W
MA=N<XQCVZ]ZIVOC6]G\>R:6]K NB-*]E!=#.][I$#LIYQMP6 XZJ>:HGP]K^
MF>+K35+>U-^+/PX;-9?.1?.N P(7YFR,XSD\>]9!^$]]9^'(;RVUW69]<MF%
M_'9/=K]D-WG<<)C R21G/?K5Z)KMK^;_ $%NO/3\O\SI=6\?1:!XFUBTU/R4
MT^QL(KB,HI\Z61V8;!S@YP,#'XU))XHUG1O!<NN:_86XO)9%6TTZVR&R[!8X
MW8D@MR,D  <\5F7?@.+Q-X[O=4U_1U:SFTJ*"(R2*QCE.[>  3\P!&&_(TV/
MPQXEU+P'-X>U'9'J&F7"-IM_(ZLERL;!HV8 DC@;3D>_-2MM?Z5W?YV_#8+Z
MZ?UII\K_ (F-HFEWG@#Q$FN:MX=T>U@U286TESI]Y<226YD;(\Q9&*D%MH)7
M&/I6IKGC_75\97VA:'%H2/8!,PZI<-'->EE#;8>B@XXY-37=IXR\92V6FZUH
M5IH^FVUU'<7-PMZL[7/EG<!&JC*@D#[W.#5'QYX:UG7]2N(9_!.F:S"^%L]1
MAOOLLUNN/^6N>7P23@<8[9H>R_K32WZ[@MV=CKFI:W:^&[?4+5+6QNR8A/;W
M<)N-I=E4J"DBC@MUR0<5RVI^/]=TNYUJR>'3Y;BTD2.TD6%U67;&KSEEWG&
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M:]P62TBF\N0AB/D1E\SCC.163I^A^)]4\2Z;?:MHUII<.CV$MM&T%TLINV=
MHP !M48Z'OZU3TK1_'.@>$/#&GV6FK*L E34+-;U(7RS$H?,&[Y1G)VG/2A]
M;?UJ_P!+>A*OI?\ K1?J=)?^-XY+GPM)HDMK=Z?K-VT+S%6)"A2?EY&&R,'(
M_"IO'GB#6-"M-*30X[%[W4+]+-?MRN8UW!CD["#U ]?I7)Z/X+UZQ@\*P360
MSIVLW-Q<,)U8")MVUP2V6SD?[7J*Z7XB>&)?%=KHED+/[5:1ZG'+>)YH3$(5
M@QSD'OVYHMM;O^&G_!*6[OV_S_X!6TGQEJ^GZMJFE^,H]-BDL;(:@UUIGF-$
M(LX(96RV[C/'6M:'XA>%)]'N=6CUJ#[!;.(Y9BK ;R-P4 C+''89K.O_  !I
M6D>"->TSPMI$<-S?6KQA1(2TC%2 "[L>.>YQ46M>&M5/A[PO-IME;SWVB&.5
MM/ED")*1&5*AN0&!/!Z4K_I^NOY!U^_]/S.@T_QCX=U70YM9L]6MY-/@SYTQ
M)3R_]X, 1^(K TWXE:;K?BV.STJ\M;G2!ILMW-,$<2QNC@8(."!@YP5R>U8E
MUX)\0>(M+\3:A>6=KIFHZJULT6G^<)4'D$$"1U&"6Z<=L5;L-(\4:UXR_M;6
M/#\&D6[:-+8XCO$F(8L,;MN.V2,9 '?-'^7Z/];#5OZ]5^ESM$\4:-);:5<)
M>9BU9@EDWE/^])!8=OEX!ZXJH?'?AA?$?_"/G6;<:INV^3\V-W]W=C;N]LYK
MA='T#QH3X/L+_0H+>ST&ZQ)<+>I(TJA"H<* ,+SC&2W/2M#3-#\4:5<R:"OA
M_2KW3'U)KX:K>2K( K/NYAX8RCLV<=*JRYO+_AO^'(N[?UY_\#[S9TWXG^&M
M1U76+'[7]G_LL$RRS*55E4@,P., !B!SR>PK6\.>,O#_ (L68Z'J4=V8<>8N
MQD9<]#M8 X]\8KE9/#FK_P!K>,;2X\/0:CI6K%+F%WOQ")&"JOE\ LIX)#=,
M@>N1:\!V7BZWU&[DUF&YL=*\H+!97NH+?2B3.2PE !"XXPQ)_#%*.JU[?B4]
M-NYWM%%%( HHHH **** (;S_ (\KC_KFW\JTZS+S_CRN/^N;?RK3H KI_P A
M&;_KE'_-Z;J'_'K_ -M(_P#T-:<G_(1F_P"N4?\ -Z;J'_'K_P!M(_\ T-:
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MZ*O%G\3/:A\**/E7G_/*#_OZ?_B:/*O/^>4'_?T__$U>HJ2BCY5Y_P \H/\
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MA<?WAVKF-4\87\.GV5Q:F-6ENO*<,G5::3;L93KP@KLZ[RKS_GE!_P!_3_\
M$T>5>?\ /*#_ +^G_P")J\.@HI&I1\J\_P">4'_?T_\ Q-'E7G_/*#_OZ?\
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M ']/_P 31Y5Y_P \H/\ OZ?_ (FE_M6U]+G_ ,!I/_B:3^U[7.,7/_@++_\
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M:O44 4?*O/\ GE!_W]/_ ,31Y5Y_SR@_[^G_ .)J]10!1\J\_P">4'_?T_\
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M_?T__$T>5>?\\H/^_I_^)J]41G07(M\2;RA?/EMMQG'WL;<\],YH K>5>?\
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M^7CBIJP]/OIY+@<($)P0*W*ZSU HHHH *KWO^H7_ *ZQ_P#H:U8JO>_ZA?\
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M_KYCDK_UZ_U\CAM0N+S2?%<FF6VI7[6QN--EQ-=/(=TDLBR %B2%8(/E^[Z
M5#H\%U<OH+3ZQJ[_ -IW-]#<C[?* 41I"@7!^0C:!N7#8XS7??VY8N+:>&_T
MZ2RFBDE\_P"UKRJ $LF 0RC/)R,<=<U2U7QKH&EZ/>ZD=3M+B*SVB58+A&8,
MV-H//!.>_:B_?^OZT):ZK^OZU.$EUQ9-!L+2_P!2U'[9]GN/(9M4:S69EE9%
M^=/WDL@"CY1NZY*DD53TJ]GU2*QO+N9IKB=]$>60\%F.[)X[YKU5O$.BK=6]
MJVL:>MS<J'@A-R@>53T*KG+ ^U,;Q!IMM%))J&I:9:JLDB F\7&$.#DG&&&1
MN'.W/6A.VX./-&R_K<Y[0+J_NO$"://<7+#0_-^T2,[9GW'$&X_Q_NR2<Y^8
M UVU<_83Z?I=Q=S2:M;3Q7*K=/=W%W'O(8[$&U551'@ *<\G/4\G1CUS2);&
M:^CU6Q>S@)6:X6X0QQD=0S9P,>]+IJ5U+]%5;#4]/U2)I=/OK:\C4@%[>59
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M88CCJL8S]:U]"WC3]KL68,<L1C=5.W0SI^TO[WY?\$TZ***DU"BBB@ HHHH
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MMW&\;AE$,T?#(G)42D9/7'-*?#?B5H[&_9+Q'M+Z:98[=;);UUD0+O?*F!I
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M_P 2^.YN90G))0$D*HZD]@*<?&$4=JKW&CZM;W4DRPP6<L*>9.[*6 1@Y0\
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M_P"OS_V1J\#KWSX\_P#(LZ9_U^?^R-7@=&$_AAB_X@4445T'.%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!]8^ O^1!T+_KSC_E715SO@+_ )$'
M0O\ KSC_ )5T5>+/XF>U#X48NL^);;2+ZUT];6YOM0ND>2&TM=F]D3&YLNRK
MQD=\GL#3/^$KLQ=:);O:WT4NL&00I-!Y;1E%W$2*Q!7@>A_+FN6^*/AG3?$;
M6(NXM:M;RV5GM-4TVT>X$3_W&2/+]@<X X^\.E<U?>'?'&I:'X0M)KJY35XF
MO4>_:)G,<90A#(1]UF7 R3D$]R*E;:]_\_Z_(MK7Y'K[:AMUB/3OLEV=\#3?
M:1'^Y7! V%L\,<Y ] :N5X[?:7=W.G#[#X>O+.,>%+NU^RK;.-D^]?W8XY)(
M)'=ASS6[X7T6?2O&FER0:=/;6TWAZ-;N3RF"O.K* )&[R 9Z\XJK=/ZZ_P"7
MXHF^E_ZZ?Y_@>BTA (P1D5Y%\3-,U/4M1U8P:3=/<P6<#Z9<VUF\[LP<L^US
ME82..%VLWJ> (-=\.WUU%XZOAI-W+?&2RFT^7[.Y<NL:9:+C[PY!*\]0:4=?
MZ]/\RFCTWQ#JFG^&]%GU:\MGD@A*AEA0%CN8*, D#J1WI^J:Y::+-ID5Q'+M
MU"Y%K$Z!=J.5)&[)& <8XSSBO+/%>BWMQ:>*EN]&OK[6;FZ@DL+F&T>3%J#'
M\BN!A0"&RF<GK@]:[KXBV-Y=>"Y9M.MFN;^QEAO;>%%+,[QNK8  SD@$<>M+
M97?=?=86[LNS_P" -'Q*T%E\2%?M)_X1\[;H!5_>'D?N_FYY!'..:ZV)_-B2
M0*5W*&PW49]:\6N?".M1-X4@CL)G75D0:VZHW[IA.+DE_3DNO/K6UK.DZC)>
M:^K:?<R^(9[P/HE^MNS)!%M3&)0-L0&&W*2-W/#9JK='O_E9/\7?T3"_;;_/
M;\OQ1ZE17BOBC2=62S\;6/\ 9=_<7.H7]I<VYM[221)44QAB&4%000?ESGOC
M'-3ZQX>OGB\6WT6DW3Z@-;M9K&58&+[0(@SQ<=,;@2O8'/2DE>W]=O\ /\!-
MV_KU_P CT_Q#KMKX:T2?5;R.:2"$J&6$ L=S!1@$@=2.]:8.0#ZUXUXOT6\G
MA\6)<Z-?7VKW%W"^GW,-H\@%J&C^19 ,* 0V4SD]<'K7LJ<(OTH7PW_K8;T=
MOZW(+C_7VG_74_\ H#58JO<?Z^T_ZZG_ - :K%(#(UOQ%:Z&]G!)#/<WE](8
MK6U@V;Y6 W'!=E48 SR1^=5AXNM%.D)/8:C;3:G<M:QQ7$ 1XW568[P3TPIP
M5W \8R.:Q?B;X?TOQ'IEI::G:ZL-DADAO]-MS.ULX'&Y%RY!]E/3J.M<2?#G
MCBZ\.^';&2_O&O(M5G%KJ4UL[216YA8*\BGE"23C<<C([\4+S!GLEQJ'D:G:
M67V2[D^TASY\<>8HMH!^=L_+G/'K@U<KR*72[R73/#L5MH-W:-:Z;J5O<0K
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MX7.3MAR?U/'2MWH*!I6"BBB@857O?]0O_76/_P!#6K%5[W_4+_UUC_\ 0UH
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M]9^I^#9;3PI###<O<RZ;I5Y;(B0'=.9$XP 3@\=.<YKNJQ?%>NMX<\/S:C'
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MW+_NU"!XBS8C) Z,''3CKF[X8O=2OO&NOO<7:-9_9[1X;?8V8MZ%N"6(]<X
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ME^:!Z;?UH>J]J*!THI %%%% !1110!7O_P#D'7/_ %R?^1JQ5>__ .0=<_\
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MWLHMF1E.IZGAL'.>1GBH6(3V7;\="WA6G:_?\%<\OM;=[N\AMHRH>:18U+=
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M\WJQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45Q?Q
MOKNRN/"@M;J> 3ZY!%*(I"OF(0V5;'4'T-067Q$EN&L)9]'6"RO-3FTP2BZW
M.LB%@&V[!\IV'N"#V(YH6J!Z?UZ_Y'=T5YE=^+M1UN\\)7UI!)9:5>ZN8XI$
MNCNN(U20?O$   )&0,MTYQ5SP_XNE.F:=I^GVL]]J=[)>/&FH7QPJ13,&+2B
M,G'("C;Z#/&::6@/^OQ_R/0:*XOQ'XZN?#]C%-+HZ"?[(]W<6TUZHDC52 0H
MC5RQ]\!?5A6%?^-M3U >*/W/E:1;:)%>P/:W1ANAYB,P(;80K<8_V<#[V>$-
M'J-%<;+XTD@2]6RT_P"UP:1:QS:A++=;'4,F_"#:?,;;R<E!SUJI?_$AH#K$
MUEI*75EI=K;WDD[77EF2*52WRKL/S #H2 ?44[:V$M4=[17"7_Q+MK/Q2FBB
MU@4D0MFZO!;R2K)T,09=CXSR"ZG(( -=?;7-[+J%[#/8>1;1%!;W'G!O/!7+
M':.5P>.>O6E8"Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M %=_^0C#_P!<I/YI5BJ[_P#(1A_ZY2?S2K% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%<I\0M8O]#\-Q7>G3^1.U];1%MBM\CR*K## CD$
MT=4@>USJZ*Y*'XA:9+<(GV'44@;4FTLW+QH(UG!P ?GW88]" 1ZXK+\2^.I?
M)@_L1+I(UUF"PEO3%&T4A\P+)&,DMZC=M ]#0E>UNO\ P/\ - ]+_P!=_P#)
MGH-%<;8>,(H(KI;B>[U&ZDU:XLK2V2WCCD8ISY:_.%*J ?G8KGOBKU_XR@T[
M2(=0FTG5 )-Y>%XDB:$)]XNTCJ@Z<?,=W5<CFCI<=M;'245P:?$/^T]86STZ
MRN/L$VC-J2:@ A*CD [&8< @C'4GMCFKNG>,H?[(TQ1'?ZM>2:?%>7#001HZ
M1L/]8ZEPHR0?E4L>N :=N_\ 6_\ DQ?U^7^9U]%<E<_$/2HIGCM+2_U +IRZ
MGOM$0J8"2,@LZ\C!..OID\47'Q#TB.[M;:V@O;Z2XM([W;;(A987.%;8S!W^
MB!B/3D46?]?UY =;15*+41+JLMB+.[41PI-]H>+$+[B1M5N[#'(QQD5=I %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7SG\;?\ D?E_Z\X_YM7T97SG\;?^1^7_ *\X
M_P";5TX3^(<V+_AGG%%%%>F>8%>^? ;_ )%G4_\ K\_]D6O Z]\^ W_(LZG_
M -?G_LBUSXO^&=&$_B!\>?\ D6=,_P"OS_V1J\#KWSX\_P#(LZ9_U^?^R-7@
M=&$_AAB_X@5W'@WXCS^$-!U#3([ 7!N6+QRF;9Y3%=N<;3GH#U'2N'HK:<%.
M+C+8QA-PDI1W1V?@/X@3>")+X_8?ML=V%RAF\O:RYY^Z<]:@\-^/+S0-0U*6
M6UBOK/4RQN[68X$F2>0>QY/8]:Y.BDZ<6VVM]!JI-))/9W^9V6N>.X[WPZ/#
M^B:-%HVEM)YDT:3M*\K=>6(!QP/R'I6N/BM;SKI-QJ/A>VO-2TT*L5VURRC
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M<X&%4 $]>.:X&BATH.7,UJ.-6<5RIZ'IO_"VX);S3M3NO"]M/K%G&(A=FY8
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M&N!>RJC0M&IY.49MAX^ZX5O;@XCE^(FEVVFWE[=6>H0"VM!?+$Z)OGMR<"1
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MZQERNT-Z#//;-4CXSM+KQ'I.F:;()H[N299)'@D4,J(3F)R KC< "5W"A:[
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MO-.>62V.-LCP21!P1D%=ZC<.>HR*T*&K %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5\Y_&W_D?E_Z\X_YM7T97SG\;?\ D?E_Z\X_YM73A/XA
MS8O^&><4445Z9Y@5[Y\!O^19U/\ Z_/_ &1:\#KWSX#?\BSJ?_7Y_P"R+7/B
M_P"&=&$_B!\>?^19TS_K\_\ 9&KP.O?/CS_R+.F?]?G_ +(U>!T83^&&+_B!
M11170<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'UCX"_Y$'0O
M^O./^5;DUK;W+1M/;Q2M$VZ,N@8H?49Z&L/P%_R(.A?]><?\JZ*O%E\3/:BD
MXI,*R=<T--86TE28V][93?:+6<+N"/@J<KD;E()!&1UZ@\UK5A:[J>H0:EIN
MEZ8;:.ZO?,;S[J-I$C6, GY%92Q.0/O#N><8J2BGJGAC5-=T*[T_4]<C>2X:
M(J8+(1Q1;'#?*I<L2< '+D>@%4/^%:V*>)9]4C_L_P NXNQ>2";3(IK@2#&5
M29\[4)&<;<@DX85SVB>*=1TO3[?2[>-%NI[G4;B6==/N+U%VW3#:(X?FY+?>
M) &.Y-:EEJ6LZEXB?4K:UAL+QM#C>6&^BD^4K-)E=AVL <'#'&,@E3TI_"[_
M -;#:O>/];EJ#X<O!JUK=#5D,%KJDFHQH;3,CE]VY7DW_-C=\IP,#UZU+8_#
MXV5AH%J-5).D7LUWO%N 9?,W_+@L0N-_7G..G-94GC'5=9T35]16UTO^R[:U
MMY?LMU;-*TIEB1\,=X  +?W3GVQDZ[>*=5L_%)M-2CM;'3VG,<7G6TP\Q,?*
MZW )C+$_\LV"GW/<MRZ?U_6A+=W_ %_74IVGPMLQ?W=S?3VCBXLY;23[%8BT
M:99,9:7:Q5WXX*J@SDX](T^%<"Z!J6F+<Z= ]U9_8TGM-(CA95R#ND(.Z1S@
M9^95/7:#1I6H:O+:BUT_[)#->6LNL7$EY$SEEE=MD8"LNTA0!N.<8'RFL;0O
M$=[I/ANPCL+/3_M*Z5I"+-+$=S>=*T9#L""57J!V)/K346]/Z_JY7F=Y<>%_
MM+7+/><R:7_9T7[K_59SN?KSGY>./N]:S?#_ (!_L*^CN?[3\_9HT6E;?(VY
MV$GS,[CUS]W]:P[B[U^/4O%EE?:I!<22Q6EG MO;/$$>;*AE5I'QC<2?7&<C
M%1Z%)J&D:[?V=H-,:_O]4>SBNGM''DQ10A\-^\RX P%3*X.XYYP%\7S7^?\
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MHHH **** *[_ /(1A_ZY2?S2K%5W_P"0C#_URD_FE6* "D90RE6&01@BEHH
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MX^5QQQR&&/\ 9]ZT* "BBB@ HHHH **** *[_P#(1A_ZY2?S2K%5W_Y",/\
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MI%E8Q7UUJEE!9RX\NXEN$6-\],,3@YHNM;TFQFMH;O5+*WENO^/=)KA$,O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?.?QM_Y'Y?^O./^;5]&5\Y_&W_D?E_Z\X_YM73A/XAS
M8O\ AGG%%%%>F>8%>^? ;_D6=3_Z_/\ V1:\#KWSX#?\BSJ?_7Y_[(M<^+_A
MG1A/X@?'G_D6=,_Z_/\ V1J\#KWSX\_\BSIG_7Y_[(U>!T83^&&+_B!11170
M<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'UCX"_Y$'0O^O./^
M5=%7.^ O^1!T+_KSC_E5_5=,NM0GLI+?4Y[-;>7?(D8XF']T\C^OTKQFDYM-
MGL7:A=*_](TZS-9OM/TQ+:[O(1+.)?+M$2,/*TC#&V/T)&<G(&,Y(&:TZY?Q
M;IUU+J&@:O;0RW"Z5>&6:"+EVC:-D)4=RN[..I&<<\5'5&AJZ9J\FH3207&D
M:CITR*&VW2(58'N'C9T)]MV?:EUW6K;P]I$NI7:2O#&R*5B +99@HZD#J1WK
MSS7)_&&MR:[#X>GUHZ<^G.8C?62VI6<NIV192.3&S< 3GD]:SWT34G\*:Z+2
MUN3!,;,164&C2648=9079(FD9R<?>.T XR">::5_P_- ]/Z\CV6L+3/%>GZK
MXAU?1(4GCNM**"8RJ CAAG*$$Y XSG'6I=,BLDU[67@TV[M[EVA^T7,JD1W)
M"?*8R20=HX. .:X74]*UF'4M9O=.LKGS[W5'L6948?Z/-#"IF''(1DSGI]ZD
MM?N_'H#_ *_4[CPWXDL/%VE2WUC%,+83/ 1.@&_;P2 "?E.<CV[5=T[1],T=
M)$TS3K2R21MSK;0+&&/J=H&37GDNG"QLI+&Y\.27=@=6N"HEM9IXD4*HC)A0
M'S >Q(VC&<@XJIX7\,S7L^B6NN:/+):VUOJ4;17-JRQ*#<)Y:[6) 7;RJDG@
M<$XS36JNNWZ KVU/6Z*\6U#3[^[\*Q65UX<N9M3CTI5M;FYLY[EQ(-YPG187
M&%^8LI.1][ !E\1VFW1M:N-<TN\N+^6.W?3[IK9V\F+RXPRF3&(R'#[E)!;/
M0T)782T1[)17D]QHVK-XMN9)@ZWSZDLMM=1Z/+-*MN"I"BZ\U8T3:"&0@=_E
M8D9GT?PA 'T%[C16+7%S?+J)E@/[R(M(R++D<IG:0&XZ8ZTEJKB;L>HT5XY+
MHFIBTTI;^T9M-@MYX8H+G2)[_P J03-M/EQNK(?+VA7(( '49YNOX6N;J'5F
MU.QNKVZA\.VZ6TUQ;_.;A?.(*X9AYH^7[K$C/7FCI<J*NTOZWL>EVVIVEY>W
MMG!)OFLF5)UVD;&90P&>_!!X]:MUP_@K2_[/\2>()I].:"XN_LTPG-L5\P>2
MH?Y\8)WAB5SG)R1S6->Z7=/J%\ITN\?Q,^JK+::D+=RB6OF*0!-]U4";@8]P
M).?E.<T[:I?UO;^O(5]&_P"MK_\  .^TO6H]6N;Z."UN4BM)F@-Q)L"2NIPP
M4!BW!XR0/;-1ZI9Z-8&X\176EVLEW9P-(;E;=#.%522%8\],]ZR?!^B1Z7IF
MM1PZ;'9//J-T5"P"+>FX[#T&1CIVQTKCEM]0N/#^CZ:ND:FL^GZ#>VEQOLY%
M43>4BA%)&'R0<%<@]C4OX;K>R_(N,4Y6>U_U1ZS;3K=6L-P@(25 ZANN",\U
M+7FL6FQQZ^9=;T34+Z<QV?\ 9<MO Y-N%0!U\P8$1#9+;F7<..>E9VA:)JT.
MM6[7*2)J:33->S1:-*KSH0^!)=-+LD0Y7:%!(XPHP<5+1NWG^O\ D9QU2OY?
MH>MU#=W4-C:375S(L<$*&21V/"J!DFO)6\*6EKX,\-^;H\T=S]CS<))H[WL3
MS%%SY\2$2"3@A7_AY&1P#U>M_:O^%5 W-HUK)';PM<6[2-(4C5U+@LQ)/R Y
MR2?4TY1M=>=OQL/L=797CWD:R-97%NK1I(IFV G<,[<!B01WS^&:M5YSX@TB
MXU'Q'>'[%<2VDU[I;;TC;:R*SESD=AD9],\U4N=#FM);NU_LJ<^'+?75EEL(
M;9F1[<VR_<B4'>@E.2J@C(/'%*U]=A)[GH:ZK VNR:0$D^T);+<EL#9M9BH&
M<YSE3VJ]7E5]I,LT=VVD:'J5O9+I]N8()HVWX2[:0JH))!VC(3@@$# Z5/J,
M=SJ^K:K?#2M2?2'GL3<126<B-<P*LF\"-@&8 E<IC) /!R,H<M#NK76X[W4+
MNSM[2Y=K.Z%M._R!4)C$F[ELE<,HX&<GICFM2O'XM'F-S,^FZ)?6UBVM2RP1
M-9O'MB.GE P4@%5W?*!@8.!P>*GD\,ZC8:9I\>A:?<6MW<>')([IXU,;23+Y
M.U7;C]YCS I8Y'/I5<J![V/6:HZOJL&BZ<]]<I(T2NB$1@%LNX0=2.["N,\)
MQZ7%X^OETC2YM.M_[)AS%):M;Y;S7R=C 'ZG')YR>M9GB72C+>:N+G1+Z[U:
M74K>6RNXK5Y ML&BR!( 0BC#Y0D9ZX/6DEJOZZV#O_72YZ6JI?6Y%U9%5$G$
M4X1LE6^5N"1V##N.. >*B758&UV32 DGVA+9;DM@;-K,5 SG.<J>U>:O82?V
M?%9:CX;>Z22[U!HY+JRFN8T=[ABF85XY4[@[%0!T89S5;2[)H[6Q&OZ!J]V3
MH4=N%^QRR;9UE<A2!G:P^4AC]WKD9S2?]?<5;6W];GL-9\&L6]W=7%O9I+</
M:W(MKG8 !"Q0/D[B,C#+]W/7ZX\JU#0?$#2*-7#S7C:?;1VDZZ3+?212A,/Y
M<J2HL+[^2S8!XRQ Q6A8Z!/8^)KC9I4J3OX@ANGN$LBJO$;8@N7 VX\S?D9.
M"W/WLFK?U\R>AZK6;'K,<WB"?2(K:X>2WB62:<!1''NSM4Y;<2<'H"..2*Y/
MP18065U$MWHM_'X@5)5U#4&A=(Y26R"TAPLN>-N-VT<?+5'7_#TG_"0Z]?VN
MCNR2R6+7#V\&)+F ,3,BL,%\@+N4$DX YXJ>J_KM_F)_U^/^7XGIE5+G4K6T
MOK.RFDVW%XS+ FTG=M7<W/; KS232I3<236>CWD?@_[=$\NF"S=#(@B<.RV^
M WE[S&2FWYMI.#GDL-!*>*M'U)]%F328]3F^P1R63%[6)H5"?)@M$GF!B 0
MN1TII7:"3LG8]6HKA/'=LM_?1VDV@"_5K5Q!<36DMW$LI.,>6GRJV.=[%>N
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M>Y@CN([=YHUFE#&.,L S@8R0.IQD9^M2T %%%% !1110 4444 %%%% %=_\
MD(P_]<I/YI5BJ[_\A&'_ *Y2?S2K% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M $__ (#/_A7S311]3AW8?7)]D?2W_"X_!G_/]/\ ^ S_ .%'_"X_!G_/]/\
M^ S_ .%?--%'U.'=A]<GV1]+?\+C\&?\_P!/_P" S_X4?\+C\&?\_P!/_P"
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MI/\ FG_Q5'VYO^?2?\T_^*IM% #OMS?\^D_YI_\ %4?;F_Y])_S3_P"*IM%
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MYV/VYO\ GTG_ #3_ .*H^W-_SZ3_ )I_\53:*0QWVYO^?2?\T_\ BJ/MS?\
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M_P"><_\ WX?_  JI.Z7]=6)$M%1>>O\ SSG_ ._#_P"%'GK_ ,\Y_P#OP_\
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M ,\Y_P#OP_\ A0!+147GK_SSG_[\/_A1YZ_\\Y_^_#_X4 2T5%YZ_P#/.?\
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M_P#0&JO<,8[]V*2%6B0 K&S#(+>@]Q0 ^BHO/7_GG/\ ]^'_ ,*//7_GG/\
M]^'_ ,* ):*B\]?^><__ 'X?_"CSU_YYS_\ ?A_\* ):*B\]?^><_P#WX?\
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MZ#G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^L? 7_ "(.A?\
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M.6/:Y3$B;2<'&1[>AJ6AJP!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?.?QM_Y'Y?^O./^;5]&5\Y_&W_ )'Y?^O./^;5
MTX3^(<V+_AGG%%%%>F>8%>^? ;_D6=3_ .OS_P!D6O Z]\^ W_(LZG_U^?\
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M<MC #;L9XQVQQ]: +GVNS91%N785/!0[0!D<\8 X.,]<<5,)K>1U DB9L_*
MP)SCM^!_6JDNE"2(1I<S1ILC0A,?-L.1DX[]".XJ.VT*WM;J&XCDEWQ)L )X
M/+'./7YB/RH T]JABV!N/!..:6BB@ HHHH **** "BBB@ HHHH KW'^OM/\
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MP\+"PV"TG,WVGSL[LECC;MX^]USVK4OOB==S:GX>U"RL%MIM'@,.&F\Q9@0
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M.1WJ[_PC]]KVHW5Y<:6VBQG319QH[Q.[2JX=)!Y98;4(&W)SR>!3:2?]>?\
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M)?#'B"?2[R&+3;E8DCMA%#>O:M<'RIE<1QRQD;HPH;'FD')'3FBROO\ U?\
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M81VC6MQ;WMM/<1W9N0L($84Y+ $;3N^]VQT-7_[:TU+JVLIM1LDOKA \5O\
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MG_D6=,_Z_/\ V1J\#KWSX\_\BSIG_7Y_[(U>!U>$_AF>+_B!11170<X4444
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M^O/))YINUY?@)7Y5W(].\;66HSP*+#4(+>XFDMX+F:)1')*F[<@PQ;/R-@D
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ME%C\.&L3+Y6L&'>;MD-I:B$Q&=$4E,-@;2F1QW]1DQM\-KB5KR:36+:.YNK
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M < DXW9X(R*S_KU_R_$IZ'9ZOK<&C6,-Q/#/))/(L,-M$%,DDC=$&2%SUY)
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MU"]N8]06W6\L%LID: N?E<NK*=PQU.1@YXZ4S7? UMKU[?W%S<(5N8;9%B>
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M!XLQ*S E"0W))SD_6FZKX/\ [2U6[U%;\P3R1VH@(BW>5) [NK'GY@2^"O'
M///%O0=#N]+O-4O;[4([RXU"5)',=OY*)M0)A068XXSR?SHT'T*T?B73[_4S
MLTB_N(K62:./4$M!)&LJ B15VDN#P5SM )X!)XJ*;QW:6<=ZVH:5JED]K:_;
M/+FCC+2Q;MNY0KGG)'RMM//2FIX1U"WBO+&R\026>EW#SRK%!;@3(\N2?WI)
M^4,Q8 *#G'S8K+_X5M-+)=S3ZK:B:ZL#92-;V!0'YU8.29&8D;<<L>O&.A2Z
M!+K8T9?$^G6^H27;>&[_ /M&*V5[QT@A::VMRS;2[!^0=K,$4LW^R*W=1UVS
MT[28]18O/%,8U@6 ;FF9R BKT&22.I ]2*P/$'@&UUK67U-5TQIIH4AE_M#3
M$N]H7.&CW$;&^;ON' ^6KOBC3HU\,01Q1W1:QEAE@:SMED:-HV&&\H8W*.ZK
MSC(49Q1I8-;E9O']JDYM&T;5A?"[6S^R;(M_F-$90,^9MQM'7=C\.:L1^-;%
M[E5:SODM&N!:?;F1/)$^[;Y9PQ;.[Y=VW;GC=6%X=T#4=4UR;7;^>1!'J2W4
M1DLFMS.HMC"<1.V^,98XW9/R^^:U!X)D#_8_[3']B?;O[0%G]G_>>;YGF[?-
MW8V;^<;<]MV*I):7_K^E^(/K8OQ^+K"2VTVX$-SLU"XEMH@57*M&)"2WS=/W
M;8QGJ*BT/QG9ZZUELL-0M([Z$S6<MU&BK.  6"[6)! /\0&>HR.:SE\%7EO+
M9?\ $X62QTZYGNK>V%IB1C(L@*L^_G!D."%''!SUJ/P/X;U&+1O#MUK%V2;"
MR5;>S-J87A9D ;S"6)9@,J.%QDY!/-"2L#V':QXIN=,\<-;7/VZ#2K6R28B%
M(66XDD<HJG),G)PH"A3NSGBM%_&UC!;W)N[*_M;V!XD-A(B&9VE.V,+M8H=Q
M!&=V!@YQBC7/!\>MZC/>/>-"[V\,<6V,$Q212F5'R3SSCC';KS56X\$SW[7%
M]?ZJCZS(]N\5S#:^7%"86+(!&7)(RS;LOSG@BICMK_6HWOH:MIXEAN;RSLY=
M/O[.ZNO.Q%<Q*I3RMN[)#$$'<,%2P/K6:OQ L)IHXK33=3NY"C2R)!$C-$@D
M:/<5WAGY1N$#' Z"IYO#FL33V-^^NQ-J=J\N)&L1Y/ER !D$8<,,;002['/7
M(XK'F^'-Q-H]MIDFK6EQ#$'R]UIBR2([.S^9"X<&-_FQD[AP" .<B\Q&Y=>,
M;&UO9X3:7LEM:RK!=7J1KY-O(P!"ME@Q^\N2JD#/)%9VK^,9&N;*'3+>\6%M
M6BLI+WRT,+G?MDC&26'0C=M R.#FHI_AM92:Q+>+_9LB3RI+,]YI<=S<AE51
M\DK'Y0=H)RK<DXQ5E_!ET+B&*#5TBTN+4AJ2VQM=TF_>79?,WXVEB2/ER/4C
MBFK75Q2O9V.OHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYS^-
MO_(_+_UYQ_S:OHROG/XV_P#(_+_UYQ_S:NG"?Q#FQ?\ #.0\*6,>I>+-+LYK
M?[1%+<HLD6[&]<\C.1VKO_%'Q%U/PS>W7A_0]&L-#6 [6,061SD9!R/E!P>X
M)KSC0KZ+3=?T^^FB>6*WG21D0X9@#G ]Z]VU2\T_4$AU75/AO<2-<ND22S^0
M)'9N%!!;=Z#D5UU_BBVKK]3EP_PRL[/3_@G@5_J%WJEY)>7US+<7$AR\DC;B
M:]S^ W_(LZG_ -?G_LBUY!XQFLY_$]V;'2GTN%=J?9'4*8V  .0/?FO7_@-_
MR+.I_P#7Y_[(M1B'>C=*VQ5!-5VF[[A\>?\ D6=,_P"OS_V1J\#KWSX\_P#(
MLZ9_U^?^R-7@=7A/X9&+_B!11170<X45K>&%T]_%&F+JI46!N$$V[IMSW]O7
MVKZ$U;4?$.G:F]LWA6VU'PGY>W%BJO-MQ_SS+ 'Z ?CVK*K5Y+*V_P C6E2]
MI=WV^9\RTH)5@RD@@Y!':NRTCP:GBS7=7EL)3I>B6;M))->+\T"9)"E0>2 #
MW[=:36_ D=GX='B#1-9BUG2UD\N:1(6B>)LXY4DG'(_,=J?M8Z)^7XB]C)WM
MKO\ @1Q?%#QI#:K;)KLOEJNT%HHV;'^\5W?CFLK3_%>N:7)?R6FH.LFH*5NG
M=%D:4'/4L">YY%>J>,?#/_"6^*_"^D_:_LGF:5O\WR_,QM&>F1_.N&\.^ /[
M?O\ 7[7^T_(_LC=\WD;O-P6'3<-OW??K6<9TN5MJV]_1.QJX5;I1=]K>K5S#
MA\4ZS;Z-%I$=Y_H$4PGCB:)&V.#D$$C(Y[9QR?4U;3QWXE379M;74L:C-#Y$
MDWD1\IQQMVX[#G&:[B?0?#\7P/M;H:A%#--+YK7(M&+33 /B$]P <KNZ<9[U
MG>(O"WB#5Y/"&FMJJZC)>66ZV1[=85MHPJD@LN2P [GGCWI\\')IKJU^&OY?
M<+DG&*:?2_X_\'[SBK'Q)JVFZ9?Z=:7?EVE^,7,?EH?,XQU(R.O;%95>BR_"
MZWG-_::+XFMM2U>P7=/9"W:,\=0K$D,0>/KUQ572OAW;7O@V+Q+?^((].MC*
MT<JRVQ?8 Q7C#98YQQCO5*K3W7E_P"72J/1^?^;.$HKT"_\ A7=P>(=&TZQU
M2"\MM51I(;ORR@"J-Q)7)['(YY]J@UWP'I.EV=^UKXNL[B^L3B6SN(#;.W^Y
MN;Y_P&#ZT_;0[_UM^8O8S[?UN<-1116AD%%%% 'UCX"_Y$'0O^O./^5=%7.^
M O\ D0="_P"O./\ E715XL_B9[4/A04445)0A. 3Z5P<7B_7?^$9/B9[?3I-
M/N%Q;6R^8DL3-((X][98,#G+8"[>G-=[6"/!?AX2SR-IRR"=75HY9'>-0_+[
M$8E4W'D[0,T=?Z_K_(# U7Q9K^B3S:;<)IMSJ -H\4\<4D<3)-.(F5E+L01V
M.XY].,5*WBG6HK^31'&GMJ1U!+..[$+B$*T)FW-'O)R ",;^3W%;D/@_0X(&
MB%I))ODBE:2:YEED9HF#1YD9BQ"D9 SCVJ>[\-Z3>FZ:>U)>ZD261TE='WHN
MU65E(*$ 8RI%/09YS#J&I6MQK,!%@-0>;4G^V+"Q,3)##S'\P*@YY&3T')QS
M;TOQ/J&G06D#6]C<:C/IVF1I=M$R,[3-(H\QMQ+*H&<9Y)/3=QVEIX0T*Q;=
M!8D-F4DO-(Y8RA1(3N8Y+!1G/]338_!F@1VDEK]A9XI(([<^;<22-LC9F0!F
M8D%2Q((.1QSP,$7;<FQS\_BOQ!;Z_!X=(TQ[]KQ(7NQ!((C&\,D@81[\A@8\
M$;CD=QGAL_BSQ(--22*UM@8+FYMKR\BL9KF-6B;:I$,;;P&Y).6VX[]:Z>U\
M*Z-9O!)%:,9H)S<K-+/))(TA0IN9V8LYVL1\Q.!]!3+CPAHESRUM-')YLDWF
MV]U+#)ND.7^=&#8)QE<XX''%#V*5C0TF]&I:3:7H>!_.B5RT#EHR2.=I(!(S
MZ@'VJY4-I:6]A:16EK"L-O"H2.-!@*!VJ:AVOH2M@HHHI#"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O>_ZA?\ KK'_ .AK5BJ]
M[_J%_P"NL?\ Z&M6* &3316\+33RI%$@RSNP50/<FECD2:-9(W5T895E.01Z
M@U#?6-MJ-G):7<0E@D&'0DC/XCFGVMM#9VL5M;QB.&)0J*.P%/2WF3[W-Y?C
M<=++'!$\LKJD:*69F.  .I-</;>.K^YT+7]3.GI MC?)! )<C; RQGSI>>@5
MRY'& ,'!R:ZO6])37-)FTZ2ZN+9)<;I(-F[ (./G5E(.,$$'()KE(O ^J1QZ
MSYNLO>-=:C;WL N!& _E",XD\N-<%BFW@$ !3C.<BMK?^M5_P2^G]>9M>$]=
MFUR"^,D]G>1VT_E1W]B,07(VJQ*#<^,%BI^8\C\!6T_QK9OJ^H:=J$@AEAU$
MV<+)!)Y?*J5#R8**Q+$ $C/&!3K3PQ+>37]YK#R6\UY,DI@TS4)XUCVIL&9$
M\MG)ZG( Z<<9JK<>$+R33K^U2: &XUF&_0M(Q_=(\1()QG=B,^O;FA;Z_P!;
M$OR_K1FQ!XMT2YOC9Q7N9=SJC&%Q'(RYW*DA78Y&#D*21@^E./BG1ELK6\-Y
M_H]U:O>0OY3_ #1(H9FQC(P"#@\^U<[9>#]62WTG2;F:R&EZ3<&:"XB=S/.-
MKA59"H"8W\D,V['09JFG@OQ"^FV.G3R:8L&GZ5<Z=$Z2R%I2Z*B.P*#;]WD
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M(YEG5HF525*@*1GD9/KGM5WP;I6J7-KX=U+4?L<<-CI@BMUMG9FE\Q4^9\J
MN H^4;N><]J:LQ-V=C0E\;V%KXGU32;Q9+:*PMH9FN7BDVNTC$;1\N">% P2
M6)('*FMG2]9L-9BE>RF9C$VR6.6)XI(VQG#(X#*<<\@<5R^O>$-3O_$USJME
M+:!72TDC$SL,2V\CL%8!3E6#D9SE2,X-;.A:3?V^J:GJ^I_9DN[_ ,I?(MI&
MDCB2,$#YF"EB=Q).T=AVS0K6&]]!DGC+17^UPPZAY<L,<S"62UE,1\L'>5;
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MQT<7A;1XK&XLQ;2-#<RQS3>9<2.SN@0*2S,6R/+3OSCGJ:DF\-Z3/I\]C):
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MVEQ(8I-Z[=VV0MOP<;>5P,_WA4T?BG59M-"/=Z1:W\=U<6\CM!++YGE-C='
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MVWB'S*S_ .&#X\_\BSIG_7Y_[(U>!U[Y\>?^19TS_K\_]D:O ZUPG\,RQ?\
M$"BBBN@YS2\/RZ7!KMH^M6S7&F[\3QJS*=I&,@J0>.O7M7M&CVOAO1-7CU/2
M_B,EOHRG>-*-R&&/[N&<G'_ =WO7A$,,EQ/'#"A>61@B*O5B3@"M:X\*:U::
ME=Z?/9;;FSA\^X7S4(B3 .2P..XXSGFLJL5+K8UI2:VC?^O(]+T_QAX?US4?
M&&DS7::=:ZRV;6ZE&U,A=I+>F< \X[UF7=YI?@[X9W_AZ/6;+5=2U.;<WV&7
MS(XE^7DM]%]CS[5PD'AG6+F?3H8[,^;J0)M$9U4R =^2,#T)P#VJ&31-1AUW
M^Q7M\:CYP@\G>OWR< ;LXZGKG%0J,/A3[:?X?ZU-/;3^)KO\K_UH>QW7BK1+
M3XA>%+QM3M9+6/33!-+%*KK$Q& &QG'/KTI_AY-!\.ZAXLN9/%6C3G4E=X(X
MKI3A26(!).-V6Q@9Z>]>5S>!?$ENNI-)IN!IBAKO$\9,0*[@>&YXYXS4&G^$
M==U71+G6;+3VET^VW>;+YB#&T9. 3DX![ U#I0<7[W2W3J[E1JS4E[NNG?HK
M'9PW&G:Q\$X=)75].MK^QN7G>"ZG",X!<X4=6)W#&*WY/&>CZ/K7@B[:]@G@
MBTPV]T8)!(8"RH/F"Y(((Z=>M>36_AS5;K0;G7(;7=IML_ERSF1%PW'&"<G[
MPZ ]:U[3X:>,+ZQ2\@T24PNNY2\D:,1_NLP;]*N4(7;D^M_O5O\ @D1G-I)+
MI;\;_F=YHP\/^"O$>L^*7\3:=?0S))]EM;6;?,Y=@V&4=,8Q^IQ6)J&LV-U\
M$XK7[;;?;WU!I6M1,OF %V.=N<XY]*X.ST/5-0U8Z5:V,\E^&*M %PRD=<YZ
M8]ZU-9\!>)_#]B;W4])DAM@<-(LB2!?KM8X_&DZ4%:\NUMMEL4JLW>T>]]]V
MCO-7UC39;3P"MOXFAT^>UM-LES %G-L_EH,.@;@'D'/Y=:V=8\16,GA;58?%
M.L^&M9'E%;#^SSNG9R#@LO.PYV].G/->26W@OQ!>66GWD&G[X-1E\JU?SHQY
MC\\8+9'W3UQTIDWA#7;>/4WDL>-+8+>;948Q$]. V2/<9%$J4'HY=7V[_AO8
M(UIJS4>B[]G]_P#P#$HHHKI.4**** /K'P%_R(.A?]><?\JZ*N=\!?\ (@Z%
M_P!><?\ *NBKQ9_$SVH?"ALL@BB>1@2J*6.!D\51T76+?7=.%[:I,D98KB5=
MIR/Q-:%%+2P-2YDT]!&4,I4YP1C@X/YBN!TS1H5^(>K6?V_66MK.SM;B")]8
MNV4.S2[B09#N!V+P<CCIR:[^LZ'1K:#7KW6%>4W%W!%!(I(V!8RQ! QG/SG/
M/I2_R970XSPUXJU*+PYI4>JV+21WEK,8;K[:S2R-&K,=XVY7(!PP9CZ@59T[
MQZTFH:=IRZ;%%'/%!M%UJ.V>0.BL6B61?WRKN )W[B0?E/?;3P?I\>GZ99B:
MZ\O3DDCA)9<L'0H=WR\\,<8Q5<^![1H[:V?5-4>PA$/^A/*C1.8@ IY3<OW0
M2$902.G)RU:^HG>[L7=<UVXTZ]L=.T^Q2\U&]\QHHY9_)C"( 69G"L1U 'RG
M)/:LZX\6ZBLMQ%;: 9)K&V2YOXI;M4:+<"=B;0P=\*3R5'3YN:U]9T*+5Y+6
M<7=S97EHS&"ZM2F] PPP^=64@CU!Z#O6=<>"K28DQZIJL!EMUMKIDN S7<8S
M@2,ZL<_,PW*5;!Z],+6W]?+_ ()6E_Z^?_ ,V7X@S,;FYL]&%SI=NUKON/M0
M21EG5"I5"N"1O&06'U/2I)O&VHPWPTS^PHFU,WXLO+6^_=?-"95??Y><8&"-
MN1SC/?4?P=IC6U[;(T\4-V]N[(C !/)"! N1P,(,YSWZ5E^(/"$UYKUA?6$]
MW"\NHBYNIXI(P8 MN\:L@8$'G;D$-U/&*:M?R%T\QZ^,[Z>]LM.M=&B;4)99
MX;B.6\*1P-%L+'>(R64AP0=H/3('.,M?B?8ZB7MX7LD6Z$T5L8=15[E756(:
M2$#* [3@AB>F0,UU%AX4L;"[L[M)KF2XMS,S22N"9GEV[V?CK\HQC '3&,5#
M!X2MX&>"+5=3%B ^RP691%%O!!QA=Y')PK,RCL.!B9*Z:]1IV:9@Z7XZN-)\
M/6<FO6#(O]C?;XYTNO.DF5%0-O!4;7)=2.6!R<D4L?Q/@>TO2EO87=W;QQ2I
M%IVII<(ZO(L>"X4;7!89!&.F"><;TO@[2;J*U@G:>6*TT]]-"%P-T;A,EL '
M=\BX(QUI7\))<6<UM?:SJMZLACP9I4'EA'#@ *@7J!EB"Q'>M)-.3?\ 6_\
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M:1::=#JW]DP6.CI>K((XV\]B\@.[>#\B[1G;@_-]X5Z1_8^F?VF=3_LZS_M
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M0VUA8S"=;6&$*C, =G P  3NQCJ!Z4T[/[@_X)KT444@"BBB@ HHHH ****
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MY*W]:_YBMI_79_H<U9Z4819GQ'H=]?::(+A;>W6SDF\JX-Q(VXH 2I9"NUR
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M:)+I\65N%,C".21F)V_>8*%P <G!Q?U+0H=.\8QRZ7HDCR)<0>3"VFNJ1Q@
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M%608CCVGIAS,<8&-JU7\9Z)=S^*[B]TW3W-[/HLL%O=0P'<)0X)7S0/D8IN
M)(ZX%7]+\2:9_P )!K4%J)+9UO[>%[FYCGF%R9 "%0M@(/FPH!V@?-C!K=C\
M7:'+=R6R7I+IO&\PR"-R@)<)(5VN5P<A22,&IZ)_U_5OR\Q=6O3^OO\ S,/P
MK9PQ^)I;C1=*NM,T<V02>*:U>V$ESN!#!& )8+D,^.<CDXK%O=+NGU"^4Z7>
M/XF?55EM-2%NY1+7S%( F^ZJ!-P,>X$G/RG.:Z:[^(.B1Z+>ZA9R3736]D;V
M.+[/*GGQXX9"4^9<D LN0N><58@\;:*ZVBSSRPS3I$S!K64+$TGW5D8KB,D]
M Y!/'K5:W]/\[_I;TT%T]?\ +_@W]=3B[;P7:1ZIIL\?AJWCE7Q#=NTOV!05
MAV2F-B=OW-VP@],XQVK+M- UI;"9)(IAJ@L;E;\P:+*CW+-$P DN6E*S98@K
ML5CT&%&:]=U/5[+1X$EO977S'\N-(XGEDD;!.%1 68X!. #P#6<WC30%T^&]
M^VN\<S.J)';2O+E/OYB"EQM[Y QWQ4_9M\B[N]_G^I)HV@:?:>%H]+2PB@AG
MMP+B,)M+LR ,7[ECW)YKB[G2M:O;#S[^RG>YL;ZRL8,(6,D4=PC23@#LP"DG
ML$KLCXRT 7)@%_N(@6Y:1(G:)(F4L':0+L52 <$D>G6D3QGH+VMQ<&]>-;<*
MSI-;RQR$,<*51E#.&/ *@Y/ S5<SY^;^M_Z1"7NJ/];?TS@I?"-K_8MOJ-UX
M=$UXOB*2:X=K$RSFW^TOT&TL4VD' XQS5J*._@33],&D:D]S:^(+BZD(MG6/
MRG,S(PEQM((=1P>"><5V1\:Z"+59Q<SL6E:+R%LYFG#J,L#"$\P8!!.5Z$'O
M4VJ>)+2P\(W/B*WS>6L5L;B/R03YHQD= 2!ZG''4]*ENR?;_ (8I:RTW?_!_
MS/,!IUW+<M-8>'9[$3Z/>P7216$ZNTQC!5997P9FSD!L')SACG ]"U:WND\&
M6MQ;VLDU]I\<-U% J_.S1@%D ]2NY?QJAI?Q"LI[Z\BU$M;1)]G,3?9)AL$D
M:M^]8KA/F8@%MN:W9/%.C1:J=->[/V@2+$Q$+F)9#T0R ; YR,*3GD<4VGLA
M7ZL\YL_#_B;[/>V$5O<13?99=6@N'.T+>SQ[3&#_ 'E8RGVW+2WNCR3Q,_AS
M0KZSLX[1&OX'M7A:XG6:)P0K8\QPJR9<9SD#)KTO5M?T[0S;K?S2(]RS)"D<
M$DKR, 6("HI). >U5K/Q?H5_/##;WVXS1&:-VA=$=5&6P[*%W+W7.1W HOV_
MK^M/NON#\_Z_K]3B]2M9_$&N7LZZ7J(LIK_3"#-:R1%T1F+G# , ,\Y QWZT
MDNB&ROKJWFT:XD\,V^LEVL8;5I(S$ULN"L*@[T$I)(4$9YQP:ZJ3QOHDUM<_
M9M1,$L4'VA9+FQF"-'D#>@(7S5R1RA(Y'/-79/%>BQ:G_9[WN)Q(L+-Y3F)9
M#T1I<; YR,*6SR.*%IH3W,OP+9RVOAV_BCLY[$/?W3V\5Q&4949R4.#SC&,5
MRVG6D.G^'&1O"FJW&MBU6/59A'-$D[>8N]F9<&X/5AL#G:"N1G![&7QII,C@
M6M[(1'<M;R$Z?.XD==^Z-&  WY0]-W3IR*/#'C.P\1:-%>L'M96MOM4D,L;K
MLCR1D,R@,/E/(_J*5^ODOZ_S+_S."MM"FNKB_LUT.2#29]2T^9+>'3I+: QY
M(D/EMTZ#=D+[@=Y[_P .7\7B2\CCMQ;M]KB.ERV^BR3-!"JH L4ZRI'"H(;*
M,!GGAL@5Z9-K6GV^CIJT]QY5DZ*ZR2(RDAL;1M(W9.0 ,9R<8KF];\=0);6*
M:-(QNKJ^6T?S].N'-N2I8[X@%<'&, E<@Y&0#35TTOZZ$VNF^_\ P23Q]I\5
M_I]CY\5S+'%<;RJ:>;Z$G:0/.@4[G7GC;T.#QUKB9])U>X2R?4=,6&Q6Q\FT
M@?2KG4/*E$C_ #H@E#P,5V$%R=OW=PQSZ=?:I<6GB#1M/58FCO1-YK$'(V("
M-O/'/KFBQU2>Y\3:MIKI&(;..!XV .XEPV<\X_A&.*2_S_#_ (<;=OP_'_AC
MD-/\&IJVH:C_ &[:/<7(TVSB@O;J !TE"-N=.6"N#M)*L<'')I/L.LZE:6VK
M:CI\L>I2:K:1-&J$F.&%\%L=E+F1\_W6%:$_BS4Y=;U&SLI])6XLI2D>D7&4
MNKM0 =Z.9%50<\?*PXY(SQVP)*@D8)'3TIWOK_7?_@?\$GET<?Z_KJ>4V>D7
M*^'-0MK32-2A\7M9W$=SJ(B>)97)R"92564D8V$%MO3*U%:Z$[Z=JRB"]BL)
M((EFM].T&2T#R"0$L8Y96,QQD/M7YU.,L<"O7**11R/@""6UTR\@.GI:VRW!
M,#1VDMHDH*C++;R$F(9XP, G) YKKJ**;=P2"BBBD 4444 %%%% !1110 44
M44 %%%% !1110 5\Y_&W_D?E_P"O./\ FU?1E?.?QM_Y'Y?^O./^;5TX3^(<
MV+_AGG%%%%>F>8%>^? ;_D6=3_Z_/_9%KP.O?/@-_P BSJ?_ %^?^R+7/B_X
M9T83^('QY_Y%G3/^OS_V1J\#KWSX\_\ (LZ9_P!?G_LC5X'1A/X88O\ B!11
M170<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'UCX"_P"1!T+_
M *\X_P"5=%7.^ O^1!T+_KSC_E715XL_B9[4/A04445)05Q'AOPCJ>DW<;73
MV9B@M+FUC:*5F9Q)-YBL04&WC((R>G>NV9@B,S' 49)KSNW^+6G7"&6-+"1)
M8)IK6*'4DDG/EHS[9HPN8LA3CEL=\'BEIKZ?Y_\ !':]O7_+_@%>+X=:E:VM
MJJ/#<2-IEO8W"C5+JT1&C# L!#CS5.[[K;>G49KJ]?\ #LM_X.31[$PI+!Y!
MB$C,J'RG5@I/S, =N,_,?K4%IXKOI96AN=$$<[V O[:.*[5O,3(!5BP4(P)'
M<C'?M7/ZKXTO;Z"\T](8H=1L;[3R_P#9FH>>KI+.H*;]J$-@$%2,8(YP:T]Z
M4K=;_K^C)37Q+^M/U-S^PM=M]-U;[#<VT%[>:B+M0LA"F/"!HR^PE2=I&X*<
M5RUQX?N[#6;:VU&ZMS<:OJT=PD,=W)/*JK;NDARX!(!(Y  &0,+P*V]7\3W0
MO[*VNHVL+BSU6,7*07!=)86BE93G"D@[>5(X*]^#4OAOXCV/B'5+2S3["OVV
M)I;9;?4$GE4 9*S1@ QMCG&6'!!(-0E?^NEOZ^YC^%?U_77\C/TSX=7$=JEA
M?,GD064EI%<KJ=W.[;T\O<L+MY</'8;O08J]=^'_ !/J'AZ#3KC^R$-C):R6
MZQRR8F,,BL2[;/D#!<;0K8/<]*T?%?BJY\-0370L+22TMX?.EENM06W+\_=C
M7:Q9O8[020 3V;XNU&X7PM9WM@9TDEO;(JL3[796FCRN<]P2#SCFJ3;=_-??
M<+6_'\C/7PAJWD#1VDLAI/\ :?\ :/V@2.;C/G>=Y>S;C[W&_=T_AS46J:;/
MH'@:UMOM5I'K$%ZTUA\V1+,TK,$4'!)*,P.!QDGH*GU/XA)HTSV.HVMI:ZD+
MA85$]^([;:R,ZR-,RC:,*1C:3G@ ]:H?\)SJ6LZCH)T2.Q>*6:ZAND^VAHWD
MCCR-LBQMN3D,",9X! J;Z>7]?Y6![W?G^/\ P]SJ)_#,<_@>3PUY[(LED;9I
MAR<E<%_<DDFL#4_"6NZ]:W37[Z;;W*Z3/IULMO*[(YDVYD<E 5'R#Y0&QD\F
MLG2?B?-;:!I::HVF'4I+(7D[W>II;!T+,!LW)\TAVGY<!1Q\W-=9H_BR;7]7
M$&G:?&VGBU@NGNY;@JVV525"H$.3QSEA_2JUO<+\NG]?UH7M;L]7FTB"'2+F
M**YCD0R!Y#&)4'WDWA6*9XY"GI[U1\'>'[_0FUA[^2)VOKP7*;)Y)BN8T4AF
M<9/*GVQV'09>M^+-6T3Q9K&ZUBN=,L=)CNDA6?:[.TC+G[G4XQUP  >Y ;JO
MQ'.B7;V6H6NE6]Y! MS<13:NL>48MM6$N@\Q\+DC"@9 W4D^O?\ K] M;W>W
M]?J5+[X=:E<W-Y-'J%NI>\"V[$'*63;_ #8CQ][]])CMPO-:%]X1U:6/5]*M
M9+$:3JUR)Y9W=Q/ "%#(J!<-]S@[EQGH<5+JGCMM.^RW?V"V.F7$D"1R2WZI
M/+YN,-'#M.X#=R"RG@\8&3GV/C#7XKR[MY].MKR:?7)=/M%%X46-5B+_ #'R
MN@V]<$_,?09%?;M^EO\ ),3L]>__  2U)X5UP3BTA?3SIXUD:GYSROYI4OO*
M;-N 0>C;N?0=:5/!-V^A:#ID\\"BRAN(;EXV;GS(F3*<<\MGG%+#\0)$BM+J
M_P!)6VL9I+BWDE2Z\QHYH5=G&W:,I^[;#9!)'W1UJE!\5K26RNYQ!832QV$M
M_##::FD[%4 )27:O[I^1Q\PZ\G%+ETL.SO\ U_6YJZ1H6O1^(]-OM2&FI;Z?
MI\MDOV:5V:4LT9#D,@"\(?ER<>ISQ'>>&=6D\4_;[(VEE&URDTEU;74T;RH,
M;DDM\&.0D#&\D$#&!Q5'Q+XQUNUT35HH=/ALM1AM8;J%Q=>8OE2/MY_=\.,'
MC!'/#5J^-=6UK2O#UA<:<ENEW+?6L,P:8A0'D4,H;8<@D[<X! )/48JKMM/S
MM]__  1:6MY?@BUKFD:E)KNGZWI(M9;JU@FMS!=RM&C+(5.X,JL004'&.03R
M*R;SPSXA?^UXX9M,D77+=([R9S(AMW$?ELT:8;>I'(4LN#W.:AT7Q-JEG/<B
M]L_/L)-<FLEN6NRTB,TA"!8ROW!P/O C^[BFVOQ4TZZNU1%L&AF:5+=(]11[
MG<@8YDA S&K;3@Y;J,@9J+JW]>I6J>G]=BT/!=Y%HUS813P'?J]O>QL[-_JH
MVB)#<?>Q&?;D<TR+PKK<,VF62OIQTW3]3>]68R/YTBMYAVE-N 09.NXYQVJR
MOBS6&T"UU5]%TZWCN8?M"FZU811QQ[0PWMY>0YR> I4 <L.E0VGCN]U7[(=)
MT-9Q-IJ:BYFO!&$4LRE!A&W-\O'0'N5JI-ZI]/Z_0F*5E;^K_P##F7+X!UD:
M7:VL4M@SC26T^9GF=0K>8'#+\AW#C!SC\:TI_".K/'>Z0DME_9%WJ OVN6D?
M[0G[P2-&$VX/S+P^X8!^Z<5<C\<0SZ?/<P699S%;2V<;28-PL^!'G@[?GW*>
MN,9KK!G SUIZH-W?O_7ZG'VGA2^@LM-A:6VW6VMS:BY#-@QN\K #C[V)%]N#
MS2^*_"5SXAU1)8YHDMI=-N=/G+.0Z"780Z@ AL%,$$CKU[5U]%*_]?*WZ%7U
MO_6]SE]+T75Y-?M=6UC[#$]E9O:0QV<CN)-Y0L[%E7;]P849QD_,:ZBBBANY
M*5@HHHI#*][_ *A?^NL?_H:U8JO>_P"H7_KK'_Z&M6* "BBB@#)\3WR:=X;O
MKJ1[I$2/E[3;YBY(&06! QG))Z#)[5Y<-9N9+C5K/3M7NUL6GTMK>2/59+L@
M27&R0K*V3@@ %067\R*]DFFBMX7FGE2*)%+.[L%50.I)/05FCQ!IUQ:V]W8Z
MEIMQ:2S>69Q>+LX!)"D9#,,?=R.,G/%.+2=W_7]6'TL</>W5QIVH7^FRZI?1
M:'!JD*7-Q)>2%X('MRY!F)WJIDV\[N,]0*VOAZ]N]EKK6EU)<V_]JR^5-(Y<
MNNQ,'<>6]CSD<Y/6M'3/''A[4M%AU;^U;.VM9IFA0W%S&F74D;?O8R1@XZX(
MK?>2-86D>15C"[BY. !ZYI.ZB_3_ "$_>::_K='C-CK<[>%K:?3=?U"\U5K.
MZ;4TDO'<P(L4A1BI.(R&";6 !;.<GK6AK$MYI+Z5#-J<D>G36'GFYU#7I[3S
M+HXS^]"N20.1%PO)^4XKJ_"^N:+;B;1=-O8+C2]+LHIAJ'VM)%8,T@()4!1C
M9USW[8K:/B30AIZ:@=:TX64C%4N3=)Y;$ D@-G!( /Y&FU_7]?@-O5_U_6AY
MMJ>KZA9G3KO4-<>:\%E XLH+N:RE=\G<T,;1A;AFX!1U&/\ 9S6QI^HQ2^(+
M[^U-:U"VUM;V9(-.CG;:UOM/EDP@%=F.3)@'=QN[5V*^)=!>8PIK>FM*J,Y0
M7<98*OWCC/0=SVI\OB#18-,CU*;5[".PD^Y=/<H(F^CDX/YTGJG\_P 1+<\O
MWW4?@[1Y9-1U"X?4?#][<71N+N242/Y"$':S$#&3T ]>I-/N]9ODL!_PB>IW
M-_'_ &?$;]FG9A;/YD2^C>4WEF0E57C&=N>OH2>+M&E\10Z+%>P27$UH;M&2
M9"K)GC'.22,GZ#--O_%FG0Z+/J6FW-KJ:031PN+:Y5@K,ZI@E<X(W9Q[4V[M
MNV_^=O\ @!=;?UW,CP#>7-U-J06_M;O3E\OR/(U*;4 CG=O'GR1KN_A^7+%>
M>F0*P+/57;5[D6VMWL^NKKSPI8-=.RBU\[#_ +K.W8$W'>1P1@$=*](_M?3/
M[3_LS^T;3^T-N_[+YZ^;M]=F<X]\5E:9?^&](>^M(==LC*;F:YN(Y+N,M&S9
M=P0,8 &3ST HO[R?];A]EHXNVEE@T?2;[4M9U*+3[Z_N$U*[>_E58T5I!$N[
M=B%<@ LNTG !/-+;:I+)+:QZKK%Y!X7-Q=+;:@UV\+3!?+\D-,"&(.9=I)^?
M:,EN_I_VJW^T);^?%Y\B&1(]XW,HP"P'4@9'/N*@EU;38-1BTZ;4+2.^F&8K
M9YE$CCU52<G\*2[?U_6@?U_7WGE?AK7DTC2LW6IS0VLVDSFT\UROFS"XF)VC
MO)@J< 9_*KMIJBR7=G_;^O:E8@:792Z=Y%PZM<R,#YI"C/GMG:"I5L YP,YK
MT)=?T9]0FT]-7L&O85+2VXN4,D8')++G( ]ZB/BGP\MHUV=>TL6RR>4TQO(]
M@?&=I;.,X(XIIBL>7R>1IUQK42Z[]B8:U,\UM=ZK<6JRJ44IF=23$>21GA\8
MYQQWMOJ[#X;_ -IR_P!J*R6;$L-CW)QD;@=H4DXR"5 Q@D5OWMXMKID]XDEM
MMCB,@>>;RXL 9RSX.U??!K(TKQ5#J_BC4M'M39.FGJHFD2\#2%R <",+]T9P
M6+#D8Q26W+_6@]GS?UJ></K<[-K-OI6L70LWMK.2"6/5I+PAC<A'99&S@XX*
MJQ7Z9(K>U2XN=+U+5-.&IW\>D1W-F]S,]T[/;PR!_,(E)+(I*KD@C:"<8KNX
M-=TBYOOL4&JV,MV=W[B.X1I/E.&^4'/!!!]"*=;ZOIEW>SV5MJ-I-=V_^N@B
MG5I(_P#>4'(_&@&<K\/7M'N/$[6%V]Y:_P!ICRIWF,I=?L\6/G))8>C$G(YR
M:YG1=8U.35X/[2U:W@NC+/\ VG VKSO(D(#_ /+L(@L 7Y2'# ' ^9BPKT^T
MUG2]0:X6RU*SN6MB5G$,ZN8CZ-@_+^-9MIXOTN^UBYM+:[LYK.WM!<O>Q72M
M&,NRE21P,;<YSWH;N_D/OZGG7]LZJOAK6)M1UC4[>ZC2V^P')C=K(S*%GP"=
MTC#(8D9' P-QS9U/5[V(S)H.J27GAK[1 )KZ?4Y J964RK]J =T7(BRPSM)(
MRO;OM4N= UWPU)--K%K_ &471VO(;F/RP4<,/G.5ZJ :L:#KT.O)?26XC,-M
M=-;I+'*'64!5;>".,'=[].M/J_Z_K_/785UI\S@+74[AK2R&L:V(O#K7DRF\
MM=2F*A0BF-&NRL;,N[?\X.#@*6)S7-71EN_!MS9075Y+;26.M3!%E=3*RW2E
M68 C)P3U]2.YKWJBFI6&G8\=O]6U%-0GCM-6MXECC@&C/-K,Z^<GEH=RPI')
M]JRQ())8_3K7<>-+N>UM=*\VZEL],ENPFI74,AC,46QB/G&"BEPH+ @@'J*Z
MJBDV2D>76,]WJ>KZ?8IJNHOHDFI7$=K.EW(KW-N+;=CS0=SJ'W8?.>.O>M_P
MG?:]+I$*1PV]]!%>7-O)<7E\ZS*D<[HN (V\PA0.2P)(Y/>NRHHOH%@HHHI#
M*]Q_K[3_ *ZG_P! :K%5[C_7VG_74_\ H#58H **** ,+Q'9:W=FT.D7$2QH
MS?:('G:#S 1@$2*CD8.> !G/48KC8_ASK"Z+)8FZLC(;'4K96,TC9:XE5T)+
M L< ')))SZUL^/YKA;[PU;PKJ4L=Q?NDUOIUV;:291#(P&\2)P" >6'2LGQ)
M:ZE%X6AAT@:]HM]<:E%&AOM2:XD;@D8(FDPA/!&1GN*<7RJ_];H=W?\ KS-*
M[\(:Q);ZKI,,MC_9>JSK/-<.[B>'A0ZJ@7#9V<,67&>AQ5/5/A[JEW=ZE<6N
MH6\3M<*=/9@<V\3[_/!XZMYLF.O1>E1WGB&\UCQ=X4GL;R>'3PR"YB1RJRR2
MPR/L< \[!&#@_P!ZL33=42;0;3[+?^(W\4W-S(ML99KTV\K+*V1^\/D,H0<X
M[#CFFD[_ -=[?UY7[D_"M/ZZ_P!>9U]_X4U1M?2YTP6=E$'B/VRWNIHI?+4
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M.10 Q4%F)DSG:HQQVY[6BDM-1&'KVEWMU>:;J6FM ;S3Y'80W#,D<R.I5E+
M$J>A!P>G3FH=+TW5K2YU35KF.R?4;YH@+:.=_*B1!@#S"F6/+'.P=0/>NBHH
M6@/4XS7/#VN:S:WNE7<>DWUG<,YAO;DE)[0,<@+&L9#%>,-O4\#/(R>JM5N(
M]T,JIY,:JL4OFEGDXY+#:-ISZ$Y]NE6:*.E@>H4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5\Y_&W_D?E_P"O./\ FU?1E?.?QM_Y'Y?^
MO./^;5TX3^(<V+_AGG%%%%>F>8%>^? ;_D6=3_Z_/_9%KP.O?/@-_P BSJ?_
M %^?^R+7/B_X9T83^('QY_Y%G3/^OS_V1J\#KWSX\_\ (LZ9_P!?G_LC5X'1
MA/X88O\ B!11170<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MUCX"_P"1!T+_ *\X_P"5=%7.^ O^1!T+_KSC_E715XL_B9[4/A04445)0A 8
M$$9!X(KFT\%VR6<M@-5U3^SC!)!%9"5!' KJ5.W"AFP"<!RP'8<5TM% [M'/
M:EX.T[5(PEQ+<@"R%D-CJ,(&5@W3ELH.O'J#5&3X>6$WVAI]4U22:X%N'EWQ
M(1Y,AD0J%C"KR>< ?GS77T4[N]Q)6T.;3P98EEENKN]O+G[4MU)<7#)NE949
M%5@JA0H5CPH'KZYLZ1X;31Y8O*U34IK6"/RK>TFE7RH5Z8&U0SX P-Y;':MN
MBD!S6L^"K'6KZZNI+V]MS=V_V:Y2!HP)$ 8#ED++C<?ND9[YJ[J7ARVU30(-
M(FN+I(H6A998G"R9B964YQCJHSQ^5;%%&P>9S(\%6O,[:EJ+ZGYXG&I,\?GJ
MP4H  $\O;M)&W9CG.,\U8/A:%WTV:34M0EN;&9YEN))$9Y=XPZL"NT*0>BA<
M=L5O44 <K:^!+;3X(H]/U?5+-HXO(\V%HMS0AB5C.8R,*6.& ##/WJV;#1;;
M3K^YO(I)WDN(HHG\V3?Q&"%.3R2<G)).:T:*+@]=S UCPC9:U>W%U-<W4+7-
MH+29(2@#H&W*?F4D$$GH1UYS4FH>&H[S4'O;?4M0T^>:-8;@V;H/.1<X!W*V
M"-Q^9=K<]>E;=% =;G)7GP_TZ\GNF_M#4HHKJ5)I(8Y$(,B%2&WLA<_<7@L5
M]LU<C\'V46KC4%NKO(OCJ"PDIY:RM&T;?P[L$-G!/4#&.0>AHIIM;!8YW_A#
M-+-O;6\CW$D5O>7%X%=EP[3"0.K<?=_>MC&#TY-1GP7#+IEUIUSK.KW%I/:M
M:)%),@$$;#'R[4&X@8 9]Y'KR<]-11=COK<P=4\):?JQNS<2W*FYLDLFV,HV
MJK%@PR#\V3WR..E6=6T&+6='CT^ZNKG,;Q2K<IL$@DC8,K_=VYR <;<>U:M%
M(1A+X5LA:BW,URRC4?[1W%ER9=^_'W?NY[=?>HH/"$%N6BCU34UL,2>78"51
M#'O!!QA=[#YCA69E'IP,=%11Y!UN<W/X,LI?[,:*]O;>33K86L<D9C+/%\O#
M;D(!.T?,NT^A%8UMX"DM=;B@M=0U.VTR#2TM%GCFCWR_O'9HVRI/1A\P /HV
M<UWM%#=W=_U_5P6BLOZ_JQRLGAN*3Q1H[0V$MO8:1;%4D$BB.4X 1-H)8[>3
ME@,'&,\XZJBBBX6"BBB@ HHHH **** *][_J%_ZZQ_\ H:U8JO>_ZA?^NL?_
M *&M6* "BBB@#*\26']I^'[RT^Q_;/,4?N!/Y)?!!X?'!XR.V1VKD+#0M?DN
M;2:XM)O*358KDM>?9ENBBQ.C-*T)V/C* =6QUKT2BA >36OA3Q#8BUF^RZFO
MD07%DT=D]DS,&F9PX\_<NQ@0#R&^7E2*ZZX\.73?#B/081FXCMXT$<TP<-L(
M)0N%4$$#;G:!STKJZ*.E@ZGF&J^&]<U^_P!6ODTB;2Q,E@T<;36YDE,$KLXX
M+IG!7&[*GC/?%BQ\+:I)KFGZG<6M^P_M07-Q_:$UJ9 %MY$#E(%" [F4<%B<
M G&*]'HJE*P/4X*+PM>![9WT^/<OB674)"2A/E'>%?K[KQU]JC32?$&FR?Z+
MI*O&]_>R>;"(&GB61P493(P55(SNZMT^4\UZ#14VTM_73_(;=_Z]?\SR*U\$
M^(O['CL9+(QRS:3<V3N9HBJ.9S(N_:1\KKQ\JG&>0*U=4T'6=<GFOHM$;3=M
MM;VHMGFA+S%+A)"WR,5"JJMMR<G)X'?TBBG<FR/-YO#.LR6<FB"Q,;'5SJ(U
MKS8]H3S?,Z9W^9M^3&W;COCBJ.CP;[[P5I-Q80R1V\%S$;V.:*6.[3RB&=-C
M$[23DE@.2.O6O5JS[;0M(LY[F>UTJQ@ENLBXDBMT5I<_WR!\W4]:7E_6UAO7
M^OF<]X&L[O=>7-\P<VN-+MG#[M\4+,"_U8GG_=IJZ5?V7B75&;0H]4@U&]@N
MH[J66-4MPB*OS!LMN4J67:IY/5>M=;:VEM8VL=K:6\5O;QC;'%$@1$'H .!4
MU.^M_P"OZOJ'1H\MNM!\4:A>:49=(%O'93W)DC@-M';_ +R*50\>&+G)89W;
M3R25/46[GPMJ]K!X:N+2*]0V&E&RFM]/:U\U'8)G'G@QD?*02"#TQD9KT>BE
MTL#WN<=<>';R/X4W6@6T,CWC:?+#'#),C'<P.%W!47C..  *T=!TV[LM:URX
MN(MD5S) 86W [@L*JW0\<@CFN@HIW#I8X"U\+ZC%I^FI]C6.>/Q!<7LK!TRL
M3M-A\YYRK)QU]N*RM)\$ZXEO9Z;<RZI&UC;SQ)=/-:+;[GC9<H(X_.8$MDAR
MO(SEB.?5**3UT_K:P^9[_P!;W/*H/!6M7>FR6<T>H12P:5)8Q->36@@8G;\B
M""/>R';U<@C^Z23B76?#>N>(=0N;R+1I=+46UFJH9K<O*T,Y=E&"Z=,;=PP>
M,X[>H44VVW<222L>;P>&]729-9:TU*XF348[N2SO9[033A8GCR!"JQ*P+*1E
MCG:,D5T?@ZPO+*'5Y+W3_L!N]2EN8X=Z,0C*N"=I(SD'/OGKUKI:*+_U_7H)
MJ_\ 7]=PHHHI#"BBB@ HHHH **** *]Q_K[3_KJ?_0&JQ5>X_P!?:?\ 74_^
M@-5B@ HJE?ZO8:9+;QWEPL3W+^7$""=S?@..O4U=IV=KB4DVTGJC'UWP]'KD
MFGS?;[RQN+"8SP36OEE@Q1D.1(C*1ACVJ,>&VE6 7^M:CJ!@N8[J(SK I5DS
M@?NXER#GG//N*36[Z\TS5](N1,?[,FE-K=1[!PSX\M\]1AAMQG'S^U9JZ]</
MKTLLUU<QZ<VH)IUI%!'&1)(J,TC.6&=N[*\'(,?N:2_K\/\ @#:_K[_^"6[/
MP1I-A(CV[7"E-2DU/[PYE=64@\?= ;@>PYJ3_A#]._X1F/0A+<B&*0RPSAE\
MZ*3>7#J<8!!/''3@YK#;X@W-Y>^'?[.T'4!8:I=-$;BX$*[U".3L'F[A@KDD
MCD XR2,[]MXKL+JVTB=(;H+J@<P#8"5V*6.X GL#C&:>MOZZ?\,#WU-Q 515
M+%B!@L<9/OQ2UPVN^.)8M+OH8;#4=+U 69NK1[N*/$B!E4D ,V"-R_*X4\]*
MZR\U*&QFLXYU?%TYC60 ;58(6^;GC(4TGW8NMB[17)V_Q#T2XTFWU("Z6">.
M60!HLLHC<)R 3RS,H4#.=PJ=/&EFMPMK=Z?J%E>M+#']FG1-^)6*H^5<J5R#
MG!)&.13L]AMVU.EHKF[OQI8VM\]DME?7%PM]]@5(40[Y?)\X8RP&W;QDXYZ\
M<TD?C2TGAMQ;:?J$][,\L?V%$C$T9B(63<6<)A21R&.<C&:06.EHKE_#WB*2
M;P&=>U$RR^6MQ-)B,*Y1'? V\#.U0/YU"?B!:K!/(VBZPIAMEO&0Q1Y-N<_O
M1^\Q@8.5^_\ [)H\@6JNCKJ*YJ7QMIR7$@2VO9K."1(KB^CC7R8'<*5#98,>
M&7)52!GDBIKGQ5%::G#:SZ7J<=O-<BU2]:)1"93T&"V_!/ ;9M]Z+"OU-^BN
M33Q_82:?>Z@--U/[!:PRS"Y$2,DHC.& PY*MZ"0(3VJWJ_C#3]&:=;B"[D,%
MM%<L(4#$K))Y:@#/)SV]/6@JQT-%<Q/XU@MC*)M'U13;1B6^PL3?8U.<&3;(
M<\#.$WD#KBF-X\L1>RP+IVI20QW8LC=)&AB,Q4,JCY]QW9 !QC/4B@5SJJ*Y
ME?&MI)!&(]-U%]0>X>V&G!8_.$B#+9._RP "#G?CD<Y.*:?'%F\EI#::=J5W
M<W,<[BWBC0.AA95D1][J P+>N#C@],@'445R.B^,9-<\6?8;6SE_LM],BO(K
MA@JDEV8<C=D#Y<8VYR#GC!K1O_%%O9ZNVFQ:?J%[+$B27+6D0<6ZN2%+#<&.
M<'A Q &2!3L#T-VBN??Q7#%JMO93Z5J<$-S.UM!>2Q*L4D@!. -WF ':<,4
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M2/8YW_A O"?_ $+VG_\ ?D4?\(%X3_Z%[3_^_(KHJ*.>7<.2/8YW_A O"?\
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MA6&0"&_$'(_44ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6!I;2Q6WGE612O[YPQ63:#Q\J\BI9O!%_?27$VHZY%+-+;V]N##9>6JB*;S
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&#TSUXZ54MOA_-;Q:6W]MN;O2((8+"18-J1!0!(63?\ -Y@X/(P,8YY+TO\
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MHU:*2V6.6.6"YM#+&PDD9]RKO #?-C+!@0!Q26OP[-OIGV,ZKO\ ]"LK3?\
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D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>new_003.jpg
<TEXT>
begin 644 new_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,Y!;L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYO"WA"SN_$=LBZY<*RI8P'.]P> ""V!@KDY/7\*Q(?$OQ3\L7TGA.R:TQN,
M;;+M^A<G/_ ?PI*E)Z@ZL5H>H45YUH_Q+DUSQU8:+;6:Q6T]NSW"SHPG@E4/
ME#SCC:.W>O1:F4'#1E1FI:H****DH**** /BRBBBO</#"BBB@ HHHH ****
M"BBB@#JM,^&_BS6-.@U"PTGSK6==T<GVB)=PSCH6![5;_P"%2^./^@)_Y-P_
M_%U%\-=5O[+QOI-O;WDT=O-<A)8E<['!X.5Z'M^0KZ3U[_D7M2_Z]9?_ $$U
MR8BO.D]+'7AJ$*VCO?0^<?\ A4OCC_H"?^3</_Q=8>L>$M?T!=^IZ3<V\?\
MSU*[DZX^\,C]:3PWXDU'PUJT%Y8W,L:K(&DB#'9*O<,.AXKZV>.&[M3'+&LD
M,J89'&0P(Z$4ZU6I2LW9IBHTJ=6ZU3/C&BN@\4:$=/\ &NIZ1IT,DRQ3L(HX
MU+-MZ@8')P#^E4CX=UP02SG1M0\F(;I)/LK[4'J3C %=$9Q<5+N82IRC)Q[&
M915ZPT75=55FT[3+V\5#AC;P-( ??:#526&6WE:*:-XY$.&1U(*GT(-5=7L1
M9VN,HJ:UL[F^F$-I;S7$I&=D2%V_(5I2>$_$<,9DE\/ZK&@ZLUG( /QQ2<DM
MV-1;V1CT4$8.#UHIB"O4?"7PW\+>)8@(_%QN+IHPQMHH!$\9Q\PPY)8 G&0,
M5YW8:/J>J[O[.TZ[O-OWOL\#28^NT&NQ^'.DZII/Q*T;[?I]Y9[WD \^%H\_
MNV]0*BIJFD[,TIKWKM71TOB_X1Z+X<\'WVJP7U_-=6ZJ5#L@0Y8#D!<]#ZUX
MY7U'\4O^2;ZQ_N)_Z&M?,$,$MS,L,$3RRMPJ(I8GZ 5AA:DIJ3D_ZL;XNG&'
M+RKN1T5J+X:UYT=TT34F2,9=A:N0H]3QQ6=##+<2K%#&\DC'"HBDDGV KJ33
MV.5IK<916I'X9UZ8,8M$U)PHRVVTD.![\5ET)I["::W"BGPPRW$JQ0QO)(QP
MJ(I))]@*U6\)>)%C,C>']5" 9W&RDQCZXH;2W!)O8QZ*5T:-V1U*NIPRD8(/
MI7T'\*?#FAZCX!M+F^T;3KJ=I)099[5'8@,<<D9J*E14X\Q=.FZDN4^>Z*[?
MXL6%GIWCRXM[&T@M8!#&1%!&$4$KSP.*XBG3GSQ4EU"I#DDXOH%%%%40:OAO
M0YO$GB&STB&3RVN'VF3;NV*!DMCO@ UI>.?"4/@W68]-34_MTAB$LA\CR]F2
M<#[QSTS7<_ W1XQ/J?B&Y 6.W3R(W8\ D;G/X#'YUYMXHUA]?\3ZAJ;$D3S,
M4SV0<*/R K%S;K<BV2U_0V4(JBYO=O3]3(IT<;RR+'&C.[$*JJ,DD] !3:]B
M^!GA^VN;B^UVXC#RVS"&WR/N$C+-]<8'XFM)S4(N3Z&<(.<E%=3E['X2>)[F
MQ:\O!9:7 !N+7\^S ]2 #M_'%,/PLUR>U>XTF]TC65CX8:=>"0CVY YKLOCU
M-J"OI,0,@TYE<G'W6ESW]\=/QKR;1=:OO#^JPZCITQBGB.>.C#NI'<'TK&E.
MI4CS72-ZL*=*7+9LM:CX2U[2-)CU/4=-FM;223RE:8A6W<\;"=PZ'G%8M>[?
M%'6+?Q#\*--U:WQLN+F-L9SL;:X9?P.17A-71J2FGS*S3L16IQAR\KT:N%%7
MK#1M4U0,=/TV\O O#&W@:3'Y ^HI;[1-6TM ^H:7>VBGH;BW>,'\P*TNKVN9
M<KWL4***T8= UFX"&#2;^42 %"EL[;L],8'--M+<23>QG45;?2]0BU#^SY+"
MZ2]SC[,T+"3.,_=QGIS3K_1]3TK9_:.G7EGO^[]H@:/=]-P&:5UW'ROL4J**
M*8@KHO _AV/Q3XLL]*GE:*!]SRLOWBJC) ]SC%<[6AH=UJ=CK%O=Z.)3?0G?
M'Y2;STYX[C&<T/9@MSV_Q?\ "3PW#X8O+K2K=[.[M86F#^<[B3:,D,&)ZX[8
MKP"O2_$'C3X@^(=!GM+C1IK:R"_Z3+;6,JY4#)W,20!ZXQ^5>:5SX>,U?G=_
MQ.C$2@[<BM\K!14UM:7-[,(;2WEGE/(2)"S'\!6C-X5\16\9DFT#5(HQU9[.
M10/Q(K=M+=F"BWLC(HHIR(\DBQQJSNQ 55&23Z 4Q#:*V/\ A$O$GE>;_P (
M_JOEXW;OL4F,>N<5E2Q20RM%*C1R(<,CC!!]"*2:>S&XM;H91113$%=IHWPL
M\5:Q;BY^QI96Y&1)>OY?'KMY;'?.*]!^$'@&W@L(O$NIP+)<S?-9HXR(T_OX
M]3V]!]:R_C;XJN3J,7ARUF9+=(Q+<A3C>Q^ZI]@.<>_M7-.LW4]G#<Z84%R>
MTGL<U%\*M3NWDBT_7?#M_<)]Z"UO]S_EM&/QK)F^'GBRW2\DFT6>..S0R3.[
M*JA0"25).&Z?PYKG(II+>9)H9'CE1@R.C8*D="".AKZ \/>+Y/%GPHUK[4^[
M4;.SEBG./OC8=K_B.ON#3JRJ4X\RU"C"E5FH/3YGSY116E9^'=;U"$366C:A
M<Q'D/#:NZG\0*Z&TMSF2;V,VBKU]HNJZ8H;4-,O;13QFX@:,?J!5&A-/8&FM
MPHJ[!HVJ742RV^FWDT;_ '7C@9@?H0*;=Z5J-A=):WEA=6UQ( 4BFA9';)P,
M C)YHNKV'9VO8J45H7NA:OIL"SW^E7UK$W"R3V[HI^A(K/H33V$TUN%%:EKX
M9UZ^@6>TT34KB%N5DBM)'4_B!5.\L+S3IO)O;2>VE_N3QE&_(TKJ]KCY7:]B
MO1113$36MI<7UU':VD$D\\AVI'&I9F/L!7;I\(_$4=A]MU*YTK28NYO[K9CZ
ME00/SKT#X(>'[:W\/S:Z\8:[N9&B1R.4C7C ^ISGZ"N0^.$VH'Q?#%.9!9+;
MJ;<'[I/\1'OG^E<TJS=7V43IA12I.K(Q;GX7>(5LC>Z<UCK%L,YDTRY$OY#@
MG\,U@ZOX9UG0;:TN-4L7M8[M2T.]EW,!C.5!RO4<$"K'A'Q3>^$]=AO[5V\K
M<%N(<\2IW!'KZ'L:]*^.5S!?:5X<O+=P\4WF/&X[J0A%5*=2$XIZIBA"G.,F
MM&D>+T45J6OAG7KZ!9[31-2N(6Y62*TD=3^(%;MI;G.DWL9=%6+RPO-.F\F]
MM)[:7^Y/&4;\C5C08XYO$6F12HKQO=Q*R,,A@7&01W%"UV!IK<SZ*^J]:\)>
M&XM"U"2/P]I*.EM(RLME&""%."#BOE2L:-=56TEL;UJ#I)-O<**]M^"VA:1J
MOAW4)=1TJQO)$N]JO<6Z2$#8. 6!XK ^-6E:=I6NZ;'IUA:V:/;%F6WA6,,=
MQY(4#-#KI5?9V_JUQ*@W3]I?^KV.3\#^'8_%/BRSTJ>5HH'W/*R_>*J,D#W.
M,5Z[XO\ A)X;A\,7EUI5N]G=VL+3!_.=Q)M&2&#$]<=L5XAH=UJ=CK%O=Z.)
M3?0G?'Y2;STYX[C&<UW?B#QI\0?$.@SVEQHTUM9!?])EMK&5<J!D[F)( ]<8
M_*IKQJ-KD=B\/*FD^>-_D>:44Z..2:58HD9Y'.%51DD^@%:47AG7IB1%HFI2
M%1D[;20X'Y5T-I;G,DWL9=%6;/3K[49S!8V5Q=2CDQP1,[#\ *EO]&U32@IU
M'3;RS#?=^T0-'GZ;@*+K8=F4:**GM;.ZOIO)L[::XEQG9#&7;\A0(@HK6N/"
M_B"UB,MQH6IPQCJ\EI(H'XD5DT)I[#::W"BBM6W\,>(+N%9K;0M3FB895XK2
M1E/T(%#:6XDF]C*HJ^=$U99I83I=Z)8HS+(AMWW(@ZL1C@#UJA0FGL#36X44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?0WP
M.L1;^"[B[(&ZZNV(/^RH 'Z[J^>:^EO@X1_PKBSP,'SI<^YWFN;%O]V=6$7[
MSY'=ONV_)C/H>]9=_>S6ZRM/ILDJ0V;3&6W;<=_0QH.#DCH>*U2,@C)&>XK$
M\0V#RZ-J#C4]2M\QJ^ZS(\Q G)"#'5NAKSX6OJ=U2]KHX;6=0LIM+T#0;J]O
M+73-7A:$VLL>ZY9MWRDN>GS;<?RQTG^'F@0W]W;Z]=:3J6EW>FQ?8(8;F0E9
M4"XW$%0<X)!QQFF:Q+=ZA?V=]9:?J%Y;:U;^6LTH ;2\ *95'.#SNR",XZ\\
M;_PRU2PO_"4=M8ZA=7_V)VBDGNHRC,2=PP,GC!XY[5TU&U#3^M_^&.>BDY*_
M];?\.=B %    '0"N3\<^'+34]/@U-[:[N+C26:Z@MK5]AF;@[3P3R5'3FNM
MJGJVHV^DZ3=:A=NZ6]O&7=D&2 /0>M<L6U)-'5))QLSROP??Q:;X@T^"&6XT
MJ^UR62\O;"\B,F1N8*%;:"N<,1GGGDGC/H]MIZZ%:6EM:6]Q?#[0P,L\NYXE
M<DLV3V'3 KS+2([C5VTBTT[^TKBTO)GN1KK 1RPX+*T/.>,KD_-R6SCU[C3=
M2M=0:]OCJ.JVL=Y>1VD44Z[0DB=HQS@-@@_C755C=W7]?U^AQ4YV5GI?S7_#
M=OO.KC,I#>:J [CMVL3E>V>.M-N+B"TMY+BYFCA@C7<\DC!54>I)Z"GI(D@)
MC=6 )4[3G!'4?6H[JUAO;2:UN$#P3(T<B'HRD8(_*N3KJ=W30XC5_AOX2\92
M?VQ;2M&\^3]IT^9=DA!QGH03D<D5S^I>'_%/PXTZ;6M(\1RZC8V^#-97BDC9
MD#CD^O;;5S3=!\:^ 'GL]!@M]<T9W\R**:81RQ>HY('/MD=\#)I=7M?'WCBS
M&D7>E6N@Z=*X-Q*;@2NZ@YV@*?Q[9QUKJ3:=N9./G_5SF:35^5J7E_5C'^(6
MKQ^)=-\"7DL9BL;^XWSH3D+R@(S[9>O:    !@#M7):YX!T_5O!$'AR,^7]D
MC46L[#)1U'WCZYYS]:PM.U#XG:1:IIUQX?L]4:(;([W[6J[@.A;)R?R!J':<
M4HO:Y:O"3<EO8S_B?#;K\1O!$ZX^T/=HLGKM$L>W]6:M#QS!'<?%'P1'(H91
M)(V#ZKM8?J!6/J'@/Q=J'BS0O$&H/#=72WB2720R!8[6)'0JJ!CD_P 9./UZ
MGK_$N@:EJ/C[POJEM 'L[ RFX<NHVY QP3D_A5WBN57V3(LWS.V[1V=>-^#G
MDMY_B@;?(>.28Q@=B#/C'Y"O9*X/P-X9U/1O$7BVZU&V5+;4;OS+<[U;>F^0
M\@'CAAU]:QIR2C*_E^9K4BW*-O/\B#X+0P1_#Z-XL>9)<RM+C^\#@?\ CH6N
MA\>PV\_@+7$N<>6+.1QG^\HRO_CP%<?%X9\6>!-:O)O"=M;ZEHUV_F&PEE"&
M$^Q)'TSSD=1P#2ZYI/CKQOI5Q;:C9VVD62Q.ZVD4X>6YE .Q6;. N[![?X:-
M)U.>^AFFU3Y+:AX/_P"2 W/_ %Y7O\Y*WOA5:16OPYTKRU ,RO*Y_O,7/] !
M^%5_#GAO5-/^$<^@W-NJ:B]K=1B(2*1N<OM&X''\0[UM^"-+N]%\&:9IU]&(
M[J"(K(@8-@[B>HX[U-22:E9]2J<6G&ZZ'%>*U6X^.OA:"Z_X]UMO,0'IO!E(
M_P#'E6O5:XSQ_P""9?%4-G>:==BTU:P8O;RG(#=#@D<CD @\X_&LZ'6?B:T
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MN02H_O<MS[#Z57^!7_(EWG_7^_\ Z E<9\=/^1RL_P#KR7_T-J3A'ZSR]/\
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MHUKJ-U&DD,<94(6PFY223V!Y)Z=J]E\7?\B;K7_7E-_Z :^7_"'_ ".FA_\
M7_!_Z&*^H/%W_(FZU_UY3?\ H!IXR$8\O*OZT#!3E*3YGV/FKP;XTU/P=J)D
MLC&UO.R"XA= ?,4$]#U!Y/0_7-?5;$-"2>%*U\8I_K%^HK[,/_'K_P  _I58
MZ*Y5+KK^1G@I.[CT/!;;XLP>&KM=.\/:%;1Z1%(1(TQ;SY^>7+ X!/N#_2O;
M[ZQLO$6AO:W40EM;N+HPZ C(/L1UKY F_P"/B3_?/\Z^P])_Y UC_P!>\?\
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MBNL2SZE=06*P74:6L<T6R3&]F9P1NY&/E':JD.OZM/J-S8IH<?G6ZHTF;T8
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MFN>HJ52@G>Q3JS>EPHHHJR HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY_X3'PQ_T,>D?^!T7_Q5'_"8^&/^ACTC_P #HO\ XJOD:BCZE'N'UV78VO\
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M?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\
MP!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7
M_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG_P"A
M<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_
M *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>
M)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\
M(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 3
M1_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__
M !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#
M+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\
M^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ
M_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T
M+FK_ /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_
M /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[
MQ/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\
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M^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P#
M&7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG_P"A<U?_
M , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S
M5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\
MH7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG
M_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PA
MWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'
M_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\
M$T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O
M_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X
M R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_
M /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N
M:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\
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M?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\
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M+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\
M^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ
M_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T
M+FK_ /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_
M /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[
MQ/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\
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M^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P#
M&7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG_P"A<U?_
M , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S
M5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\
MH7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG
M_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PA
MWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'
M_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\
M$T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O
M_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X
M R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_
M /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N
M:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\
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M<QPKODCMY6+JHZG#*,X]C7 5,73G\-F.2J0^*Z-+_A(M;_Z#.H?^!3_XT?\
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MD'M9]V;_ /PFWB3_ *"T_P"2_P"%'_";>)/^@M/^2_X5@44>SAV0>UGW9O\
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M* "BBB@ HHHH **** "BBB@ HHHH *\H^//_ "+.F?\ 7Y_[(U>KUY1\>?\
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MF;CE?[NW&W'MC%,U[Q5K?B=XGUB_>Z\K.P%515SUX4 9]Z2H2YHOM;]?Z_I
MZ\>62[W^>W]?TS'HHHKJ.4**** "BBB@#ZQ\!?\ (@Z%_P!><?\ *J/Q/_Y$
M'4?]P_R-7O 7_(@Z%_UYQ_RJC\3_ /D0=1_W#_(UXZ_B?/\ 4]C_ )=_+]#Y
M<HHHKV#QPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "O5A9:GJ_P-TRWT%);AHKN3[;!;9+L-S$94<G
MJIQ]*\IK7T+Q1K?AJ5Y-'U"6U,GWU #*WN58$$^^*BI%RC9=T_N+I34)7?FO
MO.KN/#_BJ+1_#EMXEN'BT.6]CB2UEDVR1!CW4C(XSW.,]J[X:GJ3?$]O!C:9
M ?#(@V?9?LPV"/R\[\X_O<>GXUXKKGB;6?$EPDVKW\ET\8P@("JOT50 /RK2
M;XB^+FTHZ:VN7!MBGED;5W[>F-^-WZUE*E.2UMU]->OJC:-6$7I?IKZ?HST!
M]7F\)_"AYM&>(O%K,T-O.\8?8NYL, 01G QGW-;9O)(OBOX8NH?+A;5]+_TL
M(@'F':S#GZ@>_%>'-K^IOX?30FN<Z:DOG+#Y:\/SSNQN[GO5J7QAKT^H:??/
MJ#?:=.C$=K(L:*8U'&.!@_CFE[!WOZ_=RV_/4;Q"M9=OQYK_ ):'I5GJE[JU
MA\3)K^;S9(H?(0[ N$4RA1P!T%7;KQ-J&@:3\/(+#R4%Y#$D[M&&9D_=@H">
M@.>WH*\NNO'?B2].H&XU+>=0B6&Z_<1CS$7.!PO'WCTQUJI<^)]8NTTM)[S>
MNE@"S'E(/* QCH.?NCKGI1&@]+VMI^":_,)5UK:]]?Q:9[!+91V^L_$VUM(0
MN^QC=8XUQR8V)P![G]:P8T>W^$'A9ID9 =95QN'5=S\UP\/CGQ)!KT^MQ:FZ
M:C.H2641IAP   5V[>P[4W6/&OB+7[(6>J:D]S )?."M&@P_(R" #W/'2E&C
M-6O_ '?PN.5>#NU_>_%'KT5M.?VAYY1$_EBSWEL<;?+"Y_/BLBVUR[\/?">]
MO[#RUNEUJ18Y)(P_EDMU ((SC(_&N(3XH^-$6%5UR3$(PN88SVQSE?F_'-8L
MOB35IM%?1Y+O-@\YN&B\M.9#U.<9_#.*2H2T3MI9?<[C>(C=R5];O_R6Q[W<
MZY/#\3M&T>*"V2UU2S,U\!"N9VV-C)QGC8/S-?/^MPQP>(=1AB4)%'=RHJCH
MH#D 5??QKXADUNTUE]0SJ%I%Y4$WDQ_(F",8VX/#'J*Q;FXEN[J6YG;?-,YD
M=L 98G).![UI2I.G)/R_6_Y:&=:LJBMZ?E9_B>YW^I:CX:\4^&?#.A6,3:%=
M0Q"2/[.&%R&.'8MCJ!\V?SR*DM=1G\/:;X^M-'N%BMM+=9+-5C4B%G!+@9'/
M/&#G&*\IT_XA>*]+TQ=.L]9FCM57:JE$8J/0,02/P/%9MIXBU:QL-0LK>\9;
M?4?^/M616,O7JQ!(ZGH:AX>337]/5/7T6A:Q$5;Y?+1K3U9<\(7,7_"=Z1<W
MSKL-\CR.W R6SD_C7<>)?#GCFX^*DUWIT5V':8-:WH!\F./L"W(  ZKWYX.:
M\GKJ[?XE>,+6P6RBUR<0JNT;D1G _P!\J6_6M9PE=2CTNOO,835G&=];/[CM
M/"-EK.EZSXJU;5[^UBN++:MW??9_M4RD\GRL' XQDD'& ,=:ZJ_\BX\;> =0
M42O/<1S[IYXECED7RN"X4  \YQVS7B&B^+=>\/7-Q<:7J,D,MQ_KF95DWGKD
MA@03R>>O-6Y?B!XHGNK*YEU5I)[)WDMY'AC)0N"&Y*\\'H<@=NE92HR<D]/Z
M37ZFT:\%%K76_P":M^1Z-X;U:3Q7\4KRVU4P26NDBY?3X#"-L;!U7. ,L0!G
MGG-5/'-YI^L^ 9+FYU235M1@NL07PT>6U4 G#1%BNWCGJ<\#O7EUMK6HV>L'
M5K:[>&_,C2&9, [F.3QTP<GCI5[7O&7B#Q-%%%J^I/<QQ'<B;%10?7"@ GW-
M'L'>-NEO^#]XOK"?-?K?_@?<85%%%=1RA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16KHGAS
M5?$-R(=-M'EYP7QA5^I_IUKVGPG\&K#3BEUK3"[N!SY>/D4_3O\ CG\*RJ5X
M4]]S6G0G4VV/-/ WA_Q7>W\=QHAFM(\@F=N$(^G\7\O<5])Z7#?062)J%PD\
MP RRKBK%O;0VL0B@B6-!T"BI:\VK5=1W:/2I4E35DPHHHK(U"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KA?BAX3U/Q?H]E::9Y/F0W!E<S/M&-
MI'H>>:[JBJC)Q:DB914DXL^<_P#A27BS^]I__?\ /_Q-'_"DO%G][3_^_P"?
M_B:^C**W^MU##ZI3/G/_ (4EXL_O:?\ ]_S_ /$T?\*2\6?WM/\ ^_Y_^)KZ
M,HH^MU ^J4SYS_X4EXL_O:?_ -_S_P#$T?\ "DO%G][3_P#O^?\ XFOHRBCZ
MW4#ZI3/G/_A27BS^]I__ '_/_P 31_PI+Q9_>T__ +_G_P")KZ,HH^MU ^J4
MSYS_ .%)>+/[VG_]_P __$T?\*2\6?WM/_[_ )_^)KZ,HH^MU ^J4SYS_P"%
M)>+/[VG_ /?\_P#Q-'_"DO%G][3_ /O^?_B:^C**/K=0/JE,^<_^%)>+/[VG
M_P#?\_\ Q-'_  I+Q9_>T_\ [_G_ .)KZ,HH^MU ^J4SYS_X4EXL_O:?_P!_
MS_\ $T?\*2\6?WM/_P"_Y_\ B:^C**/K=0/JE,^<_P#A27BS^]I__?\ /_Q-
M'_"DO%G][3_^_P"?_B:^C**/K=0/JE,^<_\ A27BS^]I_P#W_/\ \31_PI+Q
M9_>T_P#[_G_XFOHRBCZW4#ZI3/G/_A27BS^]I_\ W_/_ ,31_P *2\6?WM/_
M ._Y_P#B:^C**/K=0/JE,^<_^%)>+/[VG_\ ?\__ !-'_"DO%G][3_\ O^?_
M (FOHRBCZW4#ZI3/G/\ X4EXL_O:?_W_ #_\31_PI+Q9_>T__O\ G_XFOHRB
MCZW4#ZI3/G/_ (4EXL_O:?\ ]_S_ /$T?\*2\6?WM/\ ^_Y_^)KZ,HH^MU ^
MJ4SYS_X4EXL_O:?_ -_S_P#$T?\ "DO%G][3_P#O^?\ XFOHRBCZW4#ZI3/G
M/_A27BS^]I__ '_/_P 31_PI+Q9_>T__ +_G_P")KZ,HH^MU ^J4SYS_ .%)
M>+/[VG_]_P __$T?\*2\6?WM/_[_ )_^)KZ,HH^MU ^J4SYS_P"%)>+/[VG_
M /?\_P#Q-'_"DO%G][3_ /O^?_B:^C**/K=0/JE,^<_^%)>+/[VG_P#?\_\
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MT1]N;_GTG_-/_BJ/MS?\^D_YI_\ %4?6Z@?5*9\[_P#"F_%G_/.U_P"_A_\
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MKZ(^W-_SZ3_FG_Q5'VYO^?2?\T_^*H^MU ^J4SYW_P"%-^+/^>=K_P!_#_\
M$T?\*;\6?\\[7_OX?_B:^B/MS?\ /I/^:?\ Q5'VYO\ GTG_ #3_ .*H^MU
M^J4SYW_X4WXL_P">=K_W\/\ \31_PIOQ9_SSM?\ OX?_ (FOHC[<W_/I/^:?
M_%4?;F_Y])_S3_XJCZW4#ZI3/G?_ (4WXL_YYVO_ '\/_P 31_PIOQ9_SSM?
M^_A_^)KZ(^W-_P ^D_YI_P#%4J7H:9(V@E3>2 6VXS@GL3Z4?6Z@?5*9\[?\
M*;\6?\\[7_OX?_B:/^%-^+/^>=K_ -_#_P#$U]"2ZM!%?BS9)#(65<@#&3C'
M?WJ5[T+,\:P2OL(!*[<9P#W(]:/K=0/JE,^=O^%-^+/^>=K_ -_#_P#$T?\
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MG:_]_#_\31_PIOQ9_P \[7_OX?\ XFOHC[<W_/I/^:?_ !5'VYO^?2?\T_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4C!!]#32OJOZZ ]#HJ***0$-Y_QY7'_7-OY5%XD_Y!T?_74?R-2WG_'E<?\
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M )W 8'J#SVJIIOBV]LO"7@[2/#^F6(U75[8F"*:206]NB+DDY+.1[9S[TO\
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M^@-0!CWO_(T+_P!=8_Y+6P/^/JZ_ZZ#_ - 6L>]_Y&A?^NL?\EK8'_'U=?\
M70?^@+0 ^BBB@ HJEK'_ "!+_P#Z]Y/_ $$UX%H7Q<T#3/A</#$]GJ37HLYK
M?S$CC,>Y]V#DN#CYAVI-[]U_P1I:KL_^ ?15%>7Z-XGN/#_PQ\(6NG6B7>JZ
ME&EM:12/M0'&2S'^Z!Z5J:?XOU^RUBZT'Q-9:?'J0L7O;6XL'<P3*N<KA_F!
M'U]>E5+W6_*_X:LF.J7G_P ,=Y17CL'Q.\8IX;T3Q)=Z)I3Z;?7 MGBAED$\
MC$L%90>%''0EB?;-=-HOC#78_&-[X>\366GPO'8G4(9;!W95B#8VMNY+#U
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MKC_KFW\JB\2?\@Z/_KJ/Y&EN9/,M9D6*<LR, /)?KCZ4GB3_ )!T?_74?R-
M$H_X\-,_X#_Z+:IJAY&G:<P5V"A2=JEB!Y9'0?6E\]?^><__ 'X?_"@"6O/_
M (O36<OA#^RYM8L=-N[J5)+=[QF"-Y;JS?=5NF1V[UW?GK_SSG_[\/\ X5%,
MMM<;?/M'EV]-]LS8_-: /$O#_CC7[;7;277?B5X=NM+1\W$,,>'=<'@'R%[X
M[BMRS\5^%K;XF:GXE;Q1I1L[JQ2WCC#OY@92"21MQCCU->F_9-/_ .@<O_@&
M?_B:/LFG_P#0.7_P#/\ \31?]?Q%;]/P/$M,LOAIJ$NH:EXSUG3=1U:\NWF+
MP7=P$C0_=08VYP/45<T"\\$Z78>)/#UQXFTQ_#6HOOLXDED:6'<,,#N7'! (
M.3TYKV'[)I__ $#E_P# ,_\ Q-'V33_^@<O_ (!G_P")HZ6Z6M_7W#OK?YG@
M)O;N2*/0Y?BWI_\ PCT850T<;+<;%Q@<)G_Q\_TKKM3\2>$[GQ?X4U.V\5Z<
M;31HYDE\^60RON0*I'RG)XY)(KU#[)I__0.7_P  S_\ $T?9-/\ ^@<O_@&?
M_B::;6O]=OU"QYS>>)_#&K?$OP_K-IXETUH;6&6W:$L_F.\G"[1MP>?4BO5*
MHBUL%((T\ CD$69_^)JSYZ_\\Y_^_#_X4NE@MK<EJ*?[L?\ UUC_ /0Q1YZ_
M\\Y_^_#_ .%-=_,,:K'-GS4/,+ 8# GDB@"GJO\ R,-E_P!L_P#T,UIW7_'[
M!_USD_FE9FJ_\C#9?]L__0S6E>DK=0/LD90C@E$+8)*^@]C0 M%1>>O_ #SG
M_P"_#_X4>>O_ #SG_P"_#_X4 >?_ !.F\-W:6ME?^)(M%UJS=;NRN""6C.2,
MX'4'!'X5Q6A:[Y_B*SU/Q?\ $^PNH;%BT%M8[HQ(?]O"(,>V#GUKV^6*TG??
M-9&1L8R]JQ./Q6F?9-/_ .@<O_@&?_B:%H[H'JK'D#:UX:*^.Q_PE6D?\3\8
MM?GD^3]V5^?Y..3VS26.L^&K;5_!-V_BK1S'H5@]M<A7DR[-&%!3Y.1D=\5[
M!]DT_P#Z!R_^ 9_^)H^R:?\ ] Y?_ ,__$TT[;>7X)K]6)J_X_C;_(\E77O#
M*ZUXWO3XJTCR]=MDBM1ODRA$10[_ ).!D]LU1.I:!:Z'X6FTWQCHL6OZ!"T2
MF82/;S!AAE.%# >^,U[1]DT__H'+_P" 9_\ B:/LFG_] Y?_  #/_P 32_X'
MX7_S93=]_P"KV_R1Y9I_C2%M%U3^TOB1ID>JWC!H/LT'F6]J!_"HD7+ ]\_A
M6;X3GT:Y\?:=JU_KGA2WNXRT,%OH4$D9NY)/E!EW <Y/YFO9?LFG_P#0.7_P
M#/\ \32K;6*.'33]K*<@BT((/_?--.SNA;JQ=HJ+SU_YYS_]^'_PH\]?^><_
M_?A_\*0#C_Q]6O\ UT/_ * U9^J_\C#9?]L__0S5Y',EW;;8Y1M<DEHF4 ;6
M'4CWJCJO_(PV7_;/_P!#- &E+_R$9/\ KDG\WI:9<,8[]V*2%6B0 K&S#(+>
M@]Q3?/7_ )YS_P#?A_\ "@"6BHO/7_GG/_WX?_"CSU_YYS_]^'_PH K:Q=VE
MEH]W<7]T;2U6,B2=6*F,'C((Y!YZUX!>:EJ=Q!)HK?%G2;G0Y08W>ZB+W!0^
MN8R2???^5?0TCQ2H4D@E=#U5K=R#^E0?9-/_ .@<O_@&?_B:5M1W/)9]7\'P
MW?@I;#Q9IQM/#Y82F=W#R H%!4!2,Y'<BJ5[<>#S\6K#Q=8>*M+CLU)DNX'=
MPQDVE=R *1R-N<D=*]G^R:?_ - Y?_ ,_P#Q-'V33_\ H'+_ . 9_P#B:J[O
MS>K^\72WE;[CS7PCXM\*:!J7B.YNO%&ENFIZBUU"(F<E4(Z-E1@_3->CZ+K^
ME>(K-[O2+V*\MTD,321YP& !(Y]B/SI_V33_ /H'+_X!G_XFIHO(MT*0VTD:
MDY(2V8#/X"ET2!ZMLL45%YZ_\\Y_^_#_ .%'GK_SSG_[\/\ X4 2TP_\?5K_
M -=#_P"@-3?/7_GG/_WX?_"A',EW;;8Y1M<DEHF4 ;6'4CWH R;W_D:%_P"N
ML?\ ):V!_P ?5U_UT'_H"UCWO_(T+_UUC_DM:SN8[NYW1RG<X(*Q,P(VJ.H'
MM0!+147GK_SSG_[\/_A1YZ_\\Y_^_#_X4 4/$=[::?X=O[B^NHK6W$11II2=
MJEOE&<9[L!7FNA>)_"VF?"X>&)_%.E->BSFM_,1W,>Y]V#DJ#CYAVKU>1HIH
MS'+!*Z'JK6[D'\,5!]DT_P#Z!R_^ 9_^)I-737?^OU&G9I]OZ_0\>?4_"[>#
MO#=G#XSTNVUO0BLD$X5Y(68##*00"5(_&I-.\1Z->ZQ=:]XG\8:%)J9L7LK6
MWL%D$$*MG+9<;B3^G/6O7?LFG_\ 0.7_ , S_P#$T?9-/_Z!R_\ @&?_ (FF
M];WZW_'1B6EK=/TU/%6U#P\?AUX<\/?\)9HWVO3;V*XF?S)/+95=F(4[,DX8
M=0*VYO$WA&X^),OB"7Q/I9TZ7238-%O?S"Q?).-N,8]\^U>G_9-/_P"@<O\
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M )I_\53:*S-!WVYO^?2?\T_^*H^W-_SZ3_FG_P 53:* '?;F_P"?2?\ -/\
MXJC[<W_/I/\ FG_Q5-HH =]N;_GTG_-/_BJ/MS?\^D_YI_\ %4VB@!WVYO\
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MBSQM<Z%K-EHNDZ(^KZK=1-.L'VI+=1&#C.]^"<] * L=1]HE_P"?*?\ -/\
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M !5'VB7_ )\I_P T_P#BJL44 5_M$O\ SY3_ )I_\51]HE_Y\I_S3_XJK%%
M%?[1+_SY3_FG_P 539+QXHVD>SG"J"Q.4X _X%5JJ]__ ,@ZY_ZY/_(T 6*S
M=;UNVT"R2ZNDE>-Y!&!$ 3D@GN1Z&M*N.^)/_(NV_P#U]K_Z ]73BI229RXV
MM*CAYU(;I?Y!_P +)T?_ )]K_P#[]I_\51_PLG1_^?:__P"_:?\ Q5>6T5V_
M5J9\G_;N,[K[O^">I?\ "R='_P"?:_\ ^_:?_%4?\+)T?_GVO_\ OVG_ ,57
MEM%'U:F']NXSNON_X)ZE_P +)T?_ )]K_P#[]I_\51_PLG1_^?:__P"_:?\
MQ5>6T4?5J8?V[C.Z^[_@GJ7_  LG1_\ GVO_ /OVG_Q5'_"R='_Y]K__ +]I
M_P#%5Y;11]6IA_;N,[K[O^">I?\ "R='_P"?:_\ ^_:?_%4?\+)T?_GVO_\
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M1T_Q)IZQE?+-W]DNH)"?O+*3C9@#C&<^HKO/ML7]R?\ [\/_ (4?;8O[D_\
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M=G?^NY+5U;^MK'E7BCPSXM4>+M-TK0+/4K37F%PEX]VD;PG:J["C?>(QE3D
M>M9FM?#7Q'<>)KG9'JD^F:GY+3&SUM+2.$JBJ1+&T;^9@KP5S7M'VV+^Y/\
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M / 9_P#"CFCW#V%7^5_<_P#(SZ]*TO\ Y)]IG_75_P#T.2N%_L'6/^@3?_\
M@,_^%=]96\UKX$TZ&XADBE65MR2*58?,YY!KGQ+3AH>WD%.<<3)RBU[O9]UY
M'6V'_(.MO^N2?R%6*KV'_(.MO^N2?R%6*X3ZX**** "BBB@ HHHH **** "B
MBB@ HHHH Y_5?^1ALO\ MG_Z&:Z"N?U7_D8;+_MG_P"AFN@H **** "BBB@
MHHHH **** "BBB@ HHHH *Y_5?\ D8;+_MG_ .AFN@KG]5_Y&&R_[9_^AF@#
MH**** "BBB@ HHHH **** "BBB@ HHHH **** .7O?\ D:%_ZZQ_R6NHKE[W
M_D:%_P"NL?\ ):ZB@ HHHH **** "BBB@ HHHH **** "BBB@ KE_#?_ "$9
M/^N1_F*ZBN7\-_\ (1D_ZY'^8H ZBBBB@ HHHH **** "BBB@ HHHH ****
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MO/L:VX$_VL?/M$I.WR]O?;G/-<_KB>$D\;>+;GQ-X8U?4]EXBI=VFY88 8U
M#OYBJI)]:]8M/ 6GZ?KIU*SU+6;>$RF8Z=#?.EJ7)R6\L>I[9Q[5HVGAC3[6
MXUJ4B2==8D\RZBF(9/N!, 8'&!WS4VT7>S_3_@ZC>[[7_P _^ >?ZEI5QI_P
M?L-0UJ\^S:SI'^E6-PS^8R-N/EQDC[V5*J>OZ4WPAITOBGPQ>^(FEBN=?O;O
M-[$P*"$1Y"P@'[NWAQGJP&3WKKH?A]IB6FCV4UYJ%S9:3,9K:VGD1D)_A#?*
M"P3^$9^N:U+'PU9:;XBU#6;22>*74%47$ 8>4[KT?&,AL<$YP?2J=FWY_P#
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M$O\ SY3_ )I_\51]HE_Y\I_S3_XJ@"Q15?[1+_SY3_FG_P 51]HE_P"?*?\
M-/\ XJ@"Q15?[1+_ ,^4_P":?_%4?:)?^?*?\T_^*H L457^T2_\^4_YI_\
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M51[&IV#^U,'_ ,_%_7R.QK'\2?\ (.C_ .NH_D:QO^%DZ/\ \^U__P!^T_\
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M_,5U%<OX;_Y",G_7(_S% '44444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110 4444 %5[_\ Y!US_P!<G_D:L57O_P#D'7/_ %R?^1H
ML5QWQ)_Y%VW_ .OM?_0'KL:X[XD_\B[;_P#7VO\ Z ]:4?XB.#-/]SJ>G^1Y
M;1117IGP 4444 %%%% !1110 4444 %%%% !7I6E_P#)/M,_ZZO_ .AR5YK7
MI6E_\D^TS_KJ_P#Z')7-BO@1[O#W^\R_PO\ -'8V'_(.MO\ KDG\A5BJ]A_R
M#K;_ *Y)_(58KA/L0HHHH **** "BBB@ HHHH **** "BBB@#G]5_P"1ALO^
MV?\ Z&:Z"N?U7_D8;+_MG_Z&:Z"@ HHHH **** "BBB@ HHHH **** "BBB@
M KG]5_Y&&R_[9_\ H9KH*Y_5?^1ALO\ MG_Z&: .@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH Y>]_Y&A?\ KK'_ "6NHKE[W_D:%_ZZQ_R6NHH ****
M "BBB@ HHHH **** "BBB@ HHHH *Y?PW_R$9/\ KD?YBNHKE_#?_(1D_P"N
M1_F* .HHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0CK?_7*+^;5[C7E8G^*SU<-_"1F^>O\ SSG_ ._#_P"%'GK_ ,\Y_P#OP_\
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M10!7^VQ?W)_^_#_X4?;8O[D__?A_\*L44 5_ML7]R?\ [\/_ (4?;8O[D_\
MWX?_  JQ10!7^VQ?W)_^_#_X4?;8O[D__?A_\*L44 5_ML7]R?\ [\/_ (4?
M;8O[D_\ WX?_  JQ10!7^VQ?W)_^_#_X4?;8O[D__?A_\*L44 5_ML7]R?\
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MHH **** "BBB@ HHHH **** .7O?^1H7_KK'_):ZBN7O?^1H7_KK'_):ZB@
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MEI-TD]NS%<@C*D=F'53T.#S@BM6AJP%?[;%_<G_[\/\ X4?;8O[D_P#WX?\
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M@']H5_+[CW3_ (7/X<_Y\M5_[]1__%T?\+G\.?\ /EJO_?J/_P"+KPNBCZO
M/[0K^7W'NG_"Y_#G_/EJO_?J/_XNC_A<_AS_ )\M5_[]1_\ Q=>%T4?5X!_:
M%?R^X]T_X7/X<_Y\M5_[]1__ !='_"Y_#G_/EJO_ 'ZC_P#BZ\+HH^KP#^T*
M_E]Q[I_PN?PY_P ^6J_]^H__ (NMR;6K;Q#X5L]4M$E2">4[5E ##:74YP2.
MH/>OF^O<_"G_ "2K1O\ KK+_ .C)*RK4HPC='7@\54JU'&?8[ZP_Y!UM_P!<
MD_D*L57L/^0=;?\ 7)/Y"K%<QZ04444 %%%% !1110 4444 %%%% !1110!S
M^J_\C#9?]L__ $,UT%<_JO\ R,-E_P!L_P#T,UT% !1110 4444 %%%% !11
M10 4444 %%%% !7/ZK_R,-E_VS_]#-=!7/ZK_P C#9?]L_\ T,T =!1110 4
M444 %%%% !1110 4444 %%%% !1110!R][_R-"_]=8_Y+745R][_ ,C0O_76
M/^2UU% !1110 4444 %%%% !1110 4444 %%%% !7+^&_P#D(R?]<C_,5U%<
MOX;_ .0C)_UR/\Q0!U%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5C^)/\ D'1_]=1_(UL5C^)/^0='
M_P!=1_(T <O1110 4444 =Q?_P#(.N?^N3_R-?&E?9=__P @ZY_ZY/\ R-?&
ME=V"^T<.-^R%%%%=QPA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M >Q? +_D(ZW_ -<HOYM7M+_\A&'_ *Y2?S2O%O@%_P A'6_^N47\VKV:>:.&
M_@:61(U,4@RS #.4KRL3_%9ZN&_A(MT57^WV?_/W!_W\%'V^S_Y^X/\ OX*P
M-RQ15?[?9_\ /W!_W\%'V^S_ .?N#_OX* +%%5_M]G_S]P?]_!1]OL_^?N#_
M +^"@"Q15?[?9_\ /W!_W\%'V^S_ .?N#_OX* +%%5_M]G_S]P?]_!1]OL_^
M?N#_ +^"@"Q7F&H>"[OQ#\4M9N7U+Q#I%J+*V$=SIDYMUG;YLJ6VD-CCCMFO
M1_M]G_S]P?\ ?P4?;[/_ )^X/^_@HZW#I8\_U!=2\%>-9=<71]5UW3;O3H;1
MY+)1/<QO&3@LF06#9R2.^:YW7?#^MZ_I.JZL^EZC8-K&L6+16L0S<P0QX4RL
M%SL;O[8&:]B^WV?_ #]P?]_!1]OL_P#G[@_[^"CU_K6X>G]:6//?#/AR[\,?
M$.6+4&U?68I[8_V?J]Y+)<&!<C?"Y^ZA) (.!GI6CX>L+R#Q5X\FEM)XXKJ:
M(P.\9"R@0@':<?-SQQ78_;[/_G[@_P"_@H^WV?\ S]P?]_!0]5;R:^\.M_-/
M[CQ32O!NJ:I;_#^RN/[=TA;>PNQ<7-ENMY8&+ JK,5.W=Z'K7>>*?"YB^%NH
M:3%-J>KW5M \UK-<RF:Z,RDLA#* 2P. ,=N*Z_[?9_\ /W!_W\%'V^S_ .?N
M#_OX*)>\FNX1]UIF=X2TV/2?">EV<=N8-ELA>-@0V\C+%L\Y+$YSWK&OK*[?
MXNZ1>K:S-:1Z5/&\XC)16+J0I;H"<=*ZK[?9_P#/W!_W\%'V^S_Y^X/^_@IM
MWES?UU_S$E:/+_73_(\>O? VO:EJ/C/4[&_UNRN!J&^WLDN)(+:_C"+D'&"=
MW*[@<5KA+K1KGP]XJTOPQJ<FGPZ2UA-ID<1^U6GS*P(C?!;E2#CD\'FO2OM]
MG_S]P?\ ?P4?;[/_ )^X/^_@I+167]:-?K\N@WJ[_P!=/\CSOP/9^*=<BU\>
M)9+[^S-0@$4+7>GP65SD@JQ*)N/ ( +$].E=-JW@72=9DMGNWN3]GBBB0*RX
M*QN'&<KWQ@^H)%;WV^S_ .?N#_OX*/M]G_S]P?\ ?P4=@WO<@TO2H=&T>/3[
M9I'BB#;3(06.23V [FO*QHNJ_P##.\NF?V9>_P!H%V(M?(;S?^/G=]S&>G/3
MI7K?V^S_ .?N#_OX*/M]G_S]P?\ ?P4+3\/P=QIVM_71K]3Q_P 5:5-:^-GN
M]*\*ZC?ZE<M"Q:]TB"ZLF*@#(G)\R' 'KP1]WD4NNZ7/:?$1[C2?"NH7E]=7
M<4LDE_I$%Q9_P@NESG?%@+D G@_P\BO7_M]G_P _<'_?P4?;[/\ Y^X/^_@I
MQ=K>1+5TT>(ZW::Y!9^)M 3PSK$\EWKZ:A'=PV^Z#R3(AR&!R3\O( ..IQBJ
M^O>$/$%Q\2KTR1ZF%N[]+BUO+;18+I41=I7-R[JT6W&-H].^:]V^WV?_ #]P
M?]_!1]OL_P#G[@_[^"E'W;/M_DE^B'+WK^?_  _ZG%_%+1[S6]*T.SM5OL_V
MQ;F6:R!\R!/F!D! .W&<[N@KFAX1UG3+OQ-I ;5=2OKW3'32];NIY)2$/6!W
M/RQMNY!&,UZS]OL_^?N#_OX*/M]G_P _<'_?P4K:-=[_ (V_R_0=]O+_ #O_
M %_F?/&G>'M3L/"7BN\NH=2M$CT>2VDAN-#@L(Y&R""&C<F4C!^8KR#U[5O:
M1IMW)?0:AH/@1]/%AH<L-U#<VZ1Q:C*Z+L0%3B4'!))^AQ7KVIII&L:9<:=?
MRP36ERACEC\[;N4]1D$$?@:G@N=/MK>."*Y@6.-0B+YH. !@#K5-WO\ UT?^
M>Q-K6_KJO\MSPV'1M0N1X@N[+PIJ6F0WGAN6%;?^S$MQ).&Y"QQ#(/IN^8\X
MXKK_  7X;/\ PG-[J.IZ,=T.F:>MK<7-M]QQ&0X1F'##@''(KT?[?9_\_<'_
M '\%'V^S_P"?N#_OX*$[?UZ_YA;^ON_R.0\7PZCIGBG2/%-GI=SJMO9V\]M<
MVUJ09E5]I#HA(W'Y<$#GD5P5[!XWU_PMXMFO;;4Y[&ZM5%G!=:5%;73/YH^7
MRX]SL%48RQY]*]L^WV?_ #]P?]_!1]OL_P#G[@_[^"DOZ^^Y5];_ -:'F7BW
M1X[)=(TBS\#17>FR6DBK)9:;!+)!<,!@?O!MC!ZER#D@>E9'A_P:;J]\&#5O
M#AF6+1;B&Z-Y8Y"2!AL5]RX!'.W/X5[)]OL_^?N#_OX*/M]G_P _<'_?P4=_
M/_@_Y_@B;:)=O^!_D<;\)+1M/\#0V$VBW&EW=M*\=PL]L(C,^?\ 6#^^,$#=
MWQ[5W55_M]G_ ,_<'_?P4?;[/_G[@_[^"FW=W!*Q8HJO]OL_^?N#_OX*/M]G
M_P _<'_?P4AEBBJ_V^S_ .?N#_OX*/M]G_S]P?\ ?P4 6**K_;[/_G[@_P"_
M@H^WV?\ S]P?]_!0!8HJO]OL_P#G[@_[^"C[?9_\_<'_ '\% %BBJ_V^S_Y^
MX/\ OX*/M]G_ ,_<'_?P4 %A_P @ZV_ZY)_(5P7QG_Y$^T_Z_P!/_1<E=[8?
M\@ZV_P"N2?R%<%\9_P#D3[3_ *_T_P#1<E:4OC1SXO\ @2]#PNBBBO0/G HH
MHH **** "BBB@ HHHH **** "O<_"G_)*M&_ZZR_^C)*\,KW/PI_R2K1O^NL
MO_HR2L,3\)Z&6_Q7Z'?6'_(.MO\ KDG\A5BJ]A_R#K;_ *Y)_(58KB/;"BBB
M@ HHHH **** "BBB@ HHHH **** .?U7_D8;+_MG_P"AFN@KG]5_Y&&R_P"V
M?_H9KH* "BBB@ HHHH **** "BBB@ HHHH **** "N?U7_D8;+_MG_Z&:Z"N
M?U7_ )&&R_[9_P#H9H Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E[
MW_D:%_ZZQ_R6NHKE[W_D:%_ZZQ_R6NHH **** "BBB@ HHHH **** "BBB@
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M457^VQ?W)_\ OP_^%'VV+^Y/_P!^'_PH L457^VQ?W)_^_#_ .%'VV+^Y/\
M]^'_ ,* +%%5_ML7]R?_ +\/_A1]MB_N3_\ ?A_\* +%%5_ML7]R?_OP_P#A
M1]MB_N3_ /?A_P#"@"Q15?[;%_<G_P"_#_X4?;8O[D__ 'X?_"@"Q15?[;%_
M<G_[\/\ X4?;8O[D_P#WX?\ PH L457^VQ?W)_\ OP_^%'VV+^Y/_P!^'_PH
M L457^VQ?W)_^_#_ .%'VV+^Y/\ ]^'_ ,* +%%5_ML7]R?_ +\/_A1]MB_N
M3_\ ?A_\* +%%5_ML7]R?_OP_P#A1]MB_N3_ /?A_P#"@"Q15?[;%_<G_P"_
M#_X4?;8O[D__ 'X?_"@"Q15?[;%_<G_[\/\ X4?;8O[D_P#WX?\ PH L457^
MVQ?W)_\ OP_^%'VV+^Y/_P!^'_PH L457^VQ?W)_^_#_ .%'VV+^Y/\ ]^'_
M ,* +%%5_ML7]R?_ +\/_A1]MB_N3_\ ?A_\* +%%5_ML7]R?_OP_P#A1]MB
M_N3_ /?A_P#"@"Q15?[;%_<G_P"_#_X4?;8O[D__ 'X?_"@"Q15?[;%_<G_[
M\/\ X4?;8O[D_P#WX?\ PH L457^VQ?W)_\ OP_^%'VV+^Y/_P!^'_PH L45
M7^VQ?W)_^_#_ .%'VV+^Y/\ ]^'_ ,* +%%5_ML7]R?_ +\/_A1]MB_N3_\
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M_(U\:5W8+[1PXW[(4445W'"%%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ$8C\W[W/3[M.2MMY_U_7^1,7W\COM-\<^&=4TJ'4H=:LH[:9G5#/.D9RO+
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MW*>9&H&267.0 .<FJ&E^.?#.KZ:M_;ZS9+;M*\*F:=$)9<Y&"?0;A[<UY?\
MV7?ZKXRTJXN/!,VGRP:O(+Z:#38E@DB8. 2X!>4$8W,<+R<]L1:/X7:?3?#6
MDW7A*YB2TU^8WXFL,12IARKD@89,%5W'CC'2E%7_ *\PEI?R_P"#_D>N1>*M
M(EFNE:]M8X+<0DW+7<)C<2C*8PY89XQN SGC-:<5]:3W<]I#=027-OM,T*2
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MHH **** "BBB@ HHHH **** "BBB@#G]5_Y&&R_[9_\ H9KH*Y_5?^1ALO\
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M[^"H9-8L(I&C>?#*2I&QN"/PJ:ZOK>SV?:)-F_.WY2<X^GUH /M]G_S]P?\
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M *;?]^'_ ,*/[0@_Z;?]^'_PIE%9F@_^T(/^FW_?A_\ "C^T(/\ IM_WX?\
MPIE% #_[0@_Z;?\ ?A_\*/[0@_Z;?]^'_P *910 _P#M"#_IM_WX?_"C^T(/
M^FW_ 'X?_"F44 /_ +0@_P"FW_?A_P#"C^T(/^FW_?A_\*910 _^T(/^FW_?
MA_\ "C^T(/\ IM_WX?\ PIE% #_[0@_Z;?\ ?A_\*/[0@_Z;?]^'_P *910
M_P#M"#_IM_WX?_"C^T(/^FW_ 'X?_"F44 /_ +0@_P"FW_?A_P#"C^T(/^FW
M_?A_\*910 _^T(/^FW_?A_\ "IXI4GC$D9)4DCD$=#@\&JM/T_\ X]?^VDG_
M *&U "K?0NH91,5(R"('P1^5+]MB_N3_ /?A_P#"BP_Y!UM_UR3^0JQ0!7^V
MQ?W)_P#OP_\ A1]MB_N3_P#?A_\ "K%% %?[;%_<G_[\/_A1]MB_N3_]^'_P
MJQ69KOB'2?#.FMJ&LWL=I:@[=[Y.3Z  $D\= *+V M_;8O[D_P#WX?\ PH^V
MQ?W)_P#OP_\ A6-:>.?#5_H\&K6NJQS64UPEJDB(Y/FL0%4KC<I)(Z@=:VKJ
M\BLQ$95G;S9!&OE0/+@GH3M!VC_:. .YIV8"?;8O[D__ 'X?_"C[;%_<G_[\
M/_A5BBD!7^VQ?W)_^_#_ .%'VV+^Y/\ ]^'_ ,*L44 5_ML7]R?_ +\/_A1]
MMB_N3_\ ?A_\*@LM9L-0U"_L;6X\RYL'6.Y38P\MF7<!DC!X],UG7/C;P[9Z
M'=:S<:CY=A:W!M9I3#)E)0VTKMV[NOM0!L?;8O[D_P#WX?\ PH^VQ?W)_P#O
MP_\ A58:[IK:K;:8MTK7ES;FZBC56.Z($#=G& .1U/-:- %?[;%_<G_[\/\
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M'^_^AJ1)%D7*'(Z5E5>LO]2?]ZIG!)7*A-MV+-%%%9&H4444 %%%% !1110
M4444 %%%% !1110 5C^)/^0='_UU'\C6Q6/XD_Y!T?\ UU'\C0!R]<=J^LK8
M^/K.+4M5_L_38[0RQ!V"1W$I)4AF/H,$"NQKE?%5W*9DLW\(2:Y;;0^_Y"JM
MDC&&'7C]:-FA[ID'A/43=>)=<@L]3DU+2U*2QRLVY8Y'+%D5AP0./I78URW@
M_5ENS=Z?'X<;14M"N8CM );GH /S[UU--]">K.XO_P#D'7/_ %R?^1KXTK[+
MO_\ D'7/_7)_Y&OC2NW!?:.+&_9"BBBNXX0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /8O@%_R$=;_ .N47\VKV2Z_X_8/^N<G\TKQOX!?\A'6
M_P#KE%_-J]DNO^/V#_KG)_-*\K$_Q6>KAOX2"BBBL#<**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ I^G_\ 'K_VTD_]#:F4_3_^/7_MI)_Z&U #
MK#_D'6W_ %R3^0JQ5"RO;5+"W5KF$,(E!!D&0<"I_M]G_P _<'_?P4 6**K_
M &^S_P"?N#_OX*/M]G_S]P?]_!0!8KS_ .*PTU-)TVXU"?4K V]UYL&J65OY
MRV4@4X:1>I4]. ?PKN/M]G_S]P?]_!1]OL_^?N#_ +^"DT-'@1U75M9\)7;6
M[65R?[<L?LFMKIYM1?2%_O2)@%MIP"<5JRJEOH&AV-PFW6K;Q9 FJ.S;FFF)
M)$I/HRE2/0<=J]H^WV?_ #]P?]_!1]OL_P#G[@_[^"K3M^'X6_K[NPO^#^-_
M\SP.UT6VM=$A\3QO<#58O%;0Q2"=PJ1M<;60)G;@]^,FO2_BE?:3:>'+:'7+
M*6XTRYNEBGD629(X1@D-)Y1W,,\8Z$D5V/V^S_Y^X/\ OX*/M]G_ ,_<'_?P
M5/V5'T_)+]+AUOZ_FW^MCY^TNPCU#3] T9Y;E+&/Q5-##&/-@DC@\K<% 9BZ
M @]SG!JW=6D&E:-K&BO]M7PG8>)!'>Q0R2.T5H8@2N02VS<1G'/->[?;[/\
MY^X/^_@H^WV?_/W!_P!_!3O_ %]W^7XBM_7W_P"?X'FWPD.E'6?%QT0W)TTW
M-O\ 9S<^9OV^5Q_K/FQZ9[8K)NM(:_\ BM?^#YH,Z7<W']N2<<$&'R\?]_#G
M\*]?^WV?_/W!_P!_!1]OL_\ G[@_[^"D]6K]K?U^8+1/S=SPO1/[>U'P[XJN
M[47)U/1[&+0XVB_UC")R92F/XBN,=\T6]OI=UIWB*'P#%J,NCOHEPM^DHF*M
M=\;0HDY,F-V<5[I]OL_^?N#_ +^"C[?9_P#/W!_W\%#UO?M_7XN]NY2TV[_Y
M?Y6]#Q&#Q#IWB#5-/;39)94MO"5U#([P/&N\*H8 L!NP1R1D4WPYHZZ#<^ ;
M[2'N!J&KZ7<)<-).[B7$&Z,;22 %)X P*]P^WV?_ #]P?]_!1]OL_P#G[@_[
M^"FW>[[_ *\W_P E^ DK*W;_ "27Y'@'A<Z#_P )+X+%J=3_ .$A^VO_ &Q]
MJ\[;Y_E-NW;_ )=V>FWMUKTCQK=1:%XS\/\ B358I7T6T@N(I)HX&E%K*VTK
M(P4$@$*1D#C\:[?[?9_\_<'_ '\%'V^S_P"?N#_OX*&]K=/U"V_F>0^*-8TC
M7_ VMZGHNDRVUK/JEF?MSPF,7Q$B?.H.&P.G(_K7-3_VVWQ?F$]W8VVL_P!I
MC[*TZWQG:U##"H(U,/EE<@Y'KDCK7T']OL_^?N#_ +^"C[?9_P#/W!_W\%$7
MRM-?UHE_7W">J:_K<\*O[_2KKXCV>HZ?:7-AKD.O);7IE-S(WDEBH+NS>4BM
MV4 \$8Z<P6NBVUIHD/B>-[@:K%XK:&*03N%2-KC:R!,[<'OQDU[Y]OL_^?N#
M_OX*/M]G_P _<'_?P41]VWE_FG^GXL)>\W_71K]?P/$[-]'TOXNDVS-K.L7%
M^PDW)>V]U:HQY+9_=21K] , =:R?"W]M/\54-S=V4&MB^D-VDBWQN9;?<WRD
M!3!LQ@J>!PO-?07V^S_Y^X/^_@H^WV?_ #]P?]_!2CI;R'+WK^9YY\&]"T^W
M\./K20M_:%S/<0R2M(Q^19GPH4G"C// ZUZ75?[?9_\ /W!_W\%'V^S_ .?N
M#_OX*;=P>[?<L457^WV?_/W!_P!_!1]OL_\ G[@_[^"D!8JO?_\ (.N?^N3_
M ,C1]OL_^?N#_OX*@O;VU>PN%6YA+&)@ )!DG!H OU6O?]2/]ZK-5KW_ %(_
MWJJ'Q(F?PLHT445U'*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %7K+_4G_>JC5ZR_P!2?]ZLZGPFE/XBS1117.= 4444 %%%% !1110 4444
M %%%% !1110 5C^)/^0='_UU'\C6Q6/XD_Y!T?\ UU'\C0!RS,J(SNP55&22
M< "N2UN_U"YO$?1O%>CVEN$ 9)MDA+9/.<^F*ZN6))X7BD4-&ZE64]P>HKR[
MQ!H_A+P]XLMGU?1D@T=K4^5)'$S(9MW(?;R?EQ@>YI=1]#I_">GSQZIJ&I7V
MOVNJWMPB1D6P4+&BYQP#[FNMK@? *Z7)K6L77A^Q:'1Y%C$<S(5WR#.X+GG;
MT^AS7?53Z$KJ=Q?_ /(.N?\ KD_\C7QI7V7?_P#(.N?^N3_R-?&E=N"^T<6-
M^R%%%%=QPA1110 4444 %%%% !1110 4444 %%%% !1110 4444 >Q? +_D(
MZW_URB_FU>R77_'[!_USD_FE>-_ +_D(ZW_URB_FU>R77_'[!_USD_FE>5B?
MXK/5PW\)!7 S?%;3X[N]BC\.>);B"RG>">[M[ 20H4.&)8-T'7IG':N^KYR^
MU>&5N_%%KJOC+Q!I=])JET(["Q>3R906P,HJ$$D\$$C-<]]?D=-M/G_F>W#Q
MAI<FJ:)8P^=,=9@>XM9D4;-BJ&^;)!&0?0_A1<>,-+MO&%OX9?S_ +=/'Y@D
M"#RE."0A;/WB%8@8Z"N"M)KJ+Q+\.)M5B6UGCTNZ:9-@C" 1C^$?=X[=JRGT
MWQQK&F7WBFQBT7[)<W@U:W\TR_:PD7$:K@;!E%Q@]=QSUJVDGY:_G9?Y_(S5
MVO/3\K_UZGK<WB&S@\31Z#(LHN9+1KP28'EA%8*<G.<\^F/>JND^,=,U>QU#
M481-%I=DS*;^=56&4+]YHSG)4>N /3->?>(+!?B#XYT9+34Y[*RU#0'EE> #
M>\9<?)D].2,_0CO5A)+_ %[X8ZYX-,:IX@T>,6\EO$H03HI#(R@<8=1CZFIL
MTG??_@V;^7;YEZ-JVVGXK]?^ .T3QO=3>,5N;[7-87P_=R%;,7>@K;VTA;[B
MK<9W'V) S77^(_'6G^'=0CT\V&J:E?-'YS6VFVOG/''G&]N0 ,CUKC?$?C+3
M/&?A5O"VBVUY)KET(HFLWM)$-F0RDLY*A0%QU!]*B^)*Z'::_;7-YK6L^'-7
MAM52'5H('>"X&<^6=F22,'@XZ]Z'HDO/[]/Z_02UU_I?U_PYWK>,K"7PD/$N
MGV]UJ%AL9V%N$5T5<[B1(R],$$9S[53N/B%IUG-?07EAJ%M<6=HET\,@B)8,
M0 JE7*ELE>,XY'-5_!O]J^*?AT\'B5IO-NA+!YWE>3))%DJK[2/E)'MZ5IZA
MX*TO4M0>]N)+GS'*DA7 7Y49!V_VMWU53VIR5F[?UI_F$6FE_74WK6X2[M(;
MF,,$E19%#=0",\U+45K;I:6D-M&6*1(L:ENI &.:EH=KZ"5[:A1112&%%%%
M!1110 4_3_\ CU_[:2?^AM3*?I__ !Z_]M)/_0VH M45 U[:HQ5KF$,#@@R#
M(-)]OL_^?N#_ +^"@"Q15?[?9_\ /W!_W\%'V^S_ .?N#_OX* +%%5_M]G_S
M]P?]_!1]OL_^?N#_ +^"@"Q15?[?9_\ /W!_W\%'V^S_ .?N#_OX* +%%5_M
M]G_S]P?]_!1]OL_^?N#_ +^"@"Q15?[?9_\ /W!_W\%'V^S_ .?N#_OX* +%
M%5_M]G_S]P?]_!1]OL_^?N#_ +^"@"Q15?[?9_\ /W!_W\%'V^S_ .?N#_OX
M* +%%5_M]G_S]P?]_!1]OL_^?N#_ +^"@"Q15?[?9_\ /W!_W\%'V^S_ .?N
M#_OX* +%%5_M]G_S]P?]_!1]OL_^?N#_ +^"@"Q15?[?9_\ /W!_W\%'V^S_
M .?N#_OX* +%%5_M]G_S]P?]_!1]OL_^?N#_ +^"@"Q15?[?9_\ /W!_W\%'
MV^S_ .?N#_OX* +%%5_M]G_S]P?]_!1]OL_^?N#_ +^"@"Q15?[?9_\ /W!_
MW\%'V^S_ .?N#_OX* +%%-21)4#QNKJ>C*<@TK,JC+$ >YH 6BF>;'_ST3_O
MH4>;'_ST3_OH4[,5T/HIGFQ_\]$_[Z%'FQ_\]$_[Z%%F%T/HIGFQ_P#/1/\
MOH4>;'_ST3_OH46870^BF>;'_P ]$_[Z%'FQ_P#/1/\ OH46870^BF>;'_ST
M3_OH4>;'_P ]$_[Z%%F%T/HIGFQ_\]$_[Z%'FQ_\]$_[Z%%F%T/K'\2?\@Z/
M_KJ/Y&M7S8_^>B?]]"LK7_WU@BQ?O&$H.%Y.,&BS"Z-"P_Y!UM_UR3^0JQ56
MR=$L+=6=0PB4$$\@X%3^;'_ST3_OH46870^BF>;'_P ]$_[Z%'FQ_P#/1/\
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MZ%'FQ_\ /1/^^A19A=#Z*9YL?_/1/^^A1YL?_/1/^^A19A=#ZY_5?^1ALO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@L_^?2#_ +]BC[!9_P#/I!_W[% %BBJ_V"S_ .?2#_OV*/L%G_SZ0?\ ?L4
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M>:?]\BCVJ[![)]S+HK4\J/\ YYI_WR*/*C_YYI_WR*/:KL'LGW,NBM3RH_\
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M/^_@I;2]M+^$S6=U#<Q!BA>&0.NX'!&1W!X-3T 5_M]G_P _<'_?P4?;[/\
MY^X/^_@JQ10 U)$E0/&ZNIZ,IR#2LRJ,L0![FH++_4-_UUD_]#:DO?\ 4C_>
MIQ5W84G97)O-C_YZ)_WT*/-C_P">B?\ ?0K+HK;V2[F/M7V-3S8_^>B?]]"C
MS8_^>B?]]"LNBCV2[A[5]C4\V/\ YZ)_WT*/-C_YZ)_WT*RZ*/9+N'M7V-3S
M8_\ GHG_ 'T*/-C_ .>B?]]"LNBCV2[A[5]C4\V/_GHG_?0H\V/_ )Z)_P!]
M"LNBCV2[A[5]C4\V/_GHG_?0H\V/_GHG_?0K+HH]DNX>U?8U/-C_ .>B?]]"
MLK7_ -]8(L7[QA*#A>3C!I:*/9+N'M7V+MDZ)86ZLZAA$H()Y!P*G\V/_GHG
M_?0K+HH]DNX>U?8U/-C_ .>B?]]"CS8_^>B?]]"LNBCV2[A[5]C4\V/_ )Z)
M_P!]"CS8_P#GHG_?0K+HH]DNX>U?8U/-C_YZ)_WT*/-C_P">B?\ ?0K+HH]D
MNX>U?8U/-C_YZ)_WT*/-C_YZ)_WT*RZ*/9+N'M7V-3S8_P#GHG_?0H\V/_GH
MG_?0K+HH]DNX>U?8U/-C_P">B?\ ?0H\V/\ YZ)_WT*RZ*/9+N'M7V*^I*TF
MNV<B*61=F6 R!\Q[UN>;'_ST3_OH5ET4>R7</:OL:GFQ_P#/1/\ OH4>;'_S
MT3_OH5ET4>R7</:OL:GFQ_\ /1/^^A1YL?\ ST3_ +Z%9=%'LEW#VK[&IYL?
M_/1/^^A1YL?_ #T3_OH5ET4>R7</:OL:GFQ_\]$_[Z%'FQ_\]$_[Z%9=%'LE
MW#VK[&IYL?\ ST3_ +Z%'FQ_\]$_[Z%9=%'LEW#VK[&IYL?_ #T3_OH4>;'_
M ,]$_P"^A6711[)=P]J^QJ>;'_ST3_OH5AZDK2:[9R(I9%V98#('S'O5BBCV
M2[A[5]C4\V/_ )Z)_P!]"CS8_P#GHG_?0K+HH]DNX>U?8U/-C_YZ)_WT*/-C
M_P">B?\ ?0K+HH]DNX>U?8U/-C_YZ)_WT*/-C_YZ)_WT*RZ*/9+N'M7V-3S8
M_P#GHG_?0H\V/_GHG_?0K+HH]DNX>U?8U/-C_P">B?\ ?0H\V/\ YZ)_WT*R
MZ*/9+N'M7V-3S8_^>B?]]"CS8_\ GHG_ 'T*RZ*/9+N'M7V-3S8_^>B?]]"C
MS8_^>B?]]"LNBCV2[A[5]BA=QNWB-951C'YL9W@<8&,\UT?FQ_\ /1/^^A67
M11[)=P]J^QJ>;'_ST3_OH4>;'_ST3_OH5ET4>R7</:OL:GFQ_P#/1/\ OH4>
M;'_ST3_OH5ET4>R7</:OL:GFQ_\ /1/^^A1YL?\ ST3_ +Z%9=%'LEW#VK[&
MIYL?_/1/^^A1YL?_ #T3_OH5ET4>R7</:OL:GFQ_\]$_[Z%'FQ_\]$_[Z%9=
M%'LEW#VK[&IYL?\ ST3_ +Z%'FQ_\]$_[Z%9=%'LEW#VK[&IYL?_ #T3_OH5
MSF@1O#?NTJ-&IB(RPP,Y%7Z*/9+N'M7V-3S8_P#GHG_?0H\V/_GHG_?0K+HH
M]DNX>U?8U/-C_P">B?\ ?0H\V/\ YZ)_WT*RZ*/9+N'M7V-3S8_^>B?]]"CS
M8_\ GHG_ 'T*RZ*/9+N'M7V-3S8_^>B?]]"CS8_^>B?]]"LNBCV2[A[5]C4\
MV/\ YZ)_WT*/-C_YZ)_WT*RZ*/9+N'M7V-3S8_\ GHG_ 'T*/-C_ .>B?]]"
MLNBCV2[A[5]C4\V/_GHG_?0IRLK#*D$>QK)J]9?ZD_[U1*FHJY<:CD[%FBBB
MLS0**** "BBB@ HHHH **** "BBB@ HHHH *Q_$G_(.C_P"NH_D:V*Q_$G_(
M.C_ZZC^1H Y>BBB@ HHHH [B_P#^0=<_]<G_ )&OC2OLN_\ ^0=<_P#7)_Y&
MOC2N[!?:.'&_9"BBBNXX0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /8O@%_P A'6_^N47\VKV2Z_X_8/\ KG)_-*\;^ 7_ "$=;_ZY1?S:O9+K
M_C]@_P"N<G\TKRL3_%9ZN&_A(****P-PHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "GZ?\ \>O_ &TD_P#0VIE/T_\ X]?^VDG_ *&U #K+_4-_
MUUD_]#:EO6C2PN&E=TC$3%FC!+*,<D 9.?I267^H;_KK)_Z&U6*35U8:=G<^
M=_"LVD:!XA\.QVW_  CFO6\MV(K.]T]V@U*,OG+3QC!8 $Y#"MSX;WVH_P!M
MVUGJ,EQ:Z9YM^VFK#,52ZF$S%_-P>2 3M4\<$^E>MVV@:-9ZA)J%KI%A!>R9
MWW,5LBR-GKE@,FI$T;2XXX8TTVS6."4S1*(% CD.<NHQPQR>1SR:J^@FCQ7P
M[-KGB67PEI\GB;6+5+NTU!KF:"Z/F2!92%Y;/(X .,@=,5Z)\-]4N[OP(LVI
M7<UU-:S7$#7$GS2.L<C $^IP!]:Z6VT32K)X'M=,LH'@5EA:*W53&&.6"X'
M)Y..M3VEE:6$)AL[6&VB+%RD,81=Q.2<#N3R:&]&D#UE?S_S/$M'\2M-XRL9
MM'\4ZGJ%KJEK=R3VU[J*2M#M0LA\I$ A.>@SGZ=Y?"]QK^GQ^!=8G\2:KJ$F
ML++#<6ES/OAVA&9,#&=V0,L22?6O78O#VBP-NAT?3XV\QI<I;(#O889N!U(.
M">XJ5-'TR)+1(].M$2R.;55@4" XQ\G'R\'MBA:+3^M_\Q/5W/"M/U!-4U'P
M9J%UXNN=0UBZUE9+O2995*VK ./ECQNCQP.3@YS7?_%&]'AQ]!\6A&8:;=/%
M+MSS'+&5YQVW!*['_A'M$%Z;P:/I_P!J,HF,_P!F3?Y@& ^[&=P!//6K5]86
M>IVK6M_:07=NQ!:*>,2(2#D9!&.#2>R2T_I?\$:^)M_UO_P/N/!)=*N=%6Q\
M+2[BWBY+.><D$_OA)NN,G_=(_*M37->NH[_Q#J#^+[O3M:TJ]-OIFA1RJL4\
M8"[ 82,R;\]>V:]FFTZQN+JVNIK.WDN;;/D3/$I>+(P=I(RN1Z4R72-,N-1B
MU&;3K22^A&([EX%,B#V8C(_"G?7^OE]RT^8NFO\ 7?[WK\CQ_7_&,VG6_P 0
M[:[UU[+4!]G^P6[7A62,F)21",Y')YVU!JCZ[>W'C>^C\4:Q:1Z-:VMS;06]
MQA#)Y 8[L@_*<<@$ D\YKV*[T#1M0N7N;W2;"YG>/RFEFMD=F3^Z21DCVZ4\
MZ-I96Z4Z;9[;M0ER/(7$R@8 ?CY@!Q@]J73S*6AY+XAUQM4U22/6?%MQX?MX
M]"ANK6**9(UNY)%;?N##]X!P-H_"MB+_ )-N/_8!;_T UZ#<:)I-X+<7.EV4
MXMAM@$MNC>4,8PN1\O''%2C3; :;_9HLK;[!Y?E?9?*7RMG]W9C&/;%$M8R2
MZ_YO_/\  4='%OI_DE^GXGENBV]]JOC*"V.NZK:V5CH5C=+:VMP4CD?G[PYX
M..0,9[FL?2Y=8@^&6C>()/$NM7%YJ&I6T+K+>,41!<,"%QSR.#DG/ Z5[5#I
MEA;SF>"QMHIC$L)D2)58QK]U,@?='8=!48T72EL8K$:99BSA<216X@7RT8'(
M*KC (/.1WJN;6_\ 7Q-O\+(E1M&W]?#;\]3Q/6]>O'AUV_D\97]KK,>KK:IH
M\5P$5(%F4*0@^894Y+@X.<'-7/$/B9/^$T@O-(\4:F+J+68M/FTRXU!$B9=P
M5]ML$R5YQO8CUYXKJ+[X5R7WB6ZOW\13G3;NY2YN;*2U221RC!E03M\ZQ@@8
M3H.?6NVDT'1YKF:XETFP>>8J996MD+2%3E2QQDX(!&>F*4-%%O\ K1?GK]Y4
MM6[?UO\ EI]QX@ ^@Z1XU>Q\1:D;]-?AB:-KWYU0RI\Y P06R5)Z$+CM6AKO
MB&\&H>(M2E\87>GZWI=Z8--T-)56.X0!=F82,R[\GYNV:]>E\/Z-/+<2S:18
M227)5IW>V0F4J<J6)'S8(XSTJ272-,GU&+4)M.M)+Z$8BN7@4R(/9B,C\*(Z
M6\K?@DOT_%@]6WW_ ,_Z^X\>UY]>O=3\>WR>)-7T]=&@M[FWM+:XP@D\G<00
M0?ER.0, YYS7=^*)K35/A/<2ZO?R6$%W81F:ZCB:3RRX7DJHR5R>?;/2NG?2
M--D-X7T^T8WH"W6Z%3YX P _'S<<<YJPMO"MN+=88Q %V",*-H7&,8Z8QVI/
M6/+Z?K_P/N!-J2E_73_@_>>&>$=4CT7Q#=6UAI_AN_U+^R9VMK[P[*VQUC 9
M5GB4[=Q..>N>/>KGAW6IOMVARV/C*[UZYU>WD;5;":=)$M<1%BRH!F':V!CO
MFO7--T/2-&\S^R]*L;'S.7^RVZ1;OKM S3K;1M+LKBXN+73;.":Y_P!?)% J
MM+_O$#+?C0]5\O\ /_/\ 6G]>G^7XGC7@KQ%'H:>"UU#5Q8Z9)HER66>X\N%
MY!+QP2 6QG'>J.F%M77X<:KJOB/4HFENKM#,U[M!VNY7EN[<(>>1Q7M[>']%
M>WM;=M'T\P6C;K:,VR%83ZH,84_2@^']&-K;VITBP-O;R>;!#]F39$^<[E&,
M Y).1SS5<VM_ZW?^8DO=Y?ZVL>0PZ]J%QX>T6SU+Q)>Z7IU]JU]%>:J+C;)&
MJ,QCC$K9V XZ_P"SBFC5=:U%=&TNQ\4:A)9?\)"UE;ZM%*/,N;<0Y.3C;(0<
MC<002,]J]B;1-);3WT]M+LC92,6>V-NGEL2<DE<8))YIXTG35CM(QI]H$LSN
MME$*X@.,908^7CCBDK=?+]/\OQU'+7;S_7_/\-#DOAQ->Q-XBT>\U*\U%-,U
M)H(+B\DWRE"BMAF[X)-=S4%O96EI)/);6L,,EP_F3-'&%,C8QN8CJ<#J:GHO
M>P=RO9?ZAO\ KK)_Z&U)>_ZD?[U+9?ZAO^NLG_H;4E[_ *D?[U.'Q(F?PLHT
M445U'*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7K+_4G_>J
MC5ZR_P!2?]ZLZGPFE/XBS1117.= 4444 %%%% !1110 4444 %%%% !1110
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M,>H-9/NF<@$@19SQG'7\*PO%?A>?PKJB6LD\=S!-$L]O<QC"RQGH<=OI79^
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M]BC[!9_\^D'_ '[%6** *_V"S_Y](/\ OV*/L%G_ ,^D'_?L58HH K_8+/\
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M+/L_Q#FAW7X%GRH_^>:?]\BCRH_^>:?]\BJW]KZ;_P!!&T_[_+_C1_:^F_\
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M_P O^-']KZ;_ -!&T_[_ "_XT<L^S_$.:'=?@6?*C_YYI_WR*/*C_P">:?\
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MFI+<:<7LR6BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "L?Q)_P @Z/\
MZZC^1K8K'\2?\@Z/_KJ/Y&@#EZ*** "BBB@#N+__ )!US_UR?^1KXTK[+O\
M_D'7/_7)_P"1KXTKNP7VCAQOV0HHHKN.$**** "BBB@ HHHH **** "BBB@
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MHHH **** "BBB@#V+X!?\A'6_P#KE%_-J]DNO^/V#_KG)_-*\;^ 7_(1UO\
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M_P#&@"&/1=*BBM8H],LTCM&WVR+ H$+8QE!CY3@GI5ZJ_P!BB_OS_P#?]_\
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M ,BO_C1_PBNB_P#/E_Y%?_&CZ]3[,/J%3NCS6BO2O^$5T7_GR_\ (K_XT?\
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M%C<V[$A98-CJ<'!P1QU!% %^BJ_V"S_Y](/^_8H^P6?_ #Z0?]^Q0!8HJO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM_W_ '_QJU16!N5?[/@_Z;?]_P!_\:/[/@_Z;?\ ?]_\:M44 5?[/@_Z;?\
M?]_\:/[/@_Z;?]_W_P :M44 5?[/@_Z;?]_W_P :/[/@_P"FW_?]_P#&K5%
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M]^?_ +_O_C5BB@"O]BB_OS_]_P!_\:/L47]^?_O^_P#C5BB@"O\ 8HO[\_\
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MO_(K_P"-;-%'MJG\S^\/8T_Y5]QC?\(KHO\ SY?^17_QH_X171?^?+_R*_\
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M5_\ &MFBCVU3^9_>'L:?\J^XQO\ A%=%_P"?+_R*_P#C1_PBNB_\^7_D5_\
M&MFBCVU3^9_>'L:?\J^XQO\ A%=%_P"?+_R*_P#C1_PBNB_\^7_D5_\ &MFB
MCVU3^9_>'L:?\J^XQO\ A%=%_P"?+_R*_P#C1_PBNB_\^7_D5_\ &MFBCVU3
M^9_>'L:?\J^XQO\ A%=%_P"?+_R*_P#C1_PBNB_\^7_D5_\ &MFBCVU3^9_>
M'L:?\J^XQO\ A%=%_P"?+_R*_P#C6/J&A:;!K-K;QVVV)]FY=['.6(/>NQKG
M]5_Y&&R_[9_^AFCVU3^9_>'L:?\ *ON)_P#A%=%_Y\O_ "*_^-'_  BNB_\
M/E_Y%?\ QK9HH]M4_F?WA[&G_*ON,;_A%=%_Y\O_ "*_^-'_  BNB_\ /E_Y
M%?\ QK9HH]M4_F?WA[&G_*ON,;_A%=%_Y\O_ "*_^-'_  BNB_\ /E_Y%?\
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MB_\ /E_Y%?\ QH_X171?^?+_ ,BO_C6S11[:I_,_O#V-/^5?<8W_  BNB_\
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M"S_Y](/^_8H^P6?_ #Z0?]^Q7%?%SQ!;:+X,-K<7?V7^TYDLS*%+%(V/[QL
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M^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>\?!3_ )$V\_["
M#_\ HN.O!Z]X^"G_ ")MY_V$'_\ 1<=<>/\ X/S1V8#^-\F>D4445X9[@444
M4 %%%% !1110 4444 %%%% !1110 5C^)/\ D'1_]=1_(UL5#<VL-W&(YTWJ
M#N R1S^% '"T5V']B:=_S[_^/M_C1_8FG?\ /O\ ^/M_C0!Q]%=A_8FG?\^_
M_C[?XT?V)IW_ #[_ /C[?XT 6+__ )!US_UR?^1KXTK[1D198VC<95@5(]0:
MY_\ X0+PG_T+VG_]^1710K*E>ZW.>O1=6UGL?)U%?6/_  @7A/\ Z%[3_P#O
MR*/^$"\)_P#0O:?_ -^171]=CV.?ZE+N?)U%?6/_  @7A/\ Z%[3_P#OR*/^
M$"\)_P#0O:?_ -^11]=CV#ZE+N?)U%?6/_"!>$_^A>T__OR*/^$"\)_]"]I_
M_?D4?78]@^I2[GR=17UC_P (%X3_ .A>T_\ [\BC_A O"?\ T+VG_P#?D4?7
M8]@^I2[GR=17UC_P@7A/_H7M/_[\BC_A O"?_0O:?_WY%'UV/8/J4NY\G45]
M8_\ "!>$_P#H7M/_ ._(H_X0+PG_ -"]I_\ WY%'UV/8/J4NY\G45]8_\(%X
M3_Z%[3_^_(H_X0+PG_T+VG_]^11]=CV#ZE+N?)U%?6/_  @7A/\ Z%[3_P#O
MR*/^$"\)_P#0O:?_ -^11]=CV#ZE+N?)U%?6/_"!>$_^A>T__OR*/^$"\)_]
M"]I__?D4?78]@^I2[GF'P"_Y".M_]<HOYM7M+_\ (1A_ZY2?S2JFE^'='T22
M232].M[1I %<PIMW =,^M7I;>.9E9]X900"KLIP<9Z'V%<=6?/-R1V4H<D%%
MDM%5_L47]^?_ +_O_C1]BB_OS_\ ?]_\:S-"Q15?[%%_?G_[_O\ XT?8HO[\
M_P#W_?\ QH L457^Q1?WY_\ O^_^-'V*+^_/_P!_W_QH L457^Q1?WY_^_[_
M .-'V*+^_/\ ]_W_ ,: +%%5_L47]^?_ +_O_C1]BB_OS_\ ?]_\: +%%5_L
M47]^?_O^_P#C1]BB_OS_ /?]_P#&@"Q15?[%%_?G_P"_[_XT?8HO[\__ '_?
M_&@"Q15?[%%_?G_[_O\ XT?8HO[\_P#W_?\ QH L5FZUX?TKQ%;P0:M9K=10
M3+<1JS$;9%Z'@CUZ=#5K[%%_?G_[_O\ XT?8HO[\_P#W_?\ QH K7VA:;J6H
M65_=VWF7-D)!;OO8;-Z[6X!P<CUS5*V\%^'K22QD@TY4>QMGM+=O-<E(F^\O
M)Y^IR1FM;[%%_?G_ ._[_P"-'V*+^_/_ -_W_P : &Z;IMIH^FV^G6$7DVEL
M@CBCW%MJCH,DDG\:M57^Q1?WY_\ O^_^-'V*+^_/_P!_W_QH;OJP(+G1M/O-
M6LM4N+?S+RQ#BWD+MB/>,-\N<$D#J1FJ.J^#= UO4?M^H6'FW6Q$+B:1,JC[
MUR%8 X;GG^5:OV*+^_/_ -_W_P :/L47]^?_ +_O_C0&YFW/A+0[O^U_/L=_
M]KA%OOWKCS0HPO1OEP/[N*'\):&ZZLK661JT:Q7O[U_WJJNP#K\OR\?+BM+[
M%%_?G_[_ +_XT?8HO[\__?\ ?_&CR S4\(Z"C7)_LZ-Q=6L=G.LC,ZO"@PJD
M$D<9Z]:IZ?\ #WPII6C7VDV.CQ0V5\I2Y42.6D7T+EMV/QXK>^Q1?WY_^_[_
M .-'V*+^_/\ ]_W_ ,: *J:!ID>IVFHK;8N[2W-K!)YC?)$<97&<'H.2,U%J
M/AC1M6N;FXOK(32W-F;&4F1ANA)R5P#@<]QS[U?^Q1?WY_\ O^_^-'V*+^_/
M_P!_W_QH>NX+38RO^$,\/%&1M-C9'L5TYD9V93;J<JF"<<>O7WJII_PZ\):7
M:W%M9:+###<VQM9T#N1+&3G#9/)Y^\>?>N@^Q1?WY_\ O^_^-'V*+^_/_P!_
MW_QH>H&7HO@_0O#TOF:58_9W^SK:Y\YW_=J20OS,>['GKS3;/P7X>L!9+;Z<
M MBLJVR/*[K'YA)?AF().3R><''2M;[%%_?G_P"_[_XT?8HO[\__ '_?_&C^
MOZ^\%H0Z1I%CH6FQ:=IT)AM(L^7&9&?;DYP"Q) YZ=!VJ]5?[%%_?G_[_O\
MXT?8HO[\_P#W_?\ QH L457^Q1?WY_\ O^_^-'V*+^_/_P!_W_QH L457^Q1
M?WY_^_[_ .-'V*+^_/\ ]_W_ ,: +%%5_L47]^?_ +_O_C1]BB_OS_\ ?]_\
M: +%%5_L47]^?_O^_P#C1]BB_OS_ /?]_P#&@"Q15?[%%_?G_P"_[_XT?8HO
M[\__ '_?_&@"Q15?[%%_?G_[_O\ XT?8HO[\_P#W_?\ QH L457^Q1?WY_\
MO^_^-'V*+^_/_P!_W_QH L57O_\ D'7/_7)_Y&C[%%_?G_[_ +_XTC6,+J58
MS%2,$&=\$?G0!9KS?XU_\B;9_P#803_T7)7I%9NMZ!IGB*R2TU6V^T0)()53
MS&3# $9RI!Z$UK1FH5%)]#*M!SIN*ZGRC17TA_PJWP9_T!O_ ":F_P#BZ/\
MA5O@S_H#?^34W_Q=>I_:-+LSR_[.J]T?-]%?2'_"K?!G_0&_\FIO_BZ/^%6^
M#/\ H#?^34W_ ,71_:-+LP_LZKW1\WT5](?\*M\&?] ;_P FIO\ XNC_ (5;
MX,_Z W_DU-_\71_:-+LP_LZKW1\WT5](?\*M\&?] ;_R:F_^+H_X5;X,_P"@
M-_Y-3?\ Q=']HTNS#^SJO='S?17TA_PJWP9_T!O_ ":F_P#BZ/\ A5O@S_H#
M?^34W_Q=']HTNS#^SJO='S?17TA_PJWP9_T!O_)J;_XNC_A5O@S_ * W_DU-
M_P#%T?VC2[,/[.J]T?-]%?2'_"K?!G_0&_\ )J;_ .+K-UOX;^$[2R22#2=C
M&0*3]HE/&#ZM1_:-+LP_LZKW1X#17T5:?##P=+902/H^6:-6)^TS<DC_ 'ZF
M_P"%6^#/^@-_Y-3?_%T?VC2[,/[.J]T?-]%?2'_"K?!G_0&_\FIO_BZ/^%6^
M#/\ H#?^34W_ ,71_:-+LP_LZKW1\WT5](?\*M\&?] ;_P FIO\ XNC_ (5;
MX,_Z W_DU-_\71_:-+LP_LZKW1\WT5](?\*M\&?] ;_R:F_^+H_X5;X,_P"@
M-_Y-3?\ Q=']HTNS#^SJO='S?17TA_PJWP9_T!O_ ":F_P#BZ/\ A5O@S_H#
M?^34W_Q=']HTNS#^SJO='S?17TA_PJWP9_T!O_)J;_XNC_A5O@S_ * W_DU-
M_P#%T?VC2[,/[.J]T?-]%?2'_"K?!G_0&_\ )J;_ .+H_P"%6^#/^@-_Y-3?
M_%T?VC2[,/[.J]T?-]%>\:A\._"L&LVMO'I6V)]FY?M$ISEB#_%6Q_PJWP9_
MT!O_ ":F_P#BZ/[1I=F']G5>Z/F^BOI#_A5O@S_H#?\ DU-_\71_PJWP9_T!
MO_)J;_XNC^T:79A_9U7NCYOHKZ0_X5;X,_Z W_DU-_\ %T?\*M\&?] ;_P F
MIO\ XNC^T:79A_9U7NCYOHKZ0_X5;X,_Z W_ )-3?_%T?\*M\&?] ;_R:F_^
M+H_M&EV8?V=5[H^;Z*^D/^%6^#/^@-_Y-3?_ !='_"K?!G_0&_\ )J;_ .+H
M_M&EV8?V=5[H^;Z*^D/^%6^#/^@-_P"34W_Q='_"K?!G_0&_\FIO_BZ/[1I=
MF']G5>Z/F^BOI#_A5O@S_H#?^34W_P 71_PJWP9_T!O_ ":F_P#BZ/[1I=F'
M]G5>Z/F^BOI#_A5O@S_H#?\ DU-_\76/J'P[\*P:S:V\>E;8GV;E^T2G.6(/
M\5']HTNS#^SJO='@]%?2'_"K?!G_ $!O_)J;_P"+H_X5;X,_Z W_ )-3?_%T
M?VC2[,/[.J]T?-]%?2'_  JWP9_T!O\ R:F_^+H_X5;X,_Z W_DU-_\ %T?V
MC2[,/[.J]T?-]%?2'_"K?!G_ $!O_)J;_P"+H_X5;X,_Z W_ )-3?_%T?VC2
M[,/[.J]T?-]%?2'_  JWP9_T!O\ R:F_^+H_X5;X,_Z W_DU-_\ %T?VC2[,
M/[.J]T?-]%?2'_"K?!G_ $!O_)J;_P"+H_X5;X,_Z W_ )-3?_%T?VC2[,/[
M.J]T?-]%?2'_  JWP9_T!O\ R:F_^+H_X5;X,_Z W_DU-_\ %T?VC2[,/[.J
M]T?-]%?2'_"K?!G_ $!O_)J;_P"+H_X5;X,_Z W_ )-3?_%T?VC2[,/[.J]T
M?-]%>Y7/P^\+QZ\MLNEXA,B+M^T2]#C/.[WK>_X5;X,_Z W_ )-3?_%T?VC2
M[,/[.J]T?-]%?2'_  JWP9_T!O\ R:F_^+H_X5;X,_Z W_DU-_\ %T?VC2[,
M/[.J]T?-]%?2'_"K?!G_ $!O_)J;_P"+H_X5;X,_Z W_ )-3?_%T?VC2[,/[
M.J]T?-]%?2'_  JWP9_T!O\ R:F_^+H_X5;X,_Z W_DU-_\ %T?VC2[,/[.J
M]T?-]%?2'_"K?!G_ $!O_)J;_P"+H_X5;X,_Z W_ )-3?_%T?VC2[,/[.J]T
M?-]%?2'_  JWP9_T!O\ R:F_^+H_X5;X,_Z W_DU-_\ %T?VC2[,/[.J]T?-
M]%?2'_"K?!G_ $!O_)J;_P"+H_X5;X,_Z W_ )-3?_%T?VC2[,/[.J]T?-]%
M?2'_  JWP9_T!O\ R:F_^+K!T3X?>%[N]>.?2]ZB,L!]HE'.1Z-1_:-+LP_L
MZKW1X;17TA_PJWP9_P! ;_R:F_\ BZ/^%6^#/^@-_P"34W_Q=']HTNS#^SJO
M='S?17TA_P *M\&?] ;_ ,FIO_BZ/^%6^#/^@-_Y-3?_ !=']HTNS#^SJO='
MS?17TA_PJWP9_P! ;_R:F_\ BZ/^%6^#/^@-_P"34W_Q=']HTNS#^SJO='S?
M17TA_P *M\&?] ;_ ,FIO_BZ/^%6^#/^@-_Y-3?_ !=']HTNS#^SJO='S?17
MTA_PJWP9_P! ;_R:F_\ BZ/^%6^#/^@-_P"34W_Q=']HTNS#^SJO='S?17TA
M_P *M\&?] ;_ ,FIO_BZ/^%6^#/^@-_Y-3?_ !=']HTNS#^SJO='S?7O'P4_
MY$V\_P"P@_\ Z+CK8_X5;X,_Z W_ )-3?_%UO:)H&F>';)[32K;[/ \AE9/,
M9\L0!G+$GH!7/B<7"K3Y8IG1AL).E4YI-&E1117G'HA1110 4444 %%%% !1
M110 4444 %%%% !3))HX5W2R)&I.,LP S3ZQ_$G_ "#H_P#KJ/Y&@#0^WV?_
M #]P?]_!1]OL_P#G[@_[^"N'HH [C[?9_P#/W!_W\%'V^S_Y^X/^_@KAZ* .
M]F"F&0,YC4J<N#@J,=<]JS(X[..17_MB5MI!VM<@@^QJ]?\ _(.N?^N3_P C
M7QI6]&C[6^MK&%:M[*VE[GU_.+.>9I/[6DCS_#'<@*/H*DEDLY;=(?[2V;,?
M.DX#' QR:^/**W^I?WC#Z[_=/L.UDL[;?_Q,O-W8_P!;.&Q]*ACCLXY%?^V)
M6VD':UR"#[&OD*BCZE_>#Z[_ '3[!N6L[F0/_:C18&-L5P%'UIWF6?V/[/\
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M2Y!]CQ4ES9?:9 _VJYBP,;8I-H^M.^Q1?WY_^_[_ .-'V*+^_/\ ]_W_ ,:
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M)Y=V/]:^['TJ&/3?+D5_MMXVT@[6ER#['BIOL47]^?\ [_O_ (T?8HO[\_\
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M3ZGC]36Y6/XD_P"0='_UU'\C0!8TZUVZ<O\ I$Y\Z)>K_<X_A].OZ"I(-/\
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M/\B99/M=W)C^&23*GZC%30V_DR2OYTK^8<[7;(7KP/3K7Q)7T;\ ?^1$OO\
ML)R?^BHJRK87V4.:]RZ=;G=K'JE%%%<AL%%%% !1110 4444 %%%% !1110
M4444 %8_B3_D'1_]=1_(UL5C^)/^0='_ -=1_(T <O1110 4444 =Q?_ /(.
MN?\ KD_\C7QI7V7?_P#(.N?^N3_R-?&E=V"^T<.-^R%%%%=QPA1110 4444
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M:?#%;Z/I,\MWY)D=W,Q!"XW9XR[MDGKC%=73;37W_I^MPMK_ %W?Z6"BBBI
M**** "BBB@ HHHH *KW_ /R#KG_KD_\ (U8JO?\ _(.N?^N3_P C0!8HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *Q_$G_(.C_ZZC^1K8K'\2?\ (.C_
M .NH_D: -"P_Y!UM_P!<D_D*L57L/^0=;?\ 7)/Y"K% !1110 4444 %%%%
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M?V?\D_\ B:/L\O\ S^S_ ))_\35BBL#<K_9Y?^?V?\D_^)H^SR_\_L_Y)_\
M$U8HH K_ &>7_G]G_)/_ (FC[/+_ ,_L_P"2?_$U8HH K_9Y?^?V?\D_^)H^
MSR_\_L_Y)_\ $U8HH K_ &>7_G]G_)/_ (FC[/+_ ,_L_P"2?_$U8HH K_9Y
M?^?V?\D_^)H^SR_\_L_Y)_\ $U8HH K_ &>7_G]G_)/_ (FC[/+_ ,_L_P"2
M?_$U8HH K_9Y?^?V?\D_^)H^SR_\_L_Y)_\ $U8HH K_ &>7_G]G_)/_ (FC
M[/+_ ,_L_P"2?_$U8HH K_9Y?^?V?\D_^)H^SR_\_L_Y)_\ $U8HH K_ &>7
M_G]G_)/_ (FC[/+_ ,_L_P"2?_$U8HH K_9Y?^?V?\D_^)H^SR_\_L_Y)_\
M$U8HH K_ &>7_G]G_)/_ (FC[/+_ ,_L_P"2?_$U8HH K_9Y?^?V?\D_^)H^
MSR_\_L_Y)_\ $U8HH K_ &>7_G]G_)/_ (FC[/+_ ,_L_P"2?_$U8HH K_9Y
M?^?V?\D_^)H^SR_\_L_Y)_\ $U8HH K_ &>7_G]G_)/_ (FC[/+_ ,_L_P"2
M?_$U8HH K_9Y?^?V?\D_^)H^SR_\_L_Y)_\ $U8HH K_ &>7_G]G_)/_ (FC
M[/+_ ,_L_P"2?_$U8HH K_9Y?^?V?\D_^)H^SR_\_L_Y)_\ $U8HH K_ &>7
M_G]G_)/_ (FC[/+_ ,_L_P"2?_$U8HH K_9Y?^?V?\D_^)H^SR_\_L_Y)_\
M$U8HH K_ &>7_G]G_)/_ (FC[/+_ ,_L_P"2?_$U8HH K_9Y?^?V?\D_^)H^
MSR_\_L_Y)_\ $U8HH K_ &>7_G]G_)/_ (FC[/+_ ,_L_P"2?_$U8HH K_9Y
M?^?V?\D_^)ILEF\L;1O>3E6!4C"<@_\  :M44 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !6/XD_P"0='_UU'\C6Q6/XD_Y!T?_ %U'\C0!H6'_ "#K
M;_KDG\A5BJ]A_P @ZV_ZY)_(58H **** "BBB@ HHHH **** "BBB@ HHHH
MY_5?^1ALO^V?_H9KH*Y_5?\ D8;+_MG_ .AFN@H **** "BBB@ HHHH ****
M "BBB@ HHHH *\^\?^#M.\7ZWID6H3742Q+M7[.RJ2';G.5/H*]!KG]5_P"1
MALO^V?\ Z&:J,G%WCN)I-69Q?_"@?"O_ $$-9_[_ $7_ ,;H_P"% ^%?^@AK
M/_?Z+_XW7JE%:?6*O\Q'LH=CRO\ X4#X5_Z"&L_]_HO_ (W1_P *!\*_]!#6
M?^_T7_QNO5**/K%7^8/90['E?_"@?"O_ $$-9_[_ $7_ ,;H_P"% ^%?^@AK
M/_?Z+_XW7JE%'UBK_,'LH=CRO_A0/A7_ *"&L_\ ?Z+_ .-T?\*!\*_]!#6?
M^_T7_P ;KU2BCZQ5_F#V4.QY7_PH'PK_ -!#6?\ O]%_\;H_X4#X5_Z"&L_]
M_HO_ (W7JE%'UBK_ #![*'8\K_X4#X5_Z"&L_P#?Z+_XW1_PH'PK_P!!#6?^
M_P!%_P#&Z]4HH^L5?Y@]E#L>5_\ "@?"O_00UG_O]%_\;H_X4#X5_P"@AK/_
M '^B_P#C=>J44?6*O\P>RAV/$KCX,>'(M9%FM[JIC+HN3+'G!QG^#WK9_P"%
M ^%?^@AK/_?Z+_XW767O_(T+_P!=8_Y+744?6*O\P>RAV/*_^% ^%?\ H(:S
M_P!_HO\ XW1_PH'PK_T$-9_[_1?_ !NO5**/K%7^8/90['E?_"@?"O\ T$-9
M_P"_T7_QNC_A0/A7_H(:S_W^B_\ C=>J44?6*O\ ,'LH=CRO_A0/A7_H(:S_
M -_HO_C='_"@?"O_ $$-9_[_ $7_ ,;KU2BCZQ5_F#V4.QY7_P *!\*_]!#6
M?^_T7_QNC_A0/A7_ *"&L_\ ?Z+_ .-UZI11]8J_S![*'8\K_P"% ^%?^@AK
M/_?Z+_XW1_PH'PK_ -!#6?\ O]%_\;KU2BCZQ5_F#V4.QY7_ ,*!\*_]!#6?
M^_T7_P ;H_X4#X5_Z"&L_P#?Z+_XW7JE%'UBK_,'LH=CRO\ X4#X5_Z"&L_]
M_HO_ (W6-I/P8\.7]TT4M[JH4(6^66/.<C_8]Z]MKE_#?_(1D_ZY'^8H^L5?
MY@]E#L<G_P *!\*_]!#6?^_T7_QNC_A0/A7_ *"&L_\ ?Z+_ .-UZI11]8J_
MS![*'8\K_P"% ^%?^@AK/_?Z+_XW1_PH'PK_ -!#6?\ O]%_\;KU2BCZQ5_F
M#V4.QY7_ ,*!\*_]!#6?^_T7_P ;H_X4#X5_Z"&L_P#?Z+_XW7JE%'UBK_,'
MLH=CRO\ X4#X5_Z"&L_]_HO_ (W1_P *!\*_]!#6?^_T7_QNO5**/K%7^8/9
M0['E?_"@?"O_ $$-9_[_ $7_ ,;H_P"% ^%?^@AK/_?Z+_XW7JE%'UBK_,'L
MH=CRO_A0/A7_ *"&L_\ ?Z+_ .-T?\*!\*_]!#6?^_T7_P ;KU2BCZQ5_F#V
M4.QY7_PH'PK_ -!#6?\ O]%_\;KM/"'A#3_!6DRZ;ILUS+#+.9RURRLVXJJX
M^50,84=JZ"BIE6J35I.Y2A%.Z04445F4%%%% !1110 4444 %%%% !1110 4
M444 %8_B3_D'1_\ 74?R-;%8_B3_ )!T?_74?R- '+UY[X_T>=KXWB:OI]A:
MWULME=F\?:VP/NS'ZGDC%>A5YM\0K*5=4EOKC1Y]4M)=.>VMS#'YAMIR2=Y7
MMGCYNV*75%+4Z+PYI;PZWJ>HO<VTB%8[2WC@.?+B09&__:.ZNGKB?!,<]UK&
MIZP--N=.L[F*&-8KA=CRR*#ND*]NH'O7;53_ *_'^OF1'^OP.XO_ /D'7/\
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M\O\ \51_PFGBK_H9M9_\#Y?_ (JL.BO9Y(]C@YGW-S_A-/%7_0S:S_X'R_\
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MS:S_ .!\O_Q5'_":>*O^AFUG_P #Y?\ XJL.BCDCV#F?<W/^$T\5?]#-K/\
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MS:S_ .!\O_Q5'_":>*O^AFUG_P #Y?\ XJL.BCDCV#F?<W/^$T\5?]#-K/\
MX'R__%4?\)IXJ_Z&;6?_  /E_P#BJPZ*.2/8.9]S<_X33Q5_T,VL_P#@?+_\
M51_PFGBK_H9M9_\  ^7_ .*K#HHY(]@YGW-S_A-/%7_0S:S_ .!\O_Q5'_":
M>*O^AFUG_P #Y?\ XJL.BCDCV#F?<W/^$T\5?]#-K/\ X'R__%4?\)IXJ_Z&
M;6?_  /E_P#BJPZ*.2/8.9]S<_X33Q5_T,VL_P#@?+_\51_PFGBK_H9M9_\
M ^7_ .*K#HHY(]@YGW-S_A-/%7_0S:S_ .!\O_Q5'_":>*O^AFUG_P #Y?\
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M8HJO]GE_Y_9_R3_XFC[/+_S^S_DG_P 30!8HJO\ 9Y?^?V?\D_\ B:/L\O\
MS^S_ ))_\30!8HJO]GE_Y_9_R3_XFC[/+_S^S_DG_P 30!8HJO\ 9Y?^?V?\
MD_\ B:/L\O\ S^S_ ))_\30!8HJO]GE_Y_9_R3_XFC[/+_S^S_DG_P 30!8J
MGJNEV6MZ7<:;J,/G6=PFR6/<5W+Z9!!'X&I/L\O_ #^S_DG_ ,31]GE_Y_9_
MR3_XFAJX&!X=^'?A3PI>/>:+H\=M<LNTRM(\C >@+L<?A3;GX<>$;RUMK:YT
M2&:*VG>XB621SAW;<V3NR03R5.1[5T/V>7_G]G_)/_B:/L\O_/[/^2?_ !-
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MO=5,9=%R98\X.,_P>];/_"@?"O\ T$-9_P"_T7_QNCZY2_I!["9\Y45]&_\
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MY_\ O^_^-8&Y8HJO]BB_OS_]_P!_\:/L47]^?_O^_P#C0!8HJO\ 8HO[\_\
MW_?_ !H^Q1?WY_\ O^_^- %BBJ_V*+^_/_W_ '_QH^Q1?WY_^_[_ .- %BBJ
M_P!BB_OS_P#?]_\ &C[%%_?G_P"_[_XT 6**K_8HO[\__?\ ?_&C[%%_?G_[
M_O\ XT 6**K_ &*+^_/_ -_W_P :/L47]^?_ +_O_C0!8HJO]BB_OS_]_P!_
M\:/L47]^?_O^_P#C0!8HJO\ 8HO[\_\ W_?_ !H^Q1?WY_\ O^_^- %BBJ_V
M*+^_/_W_ '_QH^Q1?WY_^_[_ .- %BBJ_P!BB_OS_P#?]_\ &C[%%_?G_P"_
M[_XT 6**K_8HO[\__?\ ?_&C[%%_?G_[_O\ XT 6**K_ &*+^_/_ -_W_P :
M/L47]^?_ +_O_C0!8HJO]BB_OS_]_P!_\:/L47]^?_O^_P#C0!8HJO\ 8HO[
M\_\ W_?_ !H^Q1?WY_\ O^_^- %BBJ_V*+^_/_W_ '_QH^Q1?WY_^_[_ .-
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M10 4444 %%%% !1110 4444 <_JO_(PV7_;/_P!#-=!7/ZK_ ,C#9?\ ;/\
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M/J5]<WDRZ@Z"2YF:1@OEQG&6).,D\>]9U<*Z<>9LJ%93=K'I5%%%<IL%%%%
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MF9H_,=#.F%SCC!4<<#BO0-'\+6NC>%?^$>CN[V[M1&\0>\E$CA&!&W. , '
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MT?\ UU'\C0!H6'_(.MO^N2?R%6*KV'_(.MO^N2?R%6* "BBB@ HHHH ****
M"BBB@ HHHH **** .?U7_D8;+_MG_P"AFN@KG]5_Y&&R_P"V?_H9KH* "BBB
M@ HHHH **** "BBB@ HHHH **** "O!_VA?^0CH/_7*;^:U[Q7@_[0O_ "$=
M!_ZY3?S6NC"_QD95O@9XM1117LG"%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5]&_ '_D1+[_L)R?^BHJ^<J^C?@#_ ,B)??\ 83D_]%15
MRXS^%]QM0^,]4HHHKR#M"BBB@ HHHH **** "BBB@ HHHH **** "L?Q)_R#
MH_\ KJ/Y&MBL?Q)_R#H_^NH_D: ./O[5;[3[FT<D+/$T9([!AC^M<'HGA7Q%
M_:.C1ZP+-;#0T86YA<DW#8PI([8&*]$HH6CO_7]:@]58Y3PMI>K_ -L:IKVM
M0Q6US>A(X[:-]WEQIG&3W)KJZ** ZW.XO_\ D'7/_7)_Y&OC2OLN_P#^0=<_
M]<G_ )&OC2N[!?:.'&_9"BBBNXX0HHHH **** "BBB@ HHHH **** "BBB@
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M?\D_^)JQ10!7^SR_\_L_Y)_\31]GE_Y_9_R3_P")JQ10!7^SR_\ /[/^2?\
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MM_UR3^0JQ5>P_P"0=;?]<D_D*L4 %%%% !1110 4444 %%%% !1110 4444
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M@AK/_?Z+_P"-UZI11]8J_P P>RAV/*_^% ^%?^@AK/\ W^B_^-T?\*!\*_\
M00UG_O\ 1?\ QNO5**/K%7^8/90['E?_  H'PK_T$-9_[_1?_&Z/^% ^%?\
MH(:S_P!_HO\ XW7JE%'UBK_,'LH=CRO_ (4#X5_Z"&L_]_HO_C='_"@?"O\
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M $$-9_[_ $7_ ,;K&TGX,>'+^Z:*6]U4*$+?++'G.1_L>]>VUR_AO_D(R?\
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M3C9[5:_X7!X[_P"@[_Y*0?\ Q%</11[&G_*ON#GEW.X_X7!X[_Z#O_DI!_\
M$4?\+@\=_P#0=_\ )2#_ .(KAZ*/8T_Y5]P<\NYW'_"X/'?_ $'?_)2#_P"(
MH_X7!X[_ .@[_P"2D'_Q%</11[&G_*ON#GEW.X_X7!X[_P"@[_Y*0?\ Q%'_
M  N#QW_T'?\ R4@_^(KAZ*/8T_Y5]P<\NYW'_"X/'?\ T'?_ "4@_P#B*/\
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M_P 17#T4>QI_RK[@YY=SN/\ A<'CO_H._P#DI!_\11_PN#QW_P!!W_R4@_\
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M[U^UEGAGO(ECN8$9?)E*_=<C&=X'&0>E:.R\_P">\'_?D_\ Q5&R\_Y[P?\
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M>#_OR?\ XJ@"Q15?9>?\]X/^_)_^*HV7G_/>#_OR?_BJ +%%5]EY_P ]X/\
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M<?\ AG?_ *FG_P I_P#]MH_X9W_ZFG_RG_\ VVCZU1[A[&?8\.HKW'_AG?\
MZFG_ ,I__P!MH_X9W_ZFG_RG_P#VVCZU1[A[&?8\.HKW'_AG?_J:?_*?_P#;
M:/\ AG?_ *FG_P I_P#]MH^M4>X>QGV/#J*]Q_X9W_ZFG_RG_P#VVC_AG?\
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M32E3E&5VCJJ***\XZ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>new_004.jpg
<TEXT>
begin 644 new_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,Y!;L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "KFF
M:5?ZU?)9:;:R7-R_1(QV]3V ]SQ6CX3\*:AXOUE-/L0%4?--.P^6)/4^I]!W
M_,CZ:\,>%-*\)Z:+338,,0/-G?!DE/JQ_IT%85JZIZ+<WHT'4U>QYGX;^!B[
M$G\1WK;CS]EM3T]F<_T'XUZ)IO@'PII2*+;0K,LO(>9/-;/KE\FNDI 01D$'
MM7GSK3GNST84H0V1%#9VUNVZ"WAB.,91 O'IQ4U-,BB14++E@2 3R<>@ID3R
MM-,'B*(I 1MP._CDXZCTY]*S+N2T444AA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?%E%%%>X>&%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYO"WA"SN_$=LBZY<*RI8P'.]P> ""V!@KDY/7\*Q(?$OQ3\L7TGA.R:TQN,
M;;+M^A<G/_ ?PI*E)Z@ZL5H>H45YUH_Q+DUSQU8:+;6:Q6T]NSW"SHPG@E4/
ME#SCC:.W>O1:F4'#1E1FI:H****DH**** /BRBBBO</#"BBB@ HHHH ****
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MW5MXBN+R%N#+;[-K$=<=<?3G%<'\2O"%AX-UNULM/FN98IK<2L;AE9@=Q'&
M..*]0^!T4T'A;48)TDC=+]@8W!!7Y$['I7'_ !W_ .1KT_\ Z\A_Z&U<:G-5
M^3FNO^ =SA!T'/EL_P#@GE=%7+?2=2NX1+;:?=S1G@/'"S _B!27^E:CI3HF
MHV%U9NXW(MQ"T98>HW 9KMNKV.*SM>Q4HJY;Z3J-W$);;3[J:,G&^*%F&?J!
M1?Z3J6EF/^T=/N[/S 2GVB%H]X'ID#-%UL%G:]BG116A8Z%K&IQ^98:5?7:#
M^*"W>0?F!0W;<25]C/HJ[?:/J>EX_M#3KRTW' ^T0-'G\P*VOAW:V]]X^TFV
MN[>*X@DD8/%*@=6&UNH/!I75KH?*[V9S%%?2?Q!\,:!9> ]7N+70],@GCARD
ML5I&K*=PZ$#(KYLK*C656]EL:UJ+I6N]PHJ6WMI[N=8+:"2:5ONQQH68_0"M
M*7PIXC@C,DOA_58T'5GLY !^.*U;2W9DDWLC(HJQ+8WEO:PW4UI/';SY$4KQ
MD))C@[2>#CVJO3%:P4458L]/O=1E\JQM)[F3^Y!&7/Y 4 5Z*V)/"?B.%"\O
MA_58T'5FLY /Y5D$$$@C!'4&DFGLQN+6Z$HJ>VL[J]D,=I;33N!DK$A8@>N!
M5F;0=9MK-[R?2;^*U0X:9[9U13[L1BFVEN"3>QGT5H6.A:OJD9DT_2KZ[0'!
M:WMWD _$ U6N[*ZL)S!>6TUM,.L<T91A^!YHNKV%9VN0445=L-'U/5=W]G:=
M=WFW[WV>!I,?7:#1>P6N>B>$OAOX6\2Q 1^+C<731AC;10")XSCYAAR2P!.,
M@8K2\7_"/1?#G@^^U6"^OYKJW52H=D"'+ <@+GH?6N:^'.DZII/Q*T;[?I]Y
M9[WD \^%H\_NV]0*]E^*7_)-]8_W$_\ 0UKAKSG&:Y9:/_,[\/3A.+YHZK_(
M^7****[C@+FF:7?ZS>I9Z=:RW-P_2.-<G'J?0>YKLI?A)K=G:)<:KJ>B:4K\
M!;V\V'/ID*1GZ&O6?A+X?MM'\%6MXL8^UZ@OG2R8Y(R=J_0#]2:\<^*LVH2?
M$#45OS)M1@+=6Z"+'&WV//XYKF]M*57V<=+'2J,8TO:2U&:C\,?$ME:+>6UO
M#JEHPR)].E$RD>H Y(^@K!USP]JOAN[CM=6M#;3R1B54+JV5)(S\I..AXKH/
MAQXRG\*^(H4DF/\ 9ERX2YC)^49X#^Q'\LUT'QVVGQ9I[#'-D.1W^=JKGG&H
MH/5.^HE"G.G*2T:/+***U+7PSKU] L]IHFI7$+<K)%:2.I_$"MVTMSG2;V,N
MBK%Y87FG3>3>VD]M+_<GC*-^1J&..2:58HD9Y'.%51DD^@%"=]@::W&T5J1>
M&=>F)$6B:E(5&3MM)#@?E5:QTK4=3E:/3["ZNY$^\MO"TA'U !I<R[CY7V*E
M%375G<V-PUO>6TUO.OWHYD*,/J#S4--.XFK;A1110!Z3\)_ NF^++B^N]6W2
M6UIM40*Y7>S9Y)'. !V]:O\ Q6^'>D>&M,M]6T97MXVE$,ENTA<<@D,"Q)[<
M\UQ_@S7_ !)X=O)KO0+:2X5P%GB\AI(V]-VWD'KT(JYXWU_QAXB@M[G7M.N+
M.Q1L1*+5XH2Q'7+9R< ]_6N><:CJIIZ'33E35)IQN]>G];'%T45<L=(U/5"1
MI^G7=V5X/V>!I,?D#71L<UKE.BM"]T'6-,B\V_TF^M(_[\]L\8_,BL^A-/8&
MFMPHJ>TLKN_G$%G:S7,QY$<,9=OR%7KCPQX@M(3-<Z%J<,2]7DM)%4?B12;2
MW8U%O9&5113HXY)I5BB1GD<X55&23Z 4Q#:*V#X3\2"/S#X?U41XSN-E)C'K
MG%49--OXK5[J2RN4MTD\EI6B8(K_ -TG& WMUI<R[CY7V*M%%%,04444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVYDX^?\ 5SF:35^5J7E_5C'^(6KQ^)=-\"7DL9BL;^XWSH3D+R@(S[9>O:
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M%S=32%YY?F48.?NCV!/2K'QV_P"11L/^OT?^@-6$W:O%I6V_4VIJ]"2;OO\
MH<Q\'O&NI1ZS9^%YBDNGR+)Y0V -$V"_4=0>>N>M>K^.I=,@\'WTVL0R3V,>
MQY(8S@R$,"%SV!. ?:O _A/_ ,E+TG_MK_Z*:O:_BO\ \DVU7Z1_^C%IXN*5
M2+77_,>#DW!I]/\ (Y'P1\6KC5O$]KHDNDV=I83?NK9;8$&+ R ><$<8X KJ
M/BQH5MJW@>\NGC7[38KY\4F.0 ?F'T(S^E>'_#?_ )*)HG_7Q_0U]$>/?^1!
MUW_KSD_E4XF"ISBX_P!:AAIN<9*7]:,^??ASX/'C#Q(+><LMC;KYMR5."1G
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M["V>.6);@17$;H,2JI."#U!P3T]>]:\/QP\16T$<$&F:+%%&H5(T@D55 Z
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M176)9]2NH+%8+J-+6.:+9)C>S,X(W<C'RCM52'7]6GU&YL4T./SK=4:3-Z,
M-G&/E]C46B+IZ^+]6&G>7Y7V>$MY7W-^Y\XQQ^7?-26WF_\ "5^(O)_UOV:W
MV?[VU\4<L5=6Z(2G4DD^;>36EO/:Z\C9DU33XKH6LE];)<$X$32J&S],YJ2Z
MO;6QC$EW<PP(3@-*X4$_C7!Z7 +CPNZ74VCH9-WVHW:L)EDR<ER3D-G^E:<,
M<2^+!'KDD<ICL8A:23?ZMFQ^\*YXW$X]\4.BDWKL$<7.23LM;?*]]_Z6NAKZ
MIK0M[;3Y[&2">*YO8K=G!W+M8X)!!ZU?MM3L+R5HK6^MIY%^\D<JL1^ -<OX
M@MM*FTZSMM/$ @EU>!9A;$ ;CP>G0XQ5_4--L;#6-#GL[6&WD^TF$M$@7*&)
MS@XZ]!2Y(\J[Z_TRE6JJ;>C2Y>_7M_P3HZ***P.T**** "BBB@ HHHH ****
M /BRBBBO</#"BBB@ HHHH **** "BBB@#Z<U"ST#Q!X'TG1-6OH+>6[LXGM=
M\BJX<(,,H/7KT[Y->(ZW\-/%6BWC0_V5<7L6<)-9QF56'KA1D?B*Y&M.U\2:
M[8PB&SUK4;>(# 2&Z=%'X UA&E*$FXO<WE5C.*C);(]>^%'@R_\ #,]WXAU]
M5T^,P&*-)G"D*2"6;^[T YYZUS'Q6\<6_BK4;;2]*;S+&U<GS>@FD/&1[#IG
MODUP5]K&IZIC^T-1N[O!R/M$[28/XDU2H5%NI[2;V!UDJ;IP6Y[S\+OAMJWA
MO6'UC6##$_D&..!'WL"V,EB..,=B>M<Q\1OAEJEC?ZIX@LVAGTYW:XD&_;)%
MDY;@\$9/8Y]J\MHH]E/GY^;\ 56')R<OXGOWP[\?Z7:_#L)J>HV\5WIRNBPR
MS*LDJJ,KM!.3P=O'I7D6GZ1K?CWQ%=M8PB>[E9IYBTBJ%!;D\GH,CIDUSU%5
M&DHSE-;LEUG*"@]D?6'@70+CPQX0LM*NY(WN(MS.8SE068M@?3-<!\6/A_K6
MN:R=<TU89X8[8))$9 CC:221G@C!]>U>'45E]7DI^TYM?0U^L1</9N.GJ%>W
M?"SX>:_H/B$:QJL,5M"('18_-#NQ;&#\N0!^/X5XC1714BY1LG8YX2497:N?
M6_C#1)O$7A/4-*MY$CFN(P$:3.W(((SCMQ7S'XF\)ZMX2O([;588T:52T;1R
M!E<#J1CD?B!6)16-&@Z3T>AM6KJJM5L=%X:\$:[XL5Y-*MD>"-]DDLDJJJ'&
M>03D_@#7U/IMJUEI=I:.P9H(4C+#H2J@?TKXVHIUJ+JZ7T)HU53UMJ>H_$OX
M>:Y#K.K>(H4BGTYW,[LL@#1KCG*G&>?3->7445I2@X1Y6[V)JS4Y<R5KFAHN
MB:AXAU)-/TN#S[IP6";U7@<GEB!7TO\ #KPU>>%/"<>G7[Q-<F9Y6\ILJ,XP
M,X'I7RQ14UJ;J+EO9#I5%3ES-79]!?%?P%K'BJ[L[[21#*;>%HWA=]C'G(P3
MQ^9%> 2Q/#,\4@PZ,589Z$=:9111INFN6]T.M551\UK,*^A_A!X0U7PS9:A<
MZK&D+7OEF.(.&("[N21D<[AWKYXHJJD'./*G:Y%.:A+F:N?1GQ8\%ZMXLM-/
MDTE8I);0R;HG<(6# =">.W<CK7SO/#);7$D$J[9(V*.N<X(."*CHJ*-)TURW
MNBZU557>UF>M?"+X@6FBQOH.KSB&UDD\RWG<X6-CU5CV!ZY^M;/QC\'ZAK<M
MCKFCVKWNV+RID@&]BN<JP Y(Y/3VKPRM"RU[6-,B\JPU:_M(_P"Y!<O&/R!I
M3H7FJD79CA7M!TY*Z/<?A'X8N?"NC:AJVMJ+%KG;A)R$,<:Y.6S]W)/0^E<-
M\5_'D'BB]ATW3)"^G6K%C)C EDZ9'L!T^IKA+[6=4U0 :AJ5Y=@'(^T3M)C\
MR:I4*A>I[2;U&Z]J?LX(]^^$'CBUO=&A\/7TZQWUK\MOO('G1]0![CICTQ[U
M-\0_A5+XIU0:MI5U!;W;J%FCGR$?' ;(!(...G85\]@D'(.#6J_B?Q!);FW?
M7=3: C!C:[D*X],9Q4SP[Y_:0=F.&(7)[.:NCZ(^'&A6?A;0+NQ358+V:.X+
M7<D9_=Q2;5^4'V&/S[5S'Q:\-6NOSVVJP^(-*M7AA,1BN[@() "6^4C.3STQ
M7A-%+ZO+GY^;7T&L3%0Y.73U/9_@3KEM"=1T2:14GE<3P!CC?@88#WX!Q]:Z
MSXE_#VY\:+97%A=0PW5L&3;/D(ZD@]0"01CTKYN1WCD62-F1U(*LIP0?4&M.
M;Q1X@N;=K>?7=3E@8;6C>[D92/0@G%.I0<JBJ1=F*G748.G)71[W\,-&TGPW
M#JMA;:FE]>Q-&U]-'Q$APV$4^V#D^_X54^*^@67B:QLKF/7],LY;0N +NX")
M)NP<;NQ^7TYKYZHI/#MSY^;7T''$14'#ET]3V#X/^/+33(F\.ZM.L,32%[29
MSA 3U0GMD\@^Y]J]"\>^ [;QOI\)6<6][!DP3[=RD'JI]CZ]J^7:TK/Q#K>G
M0B&QUC4+6(=$@N71?R!IU</S2YXNS%2Q'+'DDKH]'M/A);^'?^)IXQUFRCT^
M [C#;LQ,V/X<L >?0 D^U<QHWB'2X/BG:ZS#:1Z?IGVKY8D&!&A!7)].N3CB
MN7O=2OM3E$M_>W-W(. \\K2$?B356M(PE>\W<SE.-K05CZ_U[2XO$7AR]TWS
M@J7<)195^8#/0^_:OGO7OAMJ_@V.VU*]O=.EC^THB)%(Y=CGK@J/3GFN7M/$
M>N:?;B"RUK4;:$=(X;IT4?@#BJ=U>75].9[RYFN)CP9)G+L?Q-9T:$Z4KIZ&
ME:O"K&THZGN'Q.\"Q^)]1DOM#G@DUJ"-1=6(D4.Z8^5L$\''KU'TKG/A9X;\
M7:9XSBD>POK&P3<+OST,:2#!P,'[W..F<5Y?#/+;3+-!*\4J\JZ,58?0BM.7
MQ7XBFB,4NOZI)&>JM>2$?EFG&E.,.1.Z\Q2JPG)3:L_(]@^-/BS3QHG_  CM
MO,DUY+*KS*ASY2J<\^Y../2O"***NC25*-D16JNK*YU?PWU&STOQ]I=U?,J0
M!V0NQP$+*5!/XD5])>)='_X2+PU?:6LPB^U1%5DQD ]0?IQ7R%6I;^)M>L[9
M;:VUO4H(%&%BBNY%4#T !Q45Z'M;-.UBZ%?V5TU>Y[1\._"$/@;Q+)!JFLV4
MFK7L!2&T@8GY 0Q8D@'/' QZ]>VU\5_"VJ>*?#MM#I,2S7%O<"0Q%PA8;2."
M2!W[FOFYKF=[G[2TTC3[MWFEB6W>N>N:T9?%/B&> P2Z]JDD1&#&]Y(5(^F:
MF>'G*2GS:HN&(A&+ARZ,]"^%7@;7(/%<&M7,"06=F\T3$R*Q9P&0J ">A[]/
M3->M>.-$N?$7@^_TNS9!<3*NSS#@$A@<9_"ODVBG5H2J23;V\B:6(5--);^9
MZ1\-O!NM_P#"=17+VRI#I5T4NV,JG8X!^4 ')^HX]Z]V\3:9-K/AC4]-MV19
MKFW>-"YP,D<9KY!HHJT'4:;>WD%*O&G>RW\ST3P=JEW\,?'DMAKB>5#*HBN0
MC!PH/*.,=AGZX)XSQ7M?BCP_8>.O"QM%N4,<N);:YCPX5AT8>HY(_&OE"K]A
MKFKZ7&T>GZI>VB,<E;>X>,$_0$4ZM!SM*^J"EB%3NK:,]@\&_#-_"7C"QO=8
MUFR\[>ZV=M 27F.TYSD#  R>,_6O0_%]G9Z[X:U#1Y=2M[1YDP7=Q\A!#<C/
M3BOE.ZO+J^G,]Y<S7$S=9)G+L?Q/-0U,\/*I9REJO(J&)C3NHQT]31UO21HN
MHFS&H6%^ H83V,WFQG/;..OM6=1174DTM3E;3>A].:A9Z!X@\#Z3HFK7T%O+
M=V<3VN^15<.$&&4'KUZ=\FO$=;^&GBK1;QH?[*N+V+.$FLXS*K#UPHR/Q%<C
M6G:^)-=L81#9ZUJ-O$!@)#=.BC\ :PC2E"3<7N;2JQG%1DMD>O?"CP9?^&9[
MOQ#KZKI\9@,4:3.%(4D$LW]WH!SSUKE_BSXZMO$]]!IVF/YFGV;%C+VED/&1
M[ <9[Y-<'?:QJ>J8_M#4;N[P<C[1.TF#^)-4J%1;J>TF]@]LHT_9P6Y[M\)/
MB!8OI$/AW5+A;>ZM_EMI)6 65">%R?XAG&.XQ6S\0?A?'XONDU*QNDM-05-C
M^8I*2@=,XY!'KSQVKYPK4MO$VO64*PVNMZE!$HP$BNY%4?@#4SP[<^>#LRJ>
M(2AR35T>BVOPEM/#@_M/QGK5G'8PG=Y-LS$S8_AR0#^ !/N*YBU\/W'C_P 6
MWLGAO3(;.Q60,4WA5A0\ D9ZG!.%%<K>7]YJ,WG7UW/=2]-\\A=OS)JO6L(S
M3YI/7\#.4X6Y8QT_$^T-G[K9G^'&:^5_%_@;6?"4PEU".(VTTA6*>.0$,>3C
M'4<>U<O165+#NG*Z?X&E7$*I'E:_$*[+X8^(SX=\:6KR/MM;L_9I^> &/!_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *='(\4BR1NR2(0RLIP5(Z$&FT4 >E^'/C3KNE(D&J1)JD"\!G;9*!_O
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M_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\
M$T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O
M_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X
M R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_
M /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N
M:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\
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M?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\
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M+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\
M^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ
M_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T
M+FK_ /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_
M /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[
MQ/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\
MA#O$_P#T+FK_ /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&
M_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW
M/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U
M*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLN
MP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^
MNR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKF
MBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:
M^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_
M^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P#
M&7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG_P"A<U?_
M , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S
M5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\
MH7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG
M_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PA
MWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'
M_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\
M$T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O
M_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X
M R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_
M /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N
M:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\
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M?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\
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M+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\
M^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ
M_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T
M+FK_ /@#+_\ $T?\(=XG_P"A<U?_ , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_
M /0N:O\ ^ ,O_P 31_PAWB?_ *%S5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[
MQ/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P# &7_XFOKFBCZ[+L'U*/<^1O\
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M^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\ H7-7_P#
M&7_XFOKFBCZ[+L'U*/<^1O\ A#O$_P#T+FK_ /@#+_\ $T?\(=XG_P"A<U?_
M , 9?_B:^N:*/KLNP?4H]SY&_P"$.\3_ /0N:O\ ^ ,O_P 31_PAWB?_ *%S
M5_\ P!E_^)KZYHH^NR[!]2CW/D;_ (0[Q/\ ]"YJ_P#X R__ !-'_"'>)_\
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M?_$T?\+.\9_]!Z?_ +X3_P")H^IS[H/KD.S/J:BOEG_A9WC/_H/3_P#?"?\
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M -_W_P :0S2HK-\A?^>D_P#W_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\
M]_W_ ,:/(7_GI/\ ]_W_ ,: -*BLWR%_YZ3_ /?]_P#&CR%_YZ3_ /?]_P#&
M@#2HK-\A?^>D_P#W_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\ ]_W_ ,:/
M(7_GI/\ ]_W_ ,: -*BLWR%_YZ3_ /?]_P#&CR%_YZ3_ /?]_P#&@#2HK-\A
M?^>D_P#W_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\ ]_W_ ,:/(7_GI/\
M]_W_ ,: -*BLWR%_YZ3_ /?]_P#&CR%_YZ3_ /?]_P#&@#2HK-\A?^>D_P#W
M_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\ ]_W_ ,:/(7_GI/\ ]_W_ ,:
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M7_P%1W^2+=0SJ&EP=K%21M8]1]* +=%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])
M_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])
M_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])
M_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])
M_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])
M_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])
M_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])
M_P#O^_\ C1Y"_P#/2?\ [_O_ (T :5%9OD+_ ,])_P#O^_\ C1Y"_P#/2?\
M[_O_ (T :5%9OD+_ ,])_P#O^_\ C5NR9GL+=F)+&)223R3@4 3T5 [,+^%<
MG:8G)&>,Y3_$T7K,EA<,I(81,00>0<&@">BLWR%_YZ3_ /?]_P#&CR%_YZ3_
M /?]_P#&@#2HK-\A?^>D_P#W_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\
M]_W_ ,:/(7_GI/\ ]_W_ ,: -*BLWR%_YZ3_ /?]_P#&CR%_YZ3_ /?]_P#&
M@#2HK-\A?^>D_P#W_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\ ]_W_ ,:/
M(7_GI/\ ]_W_ ,: -*BLWR%_YZ3_ /?]_P#&CR%_YZ3_ /?]_P#&@#2HK-\A
M?^>D_P#W_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\ ]_W_ ,:/(7_GI/\
M]_W_ ,: -*BLWR%_YZ3_ /?]_P#&CR%_YZ3_ /?]_P#&@#2HK-\A?^>D_P#W
M_?\ QH\A?^>D_P#W_?\ QH TJ*S?(7_GI/\ ]_W_ ,:/(7_GI/\ ]_W_ ,:
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M;3EF6/;C!5A*H.X9'(X.:[^P^'>BVNG7]I=RW^JM?QB*XN=1N3+,R+RJAN,
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MZ;?]_P!_\:QK!&-U'@D?,,UT?04@*O\ 9\'_ $V_[_O_ (T?V?!_TV_[_O\
MXU:HH J_V?!_TV_[_O\ XT?V?!_TV_[_ +_XU:HH J_V?!_TV_[_ +_XT?V?
M!_TV_P"_[_XU:HH IFSMA(L9,VY@6 \Y^@QGO[BG?V?!_P!-O^_[_P"-.?\
MY",/_7*3^:58H J_V?!_TV_[_O\ XT?V?!_TV_[_ +_XU:HH J_V?!_TV_[_
M +_XT?V?!_TV_P"_[_XU:HH J_V?!_TV_P"_[_XT?V?!_P!-O^_[_P"-6J*
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M>K2LXFE@";5#-)'G>JKLRV,'IFI;J6VL=)EU2ZO[J&SBA,\CO$ RH!DDKLW
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M[E2W[L';@-P,5"U_#] 9ZE>M;Z>L+76H3QB:9((SL4Y=CA1PO<]^E6?L+?\
M/W/^2?\ Q->::[K]IJ6JWLT6KN^EP:AI92>%]\:99BS(>1@\9(]/:GK=3:CJ
M5C966L:A+H<VMF&WN8KV3=-%]E=G03 [G0.#ALGD<'@8<4V*^K/2/L+?\_<_
MY)_\31]A;_G[G_)/_B:\SMY]2BM=)N(M4U*6XEU"_P!.*O=.X>*-9_+&TG!<
M&-3O^\>YI#XIOKVVT^/0]2DN]1A\-7+RQ)(7/VI1"!O!ZR [N&Y&?>BQ5M;?
MUO8]-^PM_P _<_Y)_P#$T?86_P"?N?\ )/\ XFO.I=4L8](C.D^)=3N;%[BW
M&K7!NI)1:1D-O(E()C)8*& ;Y!SA.M4KW4I"EP(/$;#08KS;937FI3V\=TOE
M*647JY;"L3M)+;CD<XX3T_K^OEW$M?Z_KY]CU+["W_/W/^2?_$U'/ EK;R7$
M]]-'%$I=W;9A0!DG[M>::MXBCN-%MHI;K6(+\:89;=;C4S:^:X+#<IB4-._R
MYQM(P5)49KHM7OI[WX8Z5=R2^;]J^P&YD_O(\D?F$X[$$YI\K_&WWB3U1I7>
MO:192)'-J-^6:)9F$5F\GE(W1I-L9\L?[^.A]#5B74]*@F6*3664M:->ASMV
M>0I +[]NW'S#OWKGM=NK"S\1ZA)'XAD\/ZB\:*T=ZD36VH +\I16Y?&=I",K
M=L<C.1<F*YNM/_M31I8H9/"TPN-/L(\,BF2(%8UX(P.0.HQZT+7^O7^OSL/;
M?^MO\SL[+6M+U"22*#4+]94C,OESV;0NZ#JR*\8+CD<KGJ/6M.WACN[:*XM[
M^62&50Z.NS#*1D'[M<CH%^)?$]C;V>O6OB6U6&4/</%$UQ8\# :2, #=P"I4
M,2,\XXV/ A;_ (1V1 288[^[C@S_ ,\Q.X4#V X'L*+?U\["_K\#;^PM_P _
M<_Y)_P#$U8AC6&&.)22J*%&>N *?12&5W_Y",/\ URD_FE2S1K-#)$Q(5U*G
M'7!%1/\ \A&'_KE)_-*L4 5/L+?\_<_Y)_\ $T?86_Y^Y_R3_P")JW10!3:S
MVJ6:\F"@9).S _\ ':BM4@OK6.YM-3:XMY!N26)HW1AZ@A<&LSQQ>RV_AUK.
MUAEFN]1D%G#%"RK(V[.\J6(&0@<\D#CK7)V6KWV@:?J&BQ6LVCXU" VOVH1.
MUO;7$F"WR.Z</Y@&3@97([4+7^OZ[H'HKGH$<44LTL,>HN\L) E16C+(2,@,
M-O&1SS4OV%O^?N?\D_\ B:X"RO;O0]6\27SZHUW;V6HV_P!NE>./<\)@56+;
M0 "F0Q*@<*>*GO->U.XTY9%UB^MKF2UEU!+:SLX?,2)F/E;WF&P*!U!P2<_,
M ,47TN.VMCN/L+?\_<_Y)_\ $T?86_Y^Y_R3_P")KSBV\2^(M6TRYOTU<VGV
M;P[;:GY<-O&RO,PE+ [E)VG8 0"#Z$=]B#6]2U+6;QY-<BTBVL%M&$,D49CN
M!*H9BY;YL$DHNUEP1SGI5.+3LQ=+G7_86_Y^Y_R3_P")J)XHH[B.W?476:4,
M8XRT89P,9(&W)QD9^M<#I'BSQ-<36FH2P7+07<TT;V\S6:0*%#D+%MD\XN-H
MR&!S\W"XJ;1;F[OO%'A&_O-8^W27NG7-R8O+C582RQY";0#M'3YBQXZTDKV!
MZ7.]^PM_S]S_ ))_\31]A;_G[G_)/_B:XGQ?XGUC1]2GTZQG)N"R7\8,2G%H
MB,9D''/,>,]1YH]J2SU_5->U2VMX=9;3[&^BN;VVN(X8B[1HZHBKO4C&,N<@
MGYA@@4EJK_U_6_W ]#M_L+?\_<_Y)_\ $T?86_Y^Y_R3_P")KAM%\8ZC>PW$
M]Y=0Q(FBM=*5551G661/-7.3M(53C)'(JC#XB\13:+JFK'6&7^SX+.9(!;Q;
M92\*-('.W."6)^4@@]\<4[:V$W8]"N(H;2,27.I/"A94#2-&H+,<*,E>I)
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M[NZE33/+C"Q-';SX1<#?D8PVXGD\8Z4>H+5V/3_L+?\ /W/^2?\ Q-'V%O\
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MVX 7(( &5!.$T+PCK%GJ&G6MX-3>*PN9IQ<&:T6V;>'Y7;'Y[%MW*L0.OS'
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M\;?^1^7_ *\X_P";5TX3^(<V+_AGG%%%%>F>8%>^? ;_ )%G4_\ K\_]D6O
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M$;W$AED.XG<QZGD\?A6T*MH2B^MOS,)TN:<)+HW^5B[1116!N%%%% !1110
M4444 5W_ .0C#_URD_FE6*KO_P A&'_KE)_-*L4 %%%% !1110 4'...M%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY*R,P9$897=A"3V5:R?">MWGB/7O!6JWYC-U/I-[YC1X 8B2-<\=,XHBKO\
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MWLEQ:2SW$-LELD$MK(5#%(@RD2QRC;\V[<N<CCC">@+4]#9E12S,%51DDG
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M#@\BLJBJA24'=>?XNY,ZTIJS\OP5@HHHK0R"BBB@#ZQ\!?\ (@Z%_P!><?\
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MG:S2"-5WX$6V3SBXVC(8'/S<+BNFO]8GM/%HLVN5CM/[*FN2K!1\ZNHW9//
M)]J3T5_ZT5PZV_K>QO+<P/=/;+/&;B-0[Q!QO53D D=0#@X/L:EKQVS\1:H7
MBU$702]U'3-'BGO#&I\KS990TFW&W//'&,D<8KH-5UC6[._T_0[+5+K4WE>X
M\Z[L([1;E#'L(B82L(MV'R?E!P.%'6JE'E=OZZ@>A45YWIFM>(=7O]/BGU-=
M/5;">XG$7V>02M',$4LPWJH(^\%/'(!&*N>#]9U:355L=:OIYI[BS^TQ@QP/
M!)@@,\$L.#Y?S#"R+NY!R>:5A7.XHHHI#"BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KI_R$9O^N4?\WJQ5=/\
MD(S?]<H_YO5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF%[;48[.*:>V8L_E!@1CS#PQRI'4GCGK5.-F_(E.Z3-:BBBI*"BBB@ HHHH
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M23S'50&?&-QQR<4^J5KK.EWUY/9VFI6=Q=6_^NAAG5WC_P!Y0<C\:NTO,-M
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MTDC7[SH[ *ZCN5) S7.1^!KR58Y)E@MY7ODFG']H7-XWEK$Z?ZV;EF^?@;5
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MG9",=0H?VQBNEU/PS>7MUJ<L4EN!=:+_ &='N8Y$F7Y/'W?F'O[4W9+3^O\
MAQQ5WK_6W_!+4WBW29(+K[-J*126YB+M-:RLNUW"JRCY=ZL> RDKGGG%2Q>+
MM#FU#[$EXQF^T-:DF"0()EZQERNT-Z#//;-8FJ^#]0OG)BFM1FPM+;YF;[T4
MXD8_=Z$=/?TJ9O"=Z^G-;&6W#-KAU$D,W^J,N['3[V/PSWI?U_7YB?PWZ_U_
MPQKVGBO1;Z[:W@O<L S*[Q.D<@7[Q21@%<#OM)QWK/LO&5OJOBRSTO3CYEI-
M9S7#R26\D;$JT84H6 #(0[?, 0<<&L#3?AO/!#!I]TR-:6L$D,5T=3NYG;=&
MT898&811$!CTW#T SQLZ1H6O1^(]-OM2&FI;Z?I\MDOV:5V:4LT9#D,@"\(?
MER<>ISQ2M?\ KS!]3;U#Q'I.E1W,E]=B%+:2..4M&WRM(0$Z#G)(Y''KT-0W
MGBW1;&XDMYKJ1KB-S&T,%O)-)D*K'"HI) #*20,#/)%97B?P=+XAUJWF,\2Z
M<]N\=Y"P.Z1@K"(CC^$R.3SZ52TSPKXAT9K#4XIM/OM7%O+#?+/(\4<C2.'W
M(P1B,$ 8*\C'(Q4K;7^OZ_)@_(ZF#Q#I-R3]GO4E M1>;HP64PDD!@0,'E3Q
MUXJC+XX\.PG#WSX\J*=F6VE98XY 2CN0N$4XZM@#OBL&W\&:UI$.W3I["XDG
MT^2TN&N&>,1NTCR;T #;AF0C:2. .:>O@G41X>UJP\ZT\Z^TBWL(VW-M#QQ,
MA+?+G;EAC&3[4U:XNJ1H>(?&UIIKQVMC()KS[;;VS[H)&B7S)$5E\P )O"L2
M%W9[XQ6C;^)-#U:]?2HY_.=_,CVR6[B*;;PZH[+LDQR"%)QSFN>NO"6N^4VG
M6K:<VGOJD.HM-+*XE&V5'>,*$(/W3AMP[#'>K&G^&M7L/$@OH_L=E9K)+),E
MG=3%+L,#@&W8%(VR02ZDDD>]&EM?ZT'KT.LO+NUTVQEN[J5(+6!"[NW 116;
M;>+-&NH]Z7,J'SX[<QS6TL4BR/\ <!1U# 'L2,>].D2ZUSPH5GL;:"YN[;Y[
M6[4RQJ6'W7'RDCMV/M7,0^$-?6REQ/;Q&.ZM[FTT^2_FNH4:)B6'FR*'4-P,
M!2%QP#FCK9B>VAT=YXOT2QN7MIKJ4W"7'V;RHK:65S+L$FT*BDL=K \9_0TB
M^,="?4([%;QS-+,;>,_9I?+>4 DH'V[21@Y /&.<5BZ9X4UA/$PUB_>P4MJ$
MEVT<$CMM5K98@H)49(*]>..?:N>M)F&KZ)X>LKJQNXK'699F$;/]JC3]Z298
MF4>6 6QO)(?(QUHMT&^IVH\9Z-::997-[J2R_:(C*)(+27&P'!D* ,8T'=F.
M!ZU/+XPT*'4$LGO&\QY5A$BP2-")&^ZAE"[ QR."V>1ZBN?TSPIKV@#3[G3G
MTV:\33A83K<2R"-,.761,*2WWCE?ESQR,4S5_"OBG5[I1<WUI+##J$-W$_VJ
M6-=B.K&/R57;P <%F;)QP#R!6NK@^MOZW-_1?$7VKP]=ZKJ7EPQVUU<Q.T2,
M0$BE9 <<G.%!/X]*M2>)='BNKZV>]436)B%P@1B4,O$8Z<D^V:KZ%H,EAH%W
MIM\8I!<7-U(?+)(V2RNP'('.&&??UKF=*\ ZK:W^EW5]J%K,ZR.^ILJG-SM(
M,&..J[5S1U_KM_P_W@^MO,ZJ#Q;HES?&SBO<R[G5&,+B.1ESN5)"NQR,'(4D
MC!]*<?%.C+96MX;S_1[JU>\A?RG^:)%#,V,9& 0<'GVKG;+P?JR6^DZ3<S60
MTO2;@S07$3N9YQM<*K(5 3&_DAFW8Z#-4T\%^(7TVQTZ>33%@T_2KG3HG260
MM*7141V!0;?N\@%L=B:3VTW*25]=CJ8?&6@3Q32K?E$AB6<F6&2/=&W"LFY1
MO!) RN>>.M9UIX[L9=2U43N\=G:_9TB!M)EN&DD#$H8BN\G@8 7./6H-8\&7
MNI364D=Q;QFTL8HDW%B#-'-'(N1C[A\O!/7GI4,_A?7-0FU:\O[319)+QK8I
M:_:)MJB,,#B8(K(WS9#A3CT[TW:_WF:NTCK]-U6RU:Q%[93>9 2RDE2A5E.&
M5E8 J01@@@$5D6GBVT_LJ#4+YRB7LCFRBMX))9'B!X;:@8GCYB0, $9]:G\.
MZ5J%AHLEIJ5T9I'=RBF=Y_)0CA/,<!GQS\S#/-<WH&DZE'IFA7.GK:OJ&BV\
MNEW%M=2-&I&4!;<JL0?W:L.,$-U'6C37^OZZ(KI]YIZ3XZL)M"L[[49@)[HS
M,D=I;R2DQI(R[]JAF"X RQX!/:KL_C?P[;R%&U'<%CCE>2*&21$CDSL=G52J
MH<'YB0!W-8.C^$_$.@?9KNT?3+F]:VDM;F.662., S/(KH0C'C>05(&>/F&.
M6VWP_O;+PWKFE175O(U]ID=G#*Y9?G57!+#!PN7XQGBA6OK_ %L)=/Z[G3W/
MBO1+34?L,U[ME#JCL(G:.-FQM5Y -B$Y& Q!.1CK3M.UO2=3U2\@L"\EU QA
MN)1:R*H9"1L,A4*2"3\N<X.>AS7.7?A#6)+?5=)AEL?[+U6=9YKAW<3P\*'5
M4"X;.SABRXST.*Z+P[I,VD6]]'.T;&>^GN5*$GY7?(!R!SCK0OZ_K^KA_7]?
MUH;%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %?.?QM_P"1^7_K
MSC_FU?1E?.?QM_Y'Y?\ KSC_ )M73A/XAS8O^&><4445Z9Y@5[Y\!O\ D6=3
M_P"OS_V1:\#KWSX#?\BSJ?\ U^?^R+7/B_X9T83^('QY_P"19TS_ *_/_9&K
MP.O?/CS_ ,BSIG_7Y_[(U>!T83^&&+_B!11170<X4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'UCX"_Y$'0O^O./^5=%7.^ O\ D0="_P"O./\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %=_\
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MV]SI5C-#*5,D<MNC*Y484D$8.  !Z8I!H&C!44:18!4E$ZC[,F%D P'''#8
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MS:V]Y"8;J"*>(D$I*@920<@X/H0#^%,^P6?^D_Z)!_I1S<?NQ^^XV_/_ 'N
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M^19TS_K\_P#9&KP.M<)_#,<7_$"BBBN@YPHHHH **** "BBB@ HHHH ****
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M=EK$B2PSP6R2KFV=PK,F8W)&1N7:-K] P!KT]M,T]X;F%[&V:*ZYN$,2E9N
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M^?\ XFC_ (4EXL_O:?\ ]_S_ /$UM_\ "_;S_H 0?^!)_P#B:/\ A?MY_P!
M"#_P)/\ \31S8GM^0<N&[_F8G_"DO%G][3_^_P"?_B:/^%)>+/[VG_\ ?\__
M !-;?_"_;S_H 0?^!)_^)H_X7[>?] "#_P "3_\ $T<V)[?D'+AN_P"9B?\
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M'_XJCS;S_GK!_P!^C_\ %4 7J*H^;>?\]8/^_1_^*H\V\_YZP?\ ?H__ !5
M%ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_ 'Z/_P 50!>HJCYMY_SU@_[]'_XJCS;S
M_GK!_P!^C_\ %4 7J*H^;>?\]8/^_1_^*H\V\_YZP?\ ?H__ !5 %ZBJ/FWG
M_/6#_OT?_BJ/-O/^>L'_ 'Z/_P 50!>HJCYMY_SU@_[]'_XJCS;S_GK!_P!^
MC_\ %4 7J*H^;>?\]8/^_1_^*H\V\_YZP?\ ?H__ !5 %ZBJ/FWG_/6#_OT?
M_BJ/-O/^>L'_ 'Z/_P 50!>HJCYMY_SU@_[]'_XJCS;S_GK!_P!^C_\ %4 7
MJ*H^;>?\]8/^_1_^*H\V\_YZP?\ ?H__ !5 %ZBJ/FWG_/6#_OT?_BJ/-O/^
M>L'_ 'Z/_P 50!>HJCYMY_SU@_[]'_XJCS;S_GK!_P!^C_\ %4 7J*H^;>?\
M]8/^_1_^*H\V\_YZP?\ ?H__ !5 %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_ 'Z/
M_P 50!>HJCYMY_SU@_[]'_XJCS;S_GK!_P!^C_\ %4 7J*H^;>?\]8/^_1_^
M*H\V\_YZP?\ ?H__ !5 %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_ 'Z/_P 50!>H
MJCYMY_SU@_[]'_XJCS;S_GK!_P!^C_\ %4 7J*H^;>?\]8/^_1_^*H\V\_YZ
MP?\ ?H__ !5 %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_ 'Z/_P 50!>HK-FN;R*"
M23S(#L4MCRCS@?[U:5 $2QL+J27(VLBJ/7(+?XBI:A5V-[+&3\JQHP'N2V?Y
M"DNY7AMR\>W=N51N&1RP']: )Z*H^;>?\]8/^_1_^*H\V\_YZP?]^C_\50!>
MHJCYMY_SU@_[]'_XJCS;S_GK!_WZ/_Q5 %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'
M_?H__%4 7J*H^;>?\]8/^_1_^*H\V\_YZP?]^C_\50!>HJCYMY_SU@_[]'_X
MJCS;S_GK!_WZ/_Q5 %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_?H__%4 7J*H^;>?
M\]8/^_1_^*H\V\_YZP?]^C_\50!>HJCYMY_SU@_[]'_XJCS;S_GK!_WZ/_Q5
M %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_?H__%4 7J*H^;>?\]8/^_1_^*H\V\_Y
MZP?]^C_\50!>HJCYMY_SU@_[]'_XJCS;S_GK!_WZ/_Q5 %ZBJ/FWG_/6#_OT
M?_BJ/-O/^>L'_?H__%4 7J*H^;>?\]8/^_1_^*H\V\_YZP?]^C_\50!>HJCY
MMY_SU@_[]'_XJCS;S_GK!_WZ/_Q5 %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_?H_
M_%4 7J*H^;>?\]8/^_1_^*H\V\_YZP?]^C_\50!>HJCYMY_SU@_[]'_XJCS;
MS_GK!_WZ/_Q5 %ZBJ/FWG_/6#_OT?_BJ/-O/^>L'_?H__%4 7J*H^;>?\]8/
M^_1_^*H\V\_YZP?]^C_\50!>HJCYMY_SU@_[]'_XJCS;S_GK!_WZ/_Q5 %ZB
MJ/FWG_/6#_OT?_BJ/-O/^>L'_?H__%4 7J*H^;>?\]8/^_1_^*H\V\_YZP?]
M^C_\50!>HJCYMY_SU@_[]'_XJI[25YK</)MW;F4[1@<,1_2@!S1L;J.7(VJC
M*?7)*_X&I:A9V%[%&#\K1NQ'N"N/YFEN9&AM9I5 +(C,,],@4 2T51\V\_YZ
MP?\ ?H__ !5'FWG_ #U@_P"_1_\ BJ +U%4?-O/^>L'_ 'Z/_P 51YMY_P ]
M8/\ OT?_ (J@"]15'S;S_GK!_P!^C_\ %4>;>?\ /6#_ +]'_P"*H O451\V
M\_YZP?\ ?H__ !5'FWG_ #U@_P"_1_\ BJ +U%4?-O/^>L'_ 'Z/_P 51YMY
M_P ]8/\ OT?_ (J@"]15'S;S_GK!_P!^C_\ %4>;>?\ /6#_ +]'_P"*H O4
M51\V\_YZP?\ ?H__ !5'FWG_ #U@_P"_1_\ BJ .3\2>";[6==OKR&:!8+B*
MT*YGDB=9+>1G R@R P8C<&!4@$ TD'A?7[*UEGL&MK:\GN$>>%M4N9S+$JL
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M<)N-I=E4J"DBC@MUR0<5RVI^/]=TNYUJR>'3Y;BTD2.TD6%U67;&KSEEWG&
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M:]P62TBF\N0AB/D1E\SCC.163I^A^)]4\2Z;?:MHUII<.CV$MM&T%TLINV=
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M&;_KE'_-Z;J'_'K_ -M(_P#T-:<G_(1F_P"N4?\ -Z;J'_'K_P!M(_\ T-:
M&4444 %%%% !1110!P^G?$.Q^V>(;76=3TFQFT^]D@MHY9UB:1 H()#-DG)(
MR,"JT/CC5H_#OAGQ%>6UI_95\ FI-$C!K=G.$=<L?DSP<YZ]:72/ EK+>>*+
MG7- L+B:[U"26SEN(8I6,908P3DKSG@XJUIOAV_C^#PT"YLU_M#^S7@-NS(P
M\PJ<#.=O7'.<4KVC?K9?\$;5Y6Z7?Z6_KU)(O&S&QU_7I(XO^$?TX,ELZ@^9
M=.GWV!)QMW?*..2"<U7T_6O'PU#3Y]2T'3&TJ^=5,5E,[7%H&&=TA;"D#OBK
M<?A22_\ A7!X8NE%K<-IR0/C!$<@4<_*<'##MUJIIUW\0Y[RPL+C1M.T^VMG
M7[7J'VH3K<H!@B.,892??I5V2E;M_P &[_KRL3>\;_UY"WGB3Q5K&M:C8^$;
M+2?(TR40W%UJDDF)),9*(J<\9')J"Y^(-X/"4FH1V,-OJ=KJ<>G7EM*2Z(Y=
M58J01D8;(-->Q\5>$-=U>?0-#MM;T_5;C[5Y?VQ;:2WE( ;)8893@'CFL_5/
M!OB!?!%\4MHK[7K_ %6/4I[>&5408=3L5WQP%4#)J8VTOY??=7^5KCEUMYV^
MY_K8]&U344TRP:Y9#(VY4CC4@&1V(55&?4D"N0L/%VN7%[.9;.$PIYQ2W$(5
MI1"X27RY1*VX@] T<><BI;>Z\5^)%DM-5\*C0A%LN+>Z.I1W(,R.K*I5 #@X
MY]JH:9X<U6PU.>6QTA;.]N1<"[O9!#Y,HDDWJ05<R,4R0-RKN[XXIV#0Z'Q9
MXDDT?P)>>(=,\F9HX%FA\T$HP8C!(!!Z'UK/N_']A)J/A^ST?4])OI;^[6&Y
MCAN%E>-"C$D!6XY &3FIO&'AV>Z^&EYX?T> S2BV2"",NJE@I7NQ Z"J6H^!
M[2WU+PQ=Z+H%A;26EZLEY+;0Q1,(_+8')&"WS$<#-"MS>5_PU$[\OG9_H-G\
M?76BRZY8:U:PG5+5U.G16ZLHOHY#MBV@DG=NX;TINM:_XUM]8T+0]-303J=Y
M9R7%RUTDPB5DVY";6)QSWS^%:/B'0+K4/'GA758;-);>P:X^T3$J#&&3"=3D
M\^F<51\76OB.V\;:-KNAZ!_:Z6UK/#+']LCM\%RN.7^G84ELK_U:_P">@WUM
M_5VORU^\C?QOK5CX>\2)J=E8Q:_HEN)RL+,]O,K+E74$AL9!!&<\56B\5>-]
M(ET:[\16_AZ73-3N(K=1IQF$R-)]TX?@@=P*9=>&/$.L:%XMU*_T^&#6-8LU
MMK?3XK@/Y2(IP&D.%+$DY/3BH;/X:Q>$]7T37/#VC132J$BU"SED#LN1S+$\
MC?*P.<@'!'2G'?7R_7_@:]&)[:>?Z?\ !]39O/$GBK6-:U&Q\(V6D^1IDHAN
M+K5)),228R414YXR.34%S\0;P>$I-0CL8;?4[74X].O+:4ET1RZJQ4@C(PV0
M::]CXJ\(:[J]QH&AVVMZ?JMQ]J\O[8MM);RD -DL,,IP#QS6?JG@WQ O@B^*
M6T5]KU_JL>I3V\,JH@PZG8KOC@*H&32C;2_E]]U?Y6N.76WG;[G^MCT36&U)
M-'NGTA;=M06,M MP"49AT!P0>>G6N3T[QY-K[Z+9:1!$-1N<R:C'.K$62(=L
M@8 @[BWRKD^]:GA[6_%&I7[PZUX0_L>V$999_P"THKC<V1\NU1D<9.?:H/#&
M@W.E^+O%E_-9I#!?W$3V\BE?W@$>&. <CYL]<>M-:/7U^[_/]!-Z:?U?_+]3
M"\2:_P#$31M5AM[9?"LPOKHPV-OBX:=US]YAD*-J\L<X'Y5'XD\;^(]-\6OH
MEK?^$K)8;**=YM8DDA$CL2"$(;IQT_6J>GOX_LO%.I:Y>>!?[2NYB8;:3^UX
M(DM[<'A$4Y//4G//M3]=T;79O&CZW)\/;/7H;G3H(S#=7EN!;R@DL 7!SC.,
M@#-);+^NFG]=QRW?]==?Z[&A?^+/%4.B>'_L,WAB\U35;U[?SX&EDL]H#$%6
M!W9^7!Z\UL>'O$&NCQ _A_Q3:Z?%J#6_VJWGT]W,,R!MK##_ #!AD?7-<]JE
MAXEFTKPW>:=X'@LKC2]1:8Z3!?0*@38PW!QA1DMT )K;T#3]>U;Q8/$OB#2X
M=),%F;2VLDN1._S-EG9E '88 JEO]_Y*WX_J+I]WYNY<\3>(M4M-5LM!\/VE
MK<:O>1O,&NY"L,$:X!=]OS')(  JM:^*=;TC0=9O?%VE0V[Z6NX363$PW0(R
M/+#?,#G Y[FG>*-)UF#Q%8>)] M(+^[MK>2UGLI9O*,T;$,-CG(5@1W]:K/I
M'B;QAX8UNQ\2PVFF)?(%L[6)O.>W(YR[CAOF / _&H^S_7?I\O\ @E:<ROMI
M_P '^ON*<WBOQMHMFFO:]I&D+H3;#+#:S2-=6R,0-S$C:V,\@5T5EXAN;KQY
M?Z'LA^QV]A#<QN =Y9V8')SC& .U<M?6GCOQ-I'_  B^IZ'9:?:NJ1W6JQWP
MD61%(W>7$!N!./XJFU*W\4Z#X_N]5T3PM_:]E/I\-L#_ &A%;["A8_Q9)ZCM
M5:7\M?R_S)UMYZ?G_D='JWB"[L/&OA_1HHX3;:BEPTS,IWKY:@C:<X'7G(-;
M&IZA#I6E7>H7!Q#;0M*Y]E&:X#7%\876K>%_$=OX1\R\LDNEN=/_ +2A'E[P
M%7]X>#D#/ /I5C6+?Q3XW\/QZ/J7A^30XKJ\1+MX]0BF9;=1N+ CN6 7&#ZG
MBDTW&RWU_/\ R*TYKO;3]36\#^)=2UVVNX-<M(;/5+9D=H8<[?*D4-&>23GJ
M#[J:RCXH\9Z\]U>^%-,T=M)MIGA5K^63S;LH<,8]O"C((&[ZTNE^"+[PMXPL
MM2T_4=6U>WNHGM=0;4KM97B0#=&RDA3@,",<_>K'U#PIKMEI=QX6'A:U\0Z%
M-=O<6TIU(VK6^YMV)!]YL%C]T\@42[K^G?\ R^_44?/^OZ?X6-/Q3XWU[2M/
M\.-!;Z5I5YJA=;A=:D816Y5<X+JPQ_\ 7'2BW\8>((?!_B#6+K4/">HRV$'F
M6_\ 8\TDR!L$D2Y;Z8P1WK"N_ >MZ3X<\(6<6@VGB%M+EGDNK,S1I$PDS@9E
MZ@$^AZ5JG2]9U'P7XCTJ'X?V?AV6YM2L*6MW;L+ESD8.P*!CU/K1+:5O/]/^
M""WC_7?_ (!;3XB7%UX9T#4;:W@2[O-3AT^^@E4GR6;._&#P>A&<\$5Z%7EF
MO^!M8?6?#=]I4(:'[1:2:K!YBC:T( $HR<$[25.,DX'6O4ZJ5M;=W^GX=A+I
MZ!1114C"BBB@ I^G_P#'K_VTD_\ 0VIE/T__ (]?^VDG_H;4 .?_ )",/_7*
M3^:47_\ R#KG_KD_\C0__(1A_P"N4G\THO\ _D'7/_7)_P"1H BHHHH ****
M "BBB@ HHHH **** "BBB@ KG+#Q#-_PDNMZ1J:PQ?8HTNK>1 1OMV!R6R3R
M&5@<8'2NCKA?B!X6U76KBPN-$*1S2!["^<D _9),;R,D9*XR/J:-;_U]X].I
M7MO'&L31>%[B2UM$AUR_EC52C;EML$QM][[Q !/;GH*H>'OBAJ%W:>)Y]7M;
M2/\ LR&2XM/(5E\U%=TP=S'G<H'&.M=!XD\/7=QJ_A Z9: V>EW9:7:RJ(HQ
M&5'!(SV&!FN%D^''B*:WT95MO))U"XCU%?.3_CT><2@\'G[O09//2FK-VZ;?
MBM?S%>VK\G^;M^2^XU[;Q=XDUKX8ZWKD]VFEZKI<LZ[;&)"CE%'#"4/W)Z$5
M7\0^,?$'A/7[=7U&>_T[^S%>42PQ>8;B7S/*/R1CC<JKZ<C.>M=;X.\/7%EI
M^OVFL6,9AO=5N9UBEV2++"Y&"0"1@^A_*NCFTG3;E]\^GVDKX1=SPJQPAW*.
M1V/(]#0[?E^6O]=P6E_G^>G]=C"^'FHZKJG@ZWN-;N!<:BLT\4T@15!*2LO1
M0!V]*I7OC6\MO'<>F):P'1$ECL[FZ.=Z7,BED4<XV_=!XZL*ZY+>*PM)%LK2
M- -T@AB54#.22?09))Y]37EJ_"B]U'0+J\OM<UFVUF]=[V2QBNU^RK<$[D!7
M!#;2%&<]N"*&US7>W]?\%_<%M+=?Z_X'XG;Z[X\\,^&;TV>L:JEI<"$3[&C<
MDH3M!&%.3GL.>^,4ZR\=>&-1UB'2;/6K:>^FB$L<2$G<I&>#C&<<[<YQVKG(
M-"UZ^\9KKE_I@A\SP[]EDS+&VRY+9*##'\^GO5/0_!^L6.D^ (9=/6.72IY7
MO@)(_P!T&5AG(/S9)'3-"6MG_6K7Z)_,3?;^M$_\T=,?B5X/&HIIYUR!;M[A
MK81,C@B13@@\?+SP"< ]B:GM?$?_ !4VOV5Y>Z<EGIL44N )%DB#*2QE9ALQ
MQQM/3K7$WG@G6W^'VO:=%IP.H7FMM=QIYL>7B\Y6#9W8'RCH3GVJ[JO@C5]7
MU7QNH06\.JVMJEI.T@VN\:\A@"2!D8.1T-);7_K9/]7]Q2M>W];M?D=7HGCG
MPSXCEN8M)U>&YEM@6D0*RL .I 8#</<9%5],^(_A'6-1MM/L-;@FNKI=T485
MP3['( #<?=.#[5A6&C>)=:\26.J:OHEKHT>E6DUM$D-TLQNBZA01@#:@QD \
MU0L_!>LV_A'P+8C3@ESIFII<WJ"5/W:Y<EL[L-U'3-4DKK^NK_X#(;=OZ[?T
MCJ_B%XBU+PQX9%]I,-O->/<Q0(EPK,AWG'12#^M<IXD^*6I6'ASP]?:7:6<E
MS?P"XNUG5BL2AD1@ &!SO?'.>AKK/'FD7VM:-96^GP>=+'J-M.Z[U7"(X+'D
MCH.U>>7?PX\1"'Q3'';>;$\T<>E1^<@S";CSGZG"X)[XZ4H;Z]U^G^?X,I[:
M=O\ /\K?B>CZO\0/"V@:G%INJZQ#;7D@!\LH[;<]-Q (7\2*KQ_$709/&TWA
M83.+N*/=OV-M9L;BHP.R\YX'89KFO&NC>-]<EUS2HK%+G2KFW7[%*M\(5B*@
M$HR  NS,/XCMK4AT;7;/QR;V/3%FL+[2([6:;[0BFVD0,<%?XLD@<<>]+I?U
M_)V_%!_P/S7^8_4/B;HMUH5U=^'=9T^2>W,)=KN"?RT5WV\A5W9/.!V.,\5T
M-QXLT2T%]]HO=CV+QQW"&)]RL^-F%QEMV>-H.:X:?P=K1^"5EX>BT]1JL;1-
M) )(QC$P9CNSM/'/6I_$7AOQ%J7BY/$MII\ .D/$EK9R,FZ_49WL6W84C<=F
M[H03QFJLKV\_T7]?CT8KMJ_E^K/2P<@$9Y]1BEIJ,61692A(R5.,CVXIU2,*
M*** "BBB@ HHHH **** "BBB@ IUC]ZZ_P"NO_LBTVG6/WKK_KK_ .R+0!;H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *^<_C;_R/R_]><?\VKZ,KYS^
M-O\ R/R_]><?\VKIPG\0YL7_  SE/!L]G;>,](GORHM4ND+EN@YX)]@<&O4]
M9T#XGW'C:2ZL-0F^PM/N@E2["P)'G@&//.!U^4Y]Z\F\,6=IJ'BC3;.^25[6
M>X2.18OO$$XP*]%\1^$_'NEZE<Z=X=DUA]#X^SA;[.%P,CJ"!G/&/SKKK.TX
MO2^N^W0Y*.L)+TVWZG,_%>>TN/B!>M:,C;51)F3H9 OS?X?A7H_P&_Y%G4_^
MOS_V1:\/U72[[1]0DLM2MW@NDP7C<@D9&1TKW#X#?\BSJ?\ U^?^R+6=:*CA
MTD[[&E*3EB&VK?T@^//_ "+.F?\ 7Y_[(U>!U[Y\>?\ D6=,_P"OS_V1J\#K
M3"?PS/%_Q HHHKH.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MZQ\!?\B#H7_7G'_*MBZAF>>*2(1G:K*0[%>I'L?2L?P%_P B#H7_ %YQ_P J
MZ*O%G\3/:A\**/E7G_/*#_OZ?_B:/*O/^>4'_?T__$U>HJ2BCY5Y_P \H/\
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MA<?WAVKF-4\87\.GV5Q:F-6ENO*<,G5::3;L93KP@KLZ[RKS_GE!_P!_3_\
M$T>5>?\ /*#_ +^G_P")J\.@HI&I1\J\_P">4'_?T_\ Q-'E7G_/*#_OZ?\
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M ']/_P 31Y5Y_P \H/\ OZ?_ (FE_M6U]+G_ ,!I/_B:3^U[7.,7/_@++_\
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M:O44 4?*O/\ GE!_W]/_ ,31Y5Y_SR@_[^G_ .)J]10!1\J\_P">4'_?T_\
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M_?T__$T>5>?\\H/^_I_^)J]41G07(M\2;RA?/EMMQG'WL;<\],YH K>5>?\
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M^7CBIJP]/OIY+@<($)P0*W*ZSU HHHH *KWO^H7_ *ZQ_P#H:U8JO>_ZA?\
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M_KYCDK_UZ_U\CAM0N+S2?%<FF6VI7[6QN--EQ-=/(=TDLBR %B2%8(/E^[Z
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M:^CU6Q>S@)6:X6X0QQD=0S9P,>]+IJ5U+]%5;#4]/U2)I=/OK:\C4@%[>59
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M88CCJL8S]:U]"WC3]KL68,<L1C=5.W0SI^TO[WY?\$TZ***DU"BBB@ HHHH
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MMW&\;AE$,T?#(G)42D9/7'-*?#?B5H[&_9+Q'M+Z:98[=;);UUD0+O?*F!I
M=V2,':>N>O4VGC:TNYXT73=12&6^;3X[AUC"-,I<, -^[ V'G'<>^)+GQC90
M.\,5I>W-V+UK&.VA5-\TBH'8J68*%"G.6(Z?2B[_ *_KS"UM/Z_K0YW3/#NJ
M:)-87PTFXOU,-U%):RW$!EA,T@?<<!(P#@A@F<9P-U6T\-ZF_P &W\/&V2+4
MFTUH!!O4@.0<+N!Q^-*_C^2#7;Q+C2+Z'3;;3([PF2)4E#,Y4@JS@]L#CJ">
MF"=;5_&5AHUS=6\UM>2R6RVS,L**=WGR&- N6&3N7G^M&KV_JS'L_P 3E[W0
M-:N;/7[(:*[OKRQM'=2S0C[$1$J;9,,3E"I9=FX9/4=:ZCQ)IM[-'H]S:P->
MMIMVMQ);!E5IP(V3@L0NX%@PR0..HJ*7QM:V[RB;2]21+4+]OEVQ,MD6 ($A
M#G/!!.S< #DXK;U'4/L%JLR6=U>N[!4AM4#,Q/N2%4>[$#WH;>X+L>='POKQ
MG&JQV5W9-'JUS=K:64EJTVR6-5#KYNZ+<"&R"0>3@^L]AX:U/1KBRO\ ^Q9]
M3C:VNH)+*:XMS)$TT@?+<)&%(!#!0<9P-PKH5\=6DBVZ)I>IM>37,MI]C"1^
M8DL:;RK'?LZ="&(YZBD/CFTN;1&L+#4;FX>.1Y((XTWVP1BC%]S <,",*6)P
M< TME_78%J_Z[G,ZEX0UF6^U.-8+Y;;5!"1%I\]HL%OLC5=C/+&9%"E25,8/
MT!JQ<^$=8N=4U#$ 6*X.H*DKRJ1B6&)$)P<\E6[=OI71Z)XA$?PZT_Q!K-P3
M_P 2^.YN90G))0$D*HZD]@*<?&$4=JKW&CZM;W4DRPP6<L*>9.[*6 1@Y0\
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M_P"OS_V1J\#KWSX\_P#(LZ9_U^?^R-7@=&$_AAB_X@4445T'.%%%% !1110
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M67V2[D^TASY\<>8HMH!^=L_+G/'K@U<KR*72[R73/#L5MH-W:-:Z;J5O<0K
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MX7.3MAR?U/'2MWH*!I6"BBB@857O?]0O_76/_P!#6K%5[W_4+_UUC_\ 0UH
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M]9^I^#9;3PI###<O<RZ;I5Y;(B0'=.9$XP 3@\=.<YKNJQ?%>NMX<\/S:C'
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MW+_NU"!XBS8C) Z,''3CKF[X8O=2OO&NOO<7:-9_9[1X;?8V8MZ%N"6(]<X
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ME^:!Z;?UH>J]J*!THI %%%% !1110!7O_P#D'7/_ %R?^1JQ5>__ .0=<_\
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MWLHMF1E.IZGAL'.>1GBH6(3V7;\="WA6G:_?\%<\OM;=[N\AMHRH>:18U+=
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M\WJQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45Q?Q
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M^B:-%HVEM)YDT:3M*\K=>6(!QP/R'I6N/BM;SKI-QJ/A>VO-2TT*L5VURRC
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M<X&%4 $]>.:X&BATH.7,UJ.-6<5RIZ'IO_"VX);S3M3NO"]M/K%G&(A=FY8
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M&N!>RJC0M&IY.49MAX^ZX5O;@XCE^(FEVVFWE[=6>H0"VM!?+$Z)OGMR<"1
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MZQERNT-Z#//;-4CXSM+KQ'I.F:;()H[N299)'@D4,J(3F)R KC< "5W"A:[
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MO-.>62V.-LCP21!P1D%=ZC<.>HR*T*&K %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5\Y_&W_D?E_Z\X_YM7T97SG\;?\ D?E_Z\X_YM73A/XA
MS8O^&><4445Z9Y@5[Y\!O^19U/\ Z_/_ &1:\#KWSX#?\BSJ?_7Y_P"R+7/B
M_P"&=&$_B!\>?^19TS_K\_\ 9&KP.O?/CS_R+.F?]?G_ +(U>!T83^&&+_B!
M11170<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'UCX"_Y$'0O
M^O./^5;DUK;W+1M/;Q2M$VZ,N@8H?49Z&L/P%_R(.A?]><?\JZ*O%E\3/:BD
MXI,*R=<T--86TE28V][93?:+6<+N"/@J<KD;E()!&1UZ@\UK5A:[J>H0:EIN
MEZ8;:.ZO?,;S[J-I$C6, GY%92Q.0/O#N><8J2BGJGAC5-=T*[T_4]<C>2X:
M(J8+(1Q1;'#?*I<L2< '+D>@%4/^%:V*>)9]4C_L_P NXNQ>2";3(IK@2#&5
M29\[4)&<;<@DX85SVB>*=1TO3[?2[>-%NI[G4;B6==/N+U%VW3#:(X?FY+?>
M) &.Y-:EEJ6LZEXB?4K:UAL+QM#C>6&^BD^4K-)E=AVL <'#'&,@E3TI_"[_
M -;#:O>/];EJ#X<O!JUK=#5D,%KJDFHQH;3,CE]VY7DW_-C=\IP,#UZU+8_#
MXV5AH%J-5).D7LUWO%N 9?,W_+@L0N-_7G..G-94GC'5=9T35]16UTO^R[:U
MMY?LMU;-*TIEB1\,=X  +?W3GVQDZ[>*=5L_%)M-2CM;'3VG,<7G6TP\Q,?*
MZW )C+$_\LV"GW/<MRZ?U_6A+=W_ %_74IVGPMLQ?W=S?3VCBXLY;23[%8BT
M:99,9:7:Q5WXX*J@SDX](T^%<"Z!J6F+<Z= ]U9_8TGM-(CA95R#ND(.Z1S@
M9^95/7:#1I6H:O+:BUT_[)#->6LNL7$EY$SEEE=MD8"LNTA0!N.<8'RFL;0O
M$=[I/ANPCL+/3_M*Z5I"+-+$=S>=*T9#L""57J!V)/K346]/Z_JY7F=Y<>%_
MM+7+/><R:7_9T7[K_59SN?KSGY>./N]:S?#_ (!_L*^CN?[3\_9HT6E;?(VY
MV$GS,[CUS]W]:P[B[U^/4O%EE?:I!<22Q6EG MO;/$$>;*AE5I'QC<2?7&<C
M%1Z%)J&D:[?V=H-,:_O]4>SBNGM''DQ10A\-^\RX P%3*X.XYYP%\7S7^?\
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MHHH **** *[_ /(1A_ZY2?S2K%5W_P"0C#_URD_FE6* "D90RE6&01@BEHH
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MX^5QQQR&&/\ 9]ZT* "BBB@ HHHH **** *[_P#(1A_ZY2?S2K%5W_Y",/\
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MI%E8Q7UUJEE!9RX\NXEN$6-\],,3@YHNM;TFQFMH;O5+*WENO^/=)KA$,O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M WE[S&2FWYMI.#GDL-!*>*M'U)]%F328]3F^P1R63%[6)H5"?)@M$GF!B 0
MN1TII7:"3LG8]6HKA/'=LM_?1VDV@"_5K5Q!<36DMW$LI.,>6GRJV.=[%>N
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M>Y@CN([=YHUFE#&.,L S@8R0.IQD9^M2T %%%% !1110 4444 %%%% %=_\
MD(P_]<I/YI5BJ[_\A&'_ *Y2?S2K% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M $__ (#/_A7S311]3AW8?7)]D?2W_"X_!G_/]/\ ^ S_ .%'_"X_!G_/]/\
M^ S_ .%?--%'U.'=A]<GV1]+?\+C\&?\_P!/_P" S_X4?\+C\&?\_P!/_P"
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MI/\ FG_Q5'VYO^?2?\T_^*IM% #OMS?\^D_YI_\ %4?;F_Y])_S3_P"*IM%
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MYV/VYO\ GTG_ #3_ .*H^W-_SZ3_ )I_\53:*0QWVYO^?2?\T_\ BJ/MS?\
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M_P"><_\ WX?_  JI.Z7]=6)$M%1>>O\ SSG_ ._#_P"%'GK_ ,\Y_P#OP_\
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M ,\Y_P#OP_\ A0!+147GK_SSG_[\/_A1YZ_\\Y_^_#_X4 2T5%YZ_P#/.?\
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M_P#0&JO<,8[]V*2%6B0 K&S#(+>@]Q0 ^BHO/7_GG/\ ]^'_ ,*//7_GG/\
M]^'_ ,* ):*B\]?^><__ 'X?_"CSU_YYS_\ ?A_\* ):*B\]?^><_P#WX?\
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MZ#G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^L? 7_ "(.A?\
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M.6/:Y3$B;2<'&1[>AJ6AJP!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?.?QM_Y'Y?^O./^;5]&5\Y_&W_ )'Y?^O./^;5
MTX3^(<V+_AGG%%%%>F>8%>^? ;_D6=3_ .OS_P!D6O Z]\^ W_(LZG_U^?\
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M<MC #;L9XQVQQ]: +GVNS91%N785/!0[0!D<\8 X.,]<<5,)K>1U DB9L_*
MP)SCM^!_6JDNE"2(1I<S1ILC0A,?-L.1DX[]".XJ.VT*WM;J&XCDEWQ)L )X
M/+'./7YB/RH T]JABV!N/!..:6BB@ HHHH **** "BBB@ HHHH KW'^OM/\
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MP\+"PV"TG,WVGSL[LECC;MX^]USVK4OOB==S:GX>U"RL%MIM'@,.&F\Q9@0
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M.1WJ[_PC]]KVHW5Y<:6VBQG319QH[Q.[2JX=)!Y98;4(&W)SR>!3:2?]>?\
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M)?#'B"?2[R&+3;E8DCMA%#>O:M<'RIE<1QRQD;HPH;'FD')'3FBROO\ U?\
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M81VC6MQ;WMM/<1W9N0L($84Y+ $;3N^]VQT-7_[:TU+JVLIM1LDOKA \5O\
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MG_D6=,_Z_/\ V1J\#KWSX\_\BSIG_7Y_[(U>!U>$_AF>+_B!11170<X4444
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M^O/))YINUY?@)7Y5W(].\;66HSP*+#4(+>XFDMX+F:)1')*F[<@PQ;/R-@D
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ME%C\.&L3+Y6L&'>;MD-I:B$Q&=$4E,-@;2F1QW]1DQM\-KB5KR:36+:.YNK
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M < DXW9X(R*S_KU_R_$IZ'9ZOK<&C6,-Q/#/))/(L,-M$%,DDC=$&2%SUY)
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MU"]N8]06W6\L%LID: N?E<NK*=PQU.1@YXZ4S7? UMKU[?W%S<(5N8;9%B>
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M!XLQ*S E"0W))SD_6FZKX/\ [2U6[U%;\P3R1VH@(BW>5) [NK'GY@2^"O'
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MKA59"H"8W\D,V['09JFG@OQ"^FV.G3R:8L&GZ5<Z=$Z2R%I2Z*B.P*#;]WD
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M(YEG5HF525*@*1GD9/KGM5WP;I6J7-KX=U+4?L<<-CI@BMUMG9FE\Q4^9\J
MN H^4;N><]J:LQ-V=C0E\;V%KXGU32;Q9+:*PMH9FN7BDVNTC$;1\N">% P2
M6)('*FMG2]9L-9BE>RF9C$VR6.6)XI(VQG#(X#*<<\@<5R^O>$-3O_$USJME
M+:!72TDC$SL,2V\CL%8!3E6#D9SE2,X-;.A:3?V^J:GJ^I_9DN[_ ,I?(MI&
MDCB2,$#YF"EB=Q).T=AVS0K6&]]!DGC+17^UPPZAY<L,<S"62UE,1\L'>5;
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MQT<7A;1XK&XLQ;2-#<RQS3>9<2.SN@0*2S,6R/+3OSCGJ:DF\-Z3/I\]C):
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MVEQ(8I-Z[=VV0MOP<;>5P,_WA4T?BG59M-"/=Z1:W\=U<6\CM!++YGE-C='
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MVWB'S*S_ .&#X\_\BSIG_7Y_[(U>!U[Y\>?^19TS_K\_]D:O ZUPG\,RQ?\
M$"BBBN@YS2\/RZ7!KMH^M6S7&F[\3QJS*=I&,@J0>.O7M7M&CVOAO1-7CU/2
M_B,EOHRG>-*-R&&/[N&<G'_ =WO7A$,,EQ/'#"A>61@B*O5B3@"M:X\*:U::
ME=Z?/9;;FSA\^X7S4(B3 .2P..XXSGFLJL5+K8UI2:VC?^O(]+T_QAX?US4?
M&&DS7::=:ZRV;6ZE&U,A=I+>F< \X[UF7=YI?@[X9W_AZ/6;+5=2U.;<WV&7
MS(XE^7DM]%]CS[5PD'AG6+F?3H8[,^;J0)M$9U4R =^2,#T)P#VJ&31-1AUW
M^Q7M\:CYP@\G>OWR< ;LXZGKG%0J,/A3[:?X?ZU-/;3^)KO\K_UH>QW7BK1+
M3XA>%+QM3M9+6/33!-+%*KK$Q& &QG'/KTI_AY-!\.ZAXLN9/%6C3G4E=X(X
MKI3A26(!).-V6Q@9Z>]>5S>!?$ENNI-)IN!IBAKO$\9,0*[@>&YXYXS4&G^$
M==U71+G6;+3VET^VW>;+YB#&T9. 3DX![ U#I0<7[W2W3J[E1JS4E[NNG?HK
M'9PW&G:Q\$X=)75].MK^QN7G>"ZG",X!<X4=6)W#&*WY/&>CZ/K7@B[:]@G@
MBTPV]T8)!(8"RH/F"Y(((Z=>M>36_AS5;K0;G7(;7=IML_ERSF1%PW'&"<G[
MPZ ]:U[3X:>,+ZQ2\@T24PNNY2\D:,1_NLP;]*N4(7;D^M_O5O\ @D1G-I)+
MI;\;_F=YHP\/^"O$>L^*7\3:=?0S))]EM;6;?,Y=@V&4=,8Q^IQ6)J&LV-U\
M$XK7[;;?;WU!I6M1,OF %V.=N<XY]*X.ST/5-0U8Z5:V,\E^&*M %PRD=<YZ
M8]ZU-9\!>)_#]B;W4])DAM@<-(LB2!?KM8X_&DZ4%:\NUMMEL4JLW>T>]]]V
MCO-7UC39;3P"MOXFAT^>UM-LES %G-L_EH,.@;@'D'/Y=:V=8\16,GA;58?%
M.L^&M9'E%;#^SSNG9R#@LO.PYV].G/->26W@OQ!>66GWD&G[X-1E\JU?SHQY
MC\\8+9'W3UQTIDWA#7;>/4WDL>-+8+>;948Q$]. V2/<9%$J4'HY=7V[_AO8
M(UIJS4>B[]G]_P#P#$HHHKI.4**** /K'P%_R(.A?]><?\JZ*N=\!?\ (@Z%
M_P!><?\ *NBKQ9_$SVH?"ALL@BB>1@2J*6.!D\51T76+?7=.%[:I,D98KB5=
MIR/Q-:%%+2P-2YDT]!&4,I4YP1C@X/YBN!TS1H5^(>K6?V_66MK.SM;B")]8
MNV4.S2[B09#N!V+P<CCIR:[^LZ'1K:#7KW6%>4W%W!%!(I(V!8RQ! QG/SG/
M/I2_R970XSPUXJU*+PYI4>JV+21WEK,8;K[:S2R-&K,=XVY7(!PP9CZ@59T[
MQZTFH:=IRZ;%%'/%!M%UJ.V>0.BL6B61?WRKN )W[B0?E/?;3P?I\>GZ99B:
MZ\O3DDCA)9<L'0H=WR\\,<8Q5<^![1H[:V?5-4>PA$/^A/*C1.8@ IY3<OW0
M2$902.G)RU:^HG>[L7=<UVXTZ]L=.T^Q2\U&]\QHHY9_)C"( 69G"L1U 'RG
M)/:LZX\6ZBLMQ%;: 9)K&V2YOXI;M4:+<"=B;0P=\*3R5'3YN:U]9T*+5Y+6
M<7=S97EHS&"ZM2F] PPP^=64@CU!Z#O6=<>"K28DQZIJL!EMUMKIDN S7<8S
M@2,ZL<_,PW*5;!Z],+6W]?+_ ()6E_Z^?_ ,V7X@S,;FYL]&%SI=NUKON/M0
M21EG5"I5"N"1O&06'U/2I)O&VHPWPTS^PHFU,WXLO+6^_=?-"95??Y><8&"-
MN1SC/?4?P=IC6U[;(T\4-V]N[(C !/)"! N1P,(,YSWZ5E^(/"$UYKUA?6$]
MW"\NHBYNIXI(P8 MN\:L@8$'G;D$-U/&*:M?R%T\QZ^,[Z>]LM.M=&B;4)99
MX;B.6\*1P-%L+'>(R64AP0=H/3('.,M?B?8ZB7MX7LD6Z$T5L8=15[E756(:
M2$#* [3@AB>F0,UU%AX4L;"[L[M)KF2XMS,S22N"9GEV[V?CK\HQC '3&,5#
M!X2MX&>"+5=3%B ^RP691%%O!!QA=Y')PK,RCL.!B9*Z:]1IV:9@Z7XZN-)\
M/6<FO6#(O]C?;XYTNO.DF5%0-O!4;7)=2.6!R<D4L?Q/@>TO2EO87=W;QQ2I
M%IVII<(ZO(L>"X4;7!89!&.F"><;TO@[2;J*U@G:>6*TT]]-"%P-T;A,EL '
M=\BX(QUI7\))<6<UM?:SJMZLACP9I4'EA'#@ *@7J!EB"Q'>M)-.3?\ 6_\
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M:1::=#JW]DP6.CI>K((XV\]B\@.[>#\B[1G;@_-]X5Z1_8^F?VF=3_LZS_M
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M0VUA8S"=;6&$*C, =G P  3NQCJ!Z4T[/[@_X)KT444@"BBB@ HHHH ****
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MY*W]:_YBMI_79_H<U9Z4819GQ'H=]?::(+A;>W6SDF\JX-Q(VXH 2I9"NUR
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M:)+I\65N%,C".21F)V_>8*%P <G!Q?U+0H=.\8QRZ7HDCR)<0>3"VFNJ1Q@
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M%608CCVGIAS,<8&-JU7\9Z)=S^*[B]TW3W-[/HLL%O=0P'<)0X)7S0/D8IN
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M[#CFFD[_ -=[?UY7[D_"M/ZZ_P!>9U]_X4U1M?2YTP6=E$'B/VRWNIHI?+4
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M.10 Q4%F)DSG:HQQVY[6BDM-1&'KVEWMU>:;J6FM ;S3Y'80W#,D<R.I5E+
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M<'A Q &2!3L#T-VBN??Q7#%JMO93Z5J<$-S.UM!>2Q*L4D@!. -WF ':<,4
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M2/8YW_A O"?_ $+VG_\ ?D4?\(%X3_Z%[3_^_(KHJ*.>7<.2/8YW_A O"?\
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MA6&0"&_$'(_44ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6!I;2Q6WGE612O[YPQ63:#Q\J\BI9O!%_?27$VHZY%+-+;V]N##9>6JB*;S
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&#TSUXZ54MOA_-;Q:6W]MN;O2((8+"18-J1!0!(63?\ -Y@X/(P,8YY+TO\
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MHU:*2V6.6.6"YM#+&PDD9]RKO #?-C+!@0!Q26OP[-OIGV,ZKO\ ]"LK3?\
M9\?\>TA?=C=_%G&.V,\]*%;K_6PEH=!=ZPNB6.GQ7$=]>WUSB*&!5C,\SA=Q
MS@K&" "2<A?TKG[_ ,676HZKH-GI46HVR7-Y)#>E4@$D+1KDQL)"0.Q)4'*_
M=.2*Z'7-$EU.:PO+.\6TO["5I()7A\U#N4JRLF5)!![,#D#FL^P\'_8[ZROI
M+\S74=W->7+^2%$TDD>S@9^0 8P/F.!R>]"WNQ2O:R+GB&*^6"2]CU]]+L[:
M%I'\N"-BS#G+-(&&W'8 '_:KE!KGB35;>[D^W/I5WINCP7LMO'#&RR3NKL5?
M>I(4; ,*0>3S71>(O#VK:QJEG<6NL6L%G;?,;*YLFFCDE!R';;*A.., Y&>>
MN,0:CX4U2^FN)X]:M[>6_LUL]0*6)(D52V&BS)^[;#L.2XZ<<4NCMN4K716U
MF^UJ'1H]?M=78-*L)M-,6WC"3,^WY'8AG+$DX*E<>AP<Z5]J6J0^,M(LLPQ:
M?<B;<H&YY"L88$G^$ D\#KCKVJI)X6UI-<2^M-;L/LUO$L5E:W>G/*+50NTE
M2LZ L?[Q&<<# SG;N])-WK.EZB9PIL1+E G^LWJ%ZYXQCWINU[KO^&O_  "-
M;:[V_P O^":=%16ZW"QL+F6*1][$&.,H N?E&"QY QDYYZX'2I:104444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>new_005.jpg
<TEXT>
begin 644 new_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'D X\# 2(  A$! Q$!_\0
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MK7ZG+N9?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J<NX?78]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
MBJ/J4NX?7(]CZYHKY&_X3'Q/_P!#'J__ ('2_P#Q5'_"8^)_^ACU?_P.E_\
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M44:;CN&3ZT=:**!!1DT44 &3ZT9HHH$%%%% PHHHH **** #.**** "BBB@
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MR"+SFWL8W=H@3M$0.W<,-7;V=I#)B;[,D8X"+Y>QE"Y ''U8C_>H2Q\L'A9
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MI-(T;4;0,8;:=F:5.0A8+M;/X=?<>M>,:IK&HZU=?:M2O9KJ;& TC9VCT Z
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MQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH .E=YX&^)M_X4V65PAO-,+?ZLG#Q9ZE#Z=?E/'IBN
M#HJ9P4U:14)N+NCZMT?QYX:UXHEEJD'G/T@F/ER'V"MU_#-=&" !TQ7QA^M6
M(M0O;==L-W<1KZ)*P'Z&N.6#[,ZUC.Z/LC<OJ*-Z^HKX[_M?4_\ H(WG_?\
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M,>=ZJ0IP2.:/:3[L/90[#?\ A4G@C_H"_P#DU-_\71_PJ3P1_P! 7_R:F_\
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MTF^M9M"6-IH+@*KR!Q\A&. 3CIVR*?M)VO</90O:Q9_X5)X(_P"@+_Y-3?\
MQ='_  J3P1_T!?\ R:F_^+JO+\30D-N%\-:M)=7C'[%:JJ^9.@4,TN"?E09
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M!\5=*T._-K'975^88EFNW@*@6Z,,C.X@EL9.T4_:3[L/90[$_P#PJ3P1_P!
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M?P;-9^*;G5[>XC2(:0FF6<6"3$%.<D]QG'Y5L>%M"'AKPGI^CHRL]K"%=U&
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MQ1%J<JR#7)WW&'*LD)C$:+GU !_.LK1?A]JL.H:0^O:U'?66B+MTZWAMQ%R
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB\8&<GZ<'\C2>%I)7;8+%5'LCW[_ (7%X-_Y_P"?_P !G_PH_P"%Q>#?^?\
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M )_I_P#P&?\ PKYIHH^J0[L/KD^Q]+?\+B\&_P#/]/\ ^ S_ .%'_"XO!O\
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M_P (?]!B/\C7RZ.NWOZ4=<G'%'U2'<KZU/L?47_"S_"'_08C_(T?\+/\(?\
M08C_ "-?,UEIM]J<K1:?97%W(J[BD$32$#ID@#@<CGWJNZM&Q5U*LIP5(P0:
M/J<-KB^MS['U#_PL_P (?]!B/\C1_P +/\(?]!B/\C7S%;6MQ>3I;6L$D\['
MY8XD+,WT Y--GAEMYWAGB>*5#M>-UPRD=B#T-'U.&UP^MR['T_\ \+/\(?\
M08C_ "-'_"S_  A_T&(_R-?+E*JEV"J"6)P .]/ZG'N'UR78^HO^%G^$/^@Q
M'^1H_P"%G^$/^@Q'^1KYFOM.OM,G$-_97%I*R[PD\31L5Z9P1TX//M56I6$@
M^H_K<^Q]1_\ "S_"'_08C_(T?\+/\(?]!B/\C7S):6=U?W*VUG;37%P^=D4*
M%V;'/ '/8_E4MSI6HV=ND]UI]U!"Y*K)+"RJQ'4 D8)'-/ZI#:X?6Y[V/I;_
M (6?X0_Z#$?Y&C_A9_A#_H,1_D:^7.]%'U./<7UR?8^H_P#A9_A#_H,1_D:/
M^%G^$/\ H,1_D:^7**/J<>X?7)=CZC_X6?X0_P"@Q'^1H_X6?X0_Z#$?Y&OE
MRBCZG#N+ZY+L?4?_  L_PA_T&(_R-'_"S_"'_08C_(U\N44?4X=P^N2['U'_
M ,+/\(?]!B/\C1_PL_PA_P!!B/\ (U\N44?4X=P^N2['U/;_ !&\+W=PEO;:
MFDLTAPJ*IRQ]!75BODGP?_R-VF?]=A_(U];"N:O25.229U4*KJ)MBT445@;A
M1110 4444 %%%% !1110 4444 %%%% !7%_%/_D0-0^G]#7:5Q7Q3X\ :A]/
M\:NG\:(J?"SYA/4T4N*3%>R>,%%&*,4 %%&*,4 %%&*,4 %%&*,4 ==H++_P
M@WB&W^U6L<\\MJ88I+I(V?:S%B S \9'-=9JVH>$]1OKFZD:TO\ 4;/3K6-1
M),(X[F16)E(=AAFVX&3U[<X(\F/-%8SH\SO<WC5Y5:QZUI%YX=FT06$@TNWL
MY->%Q-937BNL4)@ 8ACM)PQ(!'<<9'-8VL3>&[#PY:?V;8Z5>7%Q+=0^8TH\
MR%/,_<NRY_NCN,>O6O/J*2H6=[A*M?2QZG*GA^#6+^]MY-(DN1<6+P[[M"B1
M87S2F6P6W @C.0.14FL2>%Y+[6-1":=JEZ^JY>*2^2-7MBG!1N0>3SCYAC\_
M*,44EA_,?MO(]3TZS\)R:?IHN!HI9[*[\]FNE#>8K8AS\RD$CV!/.<5#_9_A
M,:A',S:67?05=(Q=((_MO\0/)"M@\ \?E7F5&>M/V#[A[5=CU&Q7PK<VSW#V
M.BVC/J=L/L[WRRF*%@HE^8D9'4]"!DX/'%36I],MO NN:587=@0NNM)!$DT;
ML;<I\K+R2WID9(Z5YS10J.NXO:Z;"448HQ6Y@%%&*,4 %%&*,4 %%&*,4 %
MHQ2BA ?0GP0_Y%*;_KL?YFO3J\P^"'_(IS_]=C_,UZ?7CUOXC/8H_P -!7@'
MQU_Y&>Q_Z]C_ #KW^O /CI_R,]C_ ->Q_G6F%_BHSQ/\-GE=%%%>H>6%%%%
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M)\'_ /(W:9_UW'\C7UL*\[&?$CT,'\+%HHHKD.P**** "BBB@ HHHH ****
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M'8/L["'/V=2VU@-H^9),C=P<=,C+YY]PY(=B+_A67@[_ *!$?YFC_A67@_\
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M<T>[<VPO-)N0X8;<;,L#OR1E&./ER4DP+MM\0;>ZC,D>G3[8SB?<VTIB<P'
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MF;)750K;" P'.X=>X%<SI/C'4II[JYO@C6%O)="58]+GB$21,ZJPN'8QR$[
M"% ^]GC::VUO=$M-)M]>;%O$\+W40EDVL?,4.P +8W$ <=NU6+1_#\&FRZ>L
MUFL#"22:WDF!(\QBS[@3D ES^>* *<GCJP1PBV5Y*VR:1O*\IPJQ*C,<A\'B
M1>A)ZCJ*JKXU1]=:S-O,$8R"%%C5FF(, 5@Q<!?]=T(Y'.1@@MN?#_AI]0@:
MXO<PZ>DB2I/?LY8RL@Q(S.6(_=A=K'!!Q@XQ5JYTSPK<7TEW-/;BYF@)WK>E
M"$(1MZX<;>(HVW+@C:#FC0!;3QC;JBQ7D,B7!E<&-=N57SWB7@MEC\G.W/\
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MLQ7,\G[EA?\ G_O<[R]R'@R.^$W#VSBJL6A:Z;^>::)?)D6$RP+(H69DFW.
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MK*54+("8SM.0<[1N[ALDUI7>@ZC-X9&GQ7$271NI)C)O8##2N^,XSG##MZT
M=5O7.-PS]:194?.#T..A%<6WA?4T> 13PO:QS1RR6KS2*DV("C!C@G[Y5^AR
M5R>>:DE\/ZL;^WNXI85*3;F22X=T"$KD ;<E@ V&#+G/S C@ '8+(CHK \,,
MC(P?R-.W#UKBX?#>K+% C7$'G1B,&Y$SEPJPA&C *_=+@MG(ZYQD"MK0M*DT
MLRJ63RW2+"HQ/SA<.WXG!SW[T"N7M6_Y!5Q_N5=JEJW_ ""KC_<J[0,****
M"BBB@ HHHH **** "BBB@ HHHH **** "J][_J%_Z[1?^AK5BJ][_J%_Z[1?
M^AK0!8'2B@=** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH K6G6?\ ZZM5FJUIUG_ZZM5F@ JJ/^0A
M/_URC_F]6JK(,ZC-_P!<H_YO0!G6US?/JTT<H7[*<[%%NZ-'@D9,A)5\\'
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MG]QN7:-G[O(/)^;'L*[8<@4A13U%.H *K:A_R#KG_KD__H)JS5;4/^0=<_\
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M *6K?\@JX_W*NU2U;_D%7'^Y5V@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *KWO^H7_KM%_P"AK5BJ][_J%_Z[1?\ H:T 6!THH'2B@ HHHH ****
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M^;O@C=9%5&1D!7:I) QTZL3^-7$18U"J % P !@"G44 %%%% !1110 4444
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M;;C[V=Q)&!GG@$8R"[D/#1=TV[/H3>3J6IZU8W=S9?9(+,.<-(&9V8;?X<C
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MR"KC_<J[5+5O^05<?[E7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJO>_ZA?^NT7_ *&M6*KWO^H7_KK%_P"AK0!8'2B@=** "BBB@ HHHH ****
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M444 &**** "BBB@ P**** "BBB@ HHHH ,"C HHH *,#THHH **** *6K?\
M(*N/]RKM4M6_Y!5Q_N5=H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MHYH4GCV."5R#P2.0<CI4E% %;[%'_?G_ ._[_P"-'V*/^_/_ -_W_P :LT4
M5OL4?]^?_O\ O_C1]BC_ +\__?\ ?_&K-% %;[%'_?G_ ._[_P"-'V*/^_/_
M -_W_P :LT4 5OL4?]^?_O\ O_C1]BC_ +\__?\ ?_&K-% %;[%'_?G_ ._[
M_P"-'V*/^_/_ -_W_P :LT4 5OL4?]^?_O\ O_C1]BC_ +\__?\ ?_&K-% %
M;[%'_?G_ ._[_P"-'V*/^_/_ -_W_P :LT4 5OL4?]^?_O\ O_C1]BC_ +\_
M_?\ ?_&K-% %;[%'_?G_ ._[_P"-'V*/^_/_ -_W_P :LT4 5OL4?]^?_O\
MO_C1]BC_ +\__?\ ?_&K-% %;[%'_?G_ ._[_P"-'V*/^_/_ -_W_P :LT4
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M[%'_ 'Y_^_[_ .-'V*/^_/\ ]_W_ ,:LT4 5OL4?]^?_ +_O_C1]BC_OS_\
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M %.6P:>)HY+N=D;@C"#/_CM7*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;G_OG_ZU'_"[?#__ #QN?^^?_K5P6H>"[36?$SM;7+VXN==N;*16083:-^4
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M[VQLQ);02H'7DX9]IX.T8Z^M=JH4U34V<+KS]IRH]9_X7;X?_P">-S_WS_\
M6H_X7;X?_P">-S_WS_\ 6KSN#1='UC1O#4VHM]AN;V2>&22UB5-R)TE90 ,
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M1""4(+*PRQ)#("-W&,#GS\L<YR2<YY]:,YY/-5[!]Q.MY"'K1116QSA1113
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M)8_*-T3_ $7 &>*?M)]Q>RAV#_A3O@[_ )\9_P#P)?\ QH_X4[X._P"?*?\
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MZW4UW-$ZSQ1I9RJAD$/EIYQ)('S.7;@]"O49H52;ZB]G#L63\'O!P&?L,_\
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M7$@C#;RN-HSG<!R""#QD@5]0\8W?A^ZE6^AO9XU?<J.T(DV"WFD.?+!!!,)
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M=?\ '_8_[[_^@&KE4[K_ (_['_??_P! - %RBBB@"EIPS'/_ -?$G_H567&
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M0 4444 %%%% !1110 53O_OV?_7P/_06JY5._P#OV?\ U\#_ -!:@"Y1110
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M<'RT<L9%D9&!+<!1TQR:Z>@]*2=D#\BM>_ZE/^NL?_H:U9[56O/]2G_76/\
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M6D,*IW7_ !_V/^^__H!JY5.Z_P"/^Q_WW_\ 0#0!<HHHH I:;_J[C_KXD_\
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M8NM>)K2_EL]/N+<1QQW#7 _>%4<MM VD,K;N02!QT.>$'0T[/P=H5@Y:WLY
M?+,(WW,KX3!&T;F.  Q  Z=L4FBZ)H$-T^H:5"P=&EM\^;(41@P60*C':,L@
MR0.2,\]:YK0_ .I:5XGM=0ENXWMX0 @BE13$@7:(@# 7,?? D49_AXR34?A[
M=7(NY+2:UMKJZ:Z,TR?>F5YTD1&)0@KM5E.0P&X\,"<KS*26J.@E\(>'K6VF
ME:WFC1<R^8MW,'AQDDQL&W1]23LQG)ZYJ?3]#T5[R/5K6&X,PPRR23388[-N
M_:QPS%3@O@D]SQ7#7?PYUR>SL;>(Z9&;4J\<S2(98OG)>)66V7]V5/ 39CH0
M0:UY? $UPSRSBRDN(XU^RR-DF&0,AWKE>#A3R.>?<T;$LZ*;PAHEQ=O<RVLA
MD>0R.!<RA7)P2&4-M*D@':1MSDXR2:??>%-&U*_:]NK:1YFV[@+F54)7[I*!
M@NX#C.,XXZ5P.AZ5??V/XD T62VD.DFU+>1(DEW./,R[!E&YVR,E=P)/#MVT
M(?AY/= 2W%MIME^XG\B&WW.MM,Z1JLRY5</E68D8()ZDY-%B[:[G5?\ "':$
M+B.<63!T(.!/(%?!R-Z[L. 1D!@0#R*DL/"NB:9>Q7EG8+%<1"8(X=CCS7WR
M<$XY89]NV!7'1> -22Y$ZV6B10D;8]/2:7R+)_E_TB(JBDR'!R $Z\,#DFDO
MPQU5+"6*22WN[GSD=));F(1R, W[UX_LC!GY_C\P_P"V" :?]?U_7ZD]/Z_K
M^O0[Z?PKHUQ'$CVLBF)=L3Q7$D;QC)/RNK!E.2>0<X)'2F7'A#0KNX:XN;'S
MIF$ :22:1F;R6W1Y);)()Z]^^:S/#/AB_P!%\1ZE?RBR6WNURYC(>263(.[/
ME*RK]["%Y ,C&T#!Z^C:U@W,Z?0M/N-2.H212"Z*A-Z3R)T#*#@, #AV&<9Y
MZ\"J2^#=$544Q7<BK+YS++?SN)7XPT@9SYA&U<;\XP,8Q6]12 YZ+P1H$";8
M;>YB8!0LD=].LB*N<*KA]RK\Q&T$#'&, 5T"J%4*,X QR<G\Z6B@ HHHH K7
MO^I3_KK'_P"AK5GM5:]_U*?]=8__ $-:L]J "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ JG?_?L_P#KX'_H+5<JG?\ W[/_ *^!_P"@M0!<HHHH ***
M* #%(1D8JCJ=S>V[6@L['[4LDX2=O-">3&0<R8/WL$#Y1R<U=_Y9]^GK0 !0
MHP*38*YA9-4;7UTEI2L<<[7C3#J]N<[4]CO./]U/>N.L_$>JBQU /?SO-=6=
MO':OC/E2_94D=AQU(:1^?[@I;@>L; >:/*7&.<5R?V/6)=.2[L;F4W#BWE >
MX)5P &=<'( 8C' Z$XI]]/J^G>&X;7<]SJ]U.;=6CP" S%BRYP!MCW$ _P!T
M#-,74ZH@$8-)L&<_K7!-XHUI=-MQ EO'=VT,PODO(F+,\+QHP!1@!N#E@>>"
M.#FEM/%6M3321RBPVV=PD%R1$X\[-R\&4R_R< -SNZ$<YR'89WH0>])L [FN
M(L?%%_.+,[K2-6\M7MV#&68NY7>C%^%7&3D-G!Y7 S9TS6]5N]&O9+Y[7SAI
M\5[$]M&R!1(CD*=S-D@I][C.1P*3"QUH0 ]30(U%>9V_B6_CDT8R7DKBRBE2
M]W+_ *]_L[2J6XY(54;C_GI4\OBW6_GE6]TTBT%TL@%O^[N&6&.1 ,2MM(WD
M'#-G:>G0%A'HWE@]S0(P/6N%NO$NL:7.;>5K&>8W8MY91%*BQ@I"1,5WL0@+
M[2,CED)*C<:[N/[@[4#'8II0&G44 ,\M:/+6GT4 -V#U-&P>IIU% #2@)ZF@
M(!TR.U.HH 9Y8]32[!SUYIU% #/+7WI54+T^E.HH K6G6?\ ZZM5FJUIUG_Z
MZM5F@"MJ'_(.N?\ KDW\C4MO_P >T7^X/Y5%J'_(.N?^N3?R-2V__'M%_N#^
M5 %75H[&73+I-3,0L6B87!F8*GEX.[<3T&,YK)NKOPU;V<QEN+(QK;S,T:R@
MEHW^>3 SD@XSQZ5;\56<.H^%]4L;B\2R@N+22.2YDQMB4J06.2!@=>HK$O?!
M*7=]?SB_*V]Z#(T31L^V;R?*#CY@N H'&TG/1@#B@!+.W\.W-P^J75VL4LT#
MNUK<W,(\A6Q(QQ&<#[JMN#'IG/>KGE^$%18FNM.PCF0;KH9W960L<MDG*HW/
MH#5?4?!SZF'BDU!5M,O-'&L'S+,\31$EMWS)AR=N <_Q8XJY=:=:IJ&^74(8
M7N+HW,<<@ )_<"# R>>H.?<#WH8(:8_"^G/)+FR26!?.($H9XT12PP,Y"@$D
M <#/'6FRGP_=V]G;2W$-M#;3EK=!=(GF'81D;6SC$O3@Y(['FK_PBMS<M!YF
MM>=8)$5CB6%LX: Q9!W[<<[A\N1SDGJ*L_A..=KZ"XUR#SKJ$KJ"K"%/D,H!
MV N3&<J<,21ST) (-.H=#:CM/#>I7+1P&RGEA4HT<,H.P+F,Y13C(!9>F1T]
MJSO$$7A1?#VI2W#0",V[RL;:93*VZW9,IDX+&)6 [$"F:7I.FZ)?V>H/KEJT
M:PWLD>XJHD2XN$DW [N0I*KGH=PZ<"J/_"'Z)>17XM]<@D:>WND+!E<1[E\M
M&P&Z11.4QWWY.,B@$:2CPS'8Q?9H(KB'HS03*S')B0J^&RPPT8(.1A0#_"#M
MNFC:O.Z^;;W$L*;&"399!D'G!XPR @]BN1R*YE]'TN"ZN=1E\0V<<5TL<PW%
M54)M@PP;=R"+8D'I\W^SSI^&/#<6F0,UKJ2W=N(O(M)%)8QQ9Z%BS!B".H"C
MCIWH$/N-4\/6=C#Y+0W,%O(TJK;2+(4<1R2[CSU(1^3U)^II1:^%EE*,U@KK
M*K>6TX_=OYJL,+GY"9-AP,9;&>:S(_ %Z]Q<SWFN_:99X%@+FW;.%CGC!R9#
MSB?)Z#(. ,X%U?!;B"XLVOT-D?/>W00?O(I9F+,S/NPX#$E1@8[DT=!]2>5O
M#20!A)9&(DAY$N47RPC2.6W;@1AEDY'((/H</'_"+0QV]ZLFF*EHKV\4OF)B
M,. SKG.,D $CK6;<?#V*72[NQAOO*2=2BDQ;@BF"2,C&1G+RO(?4G'O3]8\-
M7HE-YITP:Z.8P60%55HEC;*EAG[H.>H]&&07H!)J-UX9T+2[A)8H9+>XLFE:
M!2'\^!  0-QP5 <8&<8SCC-6(+7PK;H[Q/8@7H>)W-P&\[(57!)/)PJ ]^!4
M-_X3N-0T:SL1?10>58/93$PF3<K!.5^9<$-&IYSQGIUIESX*EEU*YNX]255N
MIW:>)XG*M&RH"GRR+S\G4@CGE32$:9MM%AU;[2SVR7R8/S2X*F4[1\I/&\KC
MI\Q'<BJ4%IX77SO])M)W>1[IC)<J2N9/.) SPH8 \?W1G.*?X@\(KKEY#=K>
M/:S1Q,H9%W9<<Q.?7RV+,!ZFH#X'18_L45X(]+"?+ (LR*_D^1GS"W*[.<%<
MYYW8XH&79$\.V%Q-/)+90.[,'WS!0&90S<$X!88)XR1C-0R#P['JNGZ<D<#7
M(00Q1Q./W:1KO4.H/W1@$9!P2",=:;:^%KQ9I9[W4H9YI69F,=L8U&85BX!=
MO[N>O>FZ?X0ET_4;29=01[6V>200F#YR[IM;Y]W3/(&..G/& !UK=>%Y5 AG
MLX_)E^RINE"'=$WW%R<G#-]#GN#5B\MO#L6JFXO39QWKKO)FE 9@%*[L$]E+
M#/8$^IK,N/ ;SF_1=2"P7[3).GD98PRG<RJV[Y6W%L-C&" 5) -:^J>'?[3-
MR?M3P^;!'$A0?-&R.75LY]<<>W6@"NMGX6C0%#IP2X1H5_>KM?(",%YQD@*#
MCDX /:DFD\.1R/<YLY)(YE$KK<)F([RP9B6&,-D^O7@TVT\+WEE+;7,.HPB[
MRXNY#;LPF5RI.W=(2K?(H!8OWX/&*=EX 2U@BMI+T3V\#QK '1BPA1MWEL2Y
MR3TR H_V: -B+^P]'G:6.6SMI/+6W9FE ^5<NJ\GMO)_X%3M7\3:?HO%U)ES
M'YHC4C<5WHA/) P"X[^OI6.W@:1+&W@M]5;S8_-CDEF1V\V%]HVD*ZY(2.-0
M22#M)*G-:.N>&WU?R ETD"QH8V#1E\J7C?CD8.8AZ]30!H#6]-98V74;,B4D
M1D3J=Y!P0.>>>/K4$VOVT&N1Z2^#.\0E+%T54!;:H.6#$L00-H/OC(SBS>!F
MDOIKA=1^6YE=KF)HF*O&7+A0 XY!)Y.X8/W<\UIZIX?GOKJ:ZM[Q()F2 1[X
M2ZJT4A<$@,I(.<8R/K3 >_B:S&MP:4BO+--]V2/:8\XD."<]1Y3#IUQ^%ZY_
MY"%C_OO_ .@&L"Q\&R6NKV6HR:B)7MRS,H@V[R?.R?O''^N_\=]^-^Y_Y"%C
M_OO_ .@&D'4NT444 4M-_P!7<?\ 7Q)_Z%5PG%4;!2T-P <?Z1)_Z%531=#.
MCI<Y-I^]E,G^BVWD _[3C<VZ0_Q/QG X&* *]IXM2ZU V_\ 9-_'!]JDM!>/
MY7E-*A(( $A?DJ<$KBM'^W=+"-(=2LMB,%9O/7"L>@)SUX/Y5@VG@BPM-3.J
MPK -4-Y+<-="W =XY&.Z)CG)P#@-GC /J#4'@Y].@MKEM9A2XL)$-E<SPNR(
M@1XU64-+\W$K?=*#., =" =2=<TT%Q_:-F"B>8P,Z_*F,[CSP,8.?2JMWXIT
MJU3/VN*8^5)*%A<,2(\;@.>HW#BL67P09Y[MY=2\R.=9'59(23'-)&8V<?/M
MQ@GC;GDC=CBKFH^&);RZNYXKY(OM7FK(# 7(1XXTP,,.08E.>1@D8Z$" W$U
M6RDC#QW=NZF,R@K*"-@X+?3/?I0VJV2!BU[:KL;:Y:51M.W=@^^T[OISTK(T
M;0$L;_5KN53_ *9*5B1B#Y</+;>/61Y6^C@=L5EV?@MM,D9H]=F%W):M'O*#
M+/N&V7 .>%VQG&#MQR#@@$=.FN:9*\:1ZE9NTA*QA9U)<YQ@<\\\58>^@1RC
MSQ*PV@AG (W'"C\2,#UKD=-\*W,%ZM[#KJ2%KEI+B2.%MSX8?NPWFD8!5AAP
M^ <#!Y-_4M.$WB&)QJ]M;J_D226LD8,LGE.64JV\8!W$'Y3T'(Z$&:HU_2FB
M,BZI8E 0-WVA<9() SGN 3^%16WB73+FTMY_MEO#Y\ G1)I55MA7=DC/IG\C
M6/'X6+#3;VPU2+S[2U@BMYF@\R-PJR*6(##(99#C!&,=2"0<J'P;9-)/IL.O
MPR-]G2.[M^KB5(5C5PHDPHV[#M*D],,,T =LVL:>EJET]]:K;R'"3-*H1OH<
MX/0_D?2H+[Q#8Z<VGFXE BOY?*AF4@QY*DC+=@<8![DCUK.UD0WFF64=KXAM
M[%68A7W@I.H&TJ-K+G&>QP"!D$<&*T\/VD6D:1H4]Y%<C3[;[.Z%=IF41"-B
M5W97AE/?J/6@#3L_$NG74*R/=0VY::2%4N)%1F9)&C.!GG+*<?A26GBC2[R!
MKB.\A%L /WSRJJ_>9<8SD<H>H&>V<'',+X-G;18;./Q1NLXYG:9WCR'D^TF7
M/#@!MQVMG.<<!:T+;PE>61,MMJD(N(G#6K/:$J@W3'#KY@W_ "SL,@KT!]10
M!T(UG3S.D(O[3S'7<B><NYA@G(&<D8!/X5#'XAT^>^@M+>YBN'FWX:!U=5V@
M,=V#QP16#;:7I4-D?L^O0K'"\.9Q(A*,N1R2< DDXXXZ8-0Z/HT5KXDAO[GQ
M+;WEW)&-L6,%U*$ KND8X(Y[]\8[ '11>(]/D++)<Q6[">2 )/(J%F1MI(&>
M1G'YBG3>(]*@.'U"V+><D!1906#LVT @'CG/7T/I6+#H=KJ"WHM-6@G$ZW*,
M8@'V>=(K\X;MC\>O%3KX3NE:XQJBB)KA)X(1"WEQ[91)R"^"QY&5V#G.": -
M'3/$NG:JN8+B)7&W=&TJ,P+(' RK%6^4YRI(X//%.B\2:3*)B-3M L,BQ.QE
M &XJ'&#G!X/\_2L#3_ ]]I5A;6MEK,"_9Q&5>2S+980^2Q($@ZJ%(]"#G<#@
M//@N]15%MJ\<139MS!)VB6)\[)5)R(T(Z8.<[L\/0#IKG4[.S\O[3>6\ D!*
M&615W=.F3SUJA!XFM+F.[EA61XK:[6S:0;2&D+*IP <X!8 YQT.,\53U?PC_
M &E&D<-Y]F0V;V$H,6_= ^,A>1M?Y1AN1Z@\8E_X16)]&N],FECF@N;O[0RR
M1;E*^8'*$$_,"!C/OTI 7'\064-Y<VUQ,ENUN4#/,ZHK%@6 4D^@-%WXBTVT
MAE=KVW=XHFF\F.53(ZA-_P HSR=O/TK G^'MO!=O=:'+;Z3()%>.*"W*Q+\A
M5LK&R$YR#D$8([CBH]2\ 75^UO&-;*6=N/W4#0%MG[AH2!AP,8;=TSG/)!&!
M ;R^*M*:Y2 W4<>[S 7D<*JM&4#*23U^<?K^-V[U6SL2HN[RVMR_W?.E";NG
M3)]Q^=8\GA2647BO?KLG@N(4 A(*><(]Q)W<X*$]!][';)K>)_#^HZA<AK!T
M4W%N+:=G4,NP-N&,D;3UY ;/3 P& +J;8\0Z48Q)_:=CM+E ?M"8)!&1UZ\C
M\ZCE\3Z/"&)U*S;8XC?9,K;6+B/! /'S'!ST[UD7G@V\GT2#2H-8,$"PR12X
MB;Y]QR" '&".ASD$$\#K4(\!S1R0S0:I&L\#W,D1>V+*&ENTN1D!P2%,87@C
M.<\=*!G573;H%/\ TUC_ /0UJWVJI<JRP(&()\V/I_OK5OM0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %4[_[]G_U\#_T%JN53O_OV?_7P/_06H N4
M444 %%%%  0#U%&!C%%% ";1Z4A48Z4ZB@!H4>E+M'I2T4 -VCTI-@]*?10
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M PM"MKI)KBZO;22WNIMBE"4,:1KNVHFTGA<G).,D] , ;M%% !1110 4444
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M-JSAAL58>/0$F,\9P.*S9+_QC+Y922\B6-U0$62GST:Y,6]P5RI\HB0@;<$
MD 9%/L=1\93:I81S1LEK&YCF>6)D\]1-(A9E6!AGRT1AAXQELX*D 'F+8TM&
MT75K771<W#8B5KHRR^>3YZR.&A79T&Q1M]L<9#&B;PO>R:%<(MW(-1"7 M,N
M%6$R,W(90""0<9Y(R<5)=QZO!XAFN[26Z, :%/LHB4Q2@JV26*[A@XZ,!ZY[
M8=KJ7B^33&2^-Y#/,ZF.2UMR[0G:696+VP"ID*!A)#URW0T7 LGP_JXEDE6
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MW5_!=NQL=J3J5@V,P#-'M#9!!)"$G'3@9/4]!BC%# X+0/#VJ:*NG&>%F-M
MJS,)@XPL1!5 ,$$MCY3E#UX;%;^MZ?/?K93Q170>%BX:WG$4T9(QQD[6'4%6
MXZ'DBMT@&EQB@#SO7?!FJZAI=[- ;?\ M=]/2S5_N)(I5ED0@< <AAP/F4=
M2*VCH-^;77%%U.GVR5VBBAF6/@HJY#["RMD'U^E=3@4N*-U8#(\.6EW9:68+
MN-(R)7,: Y*H3D9Y(!Z\+\HXP!TJW=?\?]C_ +[_ /H!JY5.Z_X_['_??_T
MT 7**** *6F_ZNX_Z^)/_0JNU2TW_5W'_7Q)_P"A5=H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"M
M>_ZE/^NL?_H:U9[56O?]2G_76/\ ]#6K/:@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *IW_P!^S_Z^!_Z"U7*BF@CN%42 G:VX$,5(/U'UH EHJO\
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M_?\ QH L8I,5!]BB_OS_ /?]_P#&C[%%_?G_ ._[_P"- $^*,5!]BB_OS_\
M?]_\:/L47]^?_O\ O_C0!8HJO]BB_OS_ /?]_P#&C[%%_?G_ ._[_P"- %BB
MJ_V*+^_/_P!_W_QH^Q1?WY_^_P"_^- %BBJ_V*+^_/\ ]_W_ ,:/L47]^?\
M[_O_ (T 6**K_8HO[\__ '_?_&C[%%_?G_[_ +_XT 6**K_8HO[\_P#W_?\
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M8H^P6?\ SZ0?]^Q0!'=S1-&BK(A)ECX!_P!M:N5 ME:HP9;:$,#D$1C(-3T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>smti_s3000.jpg
<TEXT>
begin 644 smti_s3000.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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MOG]QL&T9&.M6/&O@F#QI:VL%Q>26XMW+@H@;.1CO5NK%U%(A4I*FXFUH/_(
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; 4U(HXR2B*I/4@4^ANX)6"BBBD,**** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
